Solid Tumor (Advanced) Clinical Trial Landscape
Data updated: May 20, 2026
9,364 clinical trials tracked since 2008
Advanced solid tumors represent a diverse group of cancers that have spread beyond their primary site, often posing significant treatment challenges. Clinical research into these cancers is extensive, with 9,317 trials registered since 2008. Currently, 3,450 trials are actively recruiting, enrolling, or active but not recruiting. The majority of these active trials are in early phases of development, with 2,041 in Phase 1 and 1,799 in Phase 2, compared to 372 in Phase 3 and 62 in Phase 4. This indicates a strong focus on initial safety and efficacy testing for novel therapies. Several major pharmaceutical companies are heavily invested in this area, with Merck leading in active trials (47), followed by Eli Lilly (34), Johnson & Johnson (33), Sichuan Baili Pharmaceutical Co., Ltd. (32), and GSK (29). The relatively small number of Phase 3 trials suggests a potential bottleneck in late-stage development and confirmatory studies.
3462 active
/
9364 total (since 2008)
2052
Phase 1 Active
5776 total
1801
Phase 2 Active
4150 total
375
Phase 3 Active
858 total
67
Phase 4 Active
249 total
Top Industry Sponsors
Sorted by active Active Done Failed
Merck 45 75 27
Eli Lilly 34 79 18
Johnson & Johnson 34 30 3
Sichuan Baili Pharmaceutical Co., Ltd. 33 0 1
GSK 30 64 33
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT03244384 ACTIVE NOT RECRUITING
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
National Cancer Institute (NCI) n=739
NCT06589804 RECRUITING
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI) n=158
NCT03793166 ACTIVE NOT RECRUITING
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI) n=1,175
NCT02595944 ACTIVE NOT RECRUITING
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI) n=903
+ 853 more Phase 3 trials — see full database below
Solid Tumor (Advanced) — Trials Started by Year (last 10 years)
2016 473
2017 513
2018 471
2019 499
2020 522
2021 588
2022 600
2023 630
2024 713
2025 801
2026 385
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Merck 147
Eli Lilly 131
Johnson & Johnson 67
Sichuan Baili Pharmaceutical Co., Ltd. 34
GSK 127
AstraZeneca 81
Pfizer 116
Jiangsu HengRui Medicine Co., Ltd. 57
Roche 134
Novartis 132
Active Trials by Phase
Phase 1 2,052
Phase 2 1,801
Phase 3 375
Phase 4 67
Enrollment Size Distribution
1-50 4,595
51-200 3,045
201-500 963
501-1k 265
1k+ 115
All Industry Sponsors
Sorted by active Active Done Failed
Merck 45 75 27
Eli Lilly 34 79 18
Johnson & Johnson 34 30 3
Sichuan Baili Pharmaceutical Co., Ltd. 33 0 1
GSK 30 64 33
AstraZeneca 28 40 13
Pfizer 22 49 45
Jiangsu HengRui Medicine Co., Ltd. 22 27 8
Roche 21 91 22
Novartis 20 79 33
Qilu Pharmaceutical Co., Ltd. 19 0 0
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 18 3 0
AbbVie 17 28 11
Bristol-Myers Squibb 15 97 35
Daiichi Sankyo 14 16 5
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT07585266 NOT YET RECRUITING
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
GlaxoSmithKline n=800
NCT03244384 ACTIVE NOT RECRUITING
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
National Cancer Institute (NCI) n=739
NCT06589804 RECRUITING
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI) n=158
NCT03793166 ACTIVE NOT RECRUITING
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI) n=1,175
NCT02595944 ACTIVE NOT RECRUITING
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI) n=903
NCT05063552 ACTIVE NOT RECRUITING
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI) n=430
NCT03233711 ACTIVE NOT RECRUITING
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI) n=344
NCT05092958 ACTIVE NOT RECRUITING
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI) n=654
NCT05918302 RECRUITING
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Grupo Espanol de Tumores Neuroendocrinos n=170
NCT03765918 ACTIVE NOT RECRUITING
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Merck Sharp & Dohme LLC n=714
NCT03486873 RECRUITING
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Merck Sharp & Dohme LLC n=3,500
NCT07444723 RECRUITING
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=193
NCT05862285 RECRUITING
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Hoffmann-La Roche n=100
NCT06161025 RECRUITING
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo n=860
NCT05451004 RECRUITING
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Canadian Cancer Trials Group n=510
NCT02320435 ACTIVE NOT RECRUITING
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Hoffmann-La Roche n=154
NCT06136650 RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Merck Sharp & Dohme LLC n=1,314
NCT01946204 ACTIVE NOT RECRUITING
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc. n=1,207
NCT07225946 RECRUITING
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC n=800
NCT02257736 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc. n=982
NCT06800092 NOT YET RECRUITING
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
The University of Texas Medical Branch, Galveston n=30
NCT07566156 RECRUITING
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )
Astellas Pharma Global Development, Inc. n=390
NCT07578649 NOT YET RECRUITING
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Pfizer n=600
NCT06925737 RECRUITING
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Merck Sharp & Dohme LLC n=1,440
NCT07318558 RECRUITING
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Merck Sharp & Dohme LLC n=900
NCT06919965 RECRUITING
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Janssen Research & Development, LLC n=220
NCT07060807 RECRUITING
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC n=1,000
NCT06824467 RECRUITING
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme LLC n=770
NCT07522073 RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Incyte Corporation n=588
NCT06211764 ACTIVE NOT RECRUITING
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Janssen Research & Development, LLC n=272
NCT06319820 RECRUITING
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Janssen Research & Development, LLC n=641
NCT04557059 ACTIVE NOT RECRUITING
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Janssen Pharmaceutica N.V., Belgium n=692
NCT06662786 RECRUITING
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Janssen Research & Development, LLC n=1,000
NCT03767244 ACTIVE NOT RECRUITING
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Janssen Research & Development, LLC n=2,517
NCT04658862 ACTIVE NOT RECRUITING
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Janssen Research & Development, LLC n=518
NCT06750094 RECRUITING
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Janssen Research & Development, LLC n=700
NCT07164443 RECRUITING
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development, LLC n=663
NCT02531516 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc. n=1,503
NCT06661720 RECRUITING
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology n=1,040
NCT03748641 ACTIVE NOT RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Janssen Research & Development, LLC n=765
NCT06966700 RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC n=2,400
NCT06500481 RECRUITING
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NRG Oncology n=115
NCT04116047 ACTIVE NOT RECRUITING
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
University of Birmingham n=785
NCT07000253 RECRUITING
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=290
NCT05438212 ACTIVE NOT RECRUITING
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NRG Oncology n=237
NCT01398085 ACTIVE NOT RECRUITING
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
University College, London n=504
NCT05506943 ACTIVE NOT RECRUITING
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics n=168
NCT02319837 ACTIVE NOT RECRUITING
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer n=1,068
NCT02446444 ACTIVE NOT RECRUITING
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
University of Sydney n=802
NCT06056830 RECRUITING
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Clarity Pharmaceuticals Ltd n=383
NCT07544654 NOT YET RECRUITING
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim n=390
NCT06841354 RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Merck Sharp & Dohme LLC n=1,000
NCT05721755 ACTIVE NOT RECRUITING
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
ECOG-ACRIN Cancer Research Group n=290
NCT05863195 RECRUITING
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
ECOG-ACRIN Cancer Research Group n=408
NCT05173987 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Merck Sharp & Dohme LLC n=280
NCT05863351 ACTIVE NOT RECRUITING
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
ECOG-ACRIN Cancer Research Group n=472
NCT07028853 RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Pfizer n=1,000
NCT05235165 RECRUITING
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Children's Oncology Group n=62
NCT01167712 ACTIVE NOT RECRUITING
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI) n=692
NCT04333537 RECRUITING
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NRG Oncology n=686
NCT04804644 RECRUITING
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NRG Oncology n=200
NCT06745024 ACTIVE NOT RECRUITING
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
NRG Oncology n=280
NCT03504397 ACTIVE NOT RECRUITING
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Astellas Pharma Global Development, Inc. n=565
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
NCT03055013 ACTIVE NOT RECRUITING
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI) n=819
NCT07441681 NOT YET RECRUITING
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology n=454
NCT02193282 ACTIVE NOT RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI) n=390
NCT05187091 RECRUITING
The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas
All India Institute of Medical Sciences n=136
NCT04444921 ACTIVE NOT RECRUITING
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
National Cancer Institute (NCI) n=205
NCT06915025 RECRUITING
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon n=500
NCT01575548 ACTIVE NOT RECRUITING
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI) n=129
NCT00588770 ACTIVE NOT RECRUITING
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI) n=403
NCT07173751 RECRUITING
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
BioNTech SE n=558
NCT04241185 ACTIVE NOT RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Merck Sharp & Dohme LLC n=520
NCT04559139 ACTIVE NOT RECRUITING
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
ECOG-ACRIN Cancer Research Group n=186
NCT06926868 RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb n=500
NCT05357846 RECRUITING
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University n=422
NCT01081262 ACTIVE NOT RECRUITING
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
National Cancer Institute (NCI) n=50
NCT06663956 RECRUITING
A Randomized Controlled Trial of a Web-based Platform for Cancer Pain Management
West China Hospital n=100
NCT07559877 RECRUITING
Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
Jiangxi Provincial Cancer Hospital n=148
NCT06901531 RECRUITING
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc. n=500
NCT07174336 RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company n=920
NCT03768063 ACTIVE NOT RECRUITING
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Hoffmann-La Roche n=1,000
NCT07549399 NOT YET RECRUITING
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
Sixth Affiliated Hospital, Sun Yat-sen University n=204
NCT06706401 RECRUITING
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Centre Leon Berard n=460
NCT05239741 RECRUITING
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Merck Sharp & Dohme LLC n=100
NCT07550205 NOT YET RECRUITING
Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer
Shanghai Municipal Hospital of Traditional Chinese Medicine n=360
NCT06905587 RECRUITING
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
Odense University Hospital n=50
NCT06960577 RECRUITING
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca n=150
NCT07545460 NOT YET RECRUITING
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd. n=404
NCT07099898 RECRUITING
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline n=420
NCT05303532 ENROLLING BY INVITATION
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
AstraZeneca n=214
NCT07222800 RECRUITING
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer n=800
NCT06346197 RECRUITING
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Centre Leon Berard n=132
NCT07542288 NOT YET RECRUITING
Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:
The Second Affiliated Hospital of Hainan Medical University n=400
NCT04114981 ACTIVE NOT RECRUITING
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
Alliance for Clinical Trials in Oncology n=242
NCT06994195 RECRUITING
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd. n=384
NCT07218380 RECRUITING
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company n=450
NCT03653507 ACTIVE NOT RECRUITING
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Astellas Pharma Global Development, Inc. n=507
NCT07445048 RECRUITING
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=370
NCT07213804 RECRUITING
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Eli Lilly and Company n=1,080
NCT05152147 ACTIVE NOT RECRUITING
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Jazz Pharmaceuticals n=920
NCT05659381 RECRUITING
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
GOG Foundation n=220
NCT04464226 ACTIVE NOT RECRUITING
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer n=402
NCT03525873 ACTIVE NOT RECRUITING
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
M.D. Anderson Cancer Center n=212
NCT06593431 RECRUITING
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
M.D. Anderson Cancer Center n=80
NCT03661320 ACTIVE NOT RECRUITING
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb n=855
NCT03081143 ACTIVE NOT RECRUITING
Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=429
NCT05059522 ACTIVE NOT RECRUITING
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer n=68
NCT02466971 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
National Cancer Institute (NCI) n=450
NCT07524413 NOT YET RECRUITING
Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University n=514
NCT02306161 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
National Cancer Institute (NCI) n=312
NCT03148418 ACTIVE NOT RECRUITING
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche n=382
NCT06496971 RECRUITING
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation n=32
NCT07410117 RECRUITING
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Regeneron Pharmaceuticals n=860
NCT05253651 RECRUITING
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Seagen, a wholly owned subsidiary of Pfizer n=400
NCT06072612 RECRUITING
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
BriaCell Therapeutics Corporation n=404
NCT05112965 ACTIVE NOT RECRUITING
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche n=49
NCT05629234 ACTIVE NOT RECRUITING
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
AstraZeneca n=37
NCT06790966 ACTIVE NOT RECRUITING
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
PDS Biotechnology Corp. n=252
NCT06867705 RECRUITING
Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only
Resilience n=1,458
NCT07218926 RECRUITING
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline n=450
NCT06506955 ENROLLING BY INVITATION
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc. n=15
NCT01349881 ACTIVE NOT RECRUITING
S0820, Adenoma and Second Primary Prevention Trial
SWOG Cancer Research Network n=354
NCT07481799 RECRUITING
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
Ming-Yuan Chen n=200
NCT05514054 ACTIVE NOT RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company n=8,000
NCT06312176 RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Merck Sharp & Dohme LLC n=1,200
NCT07197580 RECRUITING
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Telix Pharmaceuticals (Innovations) Pty Limited n=40
NCT04498117 ACTIVE NOT RECRUITING
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio Inc. n=615
NCT06388733 RECRUITING
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Ivy Brain Tumor Center n=450
NCT03815643 ACTIVE NOT RECRUITING
Avelumab Program Rollover Study
EMD Serono Research & Development Institute, Inc. n=205
NCT06391242 RECRUITING
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
Canadian Cancer Trials Group n=230
NCT07488611 RECRUITING
PROGAIN Trial in Gastric Cancer Surgery
Soonchunhyang University Hospital n=110
NCT07485855 RECRUITING
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
Asan Medical Center n=60
NCT02758951 ACTIVE NOT RECRUITING
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
Koen Rovers n=358
NCT06476639 NOT YET RECRUITING
A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer
Queensland Centre for Gynaecological Cancer n=640
NCT04095364 ACTIVE NOT RECRUITING
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology n=450
NCT07426055 RECRUITING
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,200
NCT07125755 RECRUITING
Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University n=386
NCT07426094 RECRUITING
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,600
NCT04689828 ACTIVE NOT RECRUITING
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals n=469
NCT03875235 ACTIVE NOT RECRUITING
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
AstraZeneca n=810
NCT07286266 NOT YET RECRUITING
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline n=450
NCT05281471 RECRUITING
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation n=186
NCT02491632 ACTIVE NOT RECRUITING
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center n=90
NCT07480356 NOT YET RECRUITING
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
Protara Therapeutics n=284
NCT03021486 ACTIVE NOT RECRUITING
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
M.D. Anderson Cancer Center n=70
NCT03842982 ACTIVE NOT RECRUITING
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
Centre Oscar Lambret n=362
NCT07472140 RECRUITING
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre n=120
NCT04318886 ACTIVE NOT RECRUITING
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
University of Alabama at Birmingham n=387
NCT04895358 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Merck Sharp & Dohme LLC n=340
NCT07286331 NOT YET RECRUITING
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)
GlaxoSmithKline n=600
NCT07464145 NOT YET RECRUITING
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
Relmada Therapeutics, Inc. n=393
NCT04720157 ACTIVE NOT RECRUITING
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals n=1,145
NCT02655016 ACTIVE NOT RECRUITING
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc. n=733
NCT07462143 RECRUITING
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
RemeGen Co., Ltd. n=80
NCT01592968 ACTIVE NOT RECRUITING
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases
M.D. Anderson Cancer Center n=88
NCT05116189 ACTIVE NOT RECRUITING
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Merck Sharp & Dohme LLC n=643
NCT04575935 RECRUITING
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center n=580
NCT06279130 RECRUITING
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
The Netherlands Cancer Institute n=133
NCT03435796 RECRUITING
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene n=1,541
NCT07444775 RECRUITING
Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors
University Health Network, Toronto n=148
NCT06356311 ACTIVE NOT RECRUITING
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Merck Sharp & Dohme LLC n=450
NCT07440290 NOT YET RECRUITING
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Cancer Research UK n=30
NCT06532006 RECRUITING
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech n=550
NCT07434206 ACTIVE NOT RECRUITING
Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors
South Egypt Cancer Institute n=80
NCT05113251 ACTIVE NOT RECRUITING
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca n=927
NCT05445778 RECRUITING
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie n=520
NCT00950001 ACTIVE NOT RECRUITING
Stereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases
M.D. Anderson Cancer Center n=132
NCT03194893 ACTIVE NOT RECRUITING
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche n=200
NCT06593665 RECRUITING
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
Indiana University n=142
NCT07408128 NOT YET RECRUITING
Partner4Exercise Randomized Controlled Trial
McMaster University n=183
NCT07402538 NOT YET RECRUITING
Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma
Sun Yat-sen University n=184
NCT03686202 ACTIVE NOT RECRUITING
Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients
University Health Network, Toronto n=65
NCT04749108 RECRUITING
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
Institut du Cancer de Montpellier - Val d'Aurelle n=1,075
NCT06349668 RECRUITING
Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery
Hans Bahlmann n=220
NCT07005024 RECRUITING
DOAC - Dosing Options in AntiCoagulation Prophylaxis
University of Vermont n=996
NCT05208047 ACTIVE NOT RECRUITING
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc. n=442
NCT04620239 RECRUITING
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Steba Biotech S.A. n=100
NCT07385079 NOT YET RECRUITING
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University n=412
NCT07383441 NOT YET RECRUITING
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network n=718
NCT05843877 RECRUITING
Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula
Technische Universität Dresden n=32
NCT07373990 NOT YET RECRUITING
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University n=418
NCT07366528 RECRUITING
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital n=387
NCT05855200 RECRUITING
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline n=892
NCT03875781 RECRUITING
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
Assistance Publique - Hôpitaux de Paris n=540
NCT05053867 RECRUITING
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
M.D. Anderson Cancer Center n=60
NCT06111235 ACTIVE NOT RECRUITING
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology, Inc. n=367
NCT07333274 RECRUITING
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute n=335
NCT04095299 RECRUITING
Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients
Vejle Hospital n=162
NCT04448184 RECRUITING
Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
Ottawa Hospital Research Institute n=662
NCT05365178 ACTIVE NOT RECRUITING
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=432
NCT03602859 ACTIVE NOT RECRUITING
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Tesaro, Inc. n=1,400
NCT06998069 RECRUITING
Head and Neck Cancer Study Project in the Geriatric Population
Brown University n=20
NCT07310758 RECRUITING
Contrast-enhanced Ultrasound for Sentinel Node Detection
The Netherlands Cancer Institute n=91
NCT03743649 ACTIVE NOT RECRUITING
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
M.D. Anderson Cancer Center n=110
NCT03750227 RECRUITING
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
Mayo Clinic n=140
NCT04592913 ACTIVE NOT RECRUITING
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
AstraZeneca n=957
NCT04269200 ACTIVE NOT RECRUITING
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
AstraZeneca n=805
NCT03533582 ACTIVE NOT RECRUITING
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group n=537
NCT03997123 ACTIVE NOT RECRUITING
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
AstraZeneca n=923
NCT06963268 RECRUITING
Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)
Instituto de Investigacion Sanitaria La Fe n=200
NCT07290491 RECRUITING
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
The Methodist Hospital Research Institute n=854
NCT05902533 ACTIVE NOT RECRUITING
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
University of Cincinnati n=33
NCT07287592 NOT YET RECRUITING
Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.
Ain Shams University n=70
NCT06093425 NOT YET RECRUITING
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd. n=820
NCT03422198 RECRUITING
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
University of Utah n=188
NCT07088263 RECRUITING
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Sun Yat-sen University n=192
NCT07271355 NOT YET RECRUITING
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center n=129
NCT07174453 RECRUITING
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
University of Kansas Medical Center n=192
NCT05443737 RECRUITING
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
University of California, San Diego n=2,800
NCT02341989 ACTIVE NOT RECRUITING
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
St. Olavs Hospital n=348
NCT05786716 RECRUITING
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Cancer Research UK n=30
NCT04447313 ACTIVE NOT RECRUITING
Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study
Fred Hutchinson Cancer Center n=418
NCT05770544 RECRUITING
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Cancer Research UK n=30
NCT05768178 RECRUITING
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK n=30
NCT06988475 RECRUITING
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Cancer Research UK n=30
NCT05770037 RECRUITING
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Cancer Research UK n=30
NCT05770102 RECRUITING
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Cancer Research UK n=30
NCT07238569 NOT YET RECRUITING
Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University n=516
NCT07235319 RECRUITING
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
Sun Yat-sen University n=260
NCT04228991 ACTIVE NOT RECRUITING
Hypofractionated LocoRegional Radiotherapy in Breast Cancer
Ontario Clinical Oncology Group (OCOG) n=588
NCT01579552 ACTIVE NOT RECRUITING
Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Memorial Sloan Kettering Cancer Center n=360
NCT01169259 ACTIVE NOT RECRUITING
Vitamin D and Omega-3 Trial (VITAL)
Brigham and Women's Hospital n=25,871
NCT05474846 RECRUITING
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
M.D. Anderson Cancer Center n=188
NCT02107703 ACTIVE NOT RECRUITING
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Eli Lilly and Company n=669
NCT02632409 ACTIVE NOT RECRUITING
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Bristol-Myers Squibb n=709
NCT06174987 RECRUITING
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Daiichi Sankyo n=50
NCT02000089 RECRUITING
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University n=9,000
NCT03418961 RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network n=491
NCT07207824 NOT YET RECRUITING
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Fudan University n=182
NCT07166042 RECRUITING
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
University of Utah n=34
NCT04111978 RECRUITING
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Swiss GO Trial Group n=540
NCT02505750 ACTIVE NOT RECRUITING
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
Centre Antoine Lacassagne n=148
NCT06256588 RECRUITING
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
GlaxoSmithKline n=864
NCT04158362 ACTIVE NOT RECRUITING
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer
UNICANCER n=180
NCT07156786 NOT YET RECRUITING
N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial
Fakultas Kedokteran Universitas Indonesia n=72
NCT07155525 RECRUITING
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
Minia University n=194
NCT06124976 RECRUITING
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
University of British Columbia n=70
NCT04335669 ACTIVE NOT RECRUITING
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital n=325
NCT05335928 RECRUITING
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Massachusetts General Hospital n=390
NCT05009082 RECRUITING
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group n=970
NCT05860881 ACTIVE NOT RECRUITING
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
Melanoma and Skin Cancer Trials Limited n=146
NCT04510597 RECRUITING
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
SWOG Cancer Research Network n=364
NCT03741673 RECRUITING
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
M.D. Anderson Cancer Center n=180
NCT03981796 ACTIVE NOT RECRUITING
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
Tesaro, Inc. n=785
NCT06207981 RECRUITING
Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
Federation Francophone de Cancerologie Digestive n=310
NCT07081360 RECRUITING
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Minia University n=262
NCT07132008 NOT YET RECRUITING
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
First Affiliated Hospital of Guangxi Medical University n=94
NCT04380636 ACTIVE NOT RECRUITING
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Merck Sharp & Dohme LLC n=870
NCT07124195 NOT YET RECRUITING
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
The First Affiliated Hospital of Xinxiang Medical College n=126
NCT04607421 ACTIVE NOT RECRUITING
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer n=831
NCT06379113 RECRUITING
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Xiaojun Chen n=29
NCT05316935 RECRUITING
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Xiaojun Chen n=80
NCT06866574 ACTIVE NOT RECRUITING
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University n=9,300
NCT07084454 ENROLLING BY INVITATION
Geriatric Oncology Care in Brazil: Remote Geriatric Assessment-Driven Interventions With Supportive Care
Cristiane Decat Bergerot, PhD n=350
NCT05429099 RECRUITING
Mandibular Reconstruction Preplanning (ViPMR)
University of British Columbia n=420
NCT07067749 RECRUITING
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
University of Rome Tor Vergata n=92
NCT03834493 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Merck Sharp & Dohme LLC n=1,244
NCT04879368 ACTIVE NOT RECRUITING
RegoNivo vs Standard of Care Chemotherapy in AGOC
Australasian Gastro-Intestinal Trials Group n=450
NCT04915755 ACTIVE NOT RECRUITING
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
GlaxoSmithKline n=40
NCT07062263 RECRUITING
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Tata Memorial Centre n=220
NCT04975308 ACTIVE NOT RECRUITING
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Company n=874
NCT05920343 RECRUITING
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Ottawa Hospital Research Institute n=120
NCT02885753 RECRUITING
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Federation Francophone de Cancerologie Digestive n=348
NCT05029063 RECRUITING
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
Ottawa Hospital Research Institute n=1,828
NCT05454280 RECRUITING
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Fox Chase Cancer Center n=880
NCT05288166 ACTIVE NOT RECRUITING
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company n=925
NCT05796973 RECRUITING
Measuring Oncological Value of Exercise and Statin
Tampere University Hospital n=240
NCT07035821 NOT YET RECRUITING
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy
Shanghai Children's Medical Center n=100
NCT03522246 ACTIVE NOT RECRUITING
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
pharmaand GmbH n=1,097
NCT06401356 RECRUITING
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis Pharmaceuticals n=50
NCT02804815 ACTIVE NOT RECRUITING
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
University College, London n=11,000
NCT05346224 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Shanghai Henlius Biotech n=900
NCT04634877 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Merck Sharp & Dohme LLC n=990
NCT02288962 ACTIVE NOT RECRUITING
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas
St. Olavs Hospital n=60
NCT06999512 NOT YET RECRUITING
Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer
Assistance Publique - Hôpitaux de Paris n=526
NCT06208371 RECRUITING
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
Sun Yat-sen University n=117
NCT03478488 ACTIVE NOT RECRUITING
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
3D Medicines (Sichuan) Co., Ltd. n=480
NCT06749899 RECRUITING
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Sun Yat-Sen University Cancer Center n=580
NCT04178174 RECRUITING
Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=360
NCT05141721 ACTIVE NOT RECRUITING
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Seattle Project Corporation n=700
NCT04513418 RECRUITING
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
Hecheng Li M.D., Ph.D n=244
NCT06768164 RECRUITING
Quality of Life After Billroth II or Roux-en-Y for Gastric Cancer
Assistance Publique - Hôpitaux de Paris n=250
NCT06332274 RECRUITING
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Gustave Roussy, Cancer Campus, Grand Paris n=717
NCT06028737 RECRUITING
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Ukrainian Society of Clinical Oncology n=150
NCT04833426 RECRUITING
Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
Canisius-Wilhelmina Hospital n=140
NCT05407987 RECRUITING
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
AHS Cancer Control Alberta n=82
NCT01376752 ACTIVE NOT RECRUITING
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
UNICANCER n=415
NCT05257408 ACTIVE NOT RECRUITING
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics n=381
NCT06834672 RECRUITING
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Innovent Biologics (Suzhou) Co. Ltd. n=450
NCT04711109 ACTIVE NOT RECRUITING
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Alliance for Clinical Trials in Oncology n=300
NCT06859190 RECRUITING
Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer
Qinghai Red Cross Hospital n=60
NCT06658353 RECRUITING
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Jiangsu vcare pharmaceutical technology co., LTD n=54
NCT06857773 RECRUITING
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
The Netherlands Cancer Institute n=306
NCT06737822 RECRUITING
Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:
All India Institute of Medical Sciences, Jodhpur n=346
NCT06845306 NOT YET RECRUITING
The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surgery
Vadim Kuznetsov n=1,268
NCT05955924 RECRUITING
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
Women's College Hospital n=396
NCT06836492 RECRUITING
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Yizhuo Zhang n=300
NCT02215265 ACTIVE NOT RECRUITING
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
Lisette Nixon n=1,269
NCT02859038 ACTIVE NOT RECRUITING
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
Shanghai Gynecologic Oncology Group n=489
NCT06782412 RECRUITING
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
KU Leuven n=109
NCT02446405 ACTIVE NOT RECRUITING
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
University of Sydney n=1,125
NCT05587374 ACTIVE NOT RECRUITING
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
Sun Yat-sen University n=490
NCT06504732 RECRUITING
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
SUNHO（China）BioPharmaceutical CO., Ltd. n=90
NCT03840421 ACTIVE NOT RECRUITING
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University n=468
NCT06740916 RECRUITING
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance
Siriraj Hospital n=240
NCT06276465 RECRUITING
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
UNICANCER n=336
NCT06465914 ACTIVE NOT RECRUITING
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd. n=9,000
NCT04765020 RECRUITING
Cardiorespiratory Fitness in Children and Adolescents After Cancer Treatment.
Universität Duisburg-Essen n=56
NCT06717711 RECRUITING
Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers
Regina Elena Cancer Institute n=158
NCT06714604 RECRUITING
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Sahlgrenska University Hospital n=432
NCT06672887 RECRUITING
Enhancing Successful Return to Work of Employees With Cancer, by Supporting Employers (MiLES Intervention)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=140
NCT04723875 ACTIVE NOT RECRUITING
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline
Huazhong University of Science and Technology n=306
NCT05744219 RECRUITING
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Jon Unosson n=338
NCT06275958 RECRUITING
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
Leiden University Medical Center n=587
NCT04523272 ACTIVE NOT RECRUITING
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=528
NCT06185556 RECRUITING
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
Amsterdam UMC, location VUmc n=78
NCT05833815 RECRUITING
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Banaras Hindu University n=56
NCT05939687 RECRUITING
Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection
Blokhin's Russian Cancer Research Center n=142
NCT05764044 RECRUITING
Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer
Hospital do Coracao n=365
NCT06509724 RECRUITING
Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy
Samsung Medical Center n=248
NCT06086457 RECRUITING
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=436
NCT05352178 RECRUITING
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Universitaire Ziekenhuizen KU Leuven n=873
NCT05847348 RECRUITING
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Telix Pharmaceuticals (Innovations) Pty Limited n=110
NCT06478108 RECRUITING
Interventional Software for Multi-immunotherapy of Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=60
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT04422366 RECRUITING
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=8,000
NCT06441110 RECRUITING
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Fujian Medical University Union Hospital n=76
NCT05699655 RECRUITING
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital n=130
NCT06277050 RECRUITING
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital n=264
NCT06391892 RECRUITING
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Elisabethinen Hospital n=100
NCT03659448 RECRUITING
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Surgimab n=300
NCT05027776 RECRUITING
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd. n=1,348
NCT04895020 RECRUITING
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd. n=1,200
NCT01820858 ACTIVE NOT RECRUITING
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
Ding Ma n=300
NCT06337695 NOT YET RECRUITING
VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer
University of Calgary n=298
NCT06338683 RECRUITING
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Qinghai Red Cross Hospital n=230
NCT06313463 RECRUITING
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=375
NCT04642027 RECRUITING
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
University Medical Center Groningen n=538
NCT06226857 RECRUITING
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
City Clinical Oncology Hospital No 1 n=355
NCT06208917 RECRUITING
Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children
Yizhuo Zhang n=376
NCT06149533 NOT YET RECRUITING
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=366
NCT06017583 RECRUITING
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
Yong Zhang,MD n=48
NCT05264896 RECRUITING
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong n=110
NCT04722692 RECRUITING
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Uppsala University n=500
NCT01357772 ACTIVE NOT RECRUITING
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
Andrea DeCensi n=500
NCT05430399 RECRUITING
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University n=349
NCT04019548 RECRUITING
Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy
Jules Bordet Institute n=110
NCT02429687 RECRUITING
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Beihua Kong n=129
NCT02429700 RECRUITING
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Beihua Kong n=132
NCT03458221 RECRUITING
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
Gynaecologisch Oncologisch Centrum Zuid n=148
NCT05754853 RECRUITING
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Shanghai Miracogen Inc. n=290
NCT05797077 RECRUITING
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
Sixth Affiliated Hospital, Sun Yat-sen University n=346
NCT05735145 RECRUITING
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
Fourth Affiliated Hospital of Guangxi Medical University n=108
NCT02261415 ACTIVE NOT RECRUITING
The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial
Sunnybrook Health Sciences Centre n=1,386
NCT05484024 NOT YET RECRUITING
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
Chinese Academy of Medical Sciences n=588
NCT03824275 ACTIVE NOT RECRUITING
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Columbia University n=129
NCT05172518 NOT YET RECRUITING
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University n=512
NCT04733820 RECRUITING
Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery
Huazhong University of Science and Technology n=340
NCT04453826 RECRUITING
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University n=388
NCT04515602 NOT YET RECRUITING
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
Shanghai Gynecologic Oncology Group n=410
NCT03961841 NOT YET RECRUITING
Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University n=900
NCT02497820 NOT YET RECRUITING
Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers
Tel-Aviv Sourasky Medical Center n=1,800
NCT03607539 COMPLETED
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd. n=397
NCT04251533 TERMINATED
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Novartis Pharmaceuticals n=137
NCT06295809 TERMINATED
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Merck Sharp & Dohme LLC n=46
NCT03740165 COMPLETED
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Merck Sharp & Dohme LLC n=1,367
NCT01744249 COMPLETED
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos n=256
NCT02364557 COMPLETED
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
NRG Oncology n=129
NCT02343601 COMPLETED
Perioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery
University Hospital, Caen n=160
NCT03517449 COMPLETED
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
Eisai Inc. n=827
NCT07313891 WITHDRAWN
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
Relmada Therapeutics, Inc.
NCT07342517 WITHDRAWN
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
Relmada Therapeutics, Inc.
NCT02173756 TERMINATED
Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults
University Hospital, Strasbourg, France n=25
NCT05665348 COMPLETED
Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
Federation Francophone de Cancerologie Digestive n=229
NCT04222972 TERMINATED
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=223
NCT04736199 COMPLETED
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Bayer n=669
NCT03675737 COMPLETED
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Merck Sharp & Dohme LLC n=1,579
NCT04738487 COMPLETED
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC n=1,264
NCT04221945 COMPLETED
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Merck Sharp & Dohme LLC n=1,060
NCT03683329 COMPLETED
Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock
Institut Paoli-Calmettes n=398
NCT06235099 COMPLETED
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Curium US LLC n=235
NCT03143153 COMPLETED
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
Bristol-Myers Squibb n=970
NCT03258554 COMPLETED
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI) n=196
NCT01279135 COMPLETED
Tomotherapy vs Conventional Radiation for Adjuvant Pelvic RT in Ca Cervix
Tata Memorial Hospital n=300
NCT04776148 COMPLETED
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Merck Sharp & Dohme LLC n=563
NCT03040999 COMPLETED
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Merck Sharp & Dohme LLC n=804
NCT06240741 COMPLETED
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Novartis Pharmaceuticals n=71
NCT03884101 COMPLETED
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Merck Sharp & Dohme LLC n=842
NCT05061823 COMPLETED
Bintrafusp Alfa Program Rollover Study
EMD Serono Research & Development Institute, Inc. n=22
NCT05177484 COMPLETED
Perioperative Iron for Colorectal Cancer (PICoC Study)
The Royal Wolverhampton Hospitals NHS Trust n=40
NCT02003924 COMPLETED
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Pfizer n=1,401
NCT04457297 COMPLETED
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
National Cancer Center Hospital East n=243
NCT01856478 COMPLETED
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim n=340
NCT03768414 COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
SWOG Cancer Research Network n=452
NCT03474107 COMPLETED
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Global Development, Inc. n=608
NCT05351294 SUSPENDED
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
Rutgers, The State University of New Jersey n=156
NCT04442048 COMPLETED
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
Canadian Cancer Trials Group n=195
NCT07279792 COMPLETED
Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection
Ain Shams University n=150
NCT00799188 COMPLETED
CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
Hospices Civils de Lyon n=175
NCT02926196 COMPLETED
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Istituto Oncologico Veneto IRCCS n=474
NCT03615326 COMPLETED
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Merck Sharp & Dohme LLC n=738
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT03013010 COMPLETED
PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy
Shanghai Cancer Hospital, China n=204
NCT06007586 COMPLETED
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute n=143
NCT04865289 COMPLETED
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
Merck Sharp & Dohme LLC n=130
NCT02918955 COMPLETED
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Insel Gruppe AG, University Hospital Bern n=65
NCT02743494 COMPLETED
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
Bristol-Myers Squibb n=794
NCT02442375 COMPLETED
Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity
Radboud University Medical Center n=300
NCT03371017 COMPLETED
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
Hoffmann-La Roche n=595
NCT03036488 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Merck Sharp & Dohme LLC n=1,174
NCT03136445 COMPLETED
TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
NHS Blood and Transplant n=616
NCT02297438 COMPLETED
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer n=340
NCT05694013 TERMINATED
Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
Hoffmann-La Roche n=49
NCT03269994 COMPLETED
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Memorial Sloan Kettering Cancer Center n=967
NCT04838613 COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 in BCR
Novartis Pharmaceuticals n=190
NCT04838626 COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
Novartis Pharmaceuticals n=195
NCT04161885 TERMINATED
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie n=465
NCT05870748 TERMINATED
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc. n=600
NCT04327063 COMPLETED
MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery
Institut Curie n=182
NCT01727388 COMPLETED
Informativeness to Digital Rectal Examination
Centre Hospitalier Universitaire, Amiens n=320
NCT04149574 TERMINATED
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
Bristol-Myers Squibb n=13
NCT03813784 COMPLETED
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd. n=885
NCT04534075 COMPLETED
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
Sahlgrenska University Hospital n=354
NCT02330926 COMPLETED
Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
Norwegian University of Science and Technology n=221
NCT05092360 TERMINATED
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Mural Oncology, Inc n=456
NCT04209855 COMPLETED
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
AbbVie n=453
NCT05328908 TERMINATED
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Bristol-Myers Squibb n=770
NCT04635423 COMPLETED
Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)
Merck Sharp & Dohme LLC n=1,059
NCT00680901 COMPLETED
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis Pharmaceuticals n=545
NCT02684006 COMPLETED
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Pfizer n=886
NCT03829969 COMPLETED
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd. n=514
NCT03834506 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Merck Sharp & Dohme LLC n=1,030
NCT04752332 TERMINATED
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Eli Lilly and Company n=111
NCT04616768 COMPLETED
PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers
Abramson Cancer Center at Penn Medicine n=108
NCT04503668 TERMINATED
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center n=62
NCT02667587 COMPLETED
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Bristol-Myers Squibb n=716
NCT01804790 COMPLETED
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
UNICANCER n=461
NCT02035098 COMPLETED
Improving Pain Management in Hospitalized Cancer Patients. A Before-after Cluster Phase II Trial
Azienda USL Reggio Emilia - IRCCS n=504
NCT04588246 TERMINATED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology n=19
NCT04785768 COMPLETED
IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration
Fujian Cancer Hospital n=1,372
NCT03834519 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Merck Sharp & Dohme LLC n=793
NCT00922974 COMPLETED
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Radiation Therapy Oncology Group n=399
NCT05763667 COMPLETED
Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer
Tufts Medical Center n=15
NCT02360215 COMPLETED
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
NRG Oncology n=518
NCT03822845 COMPLETED
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
Michael Graham PhD, MD n=6
NCT06910514 COMPLETED
Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions
Nakafarma S.L. n=52
NCT03578081 COMPLETED
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology n=690
NCT04316013 TERMINATED
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
Peter MacCallum Cancer Centre, Australia n=254
NCT01160211 COMPLETED
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Novartis Pharmaceuticals n=369
NCT05236647 COMPLETED
Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer Patients
University Hospital, Akershus n=60
NCT02043678 COMPLETED
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Bayer n=806
NCT03013946 TERMINATED
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
AIO-Studien-gGmbH n=121
NCT02908477 COMPLETED
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
Mayo Clinic n=228
NCT03692065 COMPLETED
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
Assistance Publique - Hôpitaux de Paris n=1,766
NCT01715285 COMPLETED
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Janssen Research & Development, LLC n=1,209
NCT03924986 COMPLETED
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
BeiGene n=263
NCT03839940 TERMINATED
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
Alliance for Clinical Trials in Oncology n=39
NCT02116530 COMPLETED
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology n=401
NCT04410042 TERMINATED
Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure
St. Jude Children's Research Hospital n=15
NCT04340193 COMPLETED
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
Bristol-Myers Squibb n=26
NCT04227522 COMPLETED
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
North Eastern German Society of Gynaecological Oncology n=42
NCT01740427 COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Pfizer n=666
NCT01793480 COMPLETED
Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.
RECORDATI GROUP n=146
NCT03189719 COMPLETED
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
Merck Sharp & Dohme LLC n=749
NCT05369234 COMPLETED
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
Covenant Health Cancer Center n=100
NCT04428333 TERMINATED
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
GlaxoSmithKline n=117
NCT03635489 COMPLETED
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche n=100
NCT02845479 COMPLETED
The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I
The Canadian College of Naturopathic Medicine n=22
NCT03747562 WITHDRAWN
Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients.
University Hospital, Ghent
NCT05865548 COMPLETED
Addition of Aspirin to Standard of Care in Oral Cancer
Banaras Hindu University n=60
NCT03016312 COMPLETED
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Hoffmann-La Roche n=759
NCT04296890 COMPLETED
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
ImmunoGen, Inc. n=106
NCT04538625 COMPLETED
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
Napo Pharmaceuticals, Inc. n=287
NCT02135419 COMPLETED
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
AIDS Malignancy Consortium n=4,446
NCT02501954 COMPLETED
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
Women's Cancer Care Associates, LLC n=48
NCT01231347 COMPLETED
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
NantCell, Inc. n=800
NCT04907227 TERMINATED
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
Merck Sharp & Dohme LLC n=81
NCT03389451 COMPLETED
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
Michael Graham PhD, MD n=30
NCT04128696 TERMINATED
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
GlaxoSmithKline n=315
NCT03506815 COMPLETED
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Ottawa Hospital Research Institute n=105
NCT03425656 COMPLETED
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
AryoGen Pharmed Co. n=108
NCT03743051 COMPLETED
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA n=318
NCT03743064 COMPLETED
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA n=318
NCT03837171 COMPLETED
TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock
Assistance Publique - Hôpitaux de Paris n=192
NCT04676334 COMPLETED
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
pharmaand GmbH n=34
NCT02928406 COMPLETED
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Hoffmann-La Roche n=1,004
NCT01884623 COMPLETED
Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=82
NCT05564286 COMPLETED
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
Shantou University Medical College n=116
NCT04844749 TERMINATED
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Veru Inc. n=105
NCT01785316 COMPLETED
The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
Vastra Gotaland Region n=93
NCT05372016 COMPLETED
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=1,200
NCT04066491 TERMINATED
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono Research & Development Institute, Inc. n=309
NCT01849874 TERMINATED
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Pfizer n=341
NCT05329545 TERMINATED
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Mersana Therapeutics n=20
NCT03040726 COMPLETED
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
M.D. Anderson Cancer Center n=53
NCT00942331 COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI) n=506
NCT01506856 COMPLETED
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Gynecologic Oncology Trial & Investigation Consortium n=655
NCT04534725 COMPLETED
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
Peter MacCallum Cancer Centre, Australia n=441
NCT00658593 TERMINATED
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
NCIC Clinical Trials Group n=19
NCT04822597 COMPLETED
Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
University of Wisconsin, Madison n=167
NCT02252042 COMPLETED
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Merck Sharp & Dohme LLC n=495
NCT02611960 COMPLETED
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
Merck Sharp & Dohme LLC n=233
NCT05096468 COMPLETED
Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.
Beijing Tiantan Hospital n=90
NCT01964430 COMPLETED
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Celgene n=866
NCT02969681 COMPLETED
Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer
Sun Yat-sen University n=442
NCT02855944 COMPLETED
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH n=349
NCT01968213 COMPLETED
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
pharmaand GmbH n=564
NCT04763135 TERMINATED
Mirtazapine in Cancer-related Poly-symptomatology
Hospices Civils de Lyon n=1
NCT01847274 COMPLETED
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Tesaro, Inc. n=596
NCT03126435 COMPLETED
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
SynCore Biotechnology Co., Ltd. n=218
NCT03495921 TERMINATED
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
Gradalis, Inc. n=32
NCT02853474 COMPLETED
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
Centre Oscar Lambret n=480
NCT04703803 COMPLETED
Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care
University of Sao Paulo n=30
NCT05809336 COMPLETED
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital n=172
NCT01337089 COMPLETED
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Jazz Pharmaceuticals n=660
NCT01361607 COMPLETED
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals n=399
NCT01424566 COMPLETED
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals n=406
NCT03019588 TERMINATED
Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
Merck Sharp & Dohme LLC n=94
NCT04241315 COMPLETED
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
On Target Laboratories, LLC n=112
NCT03941964 COMPLETED
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie n=60
NCT04189107 COMPLETED
Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS
Rigshospitalet, Denmark n=18
NCT02634294 COMPLETED
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine n=30
NCT03969121 COMPLETED
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Kyoto Breast Cancer Research Network n=141
NCT03038100 COMPLETED
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche n=1,301
NCT02609828 COMPLETED
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Pfizer n=156
NCT03674294 COMPLETED
Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy
Sun Yat-sen University n=248
NCT04613830 COMPLETED
Continuous Erector Spinae Block for Post Analgesia in Pediatric Patients
Assiut University n=60
NCT02623309 COMPLETED
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Institut Paoli-Calmettes n=108
NCT02997553 COMPLETED
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
Institut de Cancérologie de Lorraine n=744
NCT02819960 COMPLETED
Prevention of Irinotecan Induced Diarrhea by Probiotics
S&D Pharma SK s.r.o. n=233
NCT05636566 COMPLETED
Comparing TIVA Using Propofol or Dexmedetomidine Versus Sevoflurane During Anaesthesia of Children Undergoing Bone-Marrow Aspiration
Alexandria University n=60
NCT05325164 WITHDRAWN
Methadone for 'Adenocarcinopathic' Pain Treatment
Ottawa Hospital Research Institute
NCT00858364 TERMINATED
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen n=2,549
NCT01905592 TERMINATED
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Tesaro, Inc. n=216
NCT01345019 COMPLETED
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen n=1,718
NCT04109391 COMPLETED
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Tanvex BioPharma USA, Inc. n=338
NCT04943627 WITHDRAWN
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
NCT02910726 COMPLETED
A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers
Memorial Sloan Kettering Cancer Center n=6
NCT00943722 COMPLETED
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Merck Sharp & Dohme LLC n=3,074
NCT01726452 COMPLETED
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
Cancer Trials Ireland n=377
NCT01372774 COMPLETED
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Alliance for Clinical Trials in Oncology n=194
NCT03705429 COMPLETED
A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=51
NCT01462890 COMPLETED
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
AGO Study Group n=927
NCT02201381 WITHDRAWN
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
Health Clinics Limited
NCT02548715 WITHDRAWN
Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery
University of Alberta
NCT01402908 TERMINATED
A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Cellxpert Biotechnology Corp. n=520
NCT01307878 COMPLETED
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
Fudan University n=320
NCT02454855 TERMINATED
Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients
Centre Jean Perrin n=123
NCT00920816 COMPLETED
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Pfizer n=492
NCT04425291 COMPLETED
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=1,680
NCT00964977 COMPLETED
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
Johannes Gutenberg University Mainz n=209
NCT03359811 COMPLETED
Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway
M.D. Anderson Cancer Center n=75
NCT03269344 COMPLETED
Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Henry Ford Health System n=65
NCT03278600 COMPLETED
Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary
Fudan University n=182
NCT02740127 COMPLETED
Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
M.D. Anderson Cancer Center n=52
NCT01945775 COMPLETED
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Pfizer n=431
NCT03556358 COMPLETED
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Tanvex BioPharma USA, Inc. n=809
NCT03905902 WITHDRAWN
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
SOTIO a.s.
NCT04859582 WITHDRAWN
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
Merck Sharp & Dohme LLC
NCT05149248 COMPLETED
Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study
Instituto Nacional de Salud Publica, Mexico n=6,000
NCT04572776 WITHDRAWN
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
NCT02740114 TERMINATED
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
M.D. Anderson Cancer Center n=105
NCT03829618 TERMINATED
Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound
Milton S. Hershey Medical Center n=29
NCT01528618 COMPLETED
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University n=362
NCT00553358 COMPLETED
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Novartis Pharmaceuticals n=455
NCT02231086 COMPLETED
Adjuvant HIPEC in High Risk Colon Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=204
NCT02903004 COMPLETED
Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=242
NCT03137121 COMPLETED
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
University of Alabama at Birmingham n=30
NCT04059809 COMPLETED
Photobiomodulation for Breast Cancer Radiodermatitis
AC Camargo Cancer Center n=48
NCT02158988 COMPLETED
Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
Charite University, Berlin, Germany n=105
NCT01874587 COMPLETED
Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma
Center Eugene Marquis n=132
NCT01964378 TERMINATED
CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer
Tris Pharma, Inc. n=200
NCT02031432 COMPLETED
CORAL XT - Open-label Extension Trial of the CORAL Trial
Tris Pharma, Inc. n=76
NCT03682367 TERMINATED
Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery
University of California, Davis n=8
NCT03329846 COMPLETED
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Bristol-Myers Squibb n=20
NCT03031938 COMPLETED
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
Pfizer n=4
NCT01817075 COMPLETED
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Children's Oncology Group n=177
NCT01536392 COMPLETED
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
M.D. Anderson Cancer Center n=76
NCT01437514 TERMINATED
Effective Study of Preoperative Short-course Radiotherapy for the Advanced Resectable Rectal Cancer
West China Hospital n=410
NCT02453334 COMPLETED
Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®
American Regent, Inc. n=244
NCT00951496 COMPLETED
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI) n=1,560
NCT02583191 TERMINATED
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH n=246
NCT01566721 COMPLETED
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Hoffmann-La Roche n=2,577
NCT02057666 TERMINATED
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
Ipsen n=146
NCT04549675 COMPLETED
Couple-focused Intervention for Sun Protection
Rutgers, The State University of New Jersey n=150
NCT01479283 COMPLETED
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
McMaster University n=602
NCT03375515 COMPLETED
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
Fujian Cancer Hospital n=214
NCT04001010 SUSPENDED
Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
Tetra Bio-Pharma n=334
NCT01365156 COMPLETED
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
M.D. Anderson Cancer Center n=28
NCT02583932 COMPLETED
Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer
Jewish General Hospital n=179
NCT01906073 WITHDRAWN
Nasal Fentanyl for Chronic Cancer Pain
Norwegian University of Science and Technology
NCT00608933 COMPLETED
Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine
M.D. Anderson Cancer Center n=1,356
NCT01687413 TERMINATED
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer
Washington University School of Medicine n=42
NCT01235962 COMPLETED
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Novartis Pharmaceuticals n=1,538
NCT01987596 TERMINATED
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Barbara Ann Karmanos Cancer Institute n=23
NCT02631876 COMPLETED
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
ImmunoGen, Inc. n=366
NCT04237090 COMPLETED
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Ciusss de L'Est de l'Île de Montréal n=27
NCT00553059 COMPLETED
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
M.D. Anderson Cancer Center n=62
NCT00880971 COMPLETED
Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer
Chinese Academy of Medical Sciences n=394
NCT01572038 COMPLETED
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
Hoffmann-La Roche n=1,436
NCT04546607 COMPLETED
Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia
Natureceuticals Sdn Bhd n=110
NCT00676936 COMPLETED
Corticosteroids for Cancer Pain
Norwegian University of Science and Technology n=50
NCT00684632 COMPLETED
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Kyowa Kirin Co., Ltd. n=51
NCT01164722 COMPLETED
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
AIDS Malignancy Consortium n=120
NCT02585713 COMPLETED
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United n=300
NCT01602211 COMPLETED
INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant
Fred Hutchinson Cancer Center n=1,600
NCT00750009 COMPLETED
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Case Comprehensive Cancer Center n=583
NCT02979691 COMPLETED
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
Chinese Academy of Medical Sciences n=350
NCT03483194 COMPLETED
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
Weprom n=126
NCT04361552 WITHDRAWN
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Emory University
NCT03134872 COMPLETED
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd. n=419
NCT03579758 WITHDRAWN
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Emory University
NCT01836432 TERMINATED
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
NewLink Genetics Corporation n=302
NCT02650791 COMPLETED
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
Ottawa Hospital Research Institute n=100
NCT01026116 COMPLETED
A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old
Fudan University n=521
NCT01198145 COMPLETED
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Alliance for Clinical Trials in Oncology n=87
NCT02604225 COMPLETED
Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B
University of Sydney n=420
NCT03261999 COMPLETED
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
Foresee Pharmaceuticals Co., Ltd. n=144
NCT02236936 TERMINATED
Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
Arbeitsgemeinschaft medikamentoese Tumortherapie n=8
NCT03520959 TERMINATED
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=1
NCT02043288 COMPLETED
Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
Orient Europharma Co., Ltd. n=310
NCT03335059 TERMINATED
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
Medical Enterprises Ltd. n=5
NCT02135510 COMPLETED
MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
Amsterdam UMC, location VUmc n=249
NCT03453424 COMPLETED
Analgesic Efficacy of Dexmedetomidine Added to Fentanyl in PCEA
South Egypt Cancer Institute n=90
NCT02991209 COMPLETED
Study of Testosterone vs Placebo in Testicular Cancer Survivors
Mikkel Bandak n=69
NCT02083770 COMPLETED
Clinical Trials Education Program for Hispanic Americans
University of California, San Diego n=1,034
NCT03331588 COMPLETED
Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China n=200
NCT03546842 COMPLETED
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
Merck Sharp & Dohme LLC n=201
NCT01540058 COMPLETED
Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP
Gustave Roussy, Cancer Campus, Grand Paris n=243
NCT01833299 COMPLETED
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Sun Yat-sen University n=120
NCT03881111 WITHDRAWN
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
Merck Sharp & Dohme LLC
NCT03254173 COMPLETED
Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia
Catherine Naseef Hunter n=120
NCT01248403 COMPLETED
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
Krankenhaus Nordwest n=300
NCT01926236 COMPLETED
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
The Christie NHS Foundation Trust n=162
NCT03158220 COMPLETED
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC n=1,212
NCT02776683 COMPLETED
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
Boehringer Ingelheim n=123
NCT03610100 SUSPENDED
Acelarin First Line Randomised Pancreatic Study
The Clatterbridge Cancer Centre NHS Foundation Trust n=328
NCT01591746 COMPLETED
Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction
Mayo Clinic n=131
NCT03339622 TERMINATED
Safety and Efficacy of Smoked Cannabis for Improving Quality of Life in Advanced Cancer Patients
Tetra Bio-Pharma n=8
NCT02578940 COMPLETED
Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
Blue Earth Diagnostics n=104
NCT03131713 COMPLETED
Preoperative Acetaminophen and Carbohydrate Loading
Tufts Medical Center n=101
NCT01885182 COMPLETED
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd n=232
NCT01305200 COMPLETED
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group n=226
NCT02555878 COMPLETED
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Janssen Research & Development, LLC n=841
NCT01052051 COMPLETED
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
Creighton University n=2,303
NCT02488330 COMPLETED
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
Hoffmann-La Roche n=12
NCT01695135 COMPLETED
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Janssen Research & Development, LLC n=214
NCT01125566 COMPLETED
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Boehringer Ingelheim n=508
NCT01384877 COMPLETED
Subcutaneous Lidocaine For Cancer-Related Pain
British Columbia Cancer Agency n=33
NCT02408393 COMPLETED
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
Institut Curie n=380
NCT02131064 COMPLETED
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Hoffmann-La Roche n=444
NCT00693992 COMPLETED
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
National Cancer Institute (NCI) n=210
NCT00968968 TERMINATED
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis Pharmaceuticals n=37
NCT01915693 COMPLETED
ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study
Lisette Nixon n=220
NCT03936205 COMPLETED
Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer
Hotel Dieu de France Hospital n=18
NCT02935530 COMPLETED
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Huazhong University of Science and Technology n=315
NCT01953003 COMPLETED
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Pierre Fabre Medicament n=112
NCT00908531 TERMINATED
Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
Danish Breast Cancer Cooperative Group n=123
NCT01853319 COMPLETED
Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Bayer n=100
NCT02900742 COMPLETED
Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer
Shanghai University of Traditional Chinese Medicine n=71
NCT02889692 COMPLETED
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine n=23
NCT01846611 COMPLETED
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC n=581
NCT02712320 COMPLETED
Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
Foresee Pharmaceuticals Co., Ltd. n=30
NCT01198158 TERMINATED
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
National Cancer Institute (NCI) n=77
NCT02234115 COMPLETED
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
Foresee Pharmaceuticals Co., Ltd. n=137
NCT02131155 TERMINATED
LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Boehringer Ingelheim n=36
NCT01881230 COMPLETED
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Celgene n=191
NCT01376349 COMPLETED
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Alliance for Clinical Trials in Oncology n=464
NCT03003273 TERMINATED
Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study
All India Institute of Medical Sciences n=142
NCT03350490 COMPLETED
Bioinformation Therapy for Intestinal Cancer
Fuda Cancer Hospital, Guangzhou n=120
NCT00678392 COMPLETED
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Pfizer n=723
NCT01996306 COMPLETED
A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Epidemiological and Clinical Research Information Network n=650
NCT01651949 COMPLETED
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Merck Sharp & Dohme LLC n=2,520
NCT00540969 TERMINATED
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
Alliance for Clinical Trials in Oncology n=3
NCT02591017 TERMINATED
Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients
University Hospital, Basel, Switzerland n=11
NCT00869206 COMPLETED
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology n=1,822
NCT01479192 TERMINATED
Fenretinide in Healthy Young Women at Genetic and Familial Risk
European Institute of Oncology n=20
NCT00838201 COMPLETED
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen n=384
NCT01606787 COMPLETED
Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
Memorial Sloan Kettering Cancer Center n=210
NCT01810770 COMPLETED
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Bayer n=243
NCT00984282 COMPLETED
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Bayer n=417
NCT02225470 COMPLETED
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Eisai Co., Ltd. n=530
NCT02635984 COMPLETED
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
Augusta University n=108
NCT03637335 TERMINATED
Comparing Palliative Radiotherapy With or Without Carboplatin
Institut Cancerologie de l'Ouest n=26
NCT00829413 COMPLETED
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
Bracco Diagnostics, Inc n=353
NCT01700959 COMPLETED
Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort
St. Jude Children's Research Hospital n=911
NCT01522443 TERMINATED
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Exelixis n=119
NCT01675622 COMPLETED
Immediate-Release Oxycodone Capsules Study in Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd n=242
NCT01262651 COMPLETED
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
GW Pharmaceuticals Ltd n=397
NCT02155634 WITHDRAWN
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Celgene
NCT02279108 COMPLETED
Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer
Centre Hospitalier Universitaire de Saint Etienne n=99
NCT00689156 COMPLETED
Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer
Danish Breast Cancer Cooperative Group n=2,015
NCT01605227 COMPLETED
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Exelixis n=1,028
NCT00952289 COMPLETED
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Incyte Corporation n=309
NCT03460561 COMPLETED
Peri-operative Rectus Sheath Block Versus TEA Abdominal Surgeries
South Egypt Cancer Institute n=100
NCT01627379 TERMINATED
Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer
AIO-Studien-gGmbH n=300
NCT00995293 COMPLETED
Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial
Sanofi n=240
NCT02116803 COMPLETED
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Novartis Pharmaceuticals n=12
NCT01032512 WITHDRAWN
Clinical Benefits of Preoperative Nutrition Support With Enteral Immune-enhancing Formulas in Surgical Oncology
University of Chile
NCT01345682 COMPLETED
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim n=483
NCT02564276 COMPLETED
Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=132
NCT02927379 COMPLETED
Effect of Wound Infiltration by Ketamine Versus Dexmedetomidine Added to Bupivacaine on Surgical Stress
Assiut University n=90
NCT00911170 COMPLETED
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen n=847
NCT01803711 TERMINATED
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
UConn Health n=6
NCT00788697 COMPLETED
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Bracco Diagnostics, Inc n=349
NCT01345669 TERMINATED
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Boehringer Ingelheim n=617
NCT01015118 COMPLETED
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Boehringer Ingelheim n=1,366
NCT01136005 COMPLETED
Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)
Impaqtt Foundation n=160
NCT01939223 TERMINATED
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy
Bayer n=25
NCT01227889 COMPLETED
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
GlaxoSmithKline n=251
NCT03002454 TERMINATED
Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo
University of Manitoba n=4
NCT01593228 COMPLETED
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Sanofi n=37
NCT00516503 COMPLETED
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology n=208
NCT00566852 COMPLETED
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
Radiation Therapy Oncology Group n=554
NCT01434394 COMPLETED
Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Shanghai Jiao Tong University School of Medicine n=243
NCT01735175 COMPLETED
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
Sandoz n=316
NCT02149108 COMPLETED
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Boehringer Ingelheim n=768
NCT01917942 COMPLETED
Radiotherapy With Humidification in Head And Neck Cancer
Trans Tasman Radiation Oncology Group n=210
NCT01775449 COMPLETED
Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet
University Hospital, Clermont-Ferrand n=80
NCT03060070 COMPLETED
Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block
Assiut University n=90
NCT00925600 COMPLETED
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Amgen n=769
NCT01276938 COMPLETED
Exclusive Intraoperative Radiation Therapy for Breast Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy n=40
NCT01931592 TERMINATED
Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E
Maria J.G.T. Vehreschild n=29
NCT00489411 COMPLETED
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology n=231
NCT00925899 COMPLETED
Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer
Bispebjerg Hospital n=72
NCT00956813 COMPLETED
Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy
Alliance for Clinical Trials in Oncology n=210
NCT01618370 COMPLETED
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Bayer n=705
NCT00755040 COMPLETED
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Vanderbilt-Ingram Cancer Center n=164
NCT01024413 COMPLETED
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Chinese Society of Lung Cancer n=256
NCT02311907 COMPLETED
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Alliance for Clinical Trials in Oncology n=195
NCT01493505 TERMINATED
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Amgen n=1,015
NCT00719563 COMPLETED
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Alliance for Clinical Trials in Oncology n=364
NCT01435200 COMPLETED
Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy
Chulalongkorn University n=64
NCT01313377 COMPLETED
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
UNICANCER n=190
NCT01204749 COMPLETED
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Amgen n=919
NCT01631565 COMPLETED
Early Incorporation of Patient and Family to Attention and Care Program in Oncology Versus Standard of Care
Instituto Nacional de Cancerologia de Mexico n=201
NCT02739243 WITHDRAWN
A Clinical Trial on a Group Treatment for Distressed Caregivers of Cancer Patients
Heidelberg University
NCT00744497 COMPLETED
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
Bristol-Myers Squibb n=1,930
NCT00965341 COMPLETED
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
M.D. Anderson Cancer Center n=53
NCT00769405 COMPLETED
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
UNICANCER n=264
NCT02203253 COMPLETED
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
China Medical University, China n=642
NCT00376675 COMPLETED
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Alliance for Clinical Trials in Oncology n=148
NCT00880191 COMPLETED
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
Alliance for Clinical Trials in Oncology n=430
NCT01272024 COMPLETED
An Intervention to Improve Outcomes in Patients With Advanced Cancer
Yale University n=146
NCT02246244 COMPLETED
Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress
Gustave Roussy, Cancer Campus, Grand Paris n=38
NCT00634010 TERMINATED
Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain
M.D. Anderson Cancer Center n=36
NCT00625664 COMPLETED
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
Sanofi n=337
NCT00603577 TERMINATED
Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens
Sanofi n=102
NCT02727153 COMPLETED
"Ultra" Enhanced Recovery After Surgery (E.R.A.S.) in Laparoscopic Colectomy for Cancer
AUSL Romagna Rimini n=765
NCT00813540 COMPLETED
The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors
AHS Cancer Control Alberta n=52
NCT02260349 WITHDRAWN
Interest of Indocyanine Green in Neoplastic Prostatic Tissue
Centre Hospitalier Universitaire de Saint Etienne
NCT01584830 COMPLETED
Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Bayer n=204
NCT02664974 COMPLETED
Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano n=79
NCT00833898 COMPLETED
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
University of Colorado, Denver n=298
NCT02613026 COMPLETED
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer
307 Hospital of PLA n=104
NCT01423799 COMPLETED
Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment
Société des Produits Nestlé (SPN) n=300
NCT00685646 COMPLETED
Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan n=227
NCT01980498 WITHDRAWN
PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
NCT01651182 COMPLETED
Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection
Sunnybrook Health Sciences Centre n=24
NCT02548338 COMPLETED
Argon Plasma Coagulation Scalpel on Surgical Treatment of Breast Cancer
Federal University of São Paulo n=60
NCT00973609 COMPLETED
Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
AIO-Studien-gGmbH n=853
NCT01132547 TERMINATED
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
University of South Florida n=22
NCT01422928 WITHDRAWN
Acupuncture for the Immune System in Radiation Cancer Patients
British Columbia Cancer Agency
NCT01662076 COMPLETED
Homeopathic Treatment of Fatigue in Children Receiving Chemotherapy
The Hospital for Sick Children n=9
NCT00718354 COMPLETED
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
Thrombosis Research Institute n=740
NCT01829178 COMPLETED
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
Tehran University of Medical Sciences n=30
NCT01196741 COMPLETED
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
University College, London n=107
NCT01074697 COMPLETED
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Odense University Hospital n=246
NCT00891761 WITHDRAWN
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
GlaxoSmithKline
NCT01521702 COMPLETED
NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer
Institut Paoli-Calmettes n=2
NCT00949039 COMPLETED
Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=101
NCT01596933 COMPLETED
Effect of Omega-3 Supplements on the Prevention of Cachexia in Head and Neck Cancer Treated With Radio(Chemo)Therapy
General Hospital Groeninge n=91
NCT00593697 COMPLETED
The Synergism Or Long Duration (SOLD) Study
Finnish Breast Cancer Group n=2,168
NCT01731821 COMPLETED
Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
Fudan University n=308
NCT01164046 TERMINATED
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
University Medical Center Groningen n=56
NCT00939848 COMPLETED
Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
University College, London n=124
NCT01444157 COMPLETED
Family and Coping Oriented Palliative Homecare Nursing Aimed at Advanced Cancer Patients
Bispebjerg Hospital n=700
NCT00725114 COMPLETED
Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain
Wex Pharmaceuticals Inc. n=165
NCT00850772 COMPLETED
Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
Queensland Centre for Gynaecological Cancer n=109
NCT01804595 COMPLETED
A Randomized Control Trial of Sun Protection Interventions for Operating Engineers
University of Michigan n=357
NCT00638690 COMPLETED
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Cougar Biotechnology, Inc. n=1,195
NCT00960466 COMPLETED
Distress Thermometer Intervention Trial
University Hospitals Bristol and Weston NHS Foundation Trust n=220
NCT01429051 COMPLETED
A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain
Takeda n=46
NCT01038661 COMPLETED
Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy
Sanofi n=375
NCT00989131 COMPLETED
Study of Paclitaxel in Patients With Ovarian Cancer
Oasmia Pharmaceutical AB n=789
NCT01169129 WITHDRAWN
Surgery and Whole Brain Radiotherapy (RT) Versus Whole Brain Radiotherapy (RT) and Radiosurgery for 1-3 Resectable Brain Metastases
Barretos Cancer Hospital
NCT01053390 COMPLETED
New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine n=216
NCT01223105 TERMINATED
Oocyte Cryopreservation by Slow Freezing and Vitrification
Reproductive Medicine Associates of New Jersey n=2
NCT00647569 COMPLETED
Trial of Collagen Mesh for Prevention of Ventral Hernia After Surgery for Advanced Pelvic Cancer
University of Aarhus n=59
NCT00956254 COMPLETED
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
INSYS Therapeutics Inc n=18
NCT00978185 COMPLETED
Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy
University of Manchester n=699
NCT00803283 TERMINATED
A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
Johnson & Johnson Taiwan Ltd n=2
NCT01087658 COMPLETED
Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity
Sanofi n=200
NCT00641667 COMPLETED
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
Janssen Pharmaceutical K.K. n=66
NCT00808743 COMPLETED
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
Radboud University Medical Center n=37
NCT01189227 TERMINATED
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
NSABP Foundation Inc n=9
NCT01842893 COMPLETED
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
Ethypharm n=91
NCT01309386 COMPLETED
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
Janssen Pharmaceutical K.K. n=100
NCT00676650 TERMINATED
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
Pfizer n=873
NCT00694382 COMPLETED
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Sanofi n=3,212
NCT01081899 COMPLETED
The Effectiveness of the LCP in Improving End of Life Care for Dying Cancer Patients in Hospital.
Regional Palliative Care Network n=308
NCT00851162 WITHDRAWN
Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions
Emory University
NCT01066741 TERMINATED
Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer
Centre Leon Berard n=78
NCT00726011 COMPLETED
Tetrodotoxin Open-label Efficacy and Safety Continuation Study
Wex Pharmaceuticals Inc. n=113
NCT00822809 COMPLETED
CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
Neovii Biotech n=230
NCT00917748 COMPLETED
Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
Sanofi n=84
NCT01031719 COMPLETED
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
Chiltern Pesquisa Clinica Ltda n=59
NCT01009593 TERMINATED
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott n=1,035
NCT00735813 COMPLETED
Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia
Aarhus University Hospital n=129
NCT00811447 COMPLETED
Taxotere New Indication - Gastric Cancer Treatment Registration Trial
Sanofi n=243
NCT00760604 TERMINATED
A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer
Weill Medical College of Cornell University n=4
NCT01343680 TERMINATED
Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
Alberta Children's Hospital n=2
NCT01440621 COMPLETED
Modafinil in Cancer Related Fatigue
Indira Gandhi Medical College, Shimla n=217
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT01030887 COMPLETED
PEACH Trial: Prescribed Exercise After Chemotherapy
University of Dublin, Trinity College n=43
NCT01399814 COMPLETED
Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer
Nanjing PLA General Hospital n=179
NCT00782145 COMPLETED
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center n=198
NCT00798447 COMPLETED
Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery
B. Braun Melsungen AG n=100
NCT01014026 COMPLETED
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
University Hospital, Tours n=734
NCT00867295 COMPLETED
Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device
Istanbul University n=150
NCT00612443 COMPLETED
Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy
University of Wisconsin, Milwaukee n=40
NCT00635063 TERMINATED
A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects
Sosei n=150
NCT07516366 NOT YET RECRUITING
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
National Cancer Institute (NCI)
NCT04071223 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
NCT04071236 RECRUITING
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
NCT07584057 NOT YET RECRUITING
An Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia
Yunnan Baiyao Group Co., Ltd.
NCT06787612 RECRUITING
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
NCT03686124 RECRUITING
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Immatics US, Inc.
NCT04165772 RECRUITING
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT05136196 RECRUITING
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
NCT06591650 RECRUITING
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer
Fudan University
NCT04929028 ACTIVE NOT RECRUITING
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
NCT03866382 RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
NCT07281417 RECRUITING
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT07416188 RECRUITING
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institute of Neurological Disorders and Stroke (NINDS)
NCT03191149 RECRUITING
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
National Cancer Institute (NCI)
NCT05036226 RECRUITING
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
Medical University of South Carolina
NCT07038343 RECRUITING
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
NCT03237780 ACTIVE NOT RECRUITING
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT07574541 NOT YET RECRUITING
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
National Cancer Institute (NCI)
NCT04090398 ACTIVE NOT RECRUITING
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
National Cancer Institute (NCI)
NCT04981509 RECRUITING
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
NCT05564403 ACTIVE NOT RECRUITING
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT05172258 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
NCT07195734 RECRUITING
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
NCT07098988 RECRUITING
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
NCT05411081 ACTIVE NOT RECRUITING
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
National Cancer Institute (NCI)
NCT04067336 ACTIVE NOT RECRUITING
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
NCT06979596 RECRUITING
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Merck Sharp & Dohme LLC
NCT04068194 ACTIVE NOT RECRUITING
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
National Cancer Institute (NCI)
NCT06980038 RECRUITING
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
NCT06890338 RECRUITING
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
NCT06009926 ACTIVE NOT RECRUITING
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
National Cancer Institute (NCI)
NCT02834013 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
NCT07524530 NOT YET RECRUITING
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Cancer Institute (NCI)
NCT07266428 RECRUITING
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
NCT06445972 RECRUITING
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Merck Sharp & Dohme LLC
NCT05413850 RECRUITING
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
NCT05420948 RECRUITING
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
University of Chicago
NCT05919264 RECRUITING
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
NCT06941272 RECRUITING
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Merck Sharp & Dohme LLC
NCT05438329 ACTIVE NOT RECRUITING
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT07581834 RECRUITING
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Fujian Cancer Hospital
NCT06805396 RECRUITING
Timely Integration of Palliative Care in Oncology Care for Patients Referred for Palliative Radiotherapy on Bone Metastases: A Randomized Trial
Roxanne Gal
NCT05104736 RECRUITING
PT-112 in Subjects With Thymoma and Thymic Carcinoma
National Cancer Institute (NCI)
NCT07288359 RECRUITING
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT07252739 RECRUITING
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
NCT07397338 RECRUITING
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
NCT07581912 RECRUITING
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Zhejiang University
NCT04449549 RECRUITING
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Cancer Institute (NCI)
NCT02314169 ACTIVE NOT RECRUITING
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
NCT06271837 ACTIVE NOT RECRUITING
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
AstraZeneca
NCT03431350 ACTIVE NOT RECRUITING
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
NCT03286634 ACTIVE NOT RECRUITING
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
National Hospital Organization Nagoya Medical Center
NCT05903833 RECRUITING
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
AGO Research GmbH
NCT07129252 RECRUITING
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Crinetics Pharmaceuticals Inc.
NCT05979610 RECRUITING
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
University of Utah
NCT07578025 NOT YET RECRUITING
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
NCT06937177 RECRUITING
Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Colorectal Cancer Undergoing Chemotherapy
Endevica Bio
NCT03459846 ACTIVE NOT RECRUITING
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
AstraZeneca
NCT06130553 RECRUITING
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
AstraZeneca
NCT07560410 NOT YET RECRUITING
Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)
China Medical University Hospital
NCT06634589 RECRUITING
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
NCT06997068 RECRUITING
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Mayo Clinic
NCT04348747 RECRUITING
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Roswell Park Cancer Institute
NCT07341100 RECRUITING
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06474455 RECRUITING
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT07545746 NOT YET RECRUITING
Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya
UNC Lineberger Comprehensive Cancer Center
NCT05010031 RECRUITING
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Memorial Sloan Kettering Cancer Center
NCT04901702 RECRUITING
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
NCT07545265 NOT YET RECRUITING
SKB565 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06885281 RECRUITING
A Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Shanghai) Co., Ltd.
NCT07576725 NOT YET RECRUITING
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
NCT04640623 ACTIVE NOT RECRUITING
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Janssen Research & Development, LLC
NCT07529808 NOT YET RECRUITING
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
BigHat Biosciences, Inc.
NCT07384416 RECRUITING
QL1706 Plus Lenvatinib in Previously Treated Penile Cancer
Sun Yat-sen University
NCT05631262 ACTIVE NOT RECRUITING
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT03564340 RECRUITING
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
NCT04331041 ACTIVE NOT RECRUITING
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
NCT04589845 ACTIVE NOT RECRUITING
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
NCT07192432 RECRUITING
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Vironexis Biotherapeutics Inc.
NCT07480733 RECRUITING
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT02908906 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
NCT06818643 RECRUITING
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme LLC
NCT04325828 ACTIVE NOT RECRUITING
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Janssen Pharmaceutical K.K.
NCT06559228 ACTIVE NOT RECRUITING
ConnectedNest: a Digital Platform Connecting Individuals With Cancer to Social Care
University of Minnesota
NCT05265091 ACTIVE NOT RECRUITING
A Study of KL590586 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05316155 RECRUITING
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Janssen Research & Development, LLC
NCT07087860 RECRUITING
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Mayo Clinic
NCT07380386 RECRUITING
SKB105 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT07459998 RECRUITING
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06445114 RECRUITING
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Zachary Zumsteg
NCT06380816 RECRUITING
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
NCT06863272 RECRUITING
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Merck Sharp & Dohme LLC
NCT05256537 ACTIVE NOT RECRUITING
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Ronald Paquette
NCT06290687 RECRUITING
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Case Comprehensive Cancer Center
NCT06926751 RECRUITING
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07043894 RECRUITING
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05797246 ACTIVE NOT RECRUITING
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Cancer Institute (NCI)
NCT06761417 RECRUITING
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06760819 RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
NCT07570563 RECRUITING
Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors.
Chinese PLA General Hospital
NCT04728633 ACTIVE NOT RECRUITING
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
Thomas Jefferson University
NCT05985161 RECRUITING
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT06993844 RECRUITING
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
NCT06023862 RECRUITING
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Yonsei University
NCT02484404 ACTIVE NOT RECRUITING
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Cancer Institute (NCI)
NCT04083599 ACTIVE NOT RECRUITING
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT07335497 RECRUITING
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma, Inc.
NCT06892860 RECRUITING
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
Queen Mary University of London
NCT07569042 RECRUITING
A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
NCT04868604 RECRUITING
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Clarity Pharmaceuticals Ltd
NCT06239194 RECRUITING
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT05947383 ACTIVE NOT RECRUITING
Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer
Sunstone Medical
NCT05852717 RECRUITING
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Dipenkumar Modi
NCT06898450 RECRUITING
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Nimbus Wadjet, Inc.
NCT06819735 RECRUITING
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Domain Therapeutics Australia Pty Ltd
NCT07062354 ENROLLING BY INVITATION
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
SWOG Cancer Research Network
NCT01042379 RECRUITING
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
QuantumLeap Healthcare Collaborative
NCT04647916 ACTIVE NOT RECRUITING
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
SWOG Cancer Research Network
NCT06777433 ACTIVE NOT RECRUITING
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Radiopharm Theranostics, Ltd
NCT03610711 ACTIVE NOT RECRUITING
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06475300 RECRUITING
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07570966 NOT YET RECRUITING
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT06266338 RECRUITING
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
NCT06651593 RECRUITING
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
M.D. Anderson Cancer Center
NCT06936748 RECRUITING
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
Second Affiliated Hospital of Nanchang University
NCT02734537 RECRUITING
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
ECOG-ACRIN Cancer Research Group
NCT04896697 ACTIVE NOT RECRUITING
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development, Inc.
NCT04022343 ACTIVE NOT RECRUITING
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
NCT04826341 ACTIVE NOT RECRUITING
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
National Cancer Institute (NCI)
NCT04870944 RECRUITING
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
NCT05103345 RECRUITING
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
NCT04430699 ACTIVE NOT RECRUITING
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Massachusetts General Hospital
NCT02270814 ACTIVE NOT RECRUITING
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT05083481 ACTIVE NOT RECRUITING
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT06157892 RECRUITING
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07242547 RECRUITING
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Fundación GECP
NCT04166318 ACTIVE NOT RECRUITING
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
ECOG-ACRIN Cancer Research Group
NCT05663710 RECRUITING
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
NCT06214143 RECRUITING
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
NCT02332668 RECRUITING
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme LLC
NCT05038150 RECRUITING
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
NCT07354919 RECRUITING
Axelopran for Advanced Cancer in Patients Receiving Opioids
HealthPartners Institute
NCT06532279 RECRUITING
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
NCT05379972 ACTIVE NOT RECRUITING
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
University of Colorado, Denver
NCT06416007 RECRUITING
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
University of Cincinnati
NCT05286814 RECRUITING
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Cancer Institute (NCI)
NCT05584826 RECRUITING
MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other
Sunstone Medical
NCT05408845 RECRUITING
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
NCT05327686 RECRUITING
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NRG Oncology
NCT01375114 ACTIVE NOT RECRUITING
The Effects of Ginseng on Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT03393884 ACTIVE NOT RECRUITING
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Imunon
NCT07037004 NOT YET RECRUITING
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
City of Hope Medical Center
NCT04434040 RECRUITING
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
NCT05739981 RECRUITING
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT06795412 RECRUITING
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Pyxis Oncology, Inc
NCT05933265 ACTIVE NOT RECRUITING
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
NCT06050317 RECRUITING
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
NCT07298772 RECRUITING
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07057791 RECRUITING
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
PrECOG, LLC.
NCT01708954 ACTIVE NOT RECRUITING
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT06469944 RECRUITING
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Merck Sharp & Dohme LLC
NCT02498613 ACTIVE NOT RECRUITING
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00900497 ENROLLING BY INVITATION
A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
Dipnarine Maharaj
NCT07043608 NOT YET RECRUITING
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Kelly Fitzgerald, MD
NCT07325539 RECRUITING
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Sun Yat-sen University
NCT05588141 RECRUITING
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Cancer Institute (NCI)
NCT07560449 NOT YET RECRUITING
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
Qilu Pharmaceutical Co., Ltd.
NCT07047118 ACTIVE NOT RECRUITING
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
NCT02642042 ACTIVE NOT RECRUITING
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT07157033 RECRUITING
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Xerient Pharma
NCT07359820 RECRUITING
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Elevar Therapeutics
NCT07007182 RECRUITING
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Jinbo Yue
NCT05898399 RECRUITING
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Artios Pharma Ltd
NCT05128825 RECRUITING
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT06305247 ACTIVE NOT RECRUITING
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT07041788 NOT YET RECRUITING
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Second Affiliated Hospital of Nanchang University
NCT06833008 RECRUITING
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT07213830 RECRUITING
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
NCT04068649 RECRUITING
Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer
Roswell Park Cancer Institute
NCT07213817 RECRUITING
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
NCT03310879 RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
NCT06927687 ACTIVE NOT RECRUITING
Study of ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07549061 NOT YET RECRUITING
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
Shanghai Chest Hospital
NCT07556276 RECRUITING
Study of CMTS1215 Injection in Patients With Solid Tumors
The Second Hospital of Nanjing Medical University
NCT06012695 RECRUITING
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
NCT05616650 RECRUITING
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Cancer Institute (NCI)
NCT06710132 RECRUITING
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono Research & Development Institute, Inc.
NCT07555678 RECRUITING
Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase
Fudan University
NCT05327023 RECRUITING
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
National Cancer Institute (NCI)
NCT06385691 RECRUITING
Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.
Centre Leon Berard
NCT05451602 RECRUITING
HEC169096 in Participants With Advanced Solid Tumors
Sunshine Lake Pharma Co., Ltd.
NCT04959175 RECRUITING
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
National Cancer Institute (NCI)
NCT02971501 ACTIVE NOT RECRUITING
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
NCT06010342 RECRUITING
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
Teligene US
NCT07300891 NOT YET RECRUITING
T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy
Samsung Medical Center
NCT06778382 RECRUITING
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Shandong Cancer Hospital and Institute
NCT05787561 RECRUITING
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
NCT07346677 NOT YET RECRUITING
Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel
University of Basrah
NCT06223568 RECRUITING
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
National Cancer Institute (NCI)
NCT03964727 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
Gilead Sciences
NCT06814496 RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT07258121 RECRUITING
Study of ZGGS34 in Participants With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07302347 RECRUITING
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Merck Sharp & Dohme LLC
NCT06413680 RECRUITING
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Regeneron Pharmaceuticals
NCT06002789 RECRUITING
Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC
Sixth Affiliated Hospital, Sun Yat-sen University
NCT07439094 RECRUITING
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
NCT05361720 RECRUITING
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
NCT04570423 RECRUITING
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
NCT05882058 RECRUITING
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Boehringer Ingelheim
NCT06726148 RECRUITING
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT07551778 NOT YET RECRUITING
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
BOE Technology Group Co., Ltd.
NCT06144671 RECRUITING
GT201 Injection For The Treatment Of Advanced Solid Tumors
Grit Biotechnology
NCT04752137 RECRUITING
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Massachusetts General Hospital
NCT06385925 RECRUITING
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
NCT04116541 RECRUITING
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Centre Leon Berard
NCT05605496 ACTIVE NOT RECRUITING
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
Centre Leon Berard
NCT04733534 ACTIVE NOT RECRUITING
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
St. Jude Children's Research Hospital
NCT03284385 ACTIVE NOT RECRUITING
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
National Cancer Institute (NCI)
NCT06077877 ACTIVE NOT RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
GlaxoSmithKline
NCT04373031 ACTIVE NOT RECRUITING
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Providence Health & Services
NCT03190941 RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT06990880 RECRUITING
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
GlaxoSmithKline
NCT07392320 RECRUITING
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
NCT06785636 RECRUITING
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI, Inc.
NCT00840047 ACTIVE NOT RECRUITING
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
NCT03742102 ACTIVE NOT RECRUITING
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
AstraZeneca
NCT06532539 RECRUITING
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Shandong Cancer Hospital and Institute
NCT03206060 RECRUITING
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Cancer Institute (NCI)
NCT04280081 ACTIVE NOT RECRUITING
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Eli Lilly and Company
NCT03535246 RECRUITING
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
Shenzhen Geno-Immune Medical Institute
NCT06864169 ACTIVE NOT RECRUITING
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Merck Sharp & Dohme LLC
NCT04181463 NOT YET RECRUITING
Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer
M.D. Anderson Cancer Center
NCT07287995 RECRUITING
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT05491512 RECRUITING
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Memorial Sloan Kettering Cancer Center
NCT03810339 RECRUITING
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Sun Yat-sen University
NCT05951608 ACTIVE NOT RECRUITING
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Akeso
NCT06143748 ACTIVE NOT RECRUITING
Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)
Sun Yat-sen University
NCT03682289 ACTIVE NOT RECRUITING
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT06475352 RECRUITING
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme
UNICANCER
NCT05768139 RECRUITING
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT07541001 ACTIVE NOT RECRUITING
PRL3-Zumab in Patients With Advanced Solid Tumors
Intra-IMMUSG Pte Ltd
NCT07222488 RECRUITING
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Merck Sharp & Dohme LLC
NCT07209189 RECRUITING
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06576921 RECRUITING
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Xijing Hospital
NCT07407582 RECRUITING
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
NCT07547592 NOT YET RECRUITING
Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma
Yonsei University
NCT06596694 RECRUITING
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Merck Sharp & Dohme LLC
NCT07136779 RECRUITING
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
NCT03181867 ACTIVE NOT RECRUITING
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Cancer Institute (NCI)
NCT07169851 RECRUITING
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Eli Lilly and Company
NCT04349436 ACTIVE NOT RECRUITING
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Replimune, Inc.
NCT07299747 RECRUITING
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
VelaVigo Bio Inc
NCT04123366 ACTIVE NOT RECRUITING
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
Merck Sharp & Dohme LLC
NCT03736889 RECRUITING
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
BeiGene
NCT04452955 ACTIVE NOT RECRUITING
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Intra-IMMUSG Pte Ltd
NCT07543848 NOT YET RECRUITING
A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer
Chongqing University Cancer Hospital
NCT07020221 RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
NCT06922591 RECRUITING
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics, Inc.
NCT07203053 RECRUITING
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
ETOP IBCSG Partners Foundation
NCT05480384 ACTIVE NOT RECRUITING
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
NCT03919292 RECRUITING
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University
NCT03837899 ACTIVE NOT RECRUITING
Durvalumab and Tremelimumab for Pediatric Malignancies
AstraZeneca
NCT05732831 RECRUITING
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
NCT07303387 RECRUITING
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Gustave Roussy, Cancer Campus, Grand Paris
NCT07246863 RECRUITING
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
NCT06167291 ACTIVE NOT RECRUITING
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
M.D. Anderson Cancer Center
NCT06975293 RECRUITING
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
STORM Therapeutics LTD
NCT05786924 RECRUITING
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Institut de Recherches Internationales Servier
NCT05009069 ACTIVE NOT RECRUITING
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
NCT07462507 RECRUITING
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
NCT06966453 RECRUITING
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Pfizer
NCT01386385 ACTIVE NOT RECRUITING
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT05875168 RECRUITING
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT07538206 NOT YET RECRUITING
Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma
Tang-Du Hospital
NCT07476287 RECRUITING
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Pfizer
NCT04513444 RECRUITING
Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy
Institut Claudius Regaud
NCT03485209 ACTIVE NOT RECRUITING
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07227415 RECRUITING
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
NCT03441113 ACTIVE NOT RECRUITING
Extended Access of Momelotinib in Adults With Myelofibrosis
GlaxoSmithKline
NCT07540650 NOT YET RECRUITING
Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers
Institute of Oncology Ljubljana
NCT02174549 RECRUITING
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison Ltd.
NCT04393350 ACTIVE NOT RECRUITING
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
NCT07227012 RECRUITING
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
NCT07537881 NOT YET RECRUITING
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
NCT03909334 ACTIVE NOT RECRUITING
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Xiuning Le
NCT07287098 NOT YET RECRUITING
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Eli Lilly and Company
NCT06353386 RECRUITING
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Merck Sharp & Dohme LLC
NCT02713269 ACTIVE NOT RECRUITING
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
NCT03967223 ACTIVE NOT RECRUITING
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
USWM CT, LLC
NCT07406633 RECRUITING
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
NCT06365840 RECRUITING
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
ImmuneOncia Therapeutics Inc.
NCT06777316 ACTIVE NOT RECRUITING
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
NCT07535632 NOT YET RECRUITING
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
NCT06914128 RECRUITING
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Bayer
NCT07193511 RECRUITING
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
NCT03157128 ACTIVE NOT RECRUITING
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company
NCT02934568 ACTIVE NOT RECRUITING
Ribociclib (LEE011) Rollover Study for Continued Access
Novartis Pharmaceuticals
NCT06801041 RECRUITING
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
M.D. Anderson Cancer Center
NCT03934372 RECRUITING
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Biosciences International Sàrl
NCT04552288 ACTIVE NOT RECRUITING
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Memorial Sloan Kettering Cancer Center
NCT05789485 RECRUITING
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Memorial Sloan Kettering Cancer Center
NCT04796012 RECRUITING
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
University of Texas Southwestern Medical Center
NCT07533227 NOT YET RECRUITING
Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia
Hua Jiang
NCT00761618 ACTIVE NOT RECRUITING
Intrapleural Catheter Daily Versus Three Times a Week Drainage
M.D. Anderson Cancer Center
NCT06598371 RECRUITING
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT06200155 RECRUITING
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
M.D. Anderson Cancer Center
NCT06669572 RECRUITING
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
NCT06799637 RECRUITING
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Evopoint Biosciences Inc.
NCT06638931 RECRUITING
Agnostic Therapy in Rare Solid Tumors
Instituto do Cancer do Estado de São Paulo
NCT07530666 NOT YET RECRUITING
Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia
Dartsbio Pharmaceuticals Ltd.
NCT03175432 ACTIVE NOT RECRUITING
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT07126158 RECRUITING
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
NCT04219254 RECRUITING
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
BioInvent International AB
NCT05559879 RECRUITING
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
NCT06458036 RECRUITING
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Children's Hospital of Philadelphia
NCT02387905 ACTIVE NOT RECRUITING
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases
M.D. Anderson Cancer Center
NCT06721689 RECRUITING
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Theodore Laetsch
NCT04953104 ACTIVE NOT RECRUITING
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
NCT06741644 RECRUITING
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
NCT06915116 RECRUITING
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT06607692 RECRUITING
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Fundación de investigación HM
NCT05023486 ACTIVE NOT RECRUITING
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
NCT05358249 ACTIVE NOT RECRUITING
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT06906341 RECRUITING
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
NCT06470763 ACTIVE NOT RECRUITING
A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
Anaveon AG
NCT05576974 RECRUITING
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
University of Texas Southwestern Medical Center
NCT03994796 ACTIVE NOT RECRUITING
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
NCT01038778 ACTIVE NOT RECRUITING
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT04620187 RECRUITING
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
NCT04895709 RECRUITING
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT07326488 RECRUITING
A Study of MHB009C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT07505979 NOT YET RECRUITING
SMART Trial: Cognitive Sparing Brain Radiotherapy for Multiple Brain Metastases
National Taiwan University Hospital
NCT04287868 ACTIVE NOT RECRUITING
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Cancer Institute (NCI)
NCT05307939 RECRUITING
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
Memorial Sloan Kettering Cancer Center
NCT05423262 RECRUITING
A Study of TRK-950 in Patients With Advanced Solid Tumors
Toray Industries, Inc
NCT05257590 RECRUITING
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
NCT05446298 ACTIVE NOT RECRUITING
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
OncoC4, Inc.
NCT06362369 RECRUITING
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
NCT05969496 RECRUITING
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
University of Colorado, Denver
NCT07509684 NOT YET RECRUITING
A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
NCT05222620 RECRUITING
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Mayo Clinic
NCT05837455 RECRUITING
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Washington University School of Medicine
NCT02888743 ACTIVE NOT RECRUITING
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT06190899 RECRUITING
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
NCT04225117 ACTIVE NOT RECRUITING
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Global Development, Inc.
NCT06810544 RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
NCT06417476 ACTIVE NOT RECRUITING
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Pei-Rong Ding
NCT06067503 RECRUITING
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison
NCT04337580 RECRUITING
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Wake Forest University Health Sciences
NCT05887609 RECRUITING
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
NCT05075980 ACTIVE NOT RECRUITING
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
NCT06253494 RECRUITING
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
NCT06329570 RECRUITING
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
NCT07192120 RECRUITING
A Study of MHB048C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT06084780 NOT YET RECRUITING
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
Case Comprehensive Cancer Center
NCT07192107 RECRUITING
A Study of MHB042C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT05945823 ACTIVE NOT RECRUITING
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
NCT07514975 NOT YET RECRUITING
First-In-Human Study of KHN922 for Injection
Chengdu Kanghong Biotech Co., Ltd.
NCT06635785 RECRUITING
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
OncoC4, Inc.
NCT04626635 RECRUITING
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Regeneron Pharmaceuticals
NCT07518979 NOT YET RECRUITING
EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer
Jiyan Liu
NCT06695845 RECRUITING
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT07172919 RECRUITING
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
NCT06062420 ACTIVE NOT RECRUITING
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
NCT07262619 RECRUITING
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Eikon Therapeutics
NCT07415031 RECRUITING
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
NCT05993299 ACTIVE NOT RECRUITING
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
NCT04633252 RECRUITING
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Cancer Institute (NCI)
NCT06703346 ACTIVE NOT RECRUITING
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM CT, LLC
NCT07518485 NOT YET RECRUITING
Prospective Clinical Study to Identify Secondary Sentinel Lymph Nodes in Patients With N1/N2b Oral Cavity or H&N Skin Cancers Using Patent Blue V and Indocyanine Green Dyes
Centre Hospitalier Universitaire Vaudois
NCT05753306 RECRUITING
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
NCT07346209 NOT YET RECRUITING
Real-world Trial of Individualized Precision Oncology
University of California, San Diego
NCT06003231 ACTIVE NOT RECRUITING
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen, a wholly owned subsidiary of Pfizer
NCT07516210 NOT YET RECRUITING
Adaptive Radiotherapy for Safe Hypofractionation
Centre hospitalier de l'Université de Montréal (CHUM)
NCT06911827 RECRUITING
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
NCT04417660 ACTIVE NOT RECRUITING
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
National Cancer Institute (NCI)
NCT05579366 RECRUITING
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
NCT04086485 RECRUITING
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Cancer Institute (NCI)
NCT07510828 RECRUITING
PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors
Beijing Biotech
NCT07024784 RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
NCT04412629 ACTIVE NOT RECRUITING
Cabozantinib in High Grade Neuroendocrine Neoplasms
Washington University School of Medicine
NCT05386108 RECRUITING
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Stemline Therapeutics, Inc.
NCT07147348 RECRUITING
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
BioNTech SE
NCT06833073 RECRUITING
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Merck Sharp & Dohme LLC
NCT04708470 ACTIVE NOT RECRUITING
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Cancer Institute (NCI)
NCT02830724 RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
NCT07512583 NOT YET RECRUITING
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT05361798 RECRUITING
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
National Cancer Institute (NCI)
NCT03173924 ACTIVE NOT RECRUITING
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT03917381 ACTIVE NOT RECRUITING
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
NCT05533697 RECRUITING
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
NCT03505320 ACTIVE NOT RECRUITING
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc.
NCT06116136 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Servier Bio-Innovation LLC
NCT03678883 ACTIVE NOT RECRUITING
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
NCT06188702 RECRUITING
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Servier Bio-Innovation LLC
NCT05503797 RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
NCT03093116 RECRUITING
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Turning Point Therapeutics, Inc.
NCT07446153 RECRUITING
A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT05335993 ACTIVE NOT RECRUITING
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
NCT07276373 RECRUITING
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
NCT07510334 NOT YET RECRUITING
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
NCT06567782 RECRUITING
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
GlaxoSmithKline
NCT02693535 RECRUITING
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
American Society of Clinical Oncology
NCT04544189 ACTIVE NOT RECRUITING
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis Pharmaceuticals
NCT07290894 RECRUITING
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
National Cancer Institute, Naples
NCT03040973 ACTIVE NOT RECRUITING
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Novartis Pharmaceuticals
NCT07468071 NOT YET RECRUITING
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Novartis Pharmaceuticals
NCT03355976 ACTIVE NOT RECRUITING
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Brown University
NCT04713046 ACTIVE NOT RECRUITING
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07508761 NOT YET RECRUITING
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Nanjing Immunophage Biotech Co., Ltd
NCT04665206 RECRUITING
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
NCT06445062 RECRUITING
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
NCT02873962 ACTIVE NOT RECRUITING
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
NCT05605535 ACTIVE NOT RECRUITING
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
CanariaBio Inc.
NCT06365788 RECRUITING
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Universitaire Ziekenhuizen KU Leuven
NCT05318027 ACTIVE NOT RECRUITING
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Abramson Cancer Center at Penn Medicine
NCT07033026 RECRUITING
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NGM Biopharmaceuticals, Inc
NCT07449481 NOT YET RECRUITING
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT05735080 RECRUITING
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT05773820 RECRUITING
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
NCT06290193 RECRUITING
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
NCT07455734 RECRUITING
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
BioNTech SE
NCT04963283 ACTIVE NOT RECRUITING
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
NCT07504263 NOT YET RECRUITING
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Recurv Pharma Inc
NCT05267626 RECRUITING
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
NCT05094336 ACTIVE NOT RECRUITING
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Amgen
NCT07504471 RECRUITING
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
Ruijin Hospital
NCT04301765 RECRUITING
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Seattle Institute for Biomedical and Clinical Research
NCT06809946 NOT YET RECRUITING
Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy
University Medical Center Groningen
NCT03297606 RECRUITING
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Canadian Cancer Trials Group
NCT07498725 NOT YET RECRUITING
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors
LARKSPUR BIOSCIENCES, INC.
NCT07494435 NOT YET RECRUITING
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Zhejiang Haichang Biotech Co., Ltd.
NCT06395519 RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics, Inc.
NCT06554795 RECRUITING
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT05999994 RECRUITING
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Eli Lilly and Company
NCT07276360 RECRUITING
Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
Uganda Cancer Institute
NCT06425926 RECRUITING
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune Inc
NCT07497919 NOT YET RECRUITING
A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
Fudan University
NCT06953323 RECRUITING
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
NCT05853575 ACTIVE NOT RECRUITING
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
NCT06873789 ACTIVE NOT RECRUITING
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT06166836 ACTIVE NOT RECRUITING
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
InxMed (Shanghai) Co., Ltd.
NCT07492680 NOT YET RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
NCT06977737 RECRUITING
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Accession Therapeutics Limited
NCT02650401 ACTIVE NOT RECRUITING
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Hoffmann-La Roche
NCT04919512 ACTIVE NOT RECRUITING
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Janssen Research & Development, LLC
NCT07123090 RECRUITING
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Stephanie Berg
NCT04910386 NOT YET RECRUITING
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines (Sichuan) Co., Ltd.
NCT05024214 RECRUITING
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT04891198 RECRUITING
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT07489300 NOT YET RECRUITING
Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04858269 RECRUITING
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Wake Forest University Health Sciences
NCT03937830 ACTIVE NOT RECRUITING
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Cancer Institute (NCI)
NCT05849480 RECRUITING
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Cancer Institute (NCI)
NCT07491783 NOT YET RECRUITING
Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial
Sichuan Enray Pharmaceutical Sciences Company
NCT04008797 ACTIVE NOT RECRUITING
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
NCT06781125 NOT YET RECRUITING
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
NCT06253130 RECRUITING
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Eikon Therapeutics
NCT07213609 RECRUITING
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT04639219 ACTIVE NOT RECRUITING
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
AstraZeneca
NCT07222969 RECRUITING
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Vibrant Sciences Limited
NCT07487805 NOT YET RECRUITING
Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)
University of Florida
NCT05886920 ACTIVE NOT RECRUITING
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd
NCT07489066 NOT YET RECRUITING
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Pfizer
NCT06493019 RECRUITING
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Dustin Deming
NCT07109726 RECRUITING
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
NCT02503423 ACTIVE NOT RECRUITING
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
NCT07032077 RECRUITING
A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
NCT07229638 RECRUITING
A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07477444 NOT YET RECRUITING
Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer
Universitaire Ziekenhuizen KU Leuven
NCT07132190 RECRUITING
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Ayal A. Aizer, MD
NCT07130786 RECRUITING
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
Ayal A. Aizer, MD
NCT04899908 ACTIVE NOT RECRUITING
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT06876038 NOT YET RECRUITING
Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions
University of Massachusetts, Boston
NCT07472933 NOT YET RECRUITING
Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies
West China Hospital
NCT05101070 RECRUITING
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shionogi
NCT04699188 ACTIVE NOT RECRUITING
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT05098132 RECRUITING
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Synthekine
NCT04657068 RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
NCT06244771 RECRUITING
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Frontier Medicines Corporation
NCT03585465 ACTIVE NOT RECRUITING
Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
Centre Oscar Lambret
NCT05689853 RECRUITING
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Akeso
NCT04140500 ACTIVE NOT RECRUITING
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT07435701 RECRUITING
Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT03965234 RECRUITING
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Roswell Park Cancer Institute
NCT04977453 RECRUITING
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
GI Innovation, Inc.
NCT04802174 ACTIVE NOT RECRUITING
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
National Cancer Institute (NCI)
NCT07092514 RECRUITING
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Washington University School of Medicine
NCT07477418 NOT YET RECRUITING
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
University of Vermont
NCT06926075 RECRUITING
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Filamon LTD
NCT03600883 ACTIVE NOT RECRUITING
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
NCT05194995 ACTIVE NOT RECRUITING
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Allist Pharmaceuticals, Inc.
NCT07258407 RECRUITING
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
T.O.A.D. Oncology SA
NCT05468359 RECRUITING
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
NCT03607890 ACTIVE NOT RECRUITING
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05772546 ACTIVE NOT RECRUITING
Avatrombopag vs. Placebo for CIT in GI Malignancies
Hanny Al-Samkari, MD
NCT04300556 RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
NCT07469774 NOT YET RECRUITING
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.
NCT06643884 RECRUITING
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Aura Biosciences
NCT06479239 RECRUITING
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
University of Virginia
NCT03360890 ACTIVE NOT RECRUITING
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
University of Chicago
NCT06797635 RECRUITING
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme LLC
NCT05009329 ACTIVE NOT RECRUITING
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Allist Pharmaceuticals, Inc.
NCT05521997 NOT YET RECRUITING
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Washington University School of Medicine
NCT01804634 RECRUITING
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06008288 RECRUITING
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Allist Pharmaceuticals, Inc.
NCT06736704 RECRUITING
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
NCT07469683 RECRUITING
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
NCT05269381 RECRUITING
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT02896335 RECRUITING
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
NCT04585750 RECRUITING
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
NCT06057922 ACTIVE NOT RECRUITING
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07070232 RECRUITING
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BioNTech SE
NCT07466160 RECRUITING
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT01603316 ACTIVE NOT RECRUITING
Food: A Three-Arm Study Examining Food Insecurity Interventions
Memorial Sloan Kettering Cancer Center
NCT07035249 RECRUITING
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
West China Hospital
NCT07018622 RECRUITING
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
NCT07417189 RECRUITING
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Abbisko Therapeutics Co, Ltd
NCT03071406 ACTIVE NOT RECRUITING
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06384807 RECRUITING
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Biohaven Therapeutics Ltd.
NCT05265052 NOT YET RECRUITING
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
3D Medicines
NCT07435038 NOT YET RECRUITING
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Betta Pharmaceuticals Co., Ltd.
NCT07196644 RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
AbbVie
NCT07460180 RECRUITING
The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
The Netherlands Cancer Institute
NCT07461181 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors
Ruijin Hospital
NCT07460375 NOT YET RECRUITING
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
LigaChem Biosciences, Inc.
NCT04333706 RECRUITING
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
University of Southern California
NCT06499350 RECRUITING
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
FindCure Biosciences (ZhongShan) Co., Ltd.
NCT07459920 NOT YET RECRUITING
Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden
National Cancer Institute, Naples
NCT06408116 RECRUITING
Predicting Esophageal Cancer Borders Using PET-Imaging
University Hospital Heidelberg
NCT06162221 RECRUITING
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
NCT07202364 RECRUITING
A Study of YL202 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT04030455 ACTIVE NOT RECRUITING
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
NCT07069062 RECRUITING
A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
NCT01629498 ACTIVE NOT RECRUITING
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04262466 ACTIVE NOT RECRUITING
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
NCT06432036 RECRUITING
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Jonsson Comprehensive Cancer Center
NCT06656390 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
NCT02568267 ACTIVE NOT RECRUITING
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT07070466 RECRUITING
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Massachusetts General Hospital
NCT06895031 RECRUITING
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Guangzhou JOYO Pharma Co., Ltd
NCT04940299 ACTIVE NOT RECRUITING
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT07453394 NOT YET RECRUITING
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT03531645 ACTIVE NOT RECRUITING
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
M.D. Anderson Cancer Center
NCT00707473 ACTIVE NOT RECRUITING
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
M.D. Anderson Cancer Center
NCT06627270 RECRUITING
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Case Comprehensive Cancer Center
NCT06416085 ACTIVE NOT RECRUITING
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
NCT05012371 ACTIVE NOT RECRUITING
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
NCT06667960 RECRUITING
Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT03028337 ACTIVE NOT RECRUITING
Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases
M.D. Anderson Cancer Center
NCT04516070 ACTIVE NOT RECRUITING
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
NCT01644591 ACTIVE NOT RECRUITING
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT07222631 RECRUITING
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
University of California, San Diego
NCT06807593 RECRUITING
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
M.D. Anderson Cancer Center
NCT02675829 ACTIVE NOT RECRUITING
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
NCT07354100 NOT YET RECRUITING
Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
University of Chicago
NCT07450352 NOT YET RECRUITING
SEED-CRYO: Sequential 125I Seed Implantation Followed by Cryoablation vs Single-Modality Local Therapy in Unresectable Solid Tumors
Li Min
NCT05004116 RECRUITING
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05789589 RECRUITING
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Baptist Health South Florida
NCT06268665 RECRUITING
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
University of California, Davis
NCT04757363 ACTIVE NOT RECRUITING
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT05335941 ACTIVE NOT RECRUITING
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT07028281 RECRUITING
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07447050 RECRUITING
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT04683250 RECRUITING
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Taiho Pharmaceutical Co., Ltd.
NCT07072728 RECRUITING
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
NCT06657222 RECRUITING
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
NCT07444918 NOT YET RECRUITING
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT05681195 RECRUITING
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
NCT07446049 NOT YET RECRUITING
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.
NCT07446725 NOT YET RECRUITING
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT05546268 ACTIVE NOT RECRUITING
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics, Inc
NCT07217938 RECRUITING
Novel Treatment of Radiation Associated Dysphagia With Statins
Peter MacCallum Cancer Centre, Australia
NCT03781986 ACTIVE NOT RECRUITING
APG-115 in Salivary Gland Cancer Trial
University of Michigan Rogel Cancer Center
NCT06014658 RECRUITING
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
MBrace Therapeutics
NCT07443475 RECRUITING
Electrochemotherapy for Recurrent Vulvar Cancer
Institute of Oncology Ljubljana
NCT02574728 ACTIVE NOT RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Emory University
NCT04485286 RECRUITING
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Massachusetts General Hospital
NCT06075043 NOT YET RECRUITING
A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy
Kind Pharmaceuticals LLC
NCT03403465 ACTIVE NOT RECRUITING
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
Duke University
NCT05544136 RECRUITING
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT07282834 RECRUITING
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
Patrick Wagner, MD, FACS
NCT05639972 RECRUITING
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Christian Hinrichs
NCT05063916 ACTIVE NOT RECRUITING
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
M.D. Anderson Cancer Center
NCT05664178 RECRUITING
Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology
H. Lee Moffitt Cancer Center and Research Institute
NCT05686226 RECRUITING
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Christian Hinrichs
NCT07437625 NOT YET RECRUITING
Lesion-Allocated Therapy for Multiple Metastases and Tumor-Zoned Treatment for Bulky Tumors: A Phase II Study of Iodine-125 Seed Implantation Combined With Cryoablation in High-Burden Metastatic Disease
Li Min
NCT04469530 RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
Emory University
NCT06526819 RECRUITING
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT07441174 RECRUITING
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
InxMed (Shanghai) Co., Ltd.
NCT01684397 ACTIVE NOT RECRUITING
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
NCT04321954 ACTIVE NOT RECRUITING
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
NCT03270059 RECRUITING
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
OHSU Knight Cancer Institute
NCT05593094 ACTIVE NOT RECRUITING
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
NCT07432594 NOT YET RECRUITING
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05672459 ACTIVE NOT RECRUITING
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
M.D. Anderson Cancer Center
NCT07433283 RECRUITING
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
NCT07434180 NOT YET RECRUITING
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Peter MacCallum Cancer Centre, Australia
NCT07432295 RECRUITING
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT04605913 RECRUITING
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
NCT05261750 ACTIVE NOT RECRUITING
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
PT. Prodia Stem Cell Indonesia
NCT05081609 ACTIVE NOT RECRUITING
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Ascendis Pharma Oncology Division A/S
NCT05438420 ACTIVE NOT RECRUITING
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co., Ltd.
NCT05523947 RECRUITING
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Yuhan Corporation
NCT06005493 RECRUITING
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AstraZeneca
NCT03174275 ACTIVE NOT RECRUITING
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT06058988 RECRUITING
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
NCT07285057 RECRUITING
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Icahn School of Medicine at Mount Sinai
NCT04258462 ACTIVE NOT RECRUITING
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
Zhen Wang, MD
NCT07389239 NOT YET RECRUITING
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
University of Chicago
NCT05778825 ACTIVE NOT RECRUITING
A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
Memorial Sloan Kettering Cancer Center
NCT07424664 NOT YET RECRUITING
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT07425054 NOT YET RECRUITING
HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer
Jennifer Dorth
NCT06096038 RECRUITING
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
UNC Lineberger Comprehensive Cancer Center
NCT06051695 RECRUITING
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT07063212 RECRUITING
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT04644068 ACTIVE NOT RECRUITING
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT07023731 RECRUITING
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
NCT04892953 RECRUITING
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
NCT07408583 NOT YET RECRUITING
Prenatal Transplantation for Fetuses With Fanconi Anemia
Agnieszka Czechowicz
NCT04848519 ACTIVE NOT RECRUITING
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
NCT07146646 RECRUITING
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NCT06754501 ACTIVE NOT RECRUITING
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
M.D. Anderson Cancer Center
NCT07410676 RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Essen Biotech
NCT07417501 NOT YET RECRUITING
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
NCT07030257 RECRUITING
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT03742895 ACTIVE NOT RECRUITING
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Merck Sharp & Dohme LLC
NCT07410494 RECRUITING
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT06237881 ACTIVE NOT RECRUITING
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT07418034 NOT YET RECRUITING
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
University of Maryland, Baltimore
NCT06629584 RECRUITING
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
NCT07145255 RECRUITING
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
NCT06995508 RECRUITING
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Roswell Park Cancer Institute
NCT05117931 ACTIVE NOT RECRUITING
A Study of Amivantamab in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT03822897 ACTIVE NOT RECRUITING
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
Canadian Cancer Trials Group
NCT02152254 ACTIVE NOT RECRUITING
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
M.D. Anderson Cancer Center
NCT07415863 RECRUITING
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT07293754 RECRUITING
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Repertoire Immune Medicines
NCT04761770 ACTIVE NOT RECRUITING
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
NCT04432597 ACTIVE NOT RECRUITING
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Cancer Institute (NCI)
NCT07415681 NOT YET RECRUITING
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
University of Maryland, Baltimore
NCT06261814 RECRUITING
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
john eisenbrey
NCT04041310 ACTIVE NOT RECRUITING
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Nouscom SRL
NCT06358677 RECRUITING
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
University of Utah
NCT03767348 ACTIVE NOT RECRUITING
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Replimune, Inc.
NCT06686394 RECRUITING
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Merck Sharp & Dohme LLC
NCT05460000 RECRUITING
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
North Eastern German Society of Gynaecological Oncology
NCT06517212 RECRUITING
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Baylor Research Institute
NCT07405736 NOT YET RECRUITING
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
Sun Yat-sen University
NCT06330064 RECRUITING
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
NCT02749903 ACTIVE NOT RECRUITING
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Alliance for Clinical Trials in Oncology
NCT03008408 ACTIVE NOT RECRUITING
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
NCT06644183 RECRUITING
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, MD, PhD
NCT07328217 RECRUITING
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Dizal Pharmaceuticals
NCT07404176 RECRUITING
Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors
Tata Memorial Hospital
NCT06636734 RECRUITING
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Emory University
NCT04862650 ACTIVE NOT RECRUITING
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Marcelo Bonomi
NCT04078295 ACTIVE NOT RECRUITING
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Co., Ltd.
NCT06939283 ACTIVE NOT RECRUITING
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Werewolf Therapeutics, Inc.
NCT04068753 ACTIVE NOT RECRUITING
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
University of Oklahoma
NCT04930432 RECRUITING
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Betta Pharmaceuticals Co., Ltd.
NCT03582124 RECRUITING
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford University
NCT07400094 NOT YET RECRUITING
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
National Medical Research Radiological Centre of the Ministry of Health of Russia
NCT06634849 RECRUITING
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Pathios Therapeutics Pty Ltd
NCT07151391 RECRUITING
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
NCT06232577 ACTIVE NOT RECRUITING
5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial
M.D. Anderson Cancer Center
NCT06109467 RECRUITING
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05465941 RECRUITING
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Mayo Clinic
NCT06534190 RECRUITING
CD8 PET Imaging in Metastatic Solid Tumours
University Medical Center Groningen
NCT06289049 RECRUITING
Heavy Strength Training in Head and Neck Cancer Survivors
University of Alberta
NCT07392736 RECRUITING
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Advenchen Laboratories, LLC
NCT07290621 RECRUITING
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
University of Chicago
NCT07394374 RECRUITING
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
Cullgen (Shanghai),Inc
NCT05039632 RECRUITING
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
NCT03203473 ACTIVE NOT RECRUITING
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Toni Choueiri, MD
NCT06953089 RECRUITING
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT02884648 ACTIVE NOT RECRUITING
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
M.D. Anderson Cancer Center
NCT04375228 ACTIVE NOT RECRUITING
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
NCT06778408 RECRUITING
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
University of Vermont Medical Center
NCT07359066 RECRUITING
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Shanghai SciBrunch Therapeutics Co., Ltd.
NCT03944941 ACTIVE NOT RECRUITING
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Alliance for Clinical Trials in Oncology
NCT01815359 ACTIVE NOT RECRUITING
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
Memorial Sloan Kettering Cancer Center
NCT07227610 RECRUITING
Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
Medical University of South Carolina
NCT07001241 RECRUITING
Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
University of Colorado, Denver
NCT03465592 RECRUITING
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06771622 ACTIVE NOT RECRUITING
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
NCT05518045 ACTIVE NOT RECRUITING
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
NCT07332247 RECRUITING
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
Sun Yat-sen University
NCT07382531 RECRUITING
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Binhui Biopharmaceutical Co., Ltd.
NCT07383285 NOT YET RECRUITING
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
Peking University Cancer Hospital & Institute
NCT05443126 RECRUITING
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Ellipses Pharma
NCT06697197 RECRUITING
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895735 ACTIVE NOT RECRUITING
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
NCT07381231 RECRUITING
Immunotherapy With Adaptive Pulse Radiotherapy in Solid Tumors
Samsung Medical Center
NCT05744427 ACTIVE NOT RECRUITING
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT05894083 RECRUITING
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
University of Michigan Rogel Cancer Center
NCT06710847 ACTIVE NOT RECRUITING
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT06866964 RECRUITING
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Wake Forest University Health Sciences
NCT04340882 ACTIVE NOT RECRUITING
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Emory University
NCT05043922 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Haihe Biopharma Co., Ltd.
NCT04390737 RECRUITING
Evaluate the Safety and Clinical Activity of HH2853
Haihe Biopharma Co., Ltd.
NCT04305145 ACTIVE NOT RECRUITING
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Massachusetts General Hospital
NCT06974812 RECRUITING
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT03943901 ACTIVE NOT RECRUITING
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
NCT02721732 ACTIVE NOT RECRUITING
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
NCT07148128 RECRUITING
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Auricula Biosciences Inc.
NCT03796767 ACTIVE NOT RECRUITING
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
University of Utah
NCT07371663 RECRUITING
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Beijing Tide Pharmaceutical Co., Ltd
NCT07151040 RECRUITING
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
One-carbon Therapeutics AB
NCT06208657 RECRUITING
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
NCT06172478 RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT07374419 NOT YET RECRUITING
Atamparib in Patients With Advanced Solid Tumors
Nerviano Medical Sciences (Shanghai) Ltd.
NCT04145622 RECRUITING
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
NCT05150691 RECRUITING
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT03947385 RECRUITING
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
IDEAYA Biosciences
NCT07266025 NOT YET RECRUITING
Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study
Shanghai Zhongshan Hospital
NCT05867420 RECRUITING
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
NCT06378593 RECRUITING
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
3H (Suzhou) Pharmaceuticals Co., Ltd.
NCT04243499 ACTIVE NOT RECRUITING
First-in-Human Study of ICT01 in Patients With Advanced Cancer
ImCheck Therapeutics
NCT07363057 RECRUITING
A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors
GI Innovation, Inc.
NCT04905914 ACTIVE NOT RECRUITING
Study Of ATRN-119 In Patients With Advanced Solid Tumors
Aprea Therapeutics
NCT06912763 RECRUITING
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
M.D. Anderson Cancer Center
NCT05498272 RECRUITING
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD
NCT05502315 RECRUITING
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Rana McKay, MD
NCT06323473 RECRUITING
Maitake for Integrative Cancer Care
The Canadian College of Naturopathic Medicine
NCT04992013 ACTIVE NOT RECRUITING
Niraparib in Tumors Metastatic to the CNS
Massachusetts General Hospital
NCT07364305 RECRUITING
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Eastern Hepatobiliary Surgery Hospital
NCT05807880 ACTIVE NOT RECRUITING
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
NCT07174583 RECRUITING
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
NCT07222215 RECRUITING
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT07093970 RECRUITING
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Lepu Biopharma Co., Ltd.
NCT06386146 RECRUITING
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Jacobio Pharmaceuticals Co., Ltd.
NCT04948619 RECRUITING
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
Wake Forest University Health Sciences
NCT03333616 ACTIVE NOT RECRUITING
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
NCT05673928 RECRUITING
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
M.D. Anderson Cancer Center
NCT06468280 RECRUITING
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
Shanghai Zhongshan Hospital
NCT07292168 RECRUITING
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
Kidney Cancer Research Bureau
NCT07356791 NOT YET RECRUITING
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety
RenJi Hospital
NCT03096093 ACTIVE NOT RECRUITING
Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Cancer Vaccines Limited
NCT05584670 RECRUITING
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Sanofi
NCT03937843 ACTIVE NOT RECRUITING
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Swiss Cancer Institute
NCT06959615 RECRUITING
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Jacobio Pharmaceuticals Co., Ltd.
NCT07353723 RECRUITING
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Tang-Du Hospital
NCT06973564 RECRUITING
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Jacobio Pharmaceuticals Co., Ltd.
NCT02813135 RECRUITING
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Gustave Roussy, Cancer Campus, Grand Paris
NCT05741242 ENROLLING BY INVITATION
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Jaime Leandro Foundation for Therapeutic Cancer Vaccines
NCT07339748 NOT YET RECRUITING
A Clinical Study of ZL-85FA Tablets
Chengdu Zenitar Biomedical Technology Co., Ltd
NCT05163041 ACTIVE NOT RECRUITING
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
BicycleTx Limited
NCT05210413 ACTIVE NOT RECRUITING
Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
University Hospital, Bordeaux
NCT07339488 ACTIVE NOT RECRUITING
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Chuangzhen Chen
NCT05922501 RECRUITING
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
NCT07253116 RECRUITING
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
Nanjing Jingao biomidical technology Co. Ltd.
NCT05924672 ACTIVE NOT RECRUITING
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
NCT06334432 ACTIVE NOT RECRUITING
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
NCT03977233 RECRUITING
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT07333469 NOT YET RECRUITING
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
NCT05651022 ACTIVE NOT RECRUITING
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc
NCT05944224 RECRUITING
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
Shanghai Pharmaceuticals Holding Co., Ltd
NCT07056777 RECRUITING
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Zhejiang Doer Biologics Co., Ltd.
NCT05588453 RECRUITING
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Kari Kendra
NCT03829254 RECRUITING
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
NCT04725474 ACTIVE NOT RECRUITING
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
CatalYm GmbH
NCT05544552 ACTIVE NOT RECRUITING
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Tyra Biosciences, Inc
NCT07268040 RECRUITING
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT07333664 NOT YET RECRUITING
Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions
Li Min
NCT07334431 RECRUITING
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Henan Cancer Hospital
NCT07333937 NOT YET RECRUITING
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
Xijing Hospital
NCT06737731 RECRUITING
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07258160 RECRUITING
Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors
Second Affiliated Hospital of Soochow University
NCT03541902 ACTIVE NOT RECRUITING
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT07110571 RECRUITING
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT03587662 ACTIVE NOT RECRUITING
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
NCT07231211 RECRUITING
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shanghai Shengdi Pharmaceutical Co., Ltd
NCT05490472 RECRUITING
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT07327411 NOT YET RECRUITING
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
NCT07131202 RECRUITING
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd
NCT05723562 ACTIVE NOT RECRUITING
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
GlaxoSmithKline
NCT06631079 ACTIVE NOT RECRUITING
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
NEC Bio B.V
NCT06265727 RECRUITING
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals Inc.
NCT07327294 NOT YET RECRUITING
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
Evopoint Biosciences Inc.
NCT07126561 NOT YET RECRUITING
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
University of Chicago
NCT07322094 RECRUITING
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL Biotherapeutics, LLC
NCT05332002 RECRUITING
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Rutgers, The State University of New Jersey
NCT07321574 RECRUITING
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Shanghai AB PharmaTech Ltd.
NCT05405595 RECRUITING
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
NCT07259473 NOT YET RECRUITING
Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital
NCT07225114 RECRUITING
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
UNC Lineberger Comprehensive Cancer Center
NCT02690545 ACTIVE NOT RECRUITING
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
NCT07318649 NOT YET RECRUITING
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation
Suzhou Genhouse Bio Co., Ltd.
NCT05584800 RECRUITING
Study of ZGGS18 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07124117 RECRUITING
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
OBI Pharma, Inc
NCT06938880 RECRUITING
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT02286687 ACTIVE NOT RECRUITING
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
M.D. Anderson Cancer Center
NCT05277168 RECRUITING
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Jiangsu HengRui Medicine Co., Ltd.
NCT07313202 NOT YET RECRUITING
Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance
Fujian Cancer Hospital
NCT07028268 RECRUITING
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT04141449 ACTIVE NOT RECRUITING
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
Brigham and Women's Hospital
NCT07309770 RECRUITING
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Sheng Zhang
NCT07310069 ENROLLING BY INVITATION
Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
NCT07309185 RECRUITING
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
Shandong Tumor Hospital
NCT07265622 RECRUITING
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT07306156 RECRUITING
GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
Zhimin Zhai
NCT07307053 NOT YET RECRUITING
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06380660 RECRUITING
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Acerand Therapeutics (Shanghai) Limited
NCT07228247 RECRUITING
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Hutchmed
NCT05256745 RECRUITING
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Georgetown University
NCT05503251 ACTIVE NOT RECRUITING
Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases
Ohio State University Comprehensive Cancer Center
NCT06640283 RECRUITING
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
Instituto do Cancer do Estado de São Paulo
NCT04146298 RECRUITING
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Changhai Hospital
NCT07197827 RECRUITING
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07079462 RECRUITING
Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis
Fudan University
NCT06459973 RECRUITING
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06712680 RECRUITING
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
Sichuan Huiyu Pharmaceutical Co., Ltd
NCT06690775 RECRUITING
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC
NCT07108270 RECRUITING
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline
NCT07282873 NOT YET RECRUITING
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
TYK Medicines, Inc
NCT04495296 RECRUITING
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT04579380 ACTIVE NOT RECRUITING
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen, a wholly owned subsidiary of Pfizer
NCT07229586 RECRUITING
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT07192068 RECRUITING
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
UNICANCER
NCT04130516 RECRUITING
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Linnaeus Therapeutics, Inc.
NCT04198766 ACTIVE NOT RECRUITING
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
NCT03069469 ACTIVE NOT RECRUITING
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC
NCT02726997 ACTIVE NOT RECRUITING
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
M.D. Anderson Cancer Center
NCT07003321 RECRUITING
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT03391479 ACTIVE NOT RECRUITING
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
University Health Network, Toronto
NCT06825494 RECRUITING
Clinical Studies for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT04396821 ACTIVE NOT RECRUITING
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT06926634 RECRUITING
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Washington University School of Medicine
NCT03224000 ACTIVE NOT RECRUITING
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
M.D. Anderson Cancer Center
NCT05879822 ACTIVE NOT RECRUITING
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Incyte Corporation
NCT05566574 ACTIVE NOT RECRUITING
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT02910700 ACTIVE NOT RECRUITING
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
NCT03092856 ACTIVE NOT RECRUITING
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
NCT05731271 ACTIVE NOT RECRUITING
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT05296512 ACTIVE NOT RECRUITING
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
Elizabeth K. Lee MD
NCT04858009 RECRUITING
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
NCT05040360 RECRUITING
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
SWOG Cancer Research Network
NCT06411821 RECRUITING
Ulixertinib in People With Histiocytic Neoplasms
Memorial Sloan Kettering Cancer Center
NCT02755896 ACTIVE NOT RECRUITING
Trial to Compare Radiation Fibrosis With Five Versus Three Fractions
Weill Medical College of Cornell University
NCT06383884 RECRUITING
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
Samsung Medical Center
NCT03131908 ACTIVE NOT RECRUITING
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
M.D. Anderson Cancer Center
NCT06630130 RECRUITING
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Jeeyun Lee
NCT06730750 RECRUITING
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT07279532 NOT YET RECRUITING
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07280377 ACTIVE NOT RECRUITING
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Oncolytics Biotech
NCT03556228 RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
NCT07205536 RECRUITING
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Affiliated Hospital of Nantong University
NCT06518057 RECRUITING
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
University of Washington
NCT06104618 RECRUITING
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Mayo Clinic
NCT06059547 ACTIVE NOT RECRUITING
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
CatalYm GmbH
NCT07277972 NOT YET RECRUITING
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
NCT07277764 RECRUITING
Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
Jiangxi Provincial Cancer Hospital
NCT05522491 NOT YET RECRUITING
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Hebei Medical University Fourth Hospital
NCT01723774 ACTIVE NOT RECRUITING
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
NCT06230471 RECRUITING
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
NCT07273396 NOT YET RECRUITING
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
Seoul National University Hospital
NCT07272590 NOT YET RECRUITING
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06910761 RECRUITING
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
City of Hope Medical Center
NCT06341114 ACTIVE NOT RECRUITING
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
Bio-Thera Solutions
NCT07269158 NOT YET RECRUITING
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
NCT06353906 RECRUITING
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
The Netherlands Cancer Institute
NCT04925609 RECRUITING
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Princess Maxima Center for Pediatric Oncology
NCT06735144 RECRUITING
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06758700 RECRUITING
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
NCT04090528 ACTIVE NOT RECRUITING
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
NCT02932280 ACTIVE NOT RECRUITING
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
NCT07266480 RECRUITING
Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
Hebei Medical University Fourth Hospital
NCT07267234 NOT YET RECRUITING
PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
Second Affiliated Hospital of Soochow University
NCT05194397 RECRUITING
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Children's Hospital of Philadelphia
NCT07263594 NOT YET RECRUITING
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
DualityBio Inc.
NCT07264803 RECRUITING
A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to Guide Treatment in Previously Treated Cancers
Qilu Hospital of Shandong University
NCT06265285 RECRUITING
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
NCT05867615 ACTIVE NOT RECRUITING
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT06703177 RECRUITING
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT04844528 RECRUITING
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
University of Utah
NCT06753747 RECRUITING
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
West China Hospital
NCT03595124 ACTIVE NOT RECRUITING
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
NCT07070518 RECRUITING
Study of GV20-0251 in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT06925581 RECRUITING
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06001658 RECRUITING
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04204850 RECRUITING
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
University Health Network, Toronto
NCT07257653 RECRUITING
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Zhejiang University
NCT06040970 RECRUITING
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Icahn School of Medicine at Mount Sinai
NCT06840821 RECRUITING
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Mainline Biosciences (Shanghai) Co., Ltd
NCT07260058 NOT YET RECRUITING
Immune Cell Therapy for Advanced Solid Tumors
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
NCT07259590 RECRUITING
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Genfleet Therapeutics (Shanghai) Inc.
NCT06439888 RECRUITING
Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT07002203 RECRUITING
Personalized Neoantigen Peptide Vaccines for Solid Tumors
Seqker Biosciences, Inc.
NCT07256782 RECRUITING
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT07256223 NOT YET RECRUITING
A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
Fudan University
NCT06220318 ACTIVE NOT RECRUITING
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Fujian Haixi Pharmaceuticals Co., Ltd.
NCT07241936 RECRUITING
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT07254962 NOT YET RECRUITING
CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)
Sir Mortimer B. Davis - Jewish General Hospital
NCT07136181 RECRUITING
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Novelwise Pharmaceutical Corporation
NCT06107686 RECRUITING
A Study of YL202 in Selected Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07105215 RECRUITING
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
NCT06311851 RECRUITING
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Pardis Noor Medical Imaging and Cancer Center
NCT07249892 NOT YET RECRUITING
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
Chengdu Syncor Pharmaceutical Co., Ltd.
NCT07083323 RECRUITING
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
NCT07243951 NOT YET RECRUITING
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
NCT07246668 RECRUITING
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Yonsei University
NCT01697527 ACTIVE NOT RECRUITING
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Jonsson Comprehensive Cancer Center
NCT07245381 NOT YET RECRUITING
Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation
Dr. Itay GoorAryeh
NCT07245901 NOT YET RECRUITING
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06574880 RECRUITING
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Angela Y. Jia, MD PhD
NCT04590326 RECRUITING
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
NCT05914116 RECRUITING
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT07095868 RECRUITING
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Everest Medicines (Beijing) Co., Ltd.
NCT04299191 RECRUITING
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Laminar Pharmaceuticals
NCT06345482 ACTIVE NOT RECRUITING
A Study of MHB039A for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
NCT07071103 RECRUITING
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Chuangzhen Chen
NCT06500676 RECRUITING
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.
NCT06184035 RECRUITING
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Spago Nanomedical AB
NCT04315701 ACTIVE NOT RECRUITING
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
University of Southern California
NCT05867251 RECRUITING
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
NCT06759064 RECRUITING
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
Qilu Hospital of Shandong University
NCT06373406 ACTIVE NOT RECRUITING
A Study of MHB036C for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
NCT05475171 RECRUITING
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
M.D. Anderson Cancer Center
NCT04094610 RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
NCT07233850 NOT YET RECRUITING
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
Shenyang Sunshine Pharmaceutical Co., LTD.
NCT05958121 RECRUITING
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Immatics Biotechnologies GmbH
NCT06885034 RECRUITING
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
GlaxoSmithKline
NCT07130383 RECRUITING
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT06563362 RECRUITING
Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma
University of Zurich
NCT07126665 RECRUITING
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT05887492 RECRUITING
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Tango Therapeutics, Inc.
NCT04624399 RECRUITING
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
Queen Mary University of London
NCT02479698 RECRUITING
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT06962787 RECRUITING
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05973864 RECRUITING
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
UNICANCER
NCT06640049 ACTIVE NOT RECRUITING
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
GlaxoSmithKline
NCT06848699 RECRUITING
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT07208773 RECRUITING
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06283719 RECRUITING
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT05119907 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan in Patients With Solid Tumor
Gilead Sciences
NCT04180371 ACTIVE NOT RECRUITING
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
NCT07229612 NOT YET RECRUITING
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07019779 RECRUITING
Study of CM518D1 in Patients With Advanced Solid Tumors
Keymed Biosciences Co.Ltd
NCT04561362 ACTIVE NOT RECRUITING
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
NCT05783323 RECRUITING
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Children's Hospital of Philadelphia
NCT04656041 RECRUITING
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
NCT07178938 NOT YET RECRUITING
Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases
MedSIR
NCT05997017 RECRUITING
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience, Inc.
NCT05379985 RECRUITING
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
NCT06150417 RECRUITING
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
NCT03367156 ACTIVE NOT RECRUITING
Dexamethasone in Controlling Dyspnea in Patients With Cancer
M.D. Anderson Cancer Center
NCT05434234 RECRUITING
A Study of YL201 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06088381 RECRUITING
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
University of Maryland, Baltimore
NCT02696993 ACTIVE NOT RECRUITING
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03747757 ACTIVE NOT RECRUITING
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT03674047 ACTIVE NOT RECRUITING
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Massachusetts General Hospital
NCT07226544 NOT YET RECRUITING
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
City of Hope Medical Center
NCT04982653 RECRUITING
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
M.D. Anderson Cancer Center
NCT03035409 ACTIVE NOT RECRUITING
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
M.D. Anderson Cancer Center
NCT04074967 ACTIVE NOT RECRUITING
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT07055594 RECRUITING
A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors
Shine-On Biomedical Co., Ltd.
NCT06749210 RECRUITING
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
Ohio State University Comprehensive Cancer Center
NCT06677190 RECRUITING
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06616766 RECRUITING
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
Yuhan Corporation
NCT05902988 RECRUITING
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics, Inc.
NCT04643418 RECRUITING
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
MegaPro Biomedical Co. Ltd.
NCT05384626 RECRUITING
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
NCT05607004 RECRUITING
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Atossa Therapeutics, Inc.
NCT02346747 ACTIVE NOT RECRUITING
A Trial of Vigil for Participants With Ovarian Cancer
Gradalis, Inc.
NCT06249048 RECRUITING
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Strand Therapeutics Inc.
NCT05205330 ACTIVE NOT RECRUITING
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Rottapharm Biotech
NCT05456685 ACTIVE NOT RECRUITING
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie
NCT06617923 RECRUITING
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06228326 RECRUITING
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Krystal Biotech, Inc.
NCT05118789 RECRUITING
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Nuvalent Inc.
NCT06974604 RECRUITING
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Brown University
NCT05512208 RECRUITING
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
University of Oklahoma
NCT04925544 ACTIVE NOT RECRUITING
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
NCT07218692 NOT YET RECRUITING
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
NCT05706129 RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
NCT05405413 RECRUITING
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
Dartmouth-Hitchcock Medical Center
NCT05565417 ACTIVE NOT RECRUITING
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT05642780 ACTIVE NOT RECRUITING
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Klus Pharma Inc.
NCT06660654 RECRUITING
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Daiichi Sankyo
NCT07173101 RECRUITING
Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
University of Utah
NCT04095234 ACTIVE NOT RECRUITING
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)
Memorial Sloan Kettering Cancer Center
NCT04009044 ACTIVE NOT RECRUITING
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
Northwestern University
NCT07212933 RECRUITING
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
Chinese PLA General Hospital
NCT04370587 RECRUITING
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co. Ltd
NCT03118986 RECRUITING
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
The Hospital for Sick Children
NCT04954599 RECRUITING
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
NCT04209660 ACTIVE NOT RECRUITING
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Memorial Sloan Kettering Cancer Center
NCT03383094 ACTIVE NOT RECRUITING
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Loren Mell, MD
NCT03693014 ACTIVE NOT RECRUITING
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
NCT03915678 RECRUITING
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Institut Bergonié
NCT06967155 ACTIVE NOT RECRUITING
A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
NCT05040815 RECRUITING
Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer
AHS Cancer Control Alberta
NCT05296564 RECRUITING
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
NCT06260774 ACTIVE NOT RECRUITING
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
TransCode Therapeutics
NCT04557449 ACTIVE NOT RECRUITING
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Pfizer
NCT07090174 NOT YET RECRUITING
Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
Weill Medical College of Cornell University
NCT07198321 NOT YET RECRUITING
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
NCT03785249 ACTIVE NOT RECRUITING
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
NCT07172412 NOT YET RECRUITING
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT07196540 NOT YET RECRUITING
IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx
Sun Yat-sen University
NCT04641247 RECRUITING
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
NCT05803018 RECRUITING
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05145400 RECRUITING
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
NCT05965856 RECRUITING
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05785039 RECRUITING
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06682780 RECRUITING
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
NCT07191977 NOT YET RECRUITING
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma
West China Hospital
NCT04446962 ACTIVE NOT RECRUITING
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
Institut Curie
NCT04956640 RECRUITING
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
NCT05941507 RECRUITING
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
NCT07189793 NOT YET RECRUITING
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
First Affiliated Hospital of Wenzhou Medical University
NCT06124378 ACTIVE NOT RECRUITING
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
NCT06212076 RECRUITING
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Nanjing Immunophage Biotech Co., Ltd
NCT06335069 RECRUITING
18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
Maastricht University Medical Center
NCT05877521 ACTIVE NOT RECRUITING
Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief
Memorial Sloan Kettering Cancer Center
NCT05305131 RECRUITING
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
National University Hospital, Singapore
NCT05381038 RECRUITING
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
National University Hospital, Singapore
NCT06027983 NOT YET RECRUITING
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
National University Hospital, Singapore
NCT05652686 RECRUITING
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
NCT04912765 RECRUITING
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
National Cancer Centre, Singapore
NCT04273061 RECRUITING
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
British Columbia Cancer Agency
NCT02628067 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Merck Sharp & Dohme LLC
NCT04614480 RECRUITING
Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine
Centre Georges Francois Leclerc
NCT06520488 RECRUITING
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT02701088 ACTIVE NOT RECRUITING
Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Centre Francois Baclesse
NCT06767813 RECRUITING
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT06205706 ACTIVE NOT RECRUITING
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
BioInvent International AB
NCT03029403 ACTIVE NOT RECRUITING
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
University Health Network, Toronto
NCT03283384 ACTIVE NOT RECRUITING
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
Borstkanker Onderzoek Groep
NCT06385678 ACTIVE NOT RECRUITING
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Jiangsu HengRui Medicine Co., Ltd.
NCT06577194 RECRUITING
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT06985355 RECRUITING
A Study of MHB046C Injection in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT07010692 RECRUITING
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Bruce Robinson, MD
NCT05838729 RECRUITING
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Coordination Pharmaceuticals, Inc.
NCT05329532 RECRUITING
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Scancell Ltd
NCT03647163 ACTIVE NOT RECRUITING
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Vyriad, Inc.
NCT07172802 RECRUITING
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
GI Innovation, Inc.
NCT05934331 RECRUITING
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
LaNova Medicines Zhejiang Co., Ltd.
NCT07169994 RECRUITING
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07170787 NOT YET RECRUITING
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT07168226 NOT YET RECRUITING
Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101
MetaFines
NCT06468358 RECRUITING
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
L & L Bio Co., Ltd., Ningbo, China
NCT05745623 RECRUITING
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
NCT04632108 ACTIVE NOT RECRUITING
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
NCT04511013 RECRUITING
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
NCT07034950 ACTIVE NOT RECRUITING
Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation
The First Affiliated Hospital of Xiamen University
NCT05845814 ACTIVE NOT RECRUITING
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Merck Sharp & Dohme LLC
NCT05632939 ACTIVE NOT RECRUITING
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
AskGene Pharma, Inc.
NCT01770418 ACTIVE NOT RECRUITING
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
Proton Collaborative Group
NCT06866262 RECRUITING
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
NCT02880319 ACTIVE NOT RECRUITING
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Dana-Farber Cancer Institute
NCT06682793 RECRUITING
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT01766297 RECRUITING
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Proton Collaborative Group
NCT07160283 NOT YET RECRUITING
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
The Second Affiliated Hospital of Shandong First Medical University
NCT04606914 RECRUITING
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
University of Alabama at Birmingham
NCT02992210 RECRUITING
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
Shenzhen Geno-Immune Medical Institute
NCT07158918 RECRUITING
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
NCT07040644 NOT YET RECRUITING
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT07157956 NOT YET RECRUITING
CVL006 Combination Therapy in Advanced Solid Tumors
Convalife (Shanghai) Co., Ltd.
NCT07129772 NOT YET RECRUITING
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The University of Hong Kong
NCT07128576 NOT YET RECRUITING
Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors
Zhujiang Hospital
NCT01758445 ACTIVE NOT RECRUITING
Proton Radiation for Stage II/III Breast Cancer
Proton Collaborative Group
NCT05481476 ACTIVE NOT RECRUITING
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
NCT03457948 ACTIVE NOT RECRUITING
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
Nicholas Fidelman, MD
NCT07151586 NOT YET RECRUITING
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
UNICANCER
NCT06237920 RECRUITING
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
The Netherlands Cancer Institute
NCT07153289 NOT YET RECRUITING
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
University Hospital Tuebingen
NCT05669482 ACTIVE NOT RECRUITING
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Verastem, Inc.
NCT05585320 ACTIVE NOT RECRUITING
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
NCT04685226 RECRUITING
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
NCT07150416 NOT YET RECRUITING
Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
The First Affiliated Hospital of Guangzhou Medical University
NCT07000162 RECRUITING
LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial
Azienda USL Reggio Emilia - IRCCS
NCT07146672 RECRUITING
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
Shanghai Cell Therapy Group Co.,Ltd
NCT07145931 NOT YET RECRUITING
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
Sun Yat-sen University
NCT07142837 NOT YET RECRUITING
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT05451849 ACTIVE NOT RECRUITING
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT07142200 NOT YET RECRUITING
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
RenJi Hospital
NCT07140393 NOT YET RECRUITING
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT07137039 NOT YET RECRUITING
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen
The First Affiliated Hospital of Xiamen University
NCT07136142 NOT YET RECRUITING
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06088004 RECRUITING
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
NCT04319783 ACTIVE NOT RECRUITING
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Trans Tasman Radiation Oncology Group
NCT06250036 RECRUITING
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Royal Marsden NHS Foundation Trust
NCT06907043 RECRUITING
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Eikon Therapeutics
NCT06057675 RECRUITING
Tranexamic Acid in Nasal Mohs Reconstruction
Vanderbilt University Medical Center
NCT05761223 RECRUITING
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
1ST Biotherapeutics, Inc.
NCT07127822 NOT YET RECRUITING
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
Peking University
NCT05394103 RECRUITING
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Qurient Co., Ltd.
NCT05864144 ACTIVE NOT RECRUITING
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT00788671 ACTIVE NOT RECRUITING
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
M.D. Anderson Cancer Center
NCT07125547 RECRUITING
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Tianjin Medical University Second Hospital
NCT07122063 ACTIVE NOT RECRUITING
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06376136 RECRUITING
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
Bio-Thera Solutions
NCT07121595 RECRUITING
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
University of Michigan Rogel Cancer Center
NCT05888857 NOT YET RECRUITING
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
Institut Bergonié
NCT05827835 RECRUITING
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Zhejiang University
NCT07118566 NOT YET RECRUITING
Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases
China Medical University, China
NCT07070349 RECRUITING
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT05765500 RECRUITING
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Dana-Farber Cancer Institute
NCT05057013 ACTIVE NOT RECRUITING
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
NCT04164979 ACTIVE NOT RECRUITING
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
NCT05574101 ACTIVE NOT RECRUITING
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
NCT06480240 ACTIVE NOT RECRUITING
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
OBI Pharma, Inc
NCT06356714 RECRUITING
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
Sun Jing
NCT04042753 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Memorial Sloan Kettering Cancer Center
NCT06715592 ACTIVE NOT RECRUITING
ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT07047183 RECRUITING
Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes
Yehui Tan
NCT02029001 RECRUITING
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Centre Leon Berard
NCT07109167 NOT YET RECRUITING
The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors
The Second Affiliated Hospital of Shandong First Medical University
NCT03611868 ACTIVE NOT RECRUITING
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group Inc.
NCT06688175 ENROLLING BY INVITATION
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
The First Affiliated Hospital of Xiamen University
NCT05732389 RECRUITING
Immunotherapy in Patients With Early dMMR Rectal Cancer
Odense University Hospital
NCT07107633 RECRUITING
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
NCT07104110 NOT YET RECRUITING
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
Qilu Pharmaceutical Co., Ltd.
NCT05315700 RECRUITING
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
ORIC Pharmaceuticals
NCT07102004 RECRUITING
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
Qilu Pharmaceutical Co., Ltd.
NCT02711553 ACTIVE NOT RECRUITING
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
NCT07101822 NOT YET RECRUITING
A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER
Hospital Israelita Albert Einstein
NCT06975410 RECRUITING
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Yuhan Corporation
NCT02304809 ACTIVE NOT RECRUITING
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
UNICANCER
NCT07096583 ACTIVE NOT RECRUITING
An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer
Anhui Provincial Cancer Hospital
NCT07095309 NOT YET RECRUITING
Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer
Metanoic Health Ltd.
NCT04069273 RECRUITING
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Harry H Yoon
NCT06543056 RECRUITING
A Study of ES014 in Subjects With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06105021 ACTIVE NOT RECRUITING
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Affini-T Therapeutics, Inc.
NCT04609280 ACTIVE NOT RECRUITING
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
University of Maryland, Baltimore
NCT06805617 RECRUITING
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Glenn J. Hanna
NCT02476786 RECRUITING
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
NCT06732856 RECRUITING
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
Asan Medical Center
NCT06923826 RECRUITING
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
National University Hospital, Singapore
NCT05275777 ACTIVE NOT RECRUITING
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
National University Hospital, Singapore
NCT03806309 ACTIVE NOT RECRUITING
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT05491083 RECRUITING
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
National University Hospital, Singapore
NCT05035745 RECRUITING
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
National University Hospital, Singapore
NCT06208410 RECRUITING
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
NCT04341181 RECRUITING
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Ulrik Lassen
NCT06224244 ACTIVE NOT RECRUITING
External Hypofractionated Radiotherapy With Simultaneous Integrated Boost in Early Breast Cancer Patients
Regina Elena Cancer Institute
NCT03350126 ACTIVE NOT RECRUITING
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT04268121 RECRUITING
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT05978102 RECRUITING
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NCT01594723 ACTIVE NOT RECRUITING
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Eli Lilly and Company
NCT02671435 ACTIVE NOT RECRUITING
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
NCT07077252 NOT YET RECRUITING
Phase I/II Study of SCTB39G in Advanced Solid Tumours
Sinocelltech Ltd.
NCT07077564 NOT YET RECRUITING
The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04022213 ACTIVE NOT RECRUITING
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
Memorial Sloan Kettering Cancer Center
NCT05406674 ACTIVE NOT RECRUITING
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
The Netherlands Cancer Institute
NCT07046221 NOT YET RECRUITING
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
NCT03529422 ACTIVE NOT RECRUITING
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
NCT06932458 RECRUITING
A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
Western University, Canada
NCT03304080 ACTIVE NOT RECRUITING
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Icahn School of Medicine at Mount Sinai
NCT07064863 NOT YET RECRUITING
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
Queen's University
NCT07062536 NOT YET RECRUITING
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
Seoul National University Bundang Hospital
NCT07061639 NOT YET RECRUITING
A Study of QLS5133 Monotherapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT05894824 RECRUITING
T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Yonsei University
NCT07060989 NOT YET RECRUITING
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
Nutshell Therapeutics (Shanghai) Co., LTD.
NCT07059832 ACTIVE NOT RECRUITING
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
First Hospital of China Medical University
NCT07061535 NOT YET RECRUITING
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT03467516 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
Udai Kammula
NCT03935893 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03801083 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Udai Kammula
NCT05592626 RECRUITING
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics, Inc.
NCT06277219 RECRUITING
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Latticon Antibody Therapeutics, Inc
NCT06540729 RECRUITING
RC48 in Combination With AK104 and Bevacizumab in OCCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06790082 RECRUITING
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Aalborg University Hospital
NCT06482515 RECRUITING
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
University of Maryland, Baltimore
NCT07023484 RECRUITING
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
The University of Hong Kong
NCT07022535 RECRUITING
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
The University of Hong Kong
NCT03093688 RECRUITING
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Shanghai Public Health Clinical Center
NCT04594772 ACTIVE NOT RECRUITING
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
NCT06669117 RECRUITING
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Pierre Fabre Medicament
NCT07046650 RECRUITING
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
Sheng Zhang
NCT06811844 RECRUITING
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
The First Affiliated Hospital of Xiamen University
NCT07044349 NOT YET RECRUITING
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
NCT06906887 RECRUITING
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Medical College of Wisconsin
NCT06602063 NOT YET RECRUITING
Surgery for Relapsed Ovarian Cancer in Precision
Shanghai Gynecologic Oncology Group
NCT03175224 RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
NCT06580002 RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT07039968 RECRUITING
Standard Dose Versus High Dose Stereotactic Spine Radiosurgery for Metastatic Spinal Neoplasms
National Taiwan University Hospital
NCT05451043 RECRUITING
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
NCT02817958 ACTIVE NOT RECRUITING
Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis
UNICANCER
NCT05787639 ACTIVE NOT RECRUITING
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
University of California, San Diego
NCT03314974 RECRUITING
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT07032142 NOT YET RECRUITING
Dose Optimization and Efficacy Assessment of a Fluoropyrimidine Antidote
D'Or Institute for Research and Education
NCT05071937 RECRUITING
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
NCT02637687 ACTIVE NOT RECRUITING
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Bayer
NCT05388773 RECRUITING
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Heath Skinner
NCT07026422 RECRUITING
Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)
Shandong Cancer Hospital and Institute
NCT02650986 ACTIVE NOT RECRUITING
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
NCT04916249 ACTIVE NOT RECRUITING
Testing an Herbal Pain Relief Patch to Reduce Pain in Cancer Survivors
Memorial Sloan Kettering Cancer Center
NCT06390995 ACTIVE NOT RECRUITING
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Takeda
NCT05413473 RECRUITING
Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2)
AHS Cancer Control Alberta
NCT07019181 NOT YET RECRUITING
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
The First Affiliated Hospital of Xiamen University
NCT06862323 NOT YET RECRUITING
Time Restricted Eating in Haematological Malignancies
British Columbia Cancer Agency
NCT06447103 RECRUITING
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT07018063 NOT YET RECRUITING
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
zhoujing
NCT05888831 ACTIVE NOT RECRUITING
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT03847649 RECRUITING
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
NCT07002502 NOT YET RECRUITING
Immune Modulation With PRaG-1 Treatment
Second Affiliated Hospital of Soochow University
NCT01273610 ACTIVE NOT RECRUITING
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
NCT03448835 ACTIVE NOT RECRUITING
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
The Netherlands Cancer Institute
NCT07007728 NOT YET RECRUITING
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Peking University Cancer Hospital & Institute
NCT07008703 RECRUITING
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
Shenyang Sunshine Pharmaceutical Co., LTD.
NCT03089554 RECRUITING
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Rachel Miller
NCT05712356 ACTIVE NOT RECRUITING
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Lisata Therapeutics, Inc.
NCT06653777 RECRUITING
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
UNICANCER
NCT06904300 NOT YET RECRUITING
Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer
Sun Yat-sen University
NCT06578624 RECRUITING
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Lamassu Bio Inc
NCT05241249 RECRUITING
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Susan E. Bates
NCT05440227 RECRUITING
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
PhytoHealth Corporation
NCT07003815 NOT YET RECRUITING
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
NCT07003022 RECRUITING
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Fudan University
NCT06831175 RECRUITING
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
West China Hospital
NCT06603844 RECRUITING
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Corbus Pharmaceuticals Inc.
NCT04706715 ACTIVE NOT RECRUITING
LAG3 PET Imaging in Advanced Solid Tumors
University Medical Center Groningen
NCT05010629 ACTIVE NOT RECRUITING
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Glenn J. Hanna
NCT06848439 NOT YET RECRUITING
Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer
Jiangsu Cancer Institute & Hospital
NCT06823479 RECRUITING
Towards Cure Via Only Ultra-short ICB in CSCC
The Netherlands Cancer Institute
NCT06992687 ENROLLING BY INVITATION
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
NCT06991478 NOT YET RECRUITING
SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites
Tianjin Medical University Cancer Institute and Hospital
NCT04575961 ACTIVE NOT RECRUITING
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
NCT04140526 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4, Inc.
NCT02571725 ACTIVE NOT RECRUITING
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
NCT04941287 ACTIVE NOT RECRUITING
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
National Cancer Institute (NCI)
NCT05170958 RECRUITING
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
NCT05541822 RECRUITING
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Abion Inc
NCT03833479 ACTIVE NOT RECRUITING
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
Grupo Español de Investigación en Cáncer de Ovario
NCT05724563 ACTIVE NOT RECRUITING
Domvanalimab and Zimberelimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT04007770 ACTIVE NOT RECRUITING
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
NCT06978400 RECRUITING
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
NCT06809530 RECRUITING
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
NCT05970497 RECRUITING
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Krystal Biotech, Inc.
NCT05251714 ACTIVE NOT RECRUITING
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Treadwell Therapeutics, Inc
NCT05375994 ACTIVE NOT RECRUITING
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Verastem, Inc.
NCT06976021 NOT YET RECRUITING
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
Maria Sklodowska-Curie National Research Institute of Oncology
NCT04104776 RECRUITING
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT05674825 RECRUITING
Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
Medical College of Wisconsin
NCT06908031 RECRUITING
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
NCT06532617 RECRUITING
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT03673787 ACTIVE NOT RECRUITING
A Trial of Ipatasertib in Combination With Atezolizumab
Institute of Cancer Research, United Kingdom
NCT06970132 NOT YET RECRUITING
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
Shouyao Holdings (Beijing) Co. LTD
NCT06971523 RECRUITING
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
CytosinLab Therapeutics Co., Ltd.
NCT06922357 RECRUITING
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
NCT06234748 ACTIVE NOT RECRUITING
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
University of Michigan Rogel Cancer Center
NCT05795244 RECRUITING
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Yonsei University
NCT06963060 ENROLLING BY INVITATION
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
Wei Gong
NCT06742411 RECRUITING
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
West China Hospital
NCT06949982 RECRUITING
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
Sergey Orlov, MD
NCT05263960 RECRUITING
A Study of CM350 in Patients With Advanced Solid Tumors
Keymed Biosciences Co.Ltd
NCT06234098 RECRUITING
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
Alyssum Therapeutics
NCT06955390 NOT YET RECRUITING
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
Henan Cancer Hospital
NCT04375904 RECRUITING
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
Cancer Trials Ireland
NCT04503265 RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AtlasMedx, Incorporated
NCT06078813 RECRUITING
Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases
Cancer Trials Ireland
NCT06951243 NOT YET RECRUITING
A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer
Beijing GoBroad Hospital
NCT01761968 ACTIVE NOT RECRUITING
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Italfarmaco
NCT06949761 NOT YET RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Qilu Pharmaceutical Co., Ltd.
NCT06947226 NOT YET RECRUITING
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT05736731 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT05964361 ACTIVE NOT RECRUITING
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
University Hospital, Antwerp
NCT06669975 RECRUITING
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
AP Biosciences Inc.
NCT03653052 ACTIVE NOT RECRUITING
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
Simon C Pacey, MD
NCT04875611 RECRUITING
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Maria Sklodowska-Curie National Research Institute of Oncology
NCT06940349 RECRUITING
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
Rabin Medical Center
NCT06415318 RECRUITING
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Sun Yat-sen University
NCT06939270 NOT YET RECRUITING
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT06895928 RECRUITING
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06935175 NOT YET RECRUITING
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
Shanghai Zhongshan Hospital
NCT03594396 ACTIVE NOT RECRUITING
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
Seoul National University Hospital
NCT05915351 ACTIVE NOT RECRUITING
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
University of Kansas Medical Center
NCT06928363 NOT YET RECRUITING
A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
NCT04775485 RECRUITING
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT06431243 RECRUITING
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Chengdu Zenitar Biomedical Technology Co., Ltd
NCT05275374 NOT YET RECRUITING
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
Xynomic Pharmaceuticals, Inc.
NCT04634357 RECRUITING
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Eureka Therapeutics Inc.
NCT04776447 ACTIVE NOT RECRUITING
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Fundación GECP
NCT03213002 RECRUITING
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Northwell Health
NCT05379946 ACTIVE NOT RECRUITING
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
InventisBio Co., Ltd
NCT06914674 RECRUITING
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Fudan University
NCT06911333 RECRUITING
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Avelos Therapeutics Inc.
NCT06909383 NOT YET RECRUITING
Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
Guangzhou Institute of Respiratory Disease
NCT06502743 RECRUITING
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Yonsei University
NCT06906731 NOT YET RECRUITING
A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT04969315 RECRUITING
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT05269316 RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
NCT05483400 RECRUITING
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
University Medical Center Groningen
NCT05896371 NOT YET RECRUITING
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
CHU de Quebec-Universite Laval
NCT05784688 RECRUITING
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
NCT02644369 ACTIVE NOT RECRUITING
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
University Health Network, Toronto
NCT06896552 NOT YET RECRUITING
Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.
Rabin Medical Center
NCT05473156 RECRUITING
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
AP Biosciences Inc.
NCT06895733 RECRUITING
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Tianjin Medical University Second Hospital
NCT05101096 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
Gilead Sciences
NCT06892431 NOT YET RECRUITING
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
NCT05599048 RECRUITING
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
Robert Bok, MD, PhD
NCT06892223 RECRUITING
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Istituto Clinico Humanitas
NCT06891521 NOT YET RECRUITING
Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy
Qinghai Red Cross Hospital
NCT03759431 ACTIVE NOT RECRUITING
Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
NCT05146440 RECRUITING
Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor
Grupo Espanol de Investigacion en Sarcomas
NCT05970016 RECRUITING
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
Beijing Tide Pharmaceutical Co., Ltd
NCT06889649 RECRUITING
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Peking University First Hospital
NCT06888531 ACTIVE NOT RECRUITING
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
NCT05485766 RECRUITING
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Okayama University
NCT05636215 RECRUITING
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT06775236 NOT YET RECRUITING
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06873555 RECRUITING
A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Heronova Pharmaceuticals
NCT06880757 NOT YET RECRUITING
177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.
Ankara University
NCT06757244 RECRUITING
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Hopital Foch
NCT04585035 ACTIVE NOT RECRUITING
Study to Evaluate D-1553 in Subjects With Solid Tumors
InventisBio Co., Ltd
NCT06873854 NOT YET RECRUITING
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
NCT06869174 NOT YET RECRUITING
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
Zhiguo Luo, MD, PhD
NCT05142423 RECRUITING
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Akeso
NCT06871527 NOT YET RECRUITING
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
NCT06244992 RECRUITING
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
Pyrotech Therapeutics, Inc.
NCT05185947 ACTIVE NOT RECRUITING
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Cancer Institute (NCI)
NCT05704621 RECRUITING
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
Korea University Guro Hospital
NCT05487170 RECRUITING
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Ranok Therapeutics (Hangzhou) Co., Ltd.
NCT06692270 NOT YET RECRUITING
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
NCT05020860 RECRUITING
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Baylor Breast Care Center
NCT06173219 RECRUITING
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
China-Japan Friendship Hospital
NCT06032845 RECRUITING
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)
Fudan University
NCT04191460 RECRUITING
Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
Erasmus Medical Center
NCT04785196 RECRUITING
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Ascentage Pharma Group Inc.
NCT06239155 ACTIVE NOT RECRUITING
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
Ascentawits Pharmaceuticals, Ltd
NCT06728631 ACTIVE NOT RECRUITING
Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT04165330 ACTIVE NOT RECRUITING
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
NCT05992220 RECRUITING
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
Asan Medical Center
NCT05306028 ACTIVE NOT RECRUITING
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
Fudan University
NCT05214820 RECRUITING
68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
NCT06756061 RECRUITING
Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity
Byung-Sik Cho
NCT06812728 RECRUITING
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
Menoufia University
NCT06813079 NOT YET RECRUITING
Using Tumor Models to Determine Treatments
University Health Network, Toronto
NCT06827080 NOT YET RECRUITING
Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
Zhengguo Chen
NCT05862324 ACTIVE NOT RECRUITING
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Triumvira Immunologics, Inc.
NCT05669430 RECRUITING
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT06293651 RECRUITING
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Dong-A ST Co., Ltd.
NCT06640166 RECRUITING
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT06819215 RECRUITING
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
NCT05200260 RECRUITING
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
NCT06464055 RECRUITING
A Study of GQ1010 in Subjects With Advanced Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd.
NCT06814158 NOT YET RECRUITING
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT05301881 RECRUITING
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
The Netherlands Cancer Institute
NCT06808412 RECRUITING
To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer
xiaohua li
NCT03373097 ACTIVE NOT RECRUITING
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
Bambino Gesù Hospital and Research Institute
NCT05033392 RECRUITING
PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
Wan He
NCT05662397 ACTIVE NOT RECRUITING
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
HotSpot Therapeutics, Inc
NCT03839342 ACTIVE NOT RECRUITING
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
University Health Network, Toronto
NCT06038396 RECRUITING
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
NCT05841420 RECRUITING
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Morten Ladekarl
NCT03526835 RECRUITING
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT06643793 RECRUITING
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Affiliated Hospital of Nantong University
NCT03708224 RECRUITING
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Alain Algazi
NCT04308174 ACTIVE NOT RECRUITING
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Asan Medical Center
NCT05205850 RECRUITING
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
RemeGen Co., Ltd.
NCT06527300 RECRUITING
A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
Zhejiang Wenda Pharma Technology LTD.
NCT06016062 RECRUITING
A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
RemeGen Co., Ltd.
NCT06764628 RECRUITING
A Study of SHR-4375 in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT04974008 ACTIVE NOT RECRUITING
Osteosarcoma Maintenance Therapy With OST31-164
Emerald Clinical Inc.
NCT06787950 NOT YET RECRUITING
Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors
Jiangsu Yahong Meditech Co., Ltd aka Asieris
NCT06783153 NOT YET RECRUITING
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Mansoura University
NCT03707808 RECRUITING
Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab
Universitair Ziekenhuis Brussel
NCT06581419 RECRUITING
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
NCT06649708 RECRUITING
HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
NCT03709680 ACTIVE NOT RECRUITING
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
NCT06771596 ACTIVE NOT RECRUITING
Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06572813 RECRUITING
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Zhejiang University
NCT06422403 RECRUITING
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
National University Hospital, Singapore
NCT04440735 ACTIVE NOT RECRUITING
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Kahr Medical
NCT06643754 RECRUITING
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT05688280 ACTIVE NOT RECRUITING
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Immunophotonics, Inc.
NCT06090266 RECRUITING
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
NCT06762327 NOT YET RECRUITING
Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer
Nanjing First Hospital, Nanjing Medical University
NCT05417321 RECRUITING
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
NCT05218889 RECRUITING
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
NCT06417554 RECRUITING
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06414577 ACTIVE NOT RECRUITING
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
XIANG YANQUN
NCT06748508 NOT YET RECRUITING
Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
Fudan University
NCT06430658 RECRUITING
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06750952 NOT YET RECRUITING
Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
Sun Yat-sen University
NCT06405490 RECRUITING
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05800574 RECRUITING
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Fox Chase Cancer Center
NCT03634540 ACTIVE NOT RECRUITING
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05877430 RECRUITING
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience, Inc.
NCT06139211 RECRUITING
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT06684327 RECRUITING
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Fudan University
NCT05882292 RECRUITING
c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration
Yonsei University
NCT03866525 RECRUITING
OH2 Oncolytic Viral Therapy in Solid Tumors
Binhui Biopharmaceutical Co., Ltd.
NCT06281678 RECRUITING
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
NCT06739395 RECRUITING
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
NCT05052255 ACTIVE NOT RECRUITING
RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors
Ryvu Therapeutics SA
NCT05315167 RECRUITING
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
Zhuhai Yufan Biotechnologies Co., Ltd
NCT05121038 ACTIVE NOT RECRUITING
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
Anup Kasi
NCT06735326 RECRUITING
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Qilu Hospital of Shandong University
NCT05572684 ACTIVE NOT RECRUITING
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure, Inc.
NCT04278287 RECRUITING
Chemoradiotherapy in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT03569241 ACTIVE NOT RECRUITING
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
University Hospital, Ghent
NCT02185443 RECRUITING
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
University of Sao Paulo
NCT03379428 ACTIVE NOT RECRUITING
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
US Oncology Research
NCT06645691 RECRUITING
Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body
National Heart Centre Singapore
NCT05656651 ACTIVE NOT RECRUITING
Acute Immunological Effects of Exercise in Cancer Patients
Universität Duisburg-Essen
NCT06717464 ACTIVE NOT RECRUITING
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT06150885 RECRUITING
A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors
Ever Supreme Bio Technology Co., Ltd.
NCT06112704 RECRUITING
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT05393791 RECRUITING
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Leiden University Medical Center
NCT06704828 NOT YET RECRUITING
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06117566 RECRUITING
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
NCT01542879 RECRUITING
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
Heike E Daldrup-Link
NCT05128487 ACTIVE NOT RECRUITING
A Study of NDI 1150-101 in Patients With Solid Tumors
Nimbus Saturn, Inc.
NCT05824975 RECRUITING
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
NCT03813394 ACTIVE NOT RECRUITING
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
National University Hospital, Singapore
NCT05990452 ACTIVE NOT RECRUITING
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT06292689 RECRUITING
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
Zhejiang Cancer Hospital
NCT05878288 ACTIVE NOT RECRUITING
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
Peter MacCallum Cancer Centre, Australia
NCT05682950 ACTIVE NOT RECRUITING
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Peking Union Medical College Hospital
NCT05869123 ACTIVE NOT RECRUITING
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Peking Union Medical College Hospital
NCT06696742 RECRUITING
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University
NCT02387203 ACTIVE NOT RECRUITING
Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin
Mercy Medical Center
NCT02124421 ACTIVE NOT RECRUITING
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Mercy Medical Center
NCT06117540 RECRUITING
A Study of WX390 in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
NCT05262400 ACTIVE NOT RECRUITING
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Pfizer
NCT05199272 ACTIVE NOT RECRUITING
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
NCT04787042 RECRUITING
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
NCT06643689 NOT YET RECRUITING
Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06682611 NOT YET RECRUITING
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
NCT05965479 RECRUITING
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
University of Southampton
NCT04430192 ACTIVE NOT RECRUITING
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
Peter MacCallum Cancer Centre, Australia
NCT06681636 NOT YET RECRUITING
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
National Institute of Hygiene and Epidemiology, Vietnam
NCT03979131 ACTIVE NOT RECRUITING
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Vall d'Hebron Institute of Oncology
NCT06622486 RECRUITING
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
Egle Therapeutics
NCT06530303 RECRUITING
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Essen Biotech
NCT06598007 RECRUITING
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
NCT03556384 ACTIVE NOT RECRUITING
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Adam Burgoyne, MD, PhD
NCT06410703 RECRUITING
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Canwell Biotech Limited
NCT05522582 ACTIVE NOT RECRUITING
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
Yancheng First People's Hospital
NCT04673942 RECRUITING
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
EpicentRx, Inc.
NCT04492488 ACTIVE NOT RECRUITING
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Shanghai Miracogen Inc.
NCT06605222 RECRUITING
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06646588 RECRUITING
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
NCT04767048 RECRUITING
Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination with Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy
Centre Francois Baclesse
NCT06464913 RECRUITING
Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05620134 ACTIVE NOT RECRUITING
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT04913337 ACTIVE NOT RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT06620029 NOT YET RECRUITING
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
BioMimetix JV, LLC
NCT06506643 RECRUITING
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Vector Vitale LLC
NCT06413615 RECRUITING
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT05765032 ACTIVE NOT RECRUITING
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06611137 RECRUITING
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Sun Yat-sen University
NCT04970121 RECRUITING
Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy
Yan Yang, MD, Ph.D
NCT06611826 NOT YET RECRUITING
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
Zhejiang Cancer Hospital
NCT06612632 RECRUITING
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05638698 ACTIVE NOT RECRUITING
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
University of Kansas Medical Center
NCT06137378 RECRUITING
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
University of Leipzig
NCT04166006 RECRUITING
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT06593548 NOT YET RECRUITING
Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer
Fudan University
NCT04205227 ACTIVE NOT RECRUITING
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
ENB Therapeutics, Inc
NCT04230759 ACTIVE NOT RECRUITING
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
Goethe University
NCT04539496 ACTIVE NOT RECRUITING
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
Sihuan Pharmaceutical Holdings Group Ltd.
NCT06525298 RECRUITING
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Eisbach Bio GmbH
NCT03519074 ACTIVE NOT RECRUITING
Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction
National University Hospital, Singapore
NCT05367778 RECRUITING
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT05139043 ACTIVE NOT RECRUITING
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors
City of Hope Medical Center
NCT06580574 RECRUITING
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Peking University
NCT06014190 RECRUITING
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Hansoh BioMedical R&D Company
NCT06564298 NOT YET RECRUITING
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
The First Affiliated Hospital with Nanjing Medical University
NCT04866134 ACTIVE NOT RECRUITING
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Erasca, Inc.
NCT05176665 RECRUITING
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Shanghai EpimAb Biotherapeutics Co., Ltd.
NCT06471673 RECRUITING
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
BriaCell Therapeutics Corporation
NCT06224387 RECRUITING
CTS2190 Phase I /II Clinical Study in Patients
CytosinLab Therapeutics Co., Ltd.
NCT04185831 ACTIVE NOT RECRUITING
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
Uppsala University Hospital
NCT05913674 RECRUITING
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
Ciusss de L'Est de l'Île de Montréal
NCT04770207 RECRUITING
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Second Affiliated Hospital of Guangzhou Medical University
NCT05399654 ACTIVE NOT RECRUITING
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Tallac Therapeutics
NCT06554028 NOT YET RECRUITING
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
Henan Cancer Hospital
NCT04680260 RECRUITING
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Karen-Lise Garm Spindler
NCT06551896 NOT YET RECRUITING
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06006390 RECRUITING
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT04282031 RECRUITING
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.
NCT05749549 ACTIVE NOT RECRUITING
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
Shanghai Blueray Biopharma Co., Ltd.
NCT06539559 NOT YET RECRUITING
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Wang Jiayu
NCT06537505 NOT YET RECRUITING
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors
Beidahuang Industry Group General Hospital
NCT06015048 RECRUITING
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Jiangsu HengRui Medicine Co., Ltd.
NCT06534762 RECRUITING
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
NCT06531486 NOT YET RECRUITING
A Study of XS-02 Capsules in Patients With Advanced Solid Tumors
NovaOnco Therapeutics Co., Ltd.
NCT06530719 NOT YET RECRUITING
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
Jin Ying
NCT06530524 NOT YET RECRUITING
Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery
Sir Mortimer B. Davis - Jewish General Hospital
NCT05412589 RECRUITING
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06531291 NOT YET RECRUITING
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
NCT05842785 RECRUITING
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Tyligand Bioscience (Shanghai) Limited
NCT06519110 NOT YET RECRUITING
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Convalife (Shanghai) Co., Ltd.
NCT06516926 NOT YET RECRUITING
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT03991832 RECRUITING
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
University Health Network, Toronto
NCT05159245 RECRUITING
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Helsinki University Central Hospital
NCT04706598 ACTIVE NOT RECRUITING
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Fudan University
NCT06495515 NOT YET RECRUITING
Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study
Tianjin Medical University Cancer Institute and Hospital
NCT06492408 RECRUITING
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Second Affiliated Hospital of Guangzhou Medical University
NCT05880043 RECRUITING
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
GI Cell, Inc.
NCT06310382 RECRUITING
GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
Suzhou Genhouse Bio Co., Ltd.
NCT06435455 NOT YET RECRUITING
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT06490068 RECRUITING
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06439589 RECRUITING
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05215470 ACTIVE NOT RECRUITING
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Hospital das Clínicas de Ribeirão Preto
NCT04807166 ACTIVE NOT RECRUITING
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Wenjun Cheng
NCT03694249 ACTIVE NOT RECRUITING
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Vanderbilt-Ingram Cancer Center
NCT03882840 RECRUITING
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
Second Affiliated Hospital of Guangzhou Medical University
NCT04803318 RECRUITING
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT05187338 RECRUITING
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT05532696 RECRUITING
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Anbogen Therapeutics, Inc.
NCT05060432 ACTIVE NOT RECRUITING
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
iTeos Belgium SA
NCT04295447 ACTIVE NOT RECRUITING
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
Universität Münster
NCT04343157 RECRUITING
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
Jona Hattangadi-Gluth
NCT06239298 RECRUITING
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06233292 RECRUITING
A Study of ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06456892 RECRUITING
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
Sun Yat-sen University
NCT06451211 RECRUITING
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
Sun Yat-sen University
NCT00799110 ACTIVE NOT RECRUITING
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
Beth Israel Deaconess Medical Center
NCT04592653 ACTIVE NOT RECRUITING
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Mural Oncology, Inc
NCT06447636 NOT YET RECRUITING
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
NCT06446388 NOT YET RECRUITING
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06018896 RECRUITING
Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
Fudan University
NCT05051696 ACTIVE NOT RECRUITING
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
Liu Zi
NCT05103358 ACTIVE NOT RECRUITING
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc.
NCT06081907 RECRUITING
The Efficacy and Safety of IBI363 in Solid Tumors
Hunan Province Tumor Hospital
NCT05493800 ACTIVE NOT RECRUITING
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
MitoImmune Therapeutics
NCT03714490 RECRUITING
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05964101 RECRUITING
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
The First Affiliated Hospital of Guangzhou Medical University
NCT06423170 RECRUITING
A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04092673 RECRUITING
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Effector Therapeutics
NCT04444869 RECRUITING
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
University of Missouri-Columbia
NCT06019130 RECRUITING
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
German Society for Pediatric Oncology and Hematology GPOH gGmbH
NCT06416358 NOT YET RECRUITING
A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed
AlaMab Therapeutics (Shanghai) Inc.
NCT05693844 RECRUITING
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT04713371 ACTIVE NOT RECRUITING
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
NCT05033756 ACTIVE NOT RECRUITING
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Institut fuer Frauengesundheit
NCT06394713 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06390982 NOT YET RECRUITING
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
Fudan University
NCT06385990 RECRUITING
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
Hunan Cancer Hospital
NCT03767075 RECRUITING
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Vall d'Hebron Institute of Oncology
NCT06366945 NOT YET RECRUITING
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06361979 NOT YET RECRUITING
SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases
Huihua Xiong
NCT05080556 RECRUITING
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
University College, London
NCT04510636 RECRUITING
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
University Health Network, Toronto
NCT06314373 RECRUITING
A Study for HSK39775 in Participants With Solid Tumors
Xizang Haisco Pharmaceutical Co., Ltd
NCT06310473 NOT YET RECRUITING
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
Nanfang Hospital, Southern Medical University
NCT04392505 ACTIVE NOT RECRUITING
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
Oslo University Hospital
NCT04300244 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Åslaug Helland
NCT04817956 RECRUITING
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Oslo University Hospital
NCT06255912 NOT YET RECRUITING
Clinical Trial for Advanced or Metastatic Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06022757 RECRUITING
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Evopoint Biosciences Inc.
NCT04165590 RECRUITING
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
CAS Lamvac Biotech Co., Ltd.
NCT05205200 RECRUITING
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
Fudan University
NCT03838042 RECRUITING
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
University Hospital Heidelberg
NCT05515315 RECRUITING
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Fuzhou General Hospital
NCT06245330 RECRUITING
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
Ascentawits Pharmaceuticals, Ltd
NCT05753826 RECRUITING
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Fujian Cancer Hospital
NCT06241469 NOT YET RECRUITING
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study
Wu Jun
NCT06229340 RECRUITING
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
N.N. Petrov National Medical Research Center of Oncology
NCT02735057 RECRUITING
Chemoradiotherapy in Elderly Patients With Oesophagus Cancer
Centre Hospitalier Universitaire de Besancon
NCT05492123 RECRUITING
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
Hospital Israelita Albert Einstein
NCT05851547 RECRUITING
Dose Escalation For INtraprostatic LEsions
Ottawa Hospital Research Institute
NCT06088030 RECRUITING
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Yang Li
NCT06183736 NOT YET RECRUITING
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Convalife (Shanghai) Co., Ltd.
NCT04889742 NOT YET RECRUITING
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
Charite University, Berlin, Germany
NCT06177925 RECRUITING
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
NCT05801237 RECRUITING
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Shanghai HyaMab Biotech Co.,Ltd.
NCT05681650 RECRUITING
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Chinese PLA General Hospital
NCT04989725 RECRUITING
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
NCT04901234 RECRUITING
Adaptive RadioTherapy for OroPharynx Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
NCT03691714 ACTIVE NOT RECRUITING
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Trisha Wise-Draper
NCT05978648 RECRUITING
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
wang shusen
NCT05923008 RECRUITING
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT02290145 RECRUITING
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
Shanghai Jiao Tong University School of Medicine
NCT06144723 NOT YET RECRUITING
Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.
Hansoh BioMedical R&D Company
NCT06140576 NOT YET RECRUITING
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Zhejiang Cancer Hospital
NCT06132217 NOT YET RECRUITING
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Shanghai Runshi Pharmaceutical Technology Co., Ltd
NCT06130332 RECRUITING
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06121700 RECRUITING
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
Fudan University
NCT05494060 RECRUITING
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
NCT06112041 NOT YET RECRUITING
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
Second Affiliated Hospital of Soochow University
NCT05573802 RECRUITING
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
NCT04277858 RECRUITING
Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
Nader Sadeghi
NCT05624099 RECRUITING
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Fujian Cancer Hospital
NCT05260671 RECRUITING
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Eye & ENT Hospital of Fudan University
NCT06078670 NOT YET RECRUITING
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
Fujian Cancer Hospital
NCT06063070 NOT YET RECRUITING
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Sun Yat-sen University
NCT05602935 ACTIVE NOT RECRUITING
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
The Second Affiliated Hospital of Fujian Medical University
NCT05525247 RECRUITING
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Selecxine
NCT06041490 NOT YET RECRUITING
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Peking Union Medical College Hospital
NCT06039631 RECRUITING
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Fudan University
NCT06037655 NOT YET RECRUITING
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
The First Affiliated Hospital with Nanjing Medical University
NCT06026501 NOT YET RECRUITING
A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd.
NCT05980702 RECRUITING
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05805358 NOT YET RECRUITING
Hyperpolarized 13C MRI for Cancer Immunotherapy
Chang Gung Memorial Hospital
NCT05981014 RECRUITING
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05981001 RECRUITING
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04764227 ACTIVE NOT RECRUITING
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Fudan University
NCT05076942 RECRUITING
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
University Medical Center Groningen
NCT05947487 RECRUITING
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT05941338 RECRUITING
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05919095 NOT YET RECRUITING
A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05909436 RECRUITING
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
Guangzhou Gloria Biosciences Co., Ltd.
NCT05904015 NOT YET RECRUITING
The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05898373 NOT YET RECRUITING
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
Peking Union Medical College
NCT04519151 RECRUITING
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
NCT04617756 RECRUITING
Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
Centre Hospitalier Universitaire de Nīmes
NCT03488667 ACTIVE NOT RECRUITING
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
University of Kansas Medical Center
NCT05824494 NOT YET RECRUITING
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
Women's Hospital School Of Medicine Zhejiang University
NCT05699811 RECRUITING
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT05687357 RECRUITING
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT05204862 RECRUITING
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
NCT05732051 RECRUITING
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
University Hospital, Akershus
NCT05754801 NOT YET RECRUITING
Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer
Chinese University of Hong Kong
NCT05757336 RECRUITING
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Lu Wang, MD, PhD
NCT04014530 RECRUITING
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT05642949 NOT YET RECRUITING
Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors
Minghui Pharmaceutical Pty Ltd
NCT05652855 NOT YET RECRUITING
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
Minghui Pharmaceutical Pty Ltd
NCT05252078 RECRUITING
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
Jiangxi Provincial Cancer Hospital
NCT05651672 RECRUITING
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Tianjin Medical University Cancer Institute and Hospital
NCT05000892 RECRUITING
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05628922 RECRUITING
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Fudan University
NCT05581875 NOT YET RECRUITING
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Hellenic Society of Hematology
NCT03280511 RECRUITING
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Michael Bau Mortensen
NCT04983121 RECRUITING
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
Shengjing Hospital
NCT04996121 RECRUITING
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05439993 RECRUITING
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Hallym University Medical Center
NCT05438368 RECRUITING
GD2/CD70 Bi-specific CAR-T Cell Therapy
Shenzhen Geno-Immune Medical Institute
NCT05437315 RECRUITING
GD2/PSMA Bi-specific CAR-T Cell Therapy
Shenzhen Geno-Immune Medical Institute
NCT05437341 RECRUITING
PSMA/CD70 Bi-specific CAR-T Cell Therapy
Shenzhen Geno-Immune Medical Institute
NCT05422911 NOT YET RECRUITING
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
James J. Peters Veterans Affairs Medical Center
NCT05241561 NOT YET RECRUITING
Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
Centre Hospitalier Universitaire de Besancon
NCT05395962 RECRUITING
Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT03983226 RECRUITING
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Shanghai Gynecologic Oncology Group
NCT03617133 RECRUITING
Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer
Medical University of Vienna
NCT03865082 ACTIVE NOT RECRUITING
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Idera Pharmaceuticals, Inc.
NCT05072600 RECRUITING
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
Peking University First Hospital
NCT05095467 NOT YET RECRUITING
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
Xuefei.Wang
NCT04831437 RECRUITING
Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer
Tehran University of Medical Sciences
NCT05067530 NOT YET RECRUITING
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
Medical University of Gdansk
NCT04109755 RECRUITING
Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
University Hospital, Geneva
NCT05055635 RECRUITING
Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)
University of Aarhus
NCT04993014 RECRUITING
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
AC Camargo Cancer Center
NCT04825938 NOT YET RECRUITING
Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT03985891 RECRUITING
The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Xiangya Hospital of Central South University
NCT03315546 RECRUITING
Radiotherapy Delivery in Deep Inspiration for Pediatric Patients
Rigshospitalet, Denmark
NCT04301375 NOT YET RECRUITING
Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)
David Garcia Cinca
NCT04034173 NOT YET RECRUITING
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Ludwig-Maximilians - University of Munich
NCT03919461 RECRUITING
Colorectal Metastasis Prevention International Trial 2
Assaf-Harofeh Medical Center
NCT02487992 ACTIVE NOT RECRUITING
The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer
The First People's Hospital of Changzhou
NCT02489890 ACTIVE NOT RECRUITING
CIK in Treating Patients With Bladder Cancer
The First People's Hospital of Changzhou
NCT02485015 ACTIVE NOT RECRUITING
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
The First People's Hospital of Changzhou
NCT07594028 NOT YET RECRUITING
Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours
Sinocelltech Ltd.
NCT07591597 NOT YET RECRUITING
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
National Cancer Center Hospital East
NCT07591831 NOT YET RECRUITING
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT07594431 NOT YET RECRUITING
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
Stanford University
NCT07589530 RECRUITING
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
Beijing Biotech
NCT07587879 NOT YET RECRUITING
Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors
IntraAb, Inc.
NCT07586943 NOT YET RECRUITING
SKB118 Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT07586826 RECRUITING
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Peking University People's Hospital
NCT07586813 RECRUITING
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Peking University People's Hospital
NCT04322006 COMPLETED
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
NCT05363709 WITHDRAWN
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
M.D. Anderson Cancer Center
NCT04221438 TERMINATED
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
ECOG-ACRIN Cancer Research Group
NCT04902872 COMPLETED
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04843709 COMPLETED
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Lepu Biopharma Co., Ltd.
NCT02296684 COMPLETED
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT04668833 TERMINATED
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
M.D. Anderson Cancer Center
NCT07568444 COMPLETED
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
NCT03797326 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Merck Sharp & Dohme LLC
NCT05865990 COMPLETED
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
MedSIR
NCT04083976 COMPLETED
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Janssen Research & Development, LLC
NCT04118114 COMPLETED
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
National Cancer Centre, Singapore
NCT05580770 TERMINATED
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
NCT07024537 COMPLETED
FOLFOXIRI-based HAIC Combined With Fuquintinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial
Meng Qiu
NCT01625234 COMPLETED
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Xcovery Holdings, Inc.
NCT04902040 TERMINATED
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
NCT05613088 COMPLETED
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
NCT03872778 COMPLETED
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
Advanced Accelerator Applications
NCT02649855 COMPLETED
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Cancer Institute (NCI)
NCT02576431 COMPLETED
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Bayer
NCT05729399 TERMINATED
Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors
Grit Biotechnology
NCT03818061 COMPLETED
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
Centre Leon Berard
NCT05826600 TERMINATED
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
iOmx Therapeutics AG
NCT03180294 COMPLETED
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
NCT07146919 WITHDRAWN
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
Centre Leon Berard
NCT02661542 COMPLETED
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT02874430 TERMINATED
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05975073 COMPLETED
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
NCT06614140 COMPLETED
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
Seqker Biosciences, Inc.
NCT01507428 COMPLETED
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04523207 COMPLETED
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Janssen Research & Development, LLC
NCT04095208 COMPLETED
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study
Institut Bergonié
NCT02437851 COMPLETED
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
AIDS Malignancy Consortium
NCT04174716 COMPLETED
Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)
Idience Co., Ltd.
NCT06760702 TERMINATED
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers
Aurigene Discovery Technologies Limited
NCT05848011 COMPLETED
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
NCT05275478 TERMINATED
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
NCT06597734 WITHDRAWN
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
NCT00814021 COMPLETED
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
NCT02143219 COMPLETED
Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
Institut Cancerologie de l'Ouest
NCT03575611 SUSPENDED
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT04886271 COMPLETED
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
NCT04799054 TERMINATED
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma Oncology Division A/S
NCT03869762 TERMINATED
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Cancer Trials Ireland
NCT03406299 COMPLETED
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
National Health Research Institutes, Taiwan
NCT05262530 TERMINATED
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
NCT04420884 COMPLETED
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Takeda
NCT05694819 COMPLETED
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
NCT02595905 COMPLETED
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
NCT01968109 COMPLETED
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
NCT04908111 SUSPENDED
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
NCT03459222 COMPLETED
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT02816021 COMPLETED
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT03158129 COMPLETED
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04911907 COMPLETED
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
NCT03370276 COMPLETED
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT02494258 COMPLETED
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
NCT03744468 COMPLETED
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
NCT05068752 COMPLETED
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
NCT05036681 TERMINATED
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
NCT02122185 COMPLETED
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT05982522 WITHDRAWN
IN10018 Combination Therapy in Previously-treated Solid Tumors
InxMed (Shanghai) Co., Ltd.
NCT04461509 COMPLETED
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Alessandro D'Agnolo
NCT03288545 TERMINATED
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Astellas Pharma Global Development, Inc.
NCT05046171 COMPLETED
Decreasing Polypharmacy in Older Adults With Curable Cancers Trial
University of Rochester
NCT06538623 COMPLETED
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
NCT06713798 WITHDRAWN
Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
Gustave Roussy, Cancer Campus, Grand Paris
NCT04904302 TERMINATED
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
NCT06036836 COMPLETED
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Merck Sharp & Dohme LLC
NCT04415944 COMPLETED
Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy
Wake Forest University Health Sciences
NCT03745326 TERMINATED
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT03709446 COMPLETED
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Joseph Sparano
NCT02359968 COMPLETED
PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer
Centre Oscar Lambret
NCT05198804 COMPLETED
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT04016142 TERMINATED
Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer
Centre Oscar Lambret
NCT04789668 TERMINATED
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT04251949 COMPLETED
Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis.
Centre Oscar Lambret
NCT05023655 TERMINATED
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
NCT02528955 COMPLETED
De-Intensification Radiotherapy Postoperative Head Neck
University of Erlangen-Nürnberg Medical School
NCT01198119 TERMINATED
Excision Limits of Oral Cavity Tumor by Narrow Band Imaging
Centre Oscar Lambret
NCT02439034 COMPLETED
Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304)
Centre Oscar Lambret
NCT00420563 COMPLETED
Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
Centre Oscar Lambret
NCT02386397 COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
NCT02829918 COMPLETED
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
NCT05494580 COMPLETED
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
NCT04651127 TERMINATED
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
NCT03446157 COMPLETED
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
NCT00939627 COMPLETED
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
NCT04166383 TERMINATED
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
National Cancer Institute (NCI)
NCT04332653 COMPLETED
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NCT02858310 COMPLETED
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Cancer Institute (NCI)
NCT06820320 COMPLETED
Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06242691 COMPLETED
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
Merck Sharp & Dohme LLC
NCT01761929 COMPLETED
5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases
University Health Network, Toronto
NCT05199584 COMPLETED
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
NCT01409200 COMPLETED
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
NCT03519412 COMPLETED
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
IFOM ETS - The AIRC Institute of Molecular Oncology
NCT04191135 COMPLETED
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Merck Sharp & Dohme LLC
NCT04238819 COMPLETED
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
NCT05148078 COMPLETED
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
NCT04526106 COMPLETED
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
NCT05316688 TERMINATED
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
University of Washington
NCT03400332 COMPLETED
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
NCT04172675 COMPLETED
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
NCT04426669 COMPLETED
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
NCT06005974 TERMINATED
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
NCT03785210 TERMINATED
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Cancer Institute (NCI)
NCT04282018 COMPLETED
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeiGene
NCT03165721 TERMINATED
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Cancer Institute (NCI)
NCT05000294 SUSPENDED
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
NCT04950608 COMPLETED
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
Yvan Beaussant, MD, MSci
NCT02738606 TERMINATED
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT03993353 COMPLETED
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
NCT04482933 WITHDRAWN
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Pediatric Brain Tumor Consortium
NCT05661578 COMPLETED
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
Hoffmann-La Roche
NCT05551117 TERMINATED
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
MacroGenics
NCT05499663 COMPLETED
Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors
University of Maryland, Baltimore
NCT04754425 TERMINATED
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT05325866 COMPLETED
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Amgen
NCT05756907 TERMINATED
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
NCT06682806 TERMINATED
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
NCT04634071 COMPLETED
Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment
Joseph Valentino, MD
NCT06771921 TERMINATED
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
Genmab
NCT04260529 COMPLETED
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Cytovation AS
NCT04157517 TERMINATED
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D LLC
NCT05731947 COMPLETED
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Syndax Pharmaceuticals
NCT03082534 COMPLETED
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
NCT03697304 COMPLETED
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
NCT06254911 SUSPENDED
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
Emory University
NCT03565835 COMPLETED
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Montefiore Medical Center
NCT04504942 COMPLETED
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
NCT05070247 TERMINATED
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
NCT05512377 TERMINATED
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
NCT02636569 COMPLETED
Topical Chemoprevention of Skin Cancer Biomarkers
University of Alabama at Birmingham
NCT04617054 TERMINATED
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Nuvation Bio Inc.
NCT03994601 COMPLETED
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
NCT06556108 COMPLETED
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
NCT04627740 COMPLETED
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
Xinqiao Hospital of Chongqing
NCT02668666 COMPLETED
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Oana Danciu, MD
NCT06553157 COMPLETED
Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy
Minia University
NCT05466994 COMPLETED
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)
M.D. Anderson Cancer Center
NCT07335237 COMPLETED
Clinical Study on the Prevention and Treatment of Postoperative Gastrointestinal Dysfunction by Acupuncture Under ERAS Management Based on Artificial Intelligence Monitoring
Jiangsu Province Hospital of Traditional Chinese Medicine
NCT04773782 COMPLETED
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
NCT05002270 COMPLETED
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jacobio Pharmaceuticals Co., Ltd.
NCT02264613 COMPLETED
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Aileron Therapeutics, Inc.
NCT04260802 TERMINATED
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
NCT03873818 COMPLETED
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
NCT05041257 COMPLETED
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
AbbVie
NCT06478862 TERMINATED
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Lipomedix Pharmaceuticals Inc.
NCT04284488 TERMINATED
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
NCT01995058 TERMINATED
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
NCT06173037 COMPLETED
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
NCT06545617 WITHDRAWN
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
NCT04175847 COMPLETED
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
NCT04717154 COMPLETED
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
Radboud University Medical Center
NCT07071909 WITHDRAWN
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
NCT05628857 COMPLETED
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
RemeGen Co., Ltd.
NCT05774873 COMPLETED
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Innovent Biologics (Suzhou) Co. Ltd.
NCT05174585 COMPLETED
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT06162351 TERMINATED
A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer
Institut Curie
NCT03844750 TERMINATED
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
Chloe Atreya, MD, PhD
NCT06198426 TERMINATED
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT03993678 COMPLETED
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
Swiss Cancer Institute
NCT05898854 COMPLETED
[68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer
Aalborg University Hospital
NCT06376292 COMPLETED
A Prospective Single Arm Phase II Exploratory Study on the Combination of Whole Brain Radiotherapy, Thiotepa Intrathecal Injection and Systemic Treatment of Primary Diseases in the Treatment of Solid Tumor Leptomeningeal Metastasis
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06562673 COMPLETED
Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma
Shanghai 6th People's Hospital
NCT03993379 TERMINATED
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
NCT06391775 TERMINATED
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab
NCT06322342 COMPLETED
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
NCT05307874 COMPLETED
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
ImCheck Therapeutics
NCT03225547 TERMINATED
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
University of Chicago
NCT02854436 COMPLETED
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Janssen Research & Development, LLC
NCT03290079 COMPLETED
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT01319565 COMPLETED
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Cancer Institute (NCI)
NCT03172624 COMPLETED
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
NCT04091022 COMPLETED
Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
University of Alabama at Birmingham
NCT04349267 COMPLETED
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT05001347 COMPLETED
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
NCT03534947 COMPLETED
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
Melanoma Institute Australia
NCT02772562 TERMINATED
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Medical University of South Carolina
NCT03310957 COMPLETED
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Seagen Inc.
NCT04004871 COMPLETED
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Guangxi Medical University
NCT04381650 COMPLETED
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Takeda
NCT05289830 TERMINATED
Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
Case Comprehensive Cancer Center
NCT03526679 COMPLETED
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
National Taiwan University Hospital
NCT03007732 COMPLETED
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
David Oh
NCT04844073 TERMINATED
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Takeda
NCT05358704 SUSPENDED
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Rutgers, The State University of New Jersey
NCT04021043 COMPLETED
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
NCT03274258 TERMINATED
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
M.D. Anderson Cancer Center
NCT05134948 COMPLETED
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04276376 TERMINATED
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
Gustave Roussy, Cancer Campus, Grand Paris
NCT06116578 WITHDRAWN
Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
Gustave Roussy, Cancer Campus, Grand Paris
NCT06924749 COMPLETED
Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia
Shandong Cancer Hospital and Institute
NCT05346380 COMPLETED
Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download
Massachusetts General Hospital
NCT06964165 TERMINATED
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Tesaro, Inc.
NCT05991349 COMPLETED
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT01771458 COMPLETED
A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
Institut Curie
NCT04725331 TERMINATED
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
NCT00727922 COMPLETED
Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity
Assistance Publique - Hôpitaux de Paris
NCT04370509 TERMINATED
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
NCT03498521 COMPLETED
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Hoffmann-La Roche
NCT03369223 COMPLETED
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT03011372 COMPLETED
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Incyte Corporation
NCT03777813 COMPLETED
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
UNICANCER
NCT05383482 COMPLETED
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
NCT06170190 COMPLETED
A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours
Innovent Biologics (Suzhou) Co. Ltd.
NCT05407311 COMPLETED
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Clarity Pharmaceuticals Ltd
NCT04106492 TERMINATED
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
NCT03656718 COMPLETED
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Bristol-Myers Squibb
NCT05935748 TERMINATED
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
NCT05119335 TERMINATED
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
NCT03280563 COMPLETED
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Hoffmann-La Roche
NCT05194735 TERMINATED
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
NCT05798611 TERMINATED
Study of ART0380 in Patients With Biologically Selected Solid Tumors
Artios Pharma Ltd
NCT02875548 COMPLETED
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
Epizyme, Inc.
NCT03822117 TERMINATED
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Incyte Corporation
NCT04972110 TERMINATED
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
Repare Therapeutics
NCT05169437 TERMINATED
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Tempus AI
NCT04208958 COMPLETED
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Vedanta Biosciences, Inc.
NCT05091346 COMPLETED
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
NCT02130492 SUSPENDED
A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)
Weill Medical College of Cornell University
NCT02711137 TERMINATED
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
NCT02959437 TERMINATED
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
NCT03188432 COMPLETED
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Wake Forest University Health Sciences
NCT03939689 COMPLETED
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Progenics Pharmaceuticals, Inc.
NCT02444741 COMPLETED
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04363801 TERMINATED
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
Leap Therapeutics, Inc.
NCT02158858 COMPLETED
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
NCT02285439 COMPLETED
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
NCT04447755 COMPLETED
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
Merck Sharp & Dohme LLC
NCT05407675 COMPLETED
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04616547 TERMINATED
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
National Cancer Institute (NCI)
NCT03755895 COMPLETED
Contribution of Hypnosis to Anxiety and Pain in Brachytherapy Patients
Institut de Cancérologie de Lorraine
NCT05326035 TERMINATED
A Study of WJ05129 in Advanced Malignant Solid Tumors
Suzhou Junjing BioSciences Co., Ltd.
NCT03680092 COMPLETED
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Dimitrios Tzachanis, MD PhD
NCT04985604 TERMINATED
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT04260126 COMPLETED
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
PDS Biotechnology Corp.
NCT05510895 COMPLETED
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
AIO-Studien-gGmbH
NCT02843165 COMPLETED
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
University of California, San Diego
NCT03493945 COMPLETED
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
National Cancer Institute (NCI)
NCT04257448 COMPLETED
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
GWT-TUD GmbH
NCT05271604 COMPLETED
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BioAtla, Inc.
NCT05221320 TERMINATED
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
BioMed Valley Discoveries, Inc
NCT05821777 TERMINATED
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Centessa Pharmaceuticals (UK) Limited
NCT02938793 TERMINATED
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Prisma Health-Upstate
NCT05980624 COMPLETED
ONS in Gastrointestinal Cancer Patients Undergoing Chemotherapy
Beni-Suef University
NCT03446040 TERMINATED
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT04784221 WITHDRAWN
Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse
Centre Francois Baclesse
NCT03711058 COMPLETED
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04278144 TERMINATED
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
NCT03195478 COMPLETED
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
NCT05678257 TERMINATED
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
NCT05199753 COMPLETED
Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
LaNova Australia Pty Limited
NCT05161390 COMPLETED
Study of LM-302 in Patients With Advance Solid Tumors
LaNova Medicines Zhejiang Co., Ltd.
NCT04892342 COMPLETED
Study of ESG401 in Adults With Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
NCT06690281 WITHDRAWN
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Cancer Institute (NCI)
NCT06410534 WITHDRAWN
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
National Cancer Institute (NCI)
NCT06226766 TERMINATED
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT03838367 TERMINATED
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
CytoDyn, Inc.
NCT00924027 COMPLETED
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Cancer Institute (NCI)
NCT03037437 COMPLETED
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
NCT03207555 COMPLETED
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
NCT04356170 COMPLETED
Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma
Groupe Oncologie Radiotherapie Tete et Cou
NCT05633160 TERMINATED
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
Clarity Pharmaceuticals Ltd
NCT01767675 COMPLETED
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
NCT02905578 COMPLETED
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
Joseph J. Cullen
NCT03977467 COMPLETED
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
SCRI Development Innovations, LLC
NCT05578872 COMPLETED
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Anaveon AG
NCT05014828 COMPLETED
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
NCT02923349 COMPLETED
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Biosciences International Sàrl
NCT05208177 TERMINATED
A Study of SHR-1802 in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT05071053 TERMINATED
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
Sanofi
NCT05109442 TERMINATED
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
NCT05259696 COMPLETED
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Palleon Pharmaceuticals, Inc.
NCT04080284 COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Northwell Health
NCT02807597 TERMINATED
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
Samuel Achilefu
NCT03126110 COMPLETED
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Biosciences International Sàrl
NCT05007106 COMPLETED
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Merck Sharp & Dohme LLC
NCT04611126 TERMINATED
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Inge Marie Svane
NCT03314935 COMPLETED
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
NCT01931098 COMPLETED
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Cancer Institute (NCI)
NCT04837196 COMPLETED
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Astellas Pharma Global Development, Inc.
NCT04141995 TERMINATED
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
NCT04717375 TERMINATED
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi
NCT04865731 COMPLETED
Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
NCT05949632 TERMINATED
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
NCT05980598 TERMINATED
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
Ascendis Pharma A/S
NCT02205047 COMPLETED
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT03326193 COMPLETED
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
NCT05017246 TERMINATED
Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy
Washington University School of Medicine
NCT05571293 SUSPENDED
Combination Immunotherapy in Colorectal Cancer
Weill Medical College of Cornell University
NCT01309490 TERMINATED
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
Jewish General Hospital
NCT02428712 COMPLETED
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
Fore Biotherapeutics
NCT02769962 COMPLETED
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03909152 COMPLETED
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Memorial Sloan Kettering Cancer Center
NCT04729348 TERMINATED
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Massachusetts General Hospital
NCT06024174 TERMINATED
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
NCT04381832 COMPLETED
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
NCT05714553 TERMINATED
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
NCT04923529 COMPLETED
TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
The University of Hong Kong
NCT04247282 COMPLETED
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
National Cancer Institute (NCI)
NCT03574779 COMPLETED
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
Tesaro, Inc.
NCT04577963 TERMINATED
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
NCT06498518 WITHDRAWN
A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
Karen Carty
NCT05879484 WITHDRAWN
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
National Cancer Institute (NCI)
NCT02836548 COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
The Netherlands Cancer Institute
NCT04330781 COMPLETED
Radiotherapy of Head and Neck Cancer Using an Intraoral Stent
Oslo University Hospital
NCT02611024 COMPLETED
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
NCT05159388 COMPLETED
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
Servier Bio-Innovation LLC
NCT06926673 COMPLETED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
GlaxoSmithKline
NCT04455620 TERMINATED
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
BioNTech SE
NCT03440437 TERMINATED
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
invoX Pharma Limited
NCT04926324 TERMINATED
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
University of Iowa
NCT03081858 COMPLETED
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
NCT03519295 COMPLETED
A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT03357757 COMPLETED
Avelumab With Valproic Acid in Virus-associated Cancer
AHS Cancer Control Alberta
NCT02078700 COMPLETED
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
NCT02601950 COMPLETED
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Epizyme, Inc.
NCT02432378 TERMINATED
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
NCT06728657 SUSPENDED
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma
Fudan University
NCT05161572 TERMINATED
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
Fudan University
NCT05188729 COMPLETED
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
NCT03013491 TERMINATED
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
CytomX Therapeutics
NCT03739710 COMPLETED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
NCT01197885 COMPLETED
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
Ganymed Pharmaceuticals GmbH
NCT05253053 COMPLETED
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT06067061 TERMINATED
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Institut Curie
NCT03783949 COMPLETED
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
Universitaire Ziekenhuizen KU Leuven
NCT05169684 TERMINATED
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
NCT06087289 COMPLETED
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Novakand Pharma AB
NCT02520154 COMPLETED
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
NCT06592664 WITHDRAWN
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
Lisata Therapeutics, Inc.
NCT03314805 COMPLETED
PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
PhytoHealth Corporation
NCT06790303 TERMINATED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
NCT01720563 TERMINATED
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
PhytoHealth Corporation
NCT02077621 WITHDRAWN
Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer
PhytoHealth Corporation
NCT03611712 COMPLETED
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
PhytoHealth Corporation
NCT03037385 COMPLETED
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Hoffmann-La Roche
NCT04821765 COMPLETED
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04393298 COMPLETED
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Biopharma SRL
NCT04671901 TERMINATED
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT03108131 COMPLETED
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
NCT05481463 COMPLETED
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sun Yat-sen University
NCT05840770 WITHDRAWN
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
NCT02713386 COMPLETED
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
NCT02329847 COMPLETED
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Janssen Research & Development, LLC
NCT04442126 TERMINATED
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
NCT04347226 TERMINATED
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Columbia University
NCT03416153 COMPLETED
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
University of Michigan Rogel Cancer Center
NCT02799095 COMPLETED
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Mural Oncology, Inc
NCT02899078 COMPLETED
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
University of California, Davis
NCT03274414 COMPLETED
A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
Memorial Sloan Kettering Cancer Center
NCT01350245 COMPLETED
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01871441 TERMINATED
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05972720 TERMINATED
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
CARGO Therapeutics
NCT03618641 COMPLETED
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
Diwakar Davar
NCT04914286 COMPLETED
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
NCT04383938 COMPLETED
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Aprea Therapeutics
NCT05311176 TERMINATED
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
Imugene Limited
NCT03570619 COMPLETED
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
University of Michigan Rogel Cancer Center
NCT03212469 COMPLETED
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT04420689 COMPLETED
Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Alume Biosciences, Inc.
NCT04579757 TERMINATED
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
NCT04329221 WITHDRAWN
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
NCT04642287 WITHDRAWN
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
NCT04203641 TERMINATED
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Helix BioPharma Corporation
NCT05251233 TERMINATED
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Washington University School of Medicine
NCT05388435 TERMINATED
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
SK Life Science, Inc.
NCT02632448 COMPLETED
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
NCT05830539 COMPLETED
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
InxMed (Shanghai) Co., Ltd.
NCT04479514 COMPLETED
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
Dana-Farber Cancer Institute
NCT01982682 COMPLETED
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03050879 COMPLETED
Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection
Fujian Medical University
NCT02566304 COMPLETED
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03110107 TERMINATED
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT03472586 COMPLETED
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03428958 COMPLETED
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
NCT04514692 TERMINATED
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
Stanford University
NCT04552990 COMPLETED
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT05435339 TERMINATED
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
Genmab
NCT04875806 TERMINATED
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT02913313 COMPLETED
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT03523351 COMPLETED
Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain
Memorial Sloan Kettering Cancer Center
NCT04704154 COMPLETED
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
NCT04925986 TERMINATED
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Sarah Goldberg
NCT03314324 COMPLETED
A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT03242616 COMPLETED
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Seoul National University Hospital
NCT03735095 COMPLETED
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
Roswell Park Cancer Institute
NCT02795988 COMPLETED
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
NCT05217069 COMPLETED
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
NCT02487095 COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Cancer Institute (NCI)
NCT04720976 COMPLETED
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
NCT03179436 COMPLETED
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Merck Sharp & Dohme LLC
NCT03690869 TERMINATED
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
NCT05126342 WITHDRAWN
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
NCT03903705 COMPLETED
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Hutchmed
NCT04180761 WITHDRAWN
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
University Hospital Tuebingen
NCT04383210 TERMINATED
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
NCT03733990 COMPLETED
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Faron Pharmaceuticals Ltd
NCT03829501 TERMINATED
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
NCT01867606 COMPLETED
Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery
Mayo Clinic
NCT05963386 COMPLETED
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
The First Affiliated Hospital of Xiamen University
NCT02052778 COMPLETED
A Study of TAS-120 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
NCT04084366 TERMINATED
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
OBI Pharma, Inc
NCT04716634 COMPLETED
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
NCT02272998 COMPLETED
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Sameek Roychowdhury
NCT03024437 TERMINATED
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Roberto Pili
NCT04256707 COMPLETED
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
Karyopharm Therapeutics Inc
NCT05315999 COMPLETED
Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care
Gerhild Becker
NCT02684227 COMPLETED
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
M.D. Anderson Cancer Center
NCT05543629 TERMINATED
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
NCT05223088 COMPLETED
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital
NCT04101357 TERMINATED
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
BioNTech SE
NCT06083662 COMPLETED
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Korea University Guro Hospital
NCT04761198 COMPLETED
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
NCT06257758 TERMINATED
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Valerio Therapeutics
NCT02489903 COMPLETED
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
NCT04172506 COMPLETED
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
Akeso
NCT03838263 COMPLETED
Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
UNICANCER
NCT02535338 COMPLETED
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00881621 TERMINATED
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Georgetown University
NCT01767636 COMPLETED
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
NCT05126433 TERMINATED
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Jazz Pharmaceuticals
NCT03744676 COMPLETED
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
NCT03250676 COMPLETED
Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Eisai Inc.
NCT03659136 COMPLETED
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Boehringer Ingelheim
NCT03647423 WITHDRAWN
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
ImmunityBio, Inc.
NCT04804696 TERMINATED
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
NCT01130519 COMPLETED
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Cancer Institute (NCI)
NCT05559541 TERMINATED
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Akeso
NCT04357873 COMPLETED
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
UNICANCER
NCT05188664 COMPLETED
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
LaNova Australia Pty Limited
NCT04718675 TERMINATED
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
Kronos Bio
NCT03691493 COMPLETED
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Emory University
NCT03822936 TERMINATED
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
CNAO National Center of Oncological Hadrontherapy
NCT04162873 TERMINATED
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
NCT04666688 COMPLETED
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
NCT04230408 COMPLETED
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers
Latin American Cooperative Oncology Group
NCT00748709 TERMINATED
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
NCT03662659 COMPLETED
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
NCT02780700 TERMINATED
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Boehringer Ingelheim
NCT04574583 COMPLETED
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
National Cancer Institute (NCI)
NCT05497453 TERMINATED
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
Omega Therapeutics
NCT02533765 COMPLETED
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02819843 COMPLETED
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT04492033 TERMINATED
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
NCT03674567 COMPLETED
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
NCT03127007 COMPLETED
Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer
Grand Hôpital de Charleroi
NCT04350463 COMPLETED
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Celgene
NCT02240238 COMPLETED
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
NanoCarrier Co., Ltd.
NCT03891576 TERMINATED
Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
Mario Negri Institute for Pharmacological Research
NCT04535414 COMPLETED
Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
National Cancer Institute (NCI)
NCT03518606 COMPLETED
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
UNICANCER
NCT04622774 COMPLETED
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
ImmunoGen, Inc.
NCT00780494 COMPLETED
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
NCT01884961 COMPLETED
Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02761057 COMPLETED
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
NCT03314740 COMPLETED
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
Mario Negri Institute for Pharmacological Research
NCT01876927 COMPLETED
Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02281955 COMPLETED
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
UNC Lineberger Comprehensive Cancer Center
NCT03477175 COMPLETED
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Eisai Inc.
NCT04271436 WITHDRAWN
Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
Washington University School of Medicine
NCT05007613 COMPLETED
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
NCT05302921 COMPLETED
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
NCT04791228 WITHDRAWN
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
NCT05456165 WITHDRAWN
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
NCT03535727 COMPLETED
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03950570 COMPLETED
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Orinove, Inc.
NCT02573493 COMPLETED
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Washington University School of Medicine
NCT03717415 TERMINATED
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
NCT01928394 COMPLETED
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT04731467 COMPLETED
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Famewave Ltd.
NCT03601897 TERMINATED
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
NCT05663801 COMPLETED
Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy
Beni-Suef University
NCT05500508 TERMINATED
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
NCT03084536 COMPLETED
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Washington University School of Medicine
NCT06331598 WITHDRAWN
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
Hoffmann-La Roche
NCT03946358 COMPLETED
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
Centre Hospitalier Universitaire de Besancon
NCT04534218 COMPLETED
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
Centre Hospitalier Universitaire de Besancon
NCT04029688 TERMINATED
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
NCT02861300 COMPLETED
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
David Bajor, MD
NCT06524804 TERMINATED
A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
NCT04214418 TERMINATED
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Columbia University
NCT04939701 TERMINATED
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Astellas Pharma Global Development, Inc.
NCT04020185 COMPLETED
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
NCT04168528 COMPLETED
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Universitair Ziekenhuis Brussel
NCT02362464 COMPLETED
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
National Cancer Institute (NCI)
NCT03316638 TERMINATED
A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors
Pierre Fabre Medicament
NCT01288911 COMPLETED
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
NCT05000372 COMPLETED
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
Peking University Cancer Hospital & Institute
NCT06290388 TERMINATED
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
23andMe, Inc.
NCT05060471 COMPLETED
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
Sun Yat-sen University
NCT05328973 COMPLETED
Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial
M.D. Anderson Cancer Center
NCT04508140 TERMINATED
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Highlight Therapeutics
NCT03009058 TERMINATED
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
Immodulon Therapeutics Ltd
NCT04918810 TERMINATED
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
NCT03631407 COMPLETED
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
Merck Sharp & Dohme LLC
NCT01284920 COMPLETED
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Astellas Pharma Inc
NCT05525455 TERMINATED
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
Teon Therapeutics, Inc.
NCT03248570 COMPLETED
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
NCT05416749 SUSPENDED
A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT00889382 COMPLETED
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Astellas Pharma Inc
NCT02057380 COMPLETED
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Global Development, Inc.
NCT03648372 TERMINATED
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda
NCT05261490 TERMINATED
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
NCT02561455 COMPLETED
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Astellas Pharma Global Development, Inc.
NCT01217411 TERMINATED
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
NCT03015740 COMPLETED
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
NCT04933227 TERMINATED
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Hoffmann-La Roche
NCT03769467 TERMINATED
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
NCT01530997 COMPLETED
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
UNC Lineberger Comprehensive Cancer Center
NCT01413750 TERMINATED
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05394350 TERMINATED
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
Merck Sharp & Dohme LLC
NCT01969578 COMPLETED
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT04294784 TERMINATED
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
Huazhong University of Science and Technology
NCT04493619 TERMINATED
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Opna Bio LLC
NCT01261572 COMPLETED
Study to Find Maintenance Dose for Periodic Administration of ASP3550
Astellas Pharma Inc
NCT04068519 COMPLETED
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
BeiGene
NCT03379259 TERMINATED
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
NCT04580836 WITHDRAWN
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
M.D. Anderson Cancer Center
NCT05610826 WITHDRAWN
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
University of Chicago
NCT04690699 TERMINATED
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
Istari Oncology, Inc.
NCT04987281 WITHDRAWN
Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study
M.D. Anderson Cancer Center
NCT05589857 WITHDRAWN
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use
M.D. Anderson Cancer Center
NCT02860039 COMPLETED
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
NCT01915498 COMPLETED
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Celgene
NCT03973333 WITHDRAWN
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Immunocore Ltd
NCT06648902 COMPLETED
Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue
Kidney Cancer Research Bureau
NCT02096354 COMPLETED
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
EpicentRx, Inc.
NCT03204812 COMPLETED
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT03164993 COMPLETED
Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer
Oslo University Hospital
NCT03592264 TERMINATED
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
OBI Pharma, Inc
NCT03714828 COMPLETED
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
University of Arizona
NCT02187991 COMPLETED
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
US Oncology Research
NCT03207867 TERMINATED
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis Pharmaceuticals
NCT04536077 TERMINATED
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Washington University School of Medicine
NCT04683939 TERMINATED
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
NCT05249127 COMPLETED
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Clarity Pharmaceuticals Ltd
NCT05397171 TERMINATED
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
AstraZeneca
NCT01943851 COMPLETED
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
GlaxoSmithKline
NCT03565003 COMPLETED
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Jacobio Pharmaceuticals Co., Ltd.
NCT02264210 COMPLETED
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Sun Yat-sen University
NCT01621568 COMPLETED
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
National Cancer Institute (NCI)
NCT03648489 COMPLETED
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Imperial College London
NCT04065139 COMPLETED
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study
Assistance Publique - Hôpitaux de Paris
NCT00626106 COMPLETED
QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
NantCell, Inc.
NCT04945733 TERMINATED
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Janssen Pharmaceutical K.K.
NCT04474470 COMPLETED
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
TyrNovo Ltd.
NCT03475004 COMPLETED
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
University of Colorado, Denver
NCT04721223 COMPLETED
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT02099864 COMPLETED
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
NCT05824455 TERMINATED
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
NCT04752358 TERMINATED
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
Adaptimmune
NCT03422536 COMPLETED
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
NCT03003195 WITHDRAWN
The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients
University of Arkansas
NCT01284348 TERMINATED
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
NCT06438614 COMPLETED
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma
Fundació Sant Joan de Déu
NCT02875613 TERMINATED
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
Assuntina Sacco, M.D.
NCT03473925 COMPLETED
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
Merck Sharp & Dohme LLC
NCT03693612 COMPLETED
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
NCT03219333 COMPLETED
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Astellas Pharma Inc
NCT04847050 COMPLETED
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Cancer Institute (NCI)
NCT00936936 COMPLETED
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
M.D. Anderson Cancer Center
NCT00791154 TERMINATED
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
NantCell, Inc.
NCT06105008 WITHDRAWN
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
RemeGen Co., Ltd.
NCT00819169 TERMINATED
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NantCell, Inc.
NCT04946864 SUSPENDED
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Ascentage Pharma Group Inc.
NCT06110598 WITHDRAWN
CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
Case Comprehensive Cancer Center
NCT04770688 COMPLETED
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
Shanghai Chest Hospital
NCT04645069 COMPLETED
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
Adagene Inc
NCT02773238 COMPLETED
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
University of Washington
NCT06065059 TERMINATED
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Tango Therapeutics, Inc.
NCT03181035 SUSPENDED
Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer
Sunnybrook Health Sciences Centre
NCT03647969 COMPLETED
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT04534283 TERMINATED
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Anita Turk
NCT00788957 COMPLETED
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.
NCT03327064 WITHDRAWN
A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer
University of Alabama at Birmingham
NCT02009579 COMPLETED
ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Belgian Gynaecological Oncology Group
NCT05001282 TERMINATED
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
NCT04121442 COMPLETED
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
Buzzard Pharmaceuticals
NCT05898828 WITHDRAWN
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
National Cancer Institute (NCI)
NCT03852251 COMPLETED
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Akeso
NCT05574504 WITHDRAWN
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
AdventHealth
NCT03423264 WITHDRAWN
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
University of Chicago
NCT04931420 WITHDRAWN
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
University of Chicago
NCT03323398 TERMINATED
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
NCT03339635 COMPLETED
Short-term Testosterone Replacement in Testicular Cancer Survivors
University Medical Center Groningen
NCT02554812 TERMINATED
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Pfizer
NCT03490292 COMPLETED
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
University of Wisconsin, Madison
NCT03513952 COMPLETED
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
NCT02024009 COMPLETED
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
University of Oxford
NCT06084845 WITHDRAWN
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
NCT04408599 TERMINATED
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT04393454 TERMINATED
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Albert Einstein College of Medicine
NCT01283945 COMPLETED
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Institut de Recherches Internationales Servier
NCT02923934 COMPLETED
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Olivia Newton-John Cancer Research Institute
NCT02091141 COMPLETED
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
NCT04570839 COMPLETED
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Compugen Ltd
NCT03759600 COMPLETED
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
Takeda
NCT02842580 TERMINATED
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
NCT02384759 COMPLETED
Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
Federation Francophone de Cancerologie Digestive
NCT03802123 COMPLETED
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
ImaginAb, Inc.
NCT03439085 TERMINATED
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
NCT01446731 COMPLETED
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Inge Marie Svane
NCT04111107 TERMINATED
Precision Medicine for Patients With Identified Actionable Mutations
Wake Forest University Health Sciences
NCT04541355 COMPLETED
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
Hyunseok Kang, MD
NCT04856774 COMPLETED
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT02490800 COMPLETED
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Basilea Pharmaceutica
NCT04518852 COMPLETED
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Sichuan Cancer Hospital and Research Institute
NCT01326871 COMPLETED
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience
NCT05905614 COMPLETED
Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
NCT02606305 COMPLETED
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
NCT04161391 TERMINATED
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
NCT05531422 COMPLETED
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Lee's Pharmaceutical Limited
NCT06454071 COMPLETED
Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients
Soonchunhyang University Hospital
NCT05153304 WITHDRAWN
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
University of California, San Diego
NCT05093322 COMPLETED
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
NCT03759587 COMPLETED
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
Takeda
NCT02759835 COMPLETED
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
National Cancer Institute (NCI)
NCT06446570 COMPLETED
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
NCT05160168 TERMINATED
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals
NCT04488003 TERMINATED
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
BioMed Valley Discoveries, Inc
NCT02902484 TERMINATED
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
University of Texas Southwestern Medical Center
NCT04319224 TERMINATED
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
Jounce Therapeutics, Inc.
NCT03416335 TERMINATED
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
NCT02453009 COMPLETED
Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
Santa Chiara Hospital
NCT03126812 COMPLETED
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
The Netherlands Cancer Institute
NCT04618393 TERMINATED
A Study of EMB-02 in Participants With Advanced Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.
NCT04207918 COMPLETED
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05807542 COMPLETED
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
Shanghai Zhongshan Hospital
NCT03093155 COMPLETED
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
NCT04396886 COMPLETED
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
The University of Hong Kong
NCT05493995 COMPLETED
A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT05716295 TERMINATED
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
Medikine, Inc.
NCT01851369 COMPLETED
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT02624388 TERMINATED
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
University of Virginia
NCT03044795 WITHDRAWN
Response to PARP Inhibitor Predicted by the RAD51 Assay
University Medical Center Groningen
NCT03035357 WITHDRAWN
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
M.D. Anderson Cancer Center
NCT04738292 TERMINATED
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
NCT03077243 COMPLETED
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
NCT03165994 COMPLETED
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
NCT02718300 TERMINATED
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Incyte Corporation
NCT03572387 COMPLETED
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
NCT05900648 WITHDRAWN
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
M.D. Anderson Cancer Center
NCT04742959 COMPLETED
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT04927910 TERMINATED
Self-applied Acupressure for Arthralgia-fatigue-sleep Disturbance in Breast Cancer
The Hong Kong Polytechnic University
NCT02705105 COMPLETED
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin, Inc.
NCT04808362 TERMINATED
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
Peptomyc S.L.
NCT05538624 TERMINATED
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Avenge Bio, Inc
NCT02798029 COMPLETED
Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT03311334 TERMINATED
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT05581719 TERMINATED
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Enlivex Therapeutics RDO Ltd.
NCT03272477 COMPLETED
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
Palleos Healthcare GmbH
NCT03257631 COMPLETED
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
NCT05148533 TERMINATED
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
NCT02920996 TERMINATED
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
Dana-Farber Cancer Institute
NCT02340884 COMPLETED
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Seattle Children's Hospital
NCT03861156 COMPLETED
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
InventisBio Co., Ltd
NCT04669899 COMPLETED
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
Jounce Therapeutics, Inc.
NCT04430036 TERMINATED
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
NCT02325557 COMPLETED
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Advaxis, Inc.
NCT05071183 TERMINATED
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
NCT03890731 COMPLETED
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
NCT03321630 COMPLETED
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
NYU Langone Health
NCT01962948 TERMINATED
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
NCT01897571 COMPLETED
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Epizyme, Inc.
NCT03007979 COMPLETED
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
NCT01614990 COMPLETED
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Garcia, Jose M., MD, PhD
NCT05067257 SUSPENDED
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Sorrento Therapeutics, Inc.
NCT03110159 COMPLETED
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
Medical Dermatology Specialists
NCT03342937 COMPLETED
KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
Duke University
NCT04172597 TERMINATED
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
Spectrum Pharmaceuticals, Inc
NCT05148195 TERMINATED
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT01543698 COMPLETED
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Pfizer
NCT01953926 TERMINATED
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc.
NCT03665285 COMPLETED
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT03861793 COMPLETED
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Mural Oncology, Inc
NCT05099549 TERMINATED
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
NKGen Biotech, Inc.
NCT03012581 COMPLETED
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
UNICANCER
NCT03012620 COMPLETED
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
UNICANCER
NCT02034981 COMPLETED
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
UNICANCER
NCT05357898 TERMINATED
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
NCT03709706 TERMINATED
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
GlaxoSmithKline
NCT03461952 TERMINATED
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
Canadian Cancer Trials Group
NCT03573544 TERMINATED
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
OBI Pharma, Inc
NCT02830594 COMPLETED
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
NCT03997448 TERMINATED
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Nataliya Uboha
NCT04814875 TERMINATED
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
NCT04337931 TERMINATED
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Apexigen America, Inc.
NCT03834220 TERMINATED
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Debiopharm International SA
NCT03559543 COMPLETED
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
Catalysis SL
NCT03549494 COMPLETED
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Catalysis SL
NCT03651271 COMPLETED
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
Parker Institute for Cancer Immunotherapy
NCT04071756 TERMINATED
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Dana-Farber Cancer Institute
NCT03190811 COMPLETED
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
Capital Medical University
NCT04694183 COMPLETED
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
Quan Wang
NCT03393858 TERMINATED
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Capital Medical University
NCT03757858 COMPLETED
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Capital Medical University
NCT04310410 COMPLETED
Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis
UMC Utrecht
NCT05430555 TERMINATED
A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors
T-knife GmbH
NCT03360630 COMPLETED
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
Capital Medical University
NCT05100316 TERMINATED
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
GlaxoSmithKline
NCT02478502 TERMINATED
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer
University Hospital, Akershus
NCT04250805 TERMINATED
Trial Evaluating the Efficacy of the Combination of ROpivacaine With Reference XYlocaine in the Evaluation of Pain During the Installation of Percutaneous Radiological GASTrostomy
Centre Hospitalier Universitaire de Saint Etienne
NCT03698461 COMPLETED
Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab
Asan Medical Center
NCT02399410 COMPLETED
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis
University Hospital, Ghent
NCT01311713 TERMINATED
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
NCT05074472 COMPLETED
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
ZielBio, Inc.
NCT02073968 COMPLETED
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
Albert Einstein College of Medicine
NCT04092179 TERMINATED
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
University Health Network, Toronto
NCT05331131 WITHDRAWN
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial
Northwell Health
NCT03297359 TERMINATED
WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism
Ottawa Hospital Research Institute
NCT03543813 COMPLETED
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
CytomX Therapeutics
NCT04596150 COMPLETED
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
CytomX Therapeutics
NCT02829723 TERMINATED
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Novartis Pharmaceuticals
NCT05154630 TERMINATED
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT03992131 TERMINATED
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
pharmaand GmbH
NCT03472365 COMPLETED
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT02865135 COMPLETED
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Dana-Farber Cancer Institute
NCT02915523 COMPLETED
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
NCT04508400 COMPLETED
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
Sun Yat-sen University
NCT03149549 TERMINATED
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
CytomX Therapeutics
NCT04999605 TERMINATED
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Akeso
NCT03749460 COMPLETED
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
NCT01336803 COMPLETED
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Heike E Daldrup-Link
NCT03123783 COMPLETED
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Apexigen America, Inc.
NCT04634825 TERMINATED
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
MacroGenics
NCT05363605 TERMINATED
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
NCT04405349 COMPLETED
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
Nykode Therapeutics ASA
NCT01402271 COMPLETED
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT02030067 COMPLETED
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Processa Pharmaceuticals
NCT02318784 COMPLETED
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC
NCT02859064 TERMINATED
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
NCT02195011 COMPLETED
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
SCRI Development Innovations, LLC
NCT03458728 TERMINATED
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Bayer
NCT02363374 COMPLETED
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
Prof. Dr. med. Claus Rödel
NCT01128218 COMPLETED
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Southern Illinois University
NCT04984733 COMPLETED
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
University of Southampton
NCT01190644 TERMINATED
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors
Merck Sharp & Dohme LLC
NCT03367923 COMPLETED
Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors
Stanford University
NCT02567253 COMPLETED
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
University Hospital, Ghent
NCT02258451 COMPLETED
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
NCT03531320 COMPLETED
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
InnoPharmax Inc.
NCT03735589 WITHDRAWN
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
NCT02285543 TERMINATED
A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
Shanghai Jiao Tong University School of Medicine
NCT03684811 COMPLETED
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Forma Therapeutics, Inc.
NCT01334983 COMPLETED
Rapid Easy Strength Training (REST) to Improve Function in Late Stage Cancer
Mayo Clinic
NCT03618134 TERMINATED
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Jonsson Comprehensive Cancer Center
NCT01325441 COMPLETED
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT02432690 TERMINATED
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
Sumitomo Pharma America, Inc.
NCT02024607 COMPLETED
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
NCT02488759 COMPLETED
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
Bristol-Myers Squibb
NCT03649321 TERMINATED
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
NCT02834975 TERMINATED
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
NCT03260712 COMPLETED
Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT01167114 COMPLETED
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Massachusetts General Hospital
NCT05120622 WITHDRAWN
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
University of British Columbia
NCT01545141 TERMINATED
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
NCT03649841 TERMINATED
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
NCT01041027 TERMINATED
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
Albert Einstein College of Medicine
NCT02484443 COMPLETED
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
National Cancer Institute (NCI)
NCT05255484 TERMINATED
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
NCT03833661 COMPLETED
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono Research & Development Institute, Inc.
NCT03206073 COMPLETED
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
National Cancer Institute (NCI)
NCT03003637 COMPLETED
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
The Netherlands Cancer Institute
NCT04246489 COMPLETED
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
EMD Serono Research & Development Institute, Inc.
NCT04288518 COMPLETED
Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.
Tomsk National Research Medical Center of the Russian Academy of Sciences
NCT03274661 COMPLETED
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Baptist Health South Florida
NCT02308280 COMPLETED
Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
Maisonneuve-Rosemont Hospital
NCT01914900 COMPLETED
Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT01703455 COMPLETED
Activity of Sorafenib in Salivary Gland Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT04666623 WITHDRAWN
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
University Hospital, Basel, Switzerland
NCT06090318 WITHDRAWN
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
NCT03468985 COMPLETED
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT01622868 COMPLETED
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
National Cancer Institute (NCI)
NCT03366103 TERMINATED
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
National Cancer Institute (NCI)
NCT03308942 COMPLETED
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
NCT03054909 COMPLETED
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
Masonic Cancer Center, University of Minnesota
NCT03330405 TERMINATED
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
NCT02248597 COMPLETED
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
Wake Forest University Health Sciences
NCT04455139 TERMINATED
A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
Prof. Beck Popovic Maja
NCT04259658 COMPLETED
Histopathologic Effect of Calcium Electroporation on Cancer in the Skin
Zealand University Hospital
NCT02272790 COMPLETED
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AstraZeneca
NCT01714271 COMPLETED
Promotora-based Latino Family CVD Risk Reduction
University of California, Los Angeles
NCT04171700 TERMINATED
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
pharmaand GmbH
NCT04471818 COMPLETED
Ketamine or Placebo in Patients With Major Depression and Advanced Cancer
Instituto Nacional de Cancerologia de Mexico
NCT02101385 COMPLETED
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Bryan Schneider, MD
NCT03186638 COMPLETED
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
University of Rochester NCORP Research Base
NCT03565991 TERMINATED
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Pfizer
NCT03803761 WITHDRAWN
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
National Cancer Institute (NCI)
NCT04534738 COMPLETED
The Effect of a Mediterranean Diet Intervention on Cancer-related Fatigue and Mitochondrial Function During Chemotherapy
University of Rochester
NCT02971956 COMPLETED
Pembrolizumab in Refractory Advanced Esophageal Cancer
Dana-Farber Cancer Institute
NCT03686332 COMPLETED
PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study
The Netherlands Cancer Institute
NCT04521179 COMPLETED
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT04346381 COMPLETED
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT05284214 WITHDRAWN
Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors
Partner Therapeutics, Inc.
NCT05435053 TERMINATED
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
Ismail Gögenur
NCT04538950 COMPLETED
PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
Mayo Clinic
NCT03860207 TERMINATED
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
Y-mAbs Therapeutics
NCT03953235 COMPLETED
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
Gritstone bio, Inc.
NCT05535023 WITHDRAWN
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT01298713 COMPLETED
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
ARCAGY/ GINECO GROUP
NCT03245151 COMPLETED
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
NCT02112552 TERMINATED
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
Albert Einstein College of Medicine
NCT02658890 COMPLETED
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT00993655 COMPLETED
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
NCT02034110 COMPLETED
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis Pharmaceuticals
NCT04566133 TERMINATED
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Cancer Institute (NCI)
NCT03882203 COMPLETED
CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia
Shanghai Jiao Tong University School of Medicine
NCT03682055 TERMINATED
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
NCT03636256 COMPLETED
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NanOlogy, LLC
NCT01813539 COMPLETED
A Study of ARGX-110 in Participants With Advanced Malignancies
OncoVerity, Inc.
NCT04072445 COMPLETED
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
NCT04398368 TERMINATED
Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study
Mayo Clinic
NCT04644315 TERMINATED
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Hoffmann-La Roche
NCT04157088 TERMINATED
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Bayer
NCT03926143 TERMINATED
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Bayer
NCT03602079 COMPLETED
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
NCT02499835 COMPLETED
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
NCT03520842 COMPLETED
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Stanford University
NCT02506517 COMPLETED
A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene
University Health Network, Toronto
NCT02059265 TERMINATED
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
National Cancer Institute (NCI)
NCT02988817 COMPLETED
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
NCT05190575 COMPLETED
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
NCT04424641 TERMINATED
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Genmab
NCT00769782 COMPLETED
Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
NCT00764595 COMPLETED
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
NCT03572582 COMPLETED
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
AIO-Studien-gGmbH
NCT01633541 COMPLETED
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
University of Michigan Rogel Cancer Center
NCT00788125 TERMINATED
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
NCT05109052 WITHDRAWN
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
NCT05191004 WITHDRAWN
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Nuvation Bio Inc.
NCT03283488 COMPLETED
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
University of Sao Paulo
NCT05216120 WITHDRAWN
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
HonorHealth Research Institute
NCT05116891 COMPLETED
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
NCT02904226 COMPLETED
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Jounce Therapeutics, Inc.
NCT03690921 COMPLETED
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
M.D. Anderson Cancer Center
NCT02579811 COMPLETED
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
NCT02784288 COMPLETED
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
University of Michigan Rogel Cancer Center
NCT02640534 TERMINATED
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
Swiss Cancer Institute
NCT03989115 COMPLETED
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
NCT04194034 TERMINATED
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
Transgene
NCT05159778 COMPLETED
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
HiberCell, Inc.
NCT02797977 COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Sierra Oncology LLC - a GSK company
NCT02797964 COMPLETED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
Sierra Oncology LLC - a GSK company
NCT03428126 COMPLETED
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
M.D. Anderson Cancer Center
NCT02520141 COMPLETED
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT02489201 TERMINATED
A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT00813293 COMPLETED
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Beth Israel Deaconess Medical Center
NCT01891344 COMPLETED
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
pharmaand GmbH
NCT04122625 COMPLETED
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
Debiopharm International SA
NCT03824704 TERMINATED
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
NCT04471415 TERMINATED
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Dracen Pharmaceuticals, Inc.
NCT01482715 COMPLETED
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
NCT05582031 WITHDRAWN
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
Translational Research in Oncology
NCT02440685 TERMINATED
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
NCT04510584 WITHDRAWN
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
University Health Network, Toronto
NCT01752920 COMPLETED
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Basilea Pharmaceutica
NCT03020823 TERMINATED
To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer
SynCore Biotechnology Co., Ltd.
NCT03519256 TERMINATED
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
Bristol-Myers Squibb
NCT03637803 TERMINATED
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
4D pharma plc
NCT02344810 WITHDRAWN
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
Eastern Cooperative Oncology Group
NCT04603365 WITHDRAWN
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
NCT03970070 COMPLETED
Perioperative Ostomy Self-Management Telehealth for Cancer Patients and Family Caregivers
City of Hope Medical Center
NCT01845337 COMPLETED
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
University of Edinburgh
NCT02643550 COMPLETED
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Innate Pharma
NCT04291300 COMPLETED
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
Radboud University Medical Center
NCT02895360 COMPLETED
Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Basilea Pharmaceutica
NCT02036476 TERMINATED
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
NCT02297139 COMPLETED
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Bristol-Myers Squibb
NCT03657043 COMPLETED
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
Seagen Inc.
NCT00886782 TERMINATED
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT03469284 COMPLETED
MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
M.D. Anderson Cancer Center
NCT04775680 TERMINATED
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
Adagene (Suzhou) Limited
NCT02932332 COMPLETED
High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
M.D. Anderson Cancer Center
NCT04696848 TERMINATED
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
Tae Won Kim
NCT02426892 COMPLETED
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
M.D. Anderson Cancer Center
NCT03410030 COMPLETED
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
HonorHealth Research Institute
NCT03180476 COMPLETED
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute
NCT04085991 TERMINATED
Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital
NCT03577704 COMPLETED
The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.
Shanghai Henlius Biotech
NCT03841760 TERMINATED
SUV on PSMA PET/CT in Non-Prostate Tumors
Sir Mortimer B. Davis - Jewish General Hospital
NCT03712397 COMPLETED
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
National Health Research Institutes, Taiwan
NCT02992743 COMPLETED
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
GlaxoSmithKline
NCT04489940 TERMINATED
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
EMD Serono Research & Development Institute, Inc.
NCT02754141 COMPLETED
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
Bristol-Myers Squibb
NCT02821754 COMPLETED
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Cancer Institute (NCI)
NCT04208334 COMPLETED
The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer
Phramongkutklao College of Medicine and Hospital
NCT03427411 COMPLETED
M7824 in Subjects With HPV Associated Malignancies
National Cancer Institute (NCI)
NCT03717298 COMPLETED
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Catalysis SL
NCT04730349 TERMINATED
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Bristol-Myers Squibb
NCT02061761 COMPLETED
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
Bristol-Myers Squibb
NCT02872701 COMPLETED
OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
On Target Laboratories, LLC
NCT02970500 TERMINATED
Effect of Methylphenidate on Cancer-related Cognitive Impairment
CHU de Quebec-Universite Laval
NCT03616834 COMPLETED
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Effector Therapeutics
NCT02399813 COMPLETED
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Advaxis, Inc.
NCT02291055 TERMINATED
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
Advaxis, Inc.
NCT05010525 TERMINATED
A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Shanghai Antengene Corporation Limited
NCT02659384 COMPLETED
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT05008445 TERMINATED
Study of LM-102 in Patients With Advance Solid Tumors
LaNova Medicines Development Co., Ltd.
NCT04749602 COMPLETED
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Kidney Cancer Research Bureau
NCT02598960 COMPLETED
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
Bristol-Myers Squibb
NCT02454972 COMPLETED
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
PharmaMar
NCT04169672 COMPLETED
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Hutchison Medipharma Limited
NCT03251924 TERMINATED
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
NCT05419817 WITHDRAWN
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
Haider Mahdi
NCT05222165 WITHDRAWN
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
Helsinn Healthcare SA
NCT03356223 COMPLETED
Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6
Centre Leon Berard
NCT03437200 TERMINATED
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT03121534 TERMINATED
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
M.D. Anderson Cancer Center
NCT01761877 COMPLETED
NSAID Effects on Clinical and Imaging Breast Biomarkers
Stony Brook University
NCT04592484 COMPLETED
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
Codiak BioSciences
NCT04099641 COMPLETED
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
OncXerna Theraputics, Inc.
NCT02756364 COMPLETED
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
Calithera Biosciences, Inc
NCT03043729 COMPLETED
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
AIO-Studien-gGmbH
NCT03614728 TERMINATED
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
GlaxoSmithKline
NCT03193931 TERMINATED
Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers
AIO-Studien-gGmbH
NCT01714739 COMPLETED
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04510285 TERMINATED
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
NCT04518137 TERMINATED
A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)
Shanghai Antengene Corporation Limited
NCT01446016 COMPLETED
Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
The Methodist Hospital Research Institute
NCT05553808 COMPLETED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
GlaxoSmithKline
NCT03477019 COMPLETED
Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer
St. Olavs Hospital
NCT04657315 COMPLETED
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
CHA University
NCT03582618 TERMINATED
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
NCT03617913 COMPLETED
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
NCT02393248 TERMINATED
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
NCT02759588 COMPLETED
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
NCT04515394 TERMINATED
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
EMD Serono Research & Development Institute, Inc.
NCT02963831 COMPLETED
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Ludwig Institute for Cancer Research
NCT04851834 TERMINATED
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
NCT04042116 SUSPENDED
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Clovis Oncology, Inc.
NCT01812603 COMPLETED
A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Jazz Pharmaceuticals
NCT01812616 COMPLETED
A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
Jazz Pharmaceuticals
NCT03873493 COMPLETED
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
AbbVie
NCT02996110 COMPLETED
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
Bristol-Myers Squibb
NCT03258008 TERMINATED
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
M.D. Anderson Cancer Center
NCT04372706 TERMINATED
RTX-240 Monotherapy and in Combination With Pembrolizumab
Rubius Therapeutics
NCT04481009 COMPLETED
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT02762981 COMPLETED
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
NCT02643303 COMPLETED
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
NCT02229149 TERMINATED
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
NCT04866056 TERMINATED
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT02657889 COMPLETED
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Tesaro, Inc.
NCT03980041 COMPLETED
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Infinity Pharmaceuticals, Inc.
NCT02124902 TERMINATED
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Washington University School of Medicine
NCT02612194 TERMINATED
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Wake Forest University Health Sciences
NCT02343549 TERMINATED
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
NCT02387996 COMPLETED
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
Bristol-Myers Squibb
NCT01779050 TERMINATED
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
NCT03101566 COMPLETED
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
University of Michigan Rogel Cancer Center
NCT02489448 COMPLETED
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
Yale University
NCT02593786 COMPLETED
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
NCT04928820 TERMINATED
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
Jonsson Comprehensive Cancer Center
NCT00938106 COMPLETED
Optimized Magnetic Resonance Brachytherapy (MR BT) in Cervix Cancer
University Health Network, Toronto
NCT04547101 TERMINATED
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
Akeso
NCT04172454 COMPLETED
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
Akeso
NCT02866006 COMPLETED
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
Cellid Co., Ltd.
NCT03287375 COMPLETED
Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy -
Michael Bau Mortensen
NCT03781778 TERMINATED
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
Fred Hutchinson Cancer Center
NCT04333914 COMPLETED
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
Centre Leon Berard
NCT03416244 COMPLETED
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
AIO-Studien-gGmbH
NCT03085914 COMPLETED
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
NCT03965845 COMPLETED
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
NCT02639546 COMPLETED
Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Hoffmann-La Roche
NCT02354586 COMPLETED
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Tesaro, Inc.
NCT02463877 COMPLETED
A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy
University of California, San Diego
NCT02865811 COMPLETED
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Dana-Farber Cancer Institute
NCT05041972 WITHDRAWN
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Ambrx, Inc.
NCT03955471 TERMINATED
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
Tesaro, Inc.
NCT03989362 COMPLETED
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
Jounce Therapeutics, Inc.
NCT02307500 COMPLETED
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Istituto Clinico Humanitas
NCT03455140 COMPLETED
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
University of Birmingham
NCT00936832 WITHDRAWN
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
NCT01864772 COMPLETED
Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC
Groupe Oncologie Radiotherapie Tete et Cou
NCT02141906 COMPLETED
A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin
University of Texas Southwestern Medical Center
NCT02341625 TERMINATED
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Bristol-Myers Squibb
NCT01582009 TERMINATED
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
NCT04075604 COMPLETED
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Bristol-Myers Squibb
NCT03325166 TERMINATED
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
OHSU Knight Cancer Institute
NCT04447235 TERMINATED
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
Instituto do Cancer do Estado de São Paulo
NCT03287947 TERMINATED
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Wake Forest University Health Sciences
NCT03130959 COMPLETED
A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
Bristol-Myers Squibb
NCT05191017 WITHDRAWN
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
Nuvation Bio Inc.
NCT03524820 TERMINATED
Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
Hadassah Medical Organization
NCT02404441 COMPLETED
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Novartis Pharmaceuticals
NCT05263609 WITHDRAWN
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
NCT02130466 COMPLETED
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
Merck Sharp & Dohme LLC
NCT04001413 WITHDRAWN
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02700308 TERMINATED
A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases
Centre Leon Berard
NCT03843853 WITHDRAWN
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT04315246 WITHDRAWN
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Y-mAbs Therapeutics
NCT04080843 COMPLETED
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
Zhejiang University
NCT03531827 TERMINATED
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
National Cancer Institute (NCI)
NCT02582749 TERMINATED
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Ajjai Alva, MD
NCT02499952 TERMINATED
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Nasser Hanna, M.D.
NCT03562897 COMPLETED
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Catalysis SL
NCT02317991 COMPLETED
Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
SCRI Development Innovations, LLC
NCT01320280 TERMINATED
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
Universitätsklinikum Hamburg-Eppendorf
NCT04895046 WITHDRAWN
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Walid Shaib, MD
NCT03245450 COMPLETED
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eisai Inc.
NCT02303028 COMPLETED
Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours
The Hospital for Sick Children
NCT03199144 WITHDRAWN
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
Centre Francois Baclesse, Luxembourg
NCT03913741 COMPLETED
A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Genmab
NCT04138875 WITHDRAWN
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Yale University
NCT03050060 TERMINATED
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
NCT03144687 COMPLETED
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Incyte Corporation
NCT02880371 TERMINATED
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Pfizer
NCT02447419 COMPLETED
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
Samsung Medical Center
NCT03170180 COMPLETED
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
NCT03392428 COMPLETED
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
NCT02736305 COMPLETED
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
National Cancer Centre, Singapore
NCT04475016 COMPLETED
TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer
Sun Yat-sen University
NCT01434290 COMPLETED
Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
NCT01157091 COMPLETED
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
NCT01664182 COMPLETED
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
NCT02720185 TERMINATED
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
University of Wisconsin, Madison
NCT04176952 TERMINATED
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
Judith Dixon-Hughes
NCT05165849 WITHDRAWN
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
Zhejiang Genfleet Therapeutics Co., Ltd.
NCT04327986 TERMINATED
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
National Cancer Institute (NCI)
NCT03409848 COMPLETED
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
AIO-Studien-gGmbH
NCT02138955 COMPLETED
A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer
SignPath Pharma, Inc.
NCT04003623 TERMINATED
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Incyte Corporation
NCT02832167 COMPLETED
An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT03551795 COMPLETED
Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor
Xiaoyan Zhang
NCT04200404 COMPLETED
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
CStone Pharmaceuticals
NCT03410446 COMPLETED
Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
University Health Network, Toronto
NCT03075826 COMPLETED
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Weill Medical College of Cornell University
NCT02107937 COMPLETED
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
SOTIO a.s.
NCT03469713 COMPLETED
Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
Gruppo Oncologico Italiano di Ricerca Clinica
NCT02850874 WITHDRAWN
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
NCT02154529 TERMINATED
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Kadmon Corporation, LLC
NCT03294252 TERMINATED
Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers
Institut Cancerologie de l'Ouest
NCT03695510 COMPLETED
Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
National Taiwan University Hospital
NCT03787251 WITHDRAWN
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT01134250 COMPLETED
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Philogen S.p.A.
NCT01670877 COMPLETED
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Washington University School of Medicine
NCT03684785 TERMINATED
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
NCT02859415 TERMINATED
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Cancer Institute (NCI)
NCT01336634 COMPLETED
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Novartis Pharmaceuticals
NCT04125693 COMPLETED
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Bayer
NCT03334409 TERMINATED
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
NCT02349386 TERMINATED
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
BHR Pharma, LLC
NCT02614859 COMPLETED
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
Fox Chase Cancer Center
NCT03292250 COMPLETED
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
NCT02111850 COMPLETED
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Cancer Institute (NCI)
NCT04809012 WITHDRAWN
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
NCT02674061 COMPLETED
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Merck Sharp & Dohme LLC
NCT02978716 TERMINATED
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc.
NCT02362451 TERMINATED
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
National Cancer Institute (NCI)
NCT03067610 COMPLETED
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT00855803 COMPLETED
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
University of Texas Southwestern Medical Center
NCT02810418 COMPLETED
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
National Cancer Institute (NCI)
NCT03515551 TERMINATED
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
Immunocore Ltd
NCT01515306 COMPLETED
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Eli Lilly and Company
NCT01650350 TERMINATED
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
Brown University
NCT03454620 COMPLETED
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
Green Cross Corporation
NCT03347123 TERMINATED
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Incyte Corporation
NCT03792750 COMPLETED
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
NCT03352934 COMPLETED
Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy
Johannes Gutenberg University Mainz
NCT04015336 TERMINATED
E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
NCT04832438 WITHDRAWN
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Actuate Therapeutics Inc.
NCT03868423 WITHDRAWN
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Sameek Roychowdhury
NCT03875313 TERMINATED
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Calithera Biosciences, Inc
NCT02728258 COMPLETED
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NRG Oncology
NCT02178722 COMPLETED
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
NCT01295697 TERMINATED
Study of EZN-2208 Pediatric Patients With Solid Tumors
Enzon Pharmaceuticals, Inc.
NCT01499160 TERMINATED
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
NCT02460224 COMPLETED
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT03137537 TERMINATED
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
Dana-Farber Cancer Institute
NCT05181865 WITHDRAWN
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
Flame Biosciences
NCT02392637 COMPLETED
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
NCT02083354 COMPLETED
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Novartis Pharmaceuticals
NCT03322384 COMPLETED
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
University of California, Davis
NCT05167370 TERMINATED
High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors
Children's Hospital Medical Center, Cincinnati
NCT01759836 COMPLETED
Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer
Asan Medical Center
NCT02737475 COMPLETED
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT03029611 TERMINATED
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
University of Washington
NCT02318277 COMPLETED
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
Incyte Corporation
NCT02874651 TERMINATED
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Sun Yat-sen University
NCT03132038 COMPLETED
Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
UNICANCER
NCT03220854 COMPLETED
SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx
Virginia Commonwealth University
NCT01670409 COMPLETED
Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
Chuangzhen Chen
NCT02963610 TERMINATED
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Fox Chase Cancer Center
NCT02001623 COMPLETED
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
NCT04757090 WITHDRAWN
89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Washington University School of Medicine
NCT03050814 TERMINATED
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Cancer Institute (NCI)
NCT01889186 COMPLETED
A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
AbbVie
NCT02595372 COMPLETED
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
Kathy Miller
NCT04105062 WITHDRAWN
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Washington University School of Medicine
NCT02587598 TERMINATED
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
NCT03111732 COMPLETED
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Cancer Institute (NCI)
NCT04165031 TERMINATED
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
NCT02506114 TERMINATED
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
Lawrence Fong
NCT01677741 COMPLETED
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Novartis Pharmaceuticals
NCT02725268 COMPLETED
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
Millennium Pharmaceuticals, Inc.
NCT03520231 COMPLETED
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
NCT03123588 TERMINATED
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Incyte Corporation
NCT01294670 COMPLETED
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT02137252 TERMINATED
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Dana-Farber Cancer Institute
NCT01312389 TERMINATED
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine
NCT02756572 COMPLETED
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
University of Washington
NCT03245736 COMPLETED
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen Inc.
NCT03410914 COMPLETED
Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Sunnybrook Health Sciences Centre
NCT01750918 COMPLETED
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Novartis Pharmaceuticals
NCT01035658 TERMINATED
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
NCT04381988 TERMINATED
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
Memorial Sloan Kettering Cancer Center
NCT01492582 COMPLETED
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
University of Alabama at Birmingham
NCT02643056 COMPLETED
Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer
Southern Europe New Drug Organization
NCT03096808 COMPLETED
Adaptive Radiotherapy for Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT01773785 TERMINATED
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Spectrum Pharmaceuticals, Inc
NCT02213042 TERMINATED
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Novartis Pharmaceuticals
NCT01853644 COMPLETED
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Northwestern University
NCT02115542 COMPLETED
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
NCT02508636 TERMINATED
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
University of California, San Francisco
NCT03738787 COMPLETED
Treatment of the Pancreatic Stump With Neoprene®-Based Glue After High-risk Pancreatoduodenectomy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT03276013 COMPLETED
Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer
Vall d'Hebron Institute of Oncology
NCT01816984 COMPLETED
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
University of Chicago
NCT02565901 TERMINATED
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of Washington
NCT02907918 TERMINATED
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
Washington University School of Medicine
NCT03261947 COMPLETED
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT01847001 COMPLETED
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Columbia University
NCT02423343 COMPLETED
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Eli Lilly and Company
NCT02992886 COMPLETED
Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly
Chinese Academy of Medical Sciences
NCT02599779 COMPLETED
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
Sunnybrook Health Sciences Centre
NCT01633372 COMPLETED
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
Incyte Corporation
NCT01173692 COMPLETED
Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.
M.D. Anderson Cancer Center
NCT04430933 WITHDRAWN
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
NextCure, Inc.
NCT01381718 COMPLETED
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
University of South Florida
NCT01631552 COMPLETED
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
NCT03394885 COMPLETED
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
Duke University
NCT02531737 COMPLETED
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
University Hospital, Limoges
NCT00624312 WITHDRAWN
Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations
University of Louisville
NCT01120639 COMPLETED
Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
Stanford University
NCT02521870 TERMINATED
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Dynavax Technologies Corporation
NCT02629523 COMPLETED
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA
Chonnam National University Hospital
NCT02769286 COMPLETED
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Chonnam National University Hospital
NCT02869295 COMPLETED
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Nektar Therapeutics
NCT04180384 COMPLETED
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Athenex, Inc.
NCT01094405 COMPLETED
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Chinese University of Hong Kong
NCT02765165 TERMINATED
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
NCT02925000 COMPLETED
Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy
Taiwan Liposome Company
NCT03098550 COMPLETED
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
Bristol-Myers Squibb
NCT01396733 WITHDRAWN
Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer
Asan Medical Center
NCT03277352 TERMINATED
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Biosciences International Sàrl
NCT02124772 COMPLETED
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Novartis Pharmaceuticals
NCT03097588 COMPLETED
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
OHSU Knight Cancer Institute
NCT01457118 COMPLETED
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
Nektar Therapeutics
NCT03648879 COMPLETED
Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome
National Cancer Institute (NCI)
NCT01784861 TERMINATED
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Washington University School of Medicine
NCT04655183 WITHDRAWN
Study of M4344 in Combination With Niraparib
EMD Serono Research & Development Institute, Inc.
NCT03142516 COMPLETED
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
Grupo Espanol Multidisciplinario del Cancer Digestivo
NCT02718144 COMPLETED
Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer
Pantarhei Oncology B.V.
NCT03451773 TERMINATED
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
National Cancer Institute (NCI)
NCT02092298 COMPLETED
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
M.D. Anderson Cancer Center
NCT03113825 COMPLETED
Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Avelas Biosciences, Inc.
NCT02940223 TERMINATED
Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
NCT03052478 COMPLETED
Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Samsung Medical Center
NCT01433991 TERMINATED
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
Eisai Inc.
NCT02941523 COMPLETED
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Noxopharm Limited
NCT01220128 TERMINATED
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
GlaxoSmithKline
NCT02055690 TERMINATED
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
The Christie NHS Foundation Trust
NCT01728233 COMPLETED
Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT01562626 SUSPENDED
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
Anaeropharma Science, Inc.
NCT04464967 WITHDRAWN
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
NCT03264066 COMPLETED
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Hoffmann-La Roche
NCT01406769 COMPLETED
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
Gynecologic Oncology Group
NCT01238120 COMPLETED
The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients
University of Rochester
NCT01835626 COMPLETED
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Sue Yom
NCT02845908 COMPLETED
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
Fujian Cancer Hospital
NCT02281409 COMPLETED
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT01077999 COMPLETED
Chemoradiation and Panitumumab for Esophageal Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT02394652 COMPLETED
The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial
University Health Network, Toronto
NCT03597009 TERMINATED
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
UNC Lineberger Comprehensive Cancer Center
NCT02311361 COMPLETED
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT02127710 COMPLETED
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
AstraZeneca
NCT03937791 TERMINATED
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
National Cancer Institute (NCI)
NCT03125629 COMPLETED
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
Stanford University
NCT02552121 COMPLETED
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
NCT03289819 COMPLETED
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
Institut fuer Frauengesundheit
NCT01002924 COMPLETED
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Endocyte
NCT03955224 WITHDRAWN
Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer
Institut Claudius Regaud
NCT01033240 COMPLETED
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
NCT02805660 TERMINATED
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mirati Therapeutics Inc.
NCT02128243 COMPLETED
Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
AIO-Studien-gGmbH
NCT03876925 TERMINATED
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
Sunshine Lake Pharma Co., Ltd.
NCT01967823 COMPLETED
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Cancer Institute (NCI)
NCT02750514 TERMINATED
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
Bristol-Myers Squibb
NCT03666728 TERMINATED
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
NCT03729297 TERMINATED
Cabozantinib in Advanced Salivary Gland Cancer Patients
Radboud University Medical Center
NCT01037790 COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine
NCT02162719 COMPLETED
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
Genentech, Inc.
NCT01178411 COMPLETED
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT02633540 TERMINATED
Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function
Fox Chase Cancer Center
NCT03600467 TERMINATED
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma
St Vincent's Hospital, Sydney
NCT04243954 COMPLETED
Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration
Fujian Cancer Hospital
NCT02860819 COMPLETED
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer
National Cancer Institute, Slovakia
NCT01838317 COMPLETED
A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
University of Texas Southwestern Medical Center
NCT02953782 COMPLETED
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
Gilead Sciences
NCT02697591 COMPLETED
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
Incyte Biosciences International Sàrl
NCT01610206 COMPLETED
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Linda R Duska
NCT00827359 COMPLETED
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Beth Israel Deaconess Medical Center
NCT02273739 COMPLETED
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
NCT01989546 COMPLETED
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
National Cancer Institute (NCI)
NCT03638622 COMPLETED
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.
Massachusetts General Hospital
NCT02641691 COMPLETED
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Washington University School of Medicine
NCT03233412 COMPLETED
Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions
Barretos Cancer Hospital
NCT01835158 COMPLETED
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT03368859 TERMINATED
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
NCT00768664 COMPLETED
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Pfizer
NCT04536922 WITHDRAWN
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
National Cancer Institute (NCI)
NCT02004418 COMPLETED
A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland
AHS Cancer Control Alberta
NCT02725489 COMPLETED
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Mary Crowley Medical Research Center
NCT02470533 TERMINATED
Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Erasmus Medical Center
NCT03274011 COMPLETED
Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Fudan University
NCT02495103 TERMINATED
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
National Cancer Institute (NCI)
NCT01414738 COMPLETED
Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases
University of Texas Southwestern Medical Center
NCT03081884 COMPLETED
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
Emory University
NCT02163057 COMPLETED
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
NCT02587962 TERMINATED
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
NCT03742713 COMPLETED
Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer
Cristal Therapeutics
NCT02082210 COMPLETED
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Eli Lilly and Company
NCT03363776 TERMINATED
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
Bristol-Myers Squibb
NCT03170115 TERMINATED
Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer
Instituto Nacional de Cancer, Brazil
NCT01084330 COMPLETED
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
Novartis Pharmaceuticals
NCT04437953 WITHDRAWN
Avatrombopag for Thrombocytopenia in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT03789175 COMPLETED
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome
National Heart, Lung, and Blood Institute (NHLBI)
NCT03464968 COMPLETED
mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line
Seoul National University Bundang Hospital
NCT01684215 COMPLETED
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
Pfizer
NCT01097239 WITHDRAWN
Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer
Imperial College London
NCT04635852 COMPLETED
Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients
University of Cologne
NCT02780687 COMPLETED
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
Boehringer Ingelheim
NCT03173859 WITHDRAWN
Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
University of Athens
NCT01443065 COMPLETED
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
UNICANCER
NCT03312114 TERMINATED
Anti-PD-L1 and SAbR for Ovarian Cancer
University of Texas Southwestern Medical Center
NCT03480750 COMPLETED
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
National Cheng-Kung University Hospital
NCT02788201 COMPLETED
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
NCT00970203 COMPLETED
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
Roswell Park Cancer Institute
NCT01020864 WITHDRAWN
Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer
Per Pfeiffer
NCT02605083 TERMINATED
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Effector Therapeutics
NCT00983801 COMPLETED
Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
R-Pharm
NCT01899599 COMPLETED
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
Glycotope GmbH
NCT02709889 TERMINATED
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
NCT01326923 TERMINATED
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
Louisiana State University Health Sciences Center Shreveport
NCT00633061 TERMINATED
Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer
University of Texas Southwestern Medical Center
NCT04561817 WITHDRAWN
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Icahn School of Medicine at Mount Sinai
NCT01532089 COMPLETED
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Academic and Community Cancer Research United
NCT02253992 TERMINATED
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
NCT01566435 COMPLETED
Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
Washington University School of Medicine
NCT01681472 COMPLETED
PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
Isofol Medical AB
NCT04044950 WITHDRAWN
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
NCT02038218 COMPLETED
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DEKK-TEC, Inc.
NCT03348826 WITHDRAWN
Study of Sodium Bicarbonate in Restoring Blocked Catheters
University Health Network, Toronto
NCT01616303 COMPLETED
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Quest PharmaTech Inc.
NCT01622621 TERMINATED
Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer
Mayo Clinic
NCT00749892 COMPLETED
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
M.D. Anderson Cancer Center
NCT00892424 COMPLETED
Sorafenib-RT Treatment for Liver Metastasis (SLIM)
University Health Network, Toronto
NCT02315625 TERMINATED
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Cancer Institute (NCI)
NCT04539769 COMPLETED
Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes
Kyungpook National University Chilgok Hospital
NCT01208103 COMPLETED
Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma
M.D. Anderson Cancer Center
NCT03097770 COMPLETED
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Chinese PLA General Hospital
NCT01535157 TERMINATED
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
South Plains Oncology Consortium
NCT03351231 TERMINATED
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
Bristol-Myers Squibb
NCT04525066 COMPLETED
Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma
Ayhman Al Afif
NCT01928290 COMPLETED
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Washington University School of Medicine
NCT02776137 COMPLETED
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT03187314 COMPLETED
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
Hangzhou Cancer Hospital
NCT01209325 COMPLETED
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
AIDS Malignancy Consortium
NCT02258464 TERMINATED
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
NCT01175980 COMPLETED
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
National Cancer Institute (NCI)
NCT03681951 TERMINATED
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
GlaxoSmithKline
NCT02402062 COMPLETED
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
NCT02057913 COMPLETED
A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP)
Institute of Cancer Research, United Kingdom
NCT02151448 COMPLETED
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
David Bartlett
NCT02386501 COMPLETED
Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
Advaxis, Inc.
NCT03572829 COMPLETED
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
Chinese Academy of Medical Sciences
NCT02530424 COMPLETED
"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
Fondazione Michelangelo
NCT02395627 TERMINATED
Reversing Therapy Resistance With Epigenetic-Immune Modification
University of California, San Francisco
NCT02089334 TERMINATED
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Rexahn Pharmaceuticals, Inc.
NCT01752036 COMPLETED
Radiotherapy for Solid Tumor Spine Metastases
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02462200 TERMINATED
Shave Margins in Breast Conservation Therapy
Washington University School of Medicine
NCT02444949 COMPLETED
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
China Three Gorges University, Yichang, China
NCT00753740 WITHDRAWN
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
NewLink Genetics Corporation
NCT03575806 COMPLETED
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT02380677 TERMINATED
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
NewLink Genetics Corporation
NCT02403531 COMPLETED
Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer
Mian XI
NCT04184518 WITHDRAWN
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Grupo Español Multidisciplinar de Melanoma
NCT03480152 TERMINATED
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
National Cancer Institute (NCI)
NCT02842125 TERMINATED
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
MultiVir, Inc.
NCT04016116 WITHDRAWN
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
NYU Langone Health
NCT03361228 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Incyte Corporation
NCT03704077 WITHDRAWN
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Bristol-Myers Squibb
NCT03104335 WITHDRAWN
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Peking University People's Hospital
NCT04044378 WITHDRAWN
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Peking University People's Hospital
NCT00983619 COMPLETED
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
MedImmune LLC
NCT01545882 TERMINATED
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer
Ottawa Hospital Research Institute
NCT01440270 COMPLETED
Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Shanghai Jiao Tong University School of Medicine
NCT01580696 COMPLETED
Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
COL George Peoples, MD, FACS
NCT00967616 COMPLETED
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Daiichi Sankyo
NCT01609231 TERMINATED
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
Merck Sharp & Dohme LLC
NCT02017860 COMPLETED
Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Novartis Pharmaceuticals
NCT02224599 TERMINATED
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Kiromic BioPharma Inc.
NCT00622440 COMPLETED
Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream
University of California, San Francisco
NCT01775501 COMPLETED
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Massachusetts General Hospital
NCT02103062 COMPLETED
Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
Celgene
NCT02265510 TERMINATED
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
NCT01019187 COMPLETED
Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy
Abramson Cancer Center at Penn Medicine
NCT01466660 COMPLETED
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
NCT02949947 TERMINATED
Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy
M.D. Anderson Cancer Center
NCT02452463 TERMINATED
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
NCT03002831 TERMINATED
Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer
Henan Cancer Hospital
NCT01847677 TERMINATED
Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin
Grupo Español de Investigación en Cáncer de Ovario
NCT02366871 COMPLETED
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
University of Colorado, Denver
NCT02528110 COMPLETED
Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer
Wuhan University
NCT01781429 COMPLETED
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
BioMed Valley Discoveries, Inc
NCT01044433 COMPLETED
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Abramson Cancer Center at Penn Medicine
NCT03124433 COMPLETED
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
Singapore General Hospital
NCT02830139 COMPLETED
Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer
Wuhan University
NCT01963481 COMPLETED
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
NYU Langone Health
NCT02789332 COMPLETED
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
GBG Forschungs GmbH
NCT00948935 COMPLETED
Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Abramson Cancer Center at Penn Medicine
NCT04162379 COMPLETED
Oral Prednisolone Effect on Cancer WHO Stepladder Analgesia Protocol
Mansoura University
NCT01717482 TERMINATED
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
Mayo Clinic
NCT02596711 COMPLETED
Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers
M.D. Anderson Cancer Center
NCT02705352 COMPLETED
5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Massachusetts Eye and Ear Infirmary
NCT03678090 WITHDRAWN
The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.
Yale University
NCT04260009 WITHDRAWN
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Takeda
NCT02487849 WITHDRAWN
HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma
Krankenhaus Barmherzige Schwestern Linz
NCT02819011 COMPLETED
OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
Bijan Najafi, PhD
NCT02060370 COMPLETED
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
NCT02541604 TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Hoffmann-La Roche
NCT01202409 COMPLETED
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
M.D. Anderson Cancer Center
NCT02807337 COMPLETED
Supersaturated Calcium Phosphate Oral Rinse (Caphosol®) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments
Tampere University Hospital
NCT04158700 WITHDRAWN
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
NCT01671488 TERMINATED
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
Brown University
NCT01392352 TERMINATED
HYPAZ: Hypertension Induced by Pazopanib
Cambridge University Hospitals NHS Foundation Trust
NCT00955240 TERMINATED
Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
UNICANCER
NCT02425683 TERMINATED
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
NCT03818997 WITHDRAWN
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT01490996 COMPLETED
Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
University of Leicester
NCT01681823 COMPLETED
Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA
EcoNugenics
NCT01348490 COMPLETED
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
Incyte Corporation
NCT01998542 COMPLETED
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
Mirror Biologics, Inc.
NCT01065441 COMPLETED
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
Michael Har-Noy
NCT03628079 TERMINATED
A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.
Repos Pharma
NCT03532087 WITHDRAWN
Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
Borstkanker Onderzoek Groep
NCT01730586 COMPLETED
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
M.D. Anderson Cancer Center
NCT03190616 COMPLETED
Apatinib in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT01993472 TERMINATED
Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer
Gu Yanhong
NCT02217566 COMPLETED
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Janssen Research & Development, LLC
NCT02684071 TERMINATED
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
NCT01867294 COMPLETED
Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
Academic and Community Cancer Research United
NCT01187212 COMPLETED
Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE
Asan Medical Center
NCT01118624 COMPLETED
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Acrotech Biopharma Inc.
NCT02003092 TERMINATED
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
Rexahn Pharmaceuticals, Inc.
NCT01624090 TERMINATED
Mithramycin for Lung, Esophagus, and Other Chest Cancers
National Cancer Institute (NCI)
NCT01962103 COMPLETED
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
NCT00978250 COMPLETED
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
National Cancer Institute (NCI)
NCT02115048 TERMINATED
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Translational Research in Oncology
NCT02230800 COMPLETED
PPALM-Palm Oil and Pentoxifylline Against Late Morbidity
Royal Marsden NHS Foundation Trust
NCT03191968 COMPLETED
Prostate Cancer Survivors and Exercise and Behavioral Counseling
University of Illinois at Urbana-Champaign
NCT01633255 WITHDRAWN
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment
National Cancer Institute (NCI)
NCT02178241 COMPLETED
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03300843 TERMINATED
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Cancer Institute (NCI)
NCT01369875 TERMINATED
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Cancer Institute (NCI)
NCT01218867 TERMINATED
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT01853618 COMPLETED
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
National Cancer Institute (NCI)
NCT01816048 TERMINATED
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
University of Wisconsin, Madison
NCT01128387 TERMINATED
Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer
University of Wisconsin, Madison
NCT00582816 TERMINATED
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
University of Wisconsin, Madison
NCT01312350 COMPLETED
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Samsung Medical Center
NCT01802879 COMPLETED
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator
Novartis Pharmaceuticals
NCT00628251 COMPLETED
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
AstraZeneca
NCT01766622 WITHDRAWN
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
National Institutes of Health Clinical Center (CC)
NCT03114631 COMPLETED
Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer
The Republican Research and Practical Center for Epidemiology and Microbiology
NCT00993928 TERMINATED
Home-Based Programs for Improving Sleep in Cancer Survivors
Alliance for Clinical Trials in Oncology
NCT01444924 COMPLETED
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery
University of Wisconsin, Madison
NCT02397486 COMPLETED
The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients
Ain Shams University
NCT00634751 COMPLETED
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
University of Wisconsin, Madison
NCT01353664 COMPLETED
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
Celgene
NCT02159703 COMPLETED
A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
Abramson Cancer Center at Penn Medicine
NCT02451007 COMPLETED
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
PharmaMar
NCT00670748 TERMINATED
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
National Cancer Institute (NCI)
NCT01735071 COMPLETED
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Mario Negri Institute for Pharmacological Research
NCT01679743 WITHDRAWN
GRN1005 for Brain Metastases From Breast or Lung Cancer
National Cancer Institute (NCI)
NCT02692976 COMPLETED
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
Radboud University Medical Center
NCT03891472 COMPLETED
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
Medical University of Silesia
NCT01683994 COMPLETED
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
National Cancer Institute (NCI)
NCT03697824 WITHDRAWN
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
NCT02530515 COMPLETED
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02406170 COMPLETED
Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT00351715 TERMINATED
Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients
AHS Cancer Control Alberta
NCT02318901 TERMINATED
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
Western Regional Medical Center
NCT02301481 COMPLETED
A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma
Chinese Academy of Medical Sciences
NCT03035591 COMPLETED
ODM-207 in Patients With Advance Solid Tumours
Orion Corporation, Orion Pharma
NCT02034916 TERMINATED
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Pfizer
NCT02709993 WITHDRAWN
Consolidation Therapy in Patients With Hematologic Malignancies
Kiromic BioPharma Inc.
NCT01239342 TERMINATED
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
National Cancer Institute (NCI)
NCT01065844 COMPLETED
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
University of Iowa
NCT02485470 TERMINATED
Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy
University of Michigan Rogel Cancer Center
NCT02665039 COMPLETED
A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
Dr Anders Ullén
NCT01806675 COMPLETED
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Sanjiv Sam Gambhir
NCT01248962 COMPLETED
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
NCT02062632 TERMINATED
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
NCT01606748 COMPLETED
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Eli Lilly and Company
NCT02950103 TERMINATED
Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients
Secretaria de Estado da Saúde
NCT00913835 COMPLETED
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Eli Lilly and Company
NCT01666444 COMPLETED
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Celgene
NCT02929862 COMPLETED
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Lycera Corp.
NCT01281124 COMPLETED
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT01059643 COMPLETED
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Eli Lilly and Company
NCT01898130 COMPLETED
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Northwestern University
NCT02338752 COMPLETED
Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT02178670 COMPLETED
Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine
Fuda Cancer Hospital, Guangzhou
NCT02176746 COMPLETED
A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer
Fuda Cancer Hospital, Guangzhou
NCT02849314 COMPLETED
Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer
Fuda Cancer Hospital, Guangzhou
NCT02115958 COMPLETED
The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine
Fuda Cancer Hospital, Guangzhou
NCT03007836 COMPLETED
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer
Fuda Cancer Hospital, Guangzhou
NCT02843802 COMPLETED
Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer
Fuda Cancer Hospital, Guangzhou
NCT02849327 COMPLETED
Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer
Fuda Cancer Hospital, Guangzhou
NCT02849379 COMPLETED
Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer
Fuda Cancer Hospital, Guangzhou
NCT03008330 COMPLETED
High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer
Fuda Cancer Hospital, Guangzhou
NCT02843607 COMPLETED
Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer
Fuda Cancer Hospital, Guangzhou
NCT02885727 WITHDRAWN
Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)
University of Maryland, Baltimore
NCT00977795 WITHDRAWN
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Endeavor Health
NCT00997386 COMPLETED
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
University of Arizona
NCT02747537 WITHDRAWN
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Washington University School of Medicine
NCT01516684 COMPLETED
Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures
Wake Forest University Health Sciences
NCT00813163 COMPLETED
Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer
PharmaEngine
NCT02999672 COMPLETED
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
Hoffmann-La Roche
NCT02864316 TERMINATED
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03147976 WITHDRAWN
QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors
NantPharma, LLC
NCT02352831 TERMINATED
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Washington University School of Medicine
NCT01065805 TERMINATED
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
AHS Cancer Control Alberta
NCT03507166 COMPLETED
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
RemeGen Co., Ltd.
NCT02999295 COMPLETED
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
National Cancer Center, Japan
NCT02012192 TERMINATED
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Medical University Innsbruck
NCT03204994 TERMINATED
Fluorescence Targeted Pelvic Lymph Node Mapping
Oxford University Hospitals NHS Trust
NCT02194426 COMPLETED
First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients
Molecular Partners AG
NCT00721799 COMPLETED
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
University of Iowa
NCT01162551 COMPLETED
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Children's Hospital of Philadelphia
NCT03065023 TERMINATED
Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)
Merck Sharp & Dohme LLC
NCT01611662 TERMINATED
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
Fox Chase Cancer Center
NCT02034552 COMPLETED
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Bayer
NCT00993616 COMPLETED
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
NCT00729586 COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
NCT03778879 WITHDRAWN
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Alan Katz
NCT01858883 COMPLETED
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Incyte Corporation
NCT02973672 COMPLETED
Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
Surgimab
NCT03207139 COMPLETED
Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer
Chang Gung Memorial Hospital
NCT02294786 TERMINATED
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis Pharmaceuticals
NCT02023697 COMPLETED
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Bayer
NCT01420965 TERMINATED
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Augusta University
NCT01531894 COMPLETED
Continuation Study of the Oral AKT Inhibitor GSK2110183
Novartis Pharmaceuticals
NCT01072175 COMPLETED
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
Novartis Pharmaceuticals
NCT01016769 COMPLETED
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT02773329 COMPLETED
Using Game-based Exercise to Improve Balance in Cancer Patients
Baylor College of Medicine
NCT01737450 COMPLETED
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
Centre Leon Berard
NCT02306850 COMPLETED
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
St. Louis University
NCT02160041 TERMINATED
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Novartis Pharmaceuticals
NCT01159067 TERMINATED
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
NCT02153905 TERMINATED
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Cancer Institute (NCI)
NCT01271725 COMPLETED
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Boehringer Ingelheim
NCT03697239 WITHDRAWN
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Hitendra Patel
NCT01362790 COMPLETED
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
National Cancer Institute (NCI)
NCT01582152 TERMINATED
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT01282216 TERMINATED
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03908333 WITHDRAWN
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Medical College of Wisconsin
NCT03128281 WITHDRAWN
Pneumoperitoneum Management With Low vs. Higher Pressure
M.D. Anderson Cancer Center
NCT01967875 TERMINATED
A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
China Medical University, China
NCT01610869 COMPLETED
Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
University College, London
NCT00730158 COMPLETED
A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
Edward Chu, MD
NCT01878448 COMPLETED
A Phase II Study of Anlotinib in STS Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT02839681 TERMINATED
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
National Cancer Institute (NCI)
NCT03082833 TERMINATED
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
Samsung Medical Center
NCT03061708 TERMINATED
Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy
Samsung Medical Center
NCT03166904 WITHDRAWN
Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy
Samsung Medical Center
NCT03166176 WITHDRAWN
Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy
Samsung Medical Center
NCT01191892 COMPLETED
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
NCT02889718 COMPLETED
Anesthesia Feasibility Study With the CONCERT-CL® Station
Institut Cancerologie de l'Ouest
NCT02501213 TERMINATED
Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)
Centre Oscar Lambret
NCT01556841 COMPLETED
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer
University College, London
NCT01926444 COMPLETED
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
gicare Pharma Inc.
NCT01604772 COMPLETED
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
National Cancer Institute (NCI)
NCT02123511 COMPLETED
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Mayo Clinic
NCT00904033 COMPLETED
Calcitriol, Physical Activity, and Bone Health in Cancer Survivors
University of Rochester
NCT01342172 TERMINATED
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Icahn School of Medicine at Mount Sinai
NCT01364727 COMPLETED
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Heather Wakelee
NCT03282643 COMPLETED
Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients
Capital Medical University
NCT03911921 COMPLETED
RSYR for Fatigue Reduction in Cancer Survivors
Peking University Cancer Hospital & Institute
NCT01365130 TERMINATED
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
howard safran
NCT03181581 TERMINATED
Improving Ultrasound Images in Brain Tumour Surgery With the Use of an Acoustic Coupling Fluid Mimicking Brain Tissue.
St. Olavs Hospital
NCT02946021 COMPLETED
Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema
Tactile Medical
NCT03109301 WITHDRAWN
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
National Cancer Institute (NCI)
NCT02575807 TERMINATED
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
Aduro Biotech, Inc.
NCT02950025 TERMINATED
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
Washington University School of Medicine
NCT00979641 TERMINATED
Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer
Tampere University Hospital
NCT02048488 COMPLETED
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
Tesaro, Inc.
NCT01116232 TERMINATED
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
NCT00709761 COMPLETED
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
Novartis Pharmaceuticals
NCT01605396 COMPLETED
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
Merck Sharp & Dohme LLC
NCT02504892 TERMINATED
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
National Cancer Institute (NCI)
NCT02301143 COMPLETED
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
Celgene
NCT00711997 COMPLETED
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
Anchiano Therapeutics Israel Ltd.
NCT00637247 COMPLETED
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
AmpliMed Corporation
NCT01949688 COMPLETED
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors
Shiga University
NCT01715233 COMPLETED
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01518621 TERMINATED
Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer
Oslo University Hospital
NCT02142036 COMPLETED
N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
Oslo University Hospital
NCT02423811 COMPLETED
Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy
National Cheng-Kung University Hospital
NCT03403777 COMPLETED
Avelumab in Refractory Testicular Germ Cell Cancer.
National Cancer Institute, Slovakia
NCT01553188 COMPLETED
AMG 386 and Abiraterone for Advanced Prostate Cancer
National Cancer Institute (NCI)
NCT01290536 COMPLETED
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Nicholas Fidelman, MD
NCT02072057 TERMINATED
Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.
Kantonsspital Aarau
NCT02076191 COMPLETED
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
John Mascarenhas
NCT01634555 COMPLETED
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Eli Lilly and Company
NCT00814463 TERMINATED
Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases
Duke University
NCT01083537 TERMINATED
Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
University Health Network, Toronto
NCT00934518 WITHDRAWN
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
Milton S. Hershey Medical Center
NCT02509585 TERMINATED
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Cardinal Health 414, LLC
NCT02606994 TERMINATED
Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis
Oral Defense, LLC
NCT02580448 COMPLETED
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
Innocrin Pharmaceutical
NCT01703351 COMPLETED
Prospective Randomized Trial Comparing the Effectiveness of Continuous Paravertebral Infusion of Local Anesthetics Versus Intravenous Patient-controlled Analgesia on Acute and Chronic Neuropathic Pain After VATS Lobectomy
Yonsei University
NCT02275403 COMPLETED
Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma
The Christie NHS Foundation Trust
NCT02303041 TERMINATED
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Anne Chang
NCT02796729 TERMINATED
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
British Columbia Cancer Agency
NCT01010126 COMPLETED
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
NCT01262235 COMPLETED
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Arbutus Biopharma Corporation
NCT02324335 COMPLETED
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Innovation Pharmaceuticals, Inc.
NCT02109445 TERMINATED
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Pfizer
NCT01435356 TERMINATED
Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy
European Association of Urology Research Foundation
NCT01743469 COMPLETED
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
Ipsen
NCT01420081 TERMINATED
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
NCT02299635 TERMINATED
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Pfizer
NCT02633800 TERMINATED
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
NCT01688973 COMPLETED
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03002623 TERMINATED
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Cancer Institute (NCI)
NCT02149576 COMPLETED
Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery
McMaster University
NCT02374099 TERMINATED
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Celgene
NCT02269943 COMPLETED
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
NCT02560051 TERMINATED
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
The University of Texas Health Science Center, Houston
NCT02560038 TERMINATED
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
NCT01864798 TERMINATED
A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
Jules Bordet Institute
NCT02048865 COMPLETED
Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
Ottawa Hospital Research Institute
NCT01265368 COMPLETED
A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)
Mologen AG
NCT01108094 COMPLETED
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Stanford University
NCT02465502 COMPLETED
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Bayer
NCT02669914 TERMINATED
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Washington University School of Medicine
NCT02472977 TERMINATED
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Bristol-Myers Squibb
NCT00566995 COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer
National Cancer Institute (NCI)
NCT03223662 TERMINATED
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
National Cancer Institute (NCI)
NCT01089088 COMPLETED
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
Cardiff University
NCT02375048 TERMINATED
Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI
Istituto Clinico Humanitas
NCT00672009 TERMINATED
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Cedars-Sinai Medical Center
NCT00896454 COMPLETED
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
NCT01669798 COMPLETED
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
AA Secord
NCT03029416 WITHDRAWN
Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension
Ronald McGarry
NCT02153918 COMPLETED
Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
National Cancer Institute (NCI)
NCT03220009 WITHDRAWN
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
NCT02352844 COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Washington University School of Medicine
NCT01613768 COMPLETED
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
University of Washington
NCT02334007 COMPLETED
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
McMaster University
NCT01158222 COMPLETED
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Case Comprehensive Cancer Center
NCT01708161 TERMINATED
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Novartis Pharmaceuticals
NCT01158521 COMPLETED
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Case Comprehensive Cancer Center
NCT00910000 TERMINATED
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
Dana-Farber Cancer Institute
NCT01589367 COMPLETED
Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer
Seoul National University Hospital
NCT00856180 COMPLETED
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
Dana-Farber Cancer Institute
NCT02091050 COMPLETED
2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy
AC Camargo Cancer Center
NCT02705703 WITHDRAWN
Consolidation Therapy in Patients With Metastatic Solid Malignancies
Kiromic BioPharma Inc.
NCT01234922 TERMINATED
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
Wake Forest University Health Sciences
NCT00804830 TERMINATED
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Region Skane
NCT01727089 COMPLETED
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT02223312 WITHDRAWN
Therapy for Progressive and/or Refractory Hematologic Malignancies
Kiromic BioPharma Inc.
NCT00768144 COMPLETED
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Dana-Farber Cancer Institute
NCT00954512 TERMINATED
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
NCT01613469 TERMINATED
Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer
Marks, John, M.D.
NCT02107950 COMPLETED
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
SOTIO a.s.
NCT00950261 WITHDRAWN
Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients
Korea Cancer Center Hospital
NCT01790568 COMPLETED
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
University of Michigan Rogel Cancer Center
NCT00706030 COMPLETED
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Puma Biotechnology, Inc.
NCT01015560 COMPLETED
S0916, MLN1202 in Treating Patients With Bone Metastases
SWOG Cancer Research Network
NCT00728585 WITHDRAWN
Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
Children's Oncology Group
NCT01325584 TERMINATED
Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury
Midwestern Regional Medical Center
NCT02846766 WITHDRAWN
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
Teresa Helsten, MD
NCT02747797 WITHDRAWN
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
Teresa Helsten, MD
NCT01830270 TERMINATED
Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer
Centre Hospitalier Universitaire de Besancon
NCT03207542 WITHDRAWN
Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
NCT00569673 COMPLETED
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Gynecologic Oncology Group
NCT01064713 COMPLETED
Phase II Study of Tesetaxel in Metastatic Melanoma
M.D. Anderson Cancer Center
NCT02345460 TERMINATED
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Case Comprehensive Cancer Center
NCT01335204 TERMINATED
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Medical University of South Carolina
NCT01524653 COMPLETED
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
University of Vermont
NCT00634582 TERMINATED
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
Wake Forest University Health Sciences
NCT01553539 COMPLETED
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT01610544 WITHDRAWN
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
National Cancer Institute (NCI)
NCT01580410 COMPLETED
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
Wake Forest University Health Sciences
NCT02331251 TERMINATED
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
NCT02423954 TERMINATED
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Western Regional Medical Center
NCT01652079 COMPLETED
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
Massachusetts General Hospital
NCT03123744 WITHDRAWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
Razelle Kurzrock, MD
NCT02558868 COMPLETED
Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer
Zhejiang University
NCT01864681 COMPLETED
Combination of Metformin With Gefitinib to Treat NSCLC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NCT01791894 COMPLETED
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
Stanford University
NCT01796028 COMPLETED
Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer
Centre Antoine Lacassagne
NCT00804908 COMPLETED
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
AbbVie (prior sponsor, Abbott)
NCT01091428 COMPLETED
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Millennium Pharmaceuticals, Inc.
NCT01764802 COMPLETED
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT01579812 COMPLETED
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
University of Michigan Rogel Cancer Center
NCT01596127 TERMINATED
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
M.D. Anderson Cancer Center
NCT03282214 COMPLETED
A Self-Management Energy Conservation Program for Cancer-Related Fatigue
University of Michigan
NCT00866723 TERMINATED
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Beth Israel Deaconess Medical Center
NCT01373164 COMPLETED
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
NCT00884312 COMPLETED
A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
Amgen
NCT02866981 COMPLETED
Observation for Patients With Asymptomatic CNS Metastatic Disease
The Cooper Health System
NCT01821404 COMPLETED
Atorvastatin Before Prostatectomy and Prostate Cancer
Tampere University Hospital
NCT01829841 COMPLETED
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT01857817 TERMINATED
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Vicus Therapeutics
NCT02261805 TERMINATED
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Georgetown University
NCT00859937 COMPLETED
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
National Cancer Institute (NCI)
NCT02085603 COMPLETED
SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain
Sheffield Teaching Hospitals NHS Foundation Trust
NCT01823679 TERMINATED
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Stanford University
NCT01042535 COMPLETED
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT01773889 TERMINATED
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
The University of Texas Health Science Center at San Antonio
NCT00832520 TERMINATED
Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight
New Mexico Cancer Research Alliance
NCT00789958 COMPLETED
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
SWOG Cancer Research Network
NCT01934790 COMPLETED
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Bayer
NCT01658813 COMPLETED
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
Western Regional Medical Center
NCT03004105 WITHDRAWN
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
NCT01005329 COMPLETED
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
National Cancer Institute (NCI)
NCT03456401 TERMINATED
Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT01585428 COMPLETED
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Cancer Institute (NCI)
NCT02606123 TERMINATED
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
ESSA Pharmaceuticals
NCT01316757 COMPLETED
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center
NCT00744549 COMPLETED
Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
University Health Network, Toronto
NCT02146092 COMPLETED
Incentive Spirometry Added to Physiotherapy to Reduce Postoperative Pulmonary Complications After Lung Surgery
McMaster University
NCT02558959 COMPLETED
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Zhejiang University
NCT00878436 COMPLETED
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
NYU Langone Health
NCT01851200 COMPLETED
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Fondazione Michelangelo
NCT01090466 COMPLETED
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
Cardiff University
NCT02806648 COMPLETED
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
Grupo Espanol de Tumores Neuroendocrinos
NCT01984892 TERMINATED
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
Nina Bhardwaj
NCT01234324 COMPLETED
ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
AIO-Studien-gGmbH
NCT01188876 COMPLETED
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Massachusetts General Hospital
NCT01216020 TERMINATED
Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
Azienda USL 4 Prato
NCT02479490 TERMINATED
PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02241720 TERMINATED
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
University of Utah
NCT00810394 COMPLETED
Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
University of California, Davis
NCT00742560 COMPLETED
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
AbbVie (prior sponsor, Abbott)
NCT01573156 TERMINATED
Vascular Targeted Photodynamic Therapy T1a Renal Tumours
University of Oxford
NCT01567488 COMPLETED
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
Grupo Espanol de Tumores Neuroendocrinos
NCT00955721 TERMINATED
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
University of Miami
NCT00652899 TERMINATED
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT00617929 TERMINATED
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
NCT01105650 COMPLETED
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
NCT00903630 TERMINATED
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT00847522 COMPLETED
Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
University of Utah
NCT01525927 TERMINATED
Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity
Northwell Health
NCT02225496 TERMINATED
Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT00769990 WITHDRAWN
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
NCT01328106 WITHDRAWN
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
GlaxoSmithKline
NCT01195922 COMPLETED
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
National Institute of Dental and Craniofacial Research (NIDCR)
NCT02473094 TERMINATED
Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer
University of Campinas, Brazil
NCT01313884 TERMINATED
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
Stanford University
NCT00903396 TERMINATED
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
NCT01023958 COMPLETED
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
Boehringer Ingelheim
NCT01965483 COMPLETED
Phase 2 Study of Adjuvant Radiotherapy in Breast Cancer Using a Once a Week Hypofractionated Regimen
Instituto do Cancer do Ceara
NCT02499861 COMPLETED
Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies
St. Justine's Hospital
NCT00941070 COMPLETED
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
National Cancer Institute (NCI)
NCT02707549 COMPLETED
Fluid Therapy During Brain Tumor Resection in Children
Federal University of São Paulo
NCT02298595 WITHDRAWN
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Julie E. Bauman, MD, MPH
NCT02958163 TERMINATED
Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT01139138 COMPLETED
Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
The Queen Elizabeth Hospital
NCT01435252 COMPLETED
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
University of Zurich
NCT00844792 COMPLETED
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer
University Health Network, Toronto
NCT00833859 TERMINATED
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
H. Lee Moffitt Cancer Center and Research Institute
NCT02278783 TERMINATED
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
University of Utah
NCT02100007 TERMINATED
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
NCT01227954 COMPLETED
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Radiation Therapy Oncology Group
NCT02017015 COMPLETED
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
Celgene
NCT00949364 COMPLETED
Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
University of Ulm
NCT02111863 TERMINATED
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT01765582 TERMINATED
Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
Hoffmann-La Roche
NCT00857545 COMPLETED
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Gynecologic Oncology Group
NCT02042443 COMPLETED
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02280811 COMPLETED
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Cancer Institute (NCI)
NCT00832338 TERMINATED
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Emory University
NCT01177007 COMPLETED
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
NCT01693419 COMPLETED
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Hallym University Medical Center
NCT01333709 COMPLETED
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
Institut du Cancer de Montpellier - Val d'Aurelle
NCT01525407 COMPLETED
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT00933361 COMPLETED
Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study
Cantonal Hospital of St. Gallen
NCT01875380 COMPLETED
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
NCT01127386 COMPLETED
Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome
Florian Strasser, MD ABHPM
NCT02175654 TERMINATED
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
NCT01436604 TERMINATED
Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging
Centre Francois Baclesse
NCT01375569 COMPLETED
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
National Cancer Institute (NCI)
NCT00748553 COMPLETED
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
University of Utah
NCT02732327 TERMINATED
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
Forest Laboratories
NCT01905163 COMPLETED
Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients
Centre Jean Perrin
NCT02016534 TERMINATED
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
Amgen
NCT01359735 COMPLETED
Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
Healthpoint
NCT02075385 COMPLETED
Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer
Barretos Cancer Hospital
NCT02205333 TERMINATED
A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
MedImmune LLC
NCT00691015 COMPLETED
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
NCT01774851 TERMINATED
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
NCT02246049 COMPLETED
A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
EPS Corporation
NCT02307487 COMPLETED
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
NCT01108055 COMPLETED
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Sandy Srinivas
NCT01515046 TERMINATED
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
Joseph J. Cullen
NCT01205217 WITHDRAWN
Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer
GlaxoSmithKline
NCT01189370 COMPLETED
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
University of Kansas Medical Center
NCT00708721 TERMINATED
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
University of Utah
NCT01943864 COMPLETED
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
NCT02219893 COMPLETED
Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial
Oslo University Hospital
NCT03161548 TERMINATED
A Study of Tongue Conservation Surgery for Oral Tongue Cancer
Taipei Veterans General Hospital, Taiwan
NCT01681368 TERMINATED
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
National Cancer Institute (NCI)
NCT01175343 COMPLETED
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT00795769 COMPLETED
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01174264 COMPLETED
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
National Cancer Institute (NCI)
NCT02638051 COMPLETED
Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT
Galenic Research Institute Ltd
NCT00914849 COMPLETED
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Washington University School of Medicine
NCT02417753 TERMINATED
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
National Cancer Institute (NCI)
NCT01355302 TERMINATED
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
Eisai Inc.
NCT02766842 WITHDRAWN
Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)
Johns Hopkins University
NCT01462214 COMPLETED
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
Hans J. van der Vliet, MD, PhD
NCT01472146 COMPLETED
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Susanne Crocamo
NCT02856867 WITHDRAWN
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)
European Organisation for Research and Treatment of Cancer - EORTC
NCT01031953 TERMINATED
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
OHSU Knight Cancer Institute
NCT00603460 WITHDRAWN
DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer
University of Pennsylvania
NCT02808624 COMPLETED
L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients
Cairo University
NCT00397501 WITHDRAWN
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
OHSU Knight Cancer Institute
NCT01722162 COMPLETED
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
Washington University School of Medicine
NCT03120403 COMPLETED
Safety and Efficacy of Intrathecal Morphine in Children
Alaa Ali Mohamed Elzohry
NCT01058655 COMPLETED
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
NCT00661531 TERMINATED
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
Georgetown University
NCT00651482 TERMINATED
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Sandy Srinivas
NCT01450683 TERMINATED
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
Stanford University
NCT01734564 COMPLETED
Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
Clinica Universidad de Navarra, Universidad de Navarra
NCT00976183 TERMINATED
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
Gynecologic Oncology Associates
NCT01240590 COMPLETED
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
National Cancer Institute (NCI)
NCT00971620 COMPLETED
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
National Cancer Institute (NCI)
NCT01059305 TERMINATED
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
M.D. Anderson Cancer Center
NCT01439945 COMPLETED
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
Alliance for Clinical Trials in Oncology
NCT00703976 COMPLETED
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
NCT02406794 COMPLETED
Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors
University of Malaga
NCT01229111 TERMINATED
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
National Cancer Institute (NCI)
NCT02784652 COMPLETED
Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors
Severance Hospital
NCT00952848 COMPLETED
Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
Virginia Commonwealth University
NCT02008539 TERMINATED
Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101
Apceth GmbH & Co. KG
NCT01118013 TERMINATED
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
NCT00907166 TERMINATED
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Cornerstone Pharmaceuticals
NCT01928030 TERMINATED
Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
Stanford University
NCT01289821 COMPLETED
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Bayer
NCT02857608 WITHDRAWN
A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
Cardinal Health 414, LLC
NCT02274012 WITHDRAWN
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
Columbia University
NCT01659554 TERMINATED
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
Columbia University
NCT00957905 COMPLETED
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
National Cancer Institute (NCI)
NCT01141569 COMPLETED
A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
National Cancer Institute (NCI)
NCT01522937 COMPLETED
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
University of Michigan Rogel Cancer Center
NCT02685306 WITHDRAWN
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals
NCT01060007 COMPLETED
Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
Washington University School of Medicine
NCT02930876 COMPLETED
Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients
King's College London
NCT00953849 COMPLETED
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
VA Office of Research and Development
NCT01457846 TERMINATED
Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer
AstraZeneca
NCT01525745 TERMINATED
Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis
Beth Israel Deaconess Medical Center
NCT01401166 COMPLETED
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Hoffmann-La Roche
NCT02526134 COMPLETED
Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum
Institut Paoli-Calmettes
NCT00601861 TERMINATED
Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
Novo Nordisk A/S
NCT02125318 COMPLETED
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Galena Biopharma, Inc.
NCT01576380 COMPLETED
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Novartis Pharmaceuticals
NCT02381236 COMPLETED
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
GenSpera, Inc.
NCT01137071 TERMINATED
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Recepta Biopharma
NCT02342587 COMPLETED
Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
Samsung Medical Center
NCT02449538 COMPLETED
Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
Samsung Medical Center
NCT01838642 TERMINATED
Ponatinib for Advanced Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
NCT02890511 COMPLETED
A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer
Daehwa Pharmaceutical Co., Ltd.
NCT01848756 TERMINATED
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Esanex Inc.
NCT00996567 COMPLETED
A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.
University Hospital, Ghent
NCT02273752 TERMINATED
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
NCT02050724 TERMINATED
ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT
Cantonal Hospital of St. Gallen
NCT02806544 COMPLETED
Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
Vanderbilt University
NCT02429622 COMPLETED
Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma
Chinese Academy of Medical Sciences
NCT01328574 COMPLETED
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
NCT01712685 TERMINATED
Imaging Studies of Kidney Cancer Using 18F-VM4-037
National Cancer Institute (NCI)
NCT02166320 COMPLETED
Treatment of Malignant Strictures in Esophagus and Gastroesophageal Junction With Covered or Partially Covered Stent.
Karolinska University Hospital
NCT01167192 TERMINATED
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
Washington University School of Medicine
NCT01832857 TERMINATED
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Cornerstone Pharmaceuticals
NCT03005015 WITHDRAWN
Lenvatinib in Second Line Endometrial Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT01553851 COMPLETED
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Washington University School of Medicine
NCT00872989 COMPLETED
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
NCT01669226 COMPLETED
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
Shanghai Gynecologic Oncology Group
NCT01450319 COMPLETED
Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Merck KGaA, Darmstadt, Germany
NCT01611857 COMPLETED
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
SCRI Development Innovations, LLC
NCT02906605 WITHDRAWN
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC
NCT02004769 COMPLETED
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Sun Yat-sen University
NCT02084563 COMPLETED
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Hospital Israelita Albert Einstein
NCT02647684 COMPLETED
Triple P for Parents of Children With a Diagnosis of Cancer
University of Manchester
NCT01661114 COMPLETED
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
University of Michigan Rogel Cancer Center
NCT02562729 COMPLETED
Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer
Shanghai Gynecologic Oncology Group
NCT00753675 COMPLETED
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
Genzyme, a Sanofi Company
NCT01454089 COMPLETED
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Achieve Life Sciences
NCT01498588 TERMINATED
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Emory University
NCT01188109 TERMINATED
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Emory University
NCT01205581 COMPLETED
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
St. Jude Children's Research Hospital
NCT02600299 COMPLETED
Effectiveness of a Psycho-educational Group (PEG) Intervention on Supportive Care and Survivorship Issues in Early-stage Breast Cancer Survivors Who Have Received Systemic Treatment
National University of Singapore
NCT01286753 COMPLETED
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Hoffmann-La Roche
NCT01031381 COMPLETED
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
University of Pittsburgh
NCT02879227 COMPLETED
Radiochemotherapy in Elderly Patients With Oesophagus Cancer
Centre Hospitalier Universitaire de Besancon
NCT01308840 COMPLETED
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
University of Rochester
NCT01751308 COMPLETED
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Sanofi
NCT02539017 WITHDRAWN
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
NCT01151761 TERMINATED
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Stanford University
NCT01624467 COMPLETED
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Eli Lilly and Company
NCT02270554 COMPLETED
A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy
Wakayama Medical University
NCT02200172 COMPLETED
The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study
Bruyère Health Research Institute.
NCT01888965 TERMINATED
Maintenance Dovitinib for Colorectal and Pancreas Cancer
Georgetown University
NCT01325428 COMPLETED
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
Boehringer Ingelheim
NCT01632020 TERMINATED
Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
University of Arkansas
NCT00983346 TERMINATED
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
NCT01926678 COMPLETED
Efficacy of Swedish Massage Therapy on Cancer-related Fatigue in Cancer Survivors
Emory University
NCT02656849 WITHDRAWN
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors
Dana-Farber Cancer Institute
NCT01468818 TERMINATED
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT02062359 TERMINATED
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
National Cancer Institute (NCI)
NCT01666782 COMPLETED
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
Saad Jamshed MD
NCT00800969 WITHDRAWN
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
University of Zurich
NCT01008904 COMPLETED
Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer
Virginia Commonwealth University
NCT01425879 COMPLETED
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01769508 TERMINATED
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
SCRI Development Innovations, LLC
NCT01677884 COMPLETED
Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy
Gustave Roussy, Cancer Campus, Grand Paris
NCT00851084 COMPLETED
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
Sanofi
NCT01042925 COMPLETED
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Sanofi
NCT01013324 COMPLETED
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Sanofi
NCT01188499 COMPLETED
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
TetraLogic Pharmaceuticals
NCT01278004 COMPLETED
Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study)
Royal Marsden NHS Foundation Trust
NCT01668173 TERMINATED
HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
Memorial Sloan Kettering Cancer Center
NCT00938457 TERMINATED
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
Mayo Clinic
NCT01108042 COMPLETED
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
Orlando Guntinas-Lichius, Prof. Dr. med.
NCT01445691 WITHDRAWN
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Constantinos Hadjipanayis
NCT02501278 WITHDRAWN
A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT02251730 COMPLETED
Smoking Cessation in Head and Neck Cancer Patients Receiving Curative Radiation Therapy
National Taiwan University Hospital
NCT01447706 COMPLETED
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Merrimack Pharmaceuticals
NCT02468076 COMPLETED
Radiofrequency Ablation for Biliopancreatic Malignancy
Universitaire Ziekenhuizen KU Leuven
NCT02061007 WITHDRAWN
Biomarker Correlates of Hypoxia in Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT01543542 COMPLETED
A Phase II Multi-institutional Study Assessing Simultaneous In-field Boost Helical Tomotherapy for 1-3 Brain Metastases
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT01569412 TERMINATED
Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors
Krankenhaus Nordwest
NCT00933387 COMPLETED
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
National Health Research Institutes, Taiwan
NCT00504322 WITHDRAWN
Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma
Weill Medical College of Cornell University
NCT01675128 COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
National Cancer Institute (NCI)
NCT01807156 TERMINATED
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Emory University
NCT00634894 WITHDRAWN
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
NCT02360501 COMPLETED
Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma
Sun Yat-sen University
NCT02745639 COMPLETED
Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT00613509 TERMINATED
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Sanofi Pasteur, a Sanofi Company
NCT02324595 COMPLETED
Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study
Catholic University of the Sacred Heart
NCT00569153 COMPLETED
Safety Study of TAK-700 in Subjects With Prostate Cancer.
Millennium Pharmaceuticals, Inc.
NCT01662726 TERMINATED
A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth
Imperial College London
NCT00546364 TERMINATED
Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer
R-Pharm
NCT01085565 COMPLETED
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
InSightec
NCT02296671 WITHDRAWN
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
Washington University School of Medicine
NCT01461538 COMPLETED
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Seagen Inc.
NCT00618969 COMPLETED
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
University of Arizona
NCT01460979 COMPLETED
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
AGO Study Group
NCT01680172 TERMINATED
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer
Mayo Clinic
NCT01453595 TERMINATED
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
NCT01157039 WITHDRAWN
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
AHS Cancer Control Alberta
NCT01695122 COMPLETED
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
Instituto do Cancer do Estado de São Paulo
NCT01844661 COMPLETED
Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
NCT02200315 COMPLETED
No Antimicrobial Prophylaxis for Laparoscopic Distal Gastrectomy
Korean South West East Gastric Surgery Group
NCT00919061 COMPLETED
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
Memorial Sloan Kettering Cancer Center
NCT01004393 COMPLETED
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
University of Vermont
NCT00526669 COMPLETED
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
NCT01206036 COMPLETED
CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)
Central European Society for Anticancer Drug Research
NCT00918320 COMPLETED
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
Gustave Roussy, Cancer Campus, Grand Paris
NCT00900627 COMPLETED
Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
AstraZeneca
NCT01004094 COMPLETED
Squire's Quest! II: Implementation Intentions and Children's Fruit, Juice, and Vegetable (FJV) Consumption
Baylor College of Medicine
NCT00718523 TERMINATED
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Translational Research in Oncology
NCT00719212 COMPLETED
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Translational Research in Oncology
NCT01986725 COMPLETED
The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence
St.Gallen University of Applied Sciences
NCT01324102 COMPLETED
Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors
VA Office of Research and Development
NCT00698841 COMPLETED
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
Eli Lilly and Company
NCT01109524 COMPLETED
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
Eli Lilly and Company
NCT00632398 COMPLETED
Multimedia Training for Family Caregivers in Use of Touch and Massage in Supportive Cancer Care
Collinge and Associates, Inc.
NCT01305044 COMPLETED
The HEALS Project - Health Education and Active Living for Surviving Seniors
University of Utah
NCT02323516 WITHDRAWN
Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.
Centre Francois Baclesse
NCT00899574 COMPLETED
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
NYU Langone Health
NCT01909856 COMPLETED
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT01116791 TERMINATED
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer
Baki Topal
NCT01236573 TERMINATED
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
National Institutes of Health Clinical Center (CC)
NCT00982657 TERMINATED
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Pfizer
NCT00768131 WITHDRAWN
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
Eli Lilly and Company
NCT01160445 TERMINATED
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
National Cancer Institute (NCI)
NCT00704938 TERMINATED
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
National Institutes of Health Clinical Center (CC)
NCT00924287 TERMINATED
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Cancer Institute (NCI)
NCT00612222 TERMINATED
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
National Cancer Institute (NCI)
NCT00610311 TERMINATED
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
National Cancer Institute (NCI)
NCT00923195 COMPLETED
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT01273181 TERMINATED
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Cancer Institute (NCI)
NCT02042885 TERMINATED
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Otsuka Novel Products GmbH
NCT00665470 COMPLETED
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
National Cancer Institute (NCI)
NCT01100931 COMPLETED
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
National Cancer Institute (NCI)
NCT02309658 COMPLETED
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients
Professor Fernando Figueira Integral Medicine Institute
NCT01495572 TERMINATED
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
National Cancer Institute (NCI)
NCT00838890 TERMINATED
A Study of BMS-863233 in Patients With Hematologic Cancer
Bristol-Myers Squibb
NCT00546247 TERMINATED
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
Bristol-Myers Squibb
NCT01313078 COMPLETED
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT02251951 COMPLETED
Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer
Hellenic Oncology Research Group
NCT01118091 COMPLETED
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
National Cancer Institute (NCI)
NCT01948232 WITHDRAWN
Pilot Study of Perindopril in Childhood Cancer Survivors
The Hospital for Sick Children
NCT01733797 COMPLETED
Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients
Brynn Chappell
NCT00923481 COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
National Cancer Institute (NCI)
NCT01333475 COMPLETED
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
National Cancer Institute (NCI)
NCT00791778 COMPLETED
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Bayer
NCT01501604 WITHDRAWN
BKM120 in Cancers With PIK3CA Activating Mutations
Massachusetts General Hospital
NCT02338778 COMPLETED
Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT02338700 COMPLETED
Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT02333474 COMPLETED
Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT02338804 COMPLETED
Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT00966992 TERMINATED
Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer
Washington University School of Medicine
NCT01441596 COMPLETED
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
NCT00752570 COMPLETED
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Amgen
NCT01612325 COMPLETED
Radioactive Holmium Microspheres for the Treatment of Unresectable Liver Metastases
UMC Utrecht
NCT00736970 COMPLETED
Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)
Merck Sharp & Dohme LLC
NCT01296035 TERMINATED
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
Women and Infants Hospital of Rhode Island
NCT02396433 WITHDRAWN
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
The University of Texas Health Science Center at San Antonio
NCT00983541 TERMINATED
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
University of Utah
NCT01118897 COMPLETED
Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers
Tata Memorial Hospital
NCT00732810 COMPLETED
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
Merck Sharp & Dohme LLC
NCT00936975 COMPLETED
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
National Cancer Institute (NCI)
NCT01116843 COMPLETED
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
University Health Network, Toronto
NCT01738217 COMPLETED
Assessment of Indocyanine Green as a Near-Infrared Fluorescent Contrast Agent for Image-guided Liver Surgery
Centre Leon Berard
NCT01880996 WITHDRAWN
Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies
Sheba Medical Center
NCT00855452 COMPLETED
Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors
Hadassah Medical Organization
NCT01017731 COMPLETED
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Eli Lilly and Company
NCT02120118 WITHDRAWN
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors
Shin Kong Wu Ho-Su Memorial Hospital
NCT02084823 COMPLETED
Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells
Fuda Cancer Hospital, Guangzhou
NCT02074046 COMPLETED
Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
NCT02089919 COMPLETED
Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients
Fuda Cancer Hospital, Guangzhou
NCT02460471 COMPLETED
Palliative Radiotherapy Protocol in Head and Neck Cancer
Maisonneuve-Rosemont Hospital
NCT00438100 COMPLETED
Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
Japan Breast Cancer Research Network
NCT00796757 COMPLETED
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Hoffmann-La Roche
NCT01408407 TERMINATED
Alkagin Paste in the Prevention of Radiation Dermatitis
Sir Mortimer B. Davis - Jewish General Hospital
NCT01200797 TERMINATED
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
National Cancer Institute (NCI)
NCT01262274 TERMINATED
Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
NCT00827164 COMPLETED
Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer
University of Alabama at Birmingham
NCT00885534 COMPLETED
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
NCT01244906 COMPLETED
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
Northside Hospital, Inc.
NCT01215578 TERMINATED
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Assistance Publique - Hôpitaux de Paris
NCT01757327 WITHDRAWN
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
Washington University School of Medicine
NCT02423226 COMPLETED
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
The First People's Hospital of Changzhou
NCT01039948 COMPLETED
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
NCT01790204 COMPLETED
A Study of the Effects of PEITC on Oral Cells With Mutant p53
Georgetown University
NCT01953952 WITHDRAWN
Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer
Radiation Therapy Oncology Group
NCT01547130 COMPLETED
Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation
Arya, Vijaypal, M.D., P.C.
NCT01227928 COMPLETED
Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
GlaxoSmithKline
NCT01242631 COMPLETED
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
Hannover Medical School
NCT02370849 COMPLETED
Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma
Chinese Academy of Medical Sciences
NCT01196559 COMPLETED
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
The Catholic University of Korea
NCT01711398 COMPLETED
Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors
Elro Pharma
NCT00673673 COMPLETED
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Yale University
NCT00559897 TERMINATED
Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
NCT00904839 COMPLETED
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Boehringer Ingelheim
NCT02350855 COMPLETED
Impact of Nutritional Intervention in Indian Female Cancer Cachexia Patients
University of Westminster
NCT01333852 TERMINATED
Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer
Lucas Vieira dos Santos
NCT01369888 TERMINATED
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
National Cancer Institute (NCI)
NCT01940601 WITHDRAWN
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
NCT01614522 COMPLETED
A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
ASLAN Pharmaceuticals
NCT00833040 COMPLETED
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
Talphera, Inc
NCT01032928 COMPLETED
Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer
US Department of Veterans Affairs
NCT01953536 WITHDRAWN
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Endocyte
NCT01305447 COMPLETED
Getting Physical on Cigarettes - Smoking Cessation & Relapse Prevention
University of Western Ontario, Canada
NCT00704600 COMPLETED
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
Maastricht Radiation Oncology
NCT01953445 WITHDRAWN
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer
Washington University School of Medicine
NCT01019382 COMPLETED
A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer
University Hospitals, Leicester
NCT01531452 COMPLETED
The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer
Chinese Academy of Medical Sciences
NCT01283334 COMPLETED
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
Emory University
NCT02013453 WITHDRAWN
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer
University of Michigan Rogel Cancer Center
NCT01465815 WITHDRAWN
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
OHSU Knight Cancer Institute
NCT01116479 TERMINATED
Optimal Transfusion in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal)
Rigshospitalet, Denmark
NCT01413295 COMPLETED
Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer
Fundacion Clinic per a la Recerca Biomédica
NCT01828502 WITHDRAWN
Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer
University of South Florida
NCT00928642 COMPLETED
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Henry M. Jackson Foundation for the Advancement of Military Medicine
NCT01567163 COMPLETED
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Eli Lilly and Company
NCT01020305 TERMINATED
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Sandy Srinivas
NCT01138046 COMPLETED
Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC
GlaxoSmithKline
NCT01149434 TERMINATED
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
University of Utah
NCT01449201 COMPLETED
PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Yonsei University
NCT00910039 TERMINATED
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
Case Comprehensive Cancer Center
NCT01272141 TERMINATED
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Emory University
NCT01579578 TERMINATED
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
AstraZeneca
NCT01797900 COMPLETED
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
Chinese Academy of Medical Sciences
NCT01859182 WITHDRAWN
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT01104675 COMPLETED
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
CASI Pharmaceuticals, Inc.
NCT01636128 WITHDRAWN
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Cancer Prevention Pharmaceuticals, Inc.
NCT01424930 COMPLETED
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen-Ortho Inc., Canada
NCT01151215 TERMINATED
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
AstraZeneca
NCT01514877 COMPLETED
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
Zhejiang Cancer Hospital
NCT01081301 COMPLETED
Living With Hope Program for Rural Women Caregivers
University of Saskatchewan
NCT01266512 COMPLETED
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Sanofi
NCT00709618 TERMINATED
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
GlaxoSmithKline
NCT02184975 COMPLETED
Cold Knife Conization With and Without Lateral Hemostatic Sutures
Barretos Cancer Hospital
NCT01225419 COMPLETED
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children
University Hospital, Clermont-Ferrand
NCT01145404 TERMINATED
Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
National Center for Tumor Diseases, Heidelberg
NCT01152437 COMPLETED
A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Boehringer Ingelheim
NCT01631279 TERMINATED
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
Proacta, Incorporated
NCT01163552 COMPLETED
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
St. Luke's-Roosevelt Hospital Center
NCT00813592 TERMINATED
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
University of Utah
NCT00918281 COMPLETED
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
NCT00593853 TERMINATED
Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy
University Health Network, Toronto
NCT00471536 COMPLETED
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT00941928 TERMINATED
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
NCT02034097 WITHDRAWN
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
GlaxoSmithKline
NCT01087970 COMPLETED
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
NCT00684996 TERMINATED
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT00841191 COMPLETED
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Centocor, Inc.
NCT01248611 COMPLETED
Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer
St. Olavs Hospital
NCT01194609 TERMINATED
A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer
Korea Cancer Center Hospital
NCT00705016 COMPLETED
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Merck KGaA, Darmstadt, Germany
NCT01620229 WITHDRAWN
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
NCT00786838 COMPLETED
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT00920140 COMPLETED
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
GlaxoSmithKline
NCT00949117 TERMINATED
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
University of South Florida
NCT01037127 COMPLETED
Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor
GlaxoSmithKline
NCT01941966 COMPLETED
A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.
Instituto do Cancer do Estado de São Paulo
NCT00770848 COMPLETED
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Amgen
NCT02080962 TERMINATED
Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer
Barretos Cancer Hospital
NCT01240720 COMPLETED
A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer
Philogen S.p.A.
NCT01125085 COMPLETED
131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
Philogen S.p.A.
NCT01131364 TERMINATED
Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
Philogen S.p.A.
NCT01644097 WITHDRAWN
Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy
Stanford University
NCT01169116 WITHDRAWN
Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis
Barretos Cancer Hospital
NCT01639521 WITHDRAWN
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
University of Southern California
NCT00502736 COMPLETED
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.
Hoffmann-La Roche
NCT01262859 WITHDRAWN
Pilot Study for Locally Advanced Head and Neck Cancer
University of Pittsburgh
NCT00826267 COMPLETED
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Boehringer Ingelheim
NCT00875433 COMPLETED
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
Boehringer Ingelheim
NCT01576029 COMPLETED
Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer
Sanofi
NCT01131039 WITHDRAWN
Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Emory University
NCT01982487 WITHDRAWN
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Roswell Park Cancer Institute
NCT01370876 TERMINATED
Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer
Nang Kuang Pharmaceutical Co., Ltd.
NCT00747799 COMPLETED
Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
NCT01653561 COMPLETED
A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
Fudan University
NCT01653574 COMPLETED
A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer
Fudan University
NCT01079832 COMPLETED
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Case Comprehensive Cancer Center
NCT00617773 COMPLETED
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Recepta Biopharma
NCT00811655 TERMINATED
Stereotactic Radiosurgery in Treating Patients With Brain Metastases
Duke University
NCT01337544 TERMINATED
Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
NCT01281696 COMPLETED
Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
National Taiwan University Hospital
NCT00909987 COMPLETED
Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum
Grupo Espanol Multidisciplinario del Cancer Digestivo
NCT00677079 COMPLETED
Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sanofi
NCT01231581 COMPLETED
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
GlaxoSmithKline
NCT00748358 COMPLETED
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
Assistance Publique - Hôpitaux de Paris
NCT01057589 COMPLETED
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
NCT01001221 TERMINATED
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Sanofi
NCT01338753 COMPLETED
Study to Evaluate Markers of Response in Locally Advanced Breast Cancer
Clinica Universidad de Navarra, Universidad de Navarra
NCT00698451 COMPLETED
A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT00385398 WITHDRAWN
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
University of Medicine and Dentistry of New Jersey
NCT01031875 COMPLETED
Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT00805142 COMPLETED
Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
Janssen Pharmaceutical K.K.
NCT01907646 COMPLETED
Role of Bladder Training During Post-operative Hospital Stay After Radical Hysterectomy in Patients
Catholic University of the Sacred Heart
NCT01281943 WITHDRAWN
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Washington University School of Medicine
NCT01557764 WITHDRAWN
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer
Washington University School of Medicine
NCT00780312 COMPLETED
Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer
Rigshospitalet, Denmark
NCT01255137 COMPLETED
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
National Cancer Institute (NCI)
NCT00842335 COMPLETED
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
Jubilant Innovation Ltd.
NCT01050621 COMPLETED
Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective
Jewish General Hospital
NCT00558272 COMPLETED
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
AstraZeneca
NCT01856452 COMPLETED
Comparison Study of Sentinel Lymph Node Biopsy by Multimodal Method in Breast Cancer
National Cancer Center, Korea
NCT01674374 WITHDRAWN
Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy
Roswell Park Cancer Institute
NCT00615056 COMPLETED
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
NCT01616186 WITHDRAWN
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
Andrea Harzstark
NCT01439919 TERMINATED
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
Sanofi
NCT01137994 WITHDRAWN
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
NCT00889343 TERMINATED
Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
AIO-Studien-gGmbH
NCT00950820 TERMINATED
Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer
AIO-Studien-gGmbH
NCT00823524 COMPLETED
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Asan Medical Center
NCT00791063 COMPLETED
18F ML-10 for Early Detection of Response of Brain Metastases to WBRT
Aposense Ltd.
NCT00962494 COMPLETED
Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors
Stanford University
NCT00684242 TERMINATED
Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain
M.D. Anderson Cancer Center
NCT00967031 COMPLETED
Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases
UNICANCER
NCT00817362 TERMINATED
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Infinity Pharmaceuticals, Inc.
NCT01193140 COMPLETED
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
Abbott
NCT01658176 WITHDRAWN
Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
Pfizer
NCT00609622 TERMINATED
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Pfizer
NCT00862524 COMPLETED
A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
Array BioPharma
NCT00988936 COMPLETED
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Siemens Molecular Imaging
NCT01661868 WITHDRAWN
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Dana-Farber Cancer Institute
NCT01270893 WITHDRAWN
Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)
M.D. Anderson Cancer Center
NCT00979966 COMPLETED
Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
Central European Society for Anticancer Drug Research
NCT01151748 WITHDRAWN
Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma
Stanford University
NCT01320241 COMPLETED
Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture
Southeast University, China
NCT00820924 TERMINATED
Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
GlaxoSmithKline
NCT01445587 WITHDRAWN
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma
GlaxoSmithKline
NCT01117246 COMPLETED
Pilot Study for Palliation of Pain in Bone Metastases by MR-HIFU
Philips Healthcare
NCT01132404 TERMINATED
Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
Millennium Pharmaceuticals, Inc.
NCT00554775 TERMINATED
WBRT & Erlotinib in Advanced NSCLC and Brain Metastases
University College, London
NCT01375972 COMPLETED
Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma
Asan Medical Center
NCT00865878 TERMINATED
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
DUSA Pharmaceuticals, Inc.
NCT01092468 COMPLETED
Comparison of Harmonic Scalpel to Conventional Diathermy in Perforator Flap Elevation for Head and Neck Reconstruction
Samsung Medical Center
NCT00941135 TERMINATED
Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab
Fundacion Miguel Servet
NCT00630110 COMPLETED
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Nereus Pharmaceuticals, Inc.
NCT00683085 TERMINATED
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Tokyo University
NCT01013168 TERMINATED
Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities
BioPheresis GmbH
NCT00861107 COMPLETED
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
Mirror Biologics, Inc.
NCT00792025 COMPLETED
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
Institut Curie
NCT00879775 COMPLETED
Efficacy of Caffeine Injection as an Adjuvant to Opioid Therapy in Cancer Pain
Korea Research Foundation
NCT00774878 TERMINATED
Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
Sanofi
NCT00605618 COMPLETED
Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT00661609 COMPLETED
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
AstraZeneca
NCT01247129 COMPLETED
Delaying the Superficial Inferior Epigastric Artery (SIEA) Flap and Determining the Change in SIEA Diameter and Blood Flow
University Medical Centre Ljubljana
NCT01226056 SUSPENDED
Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets
Southern Europe New Drug Organization
NCT01043913 COMPLETED
Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue
Faculdade de Medicina do ABC
NCT00888810 TERMINATED
Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
Centre Francois Baclesse
NCT03430700 COMPLETED
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
University College, London
NCT05173142 COMPLETED
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Hutchison Medipharma Limited
NCT07583771 NOT YET RECRUITING
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
NCT07583316 NOT YET RECRUITING
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
NCT07583914 NOT YET RECRUITING
Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
West China Hospital
NCT05172245 RECRUITING
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
NCT06874335 RECRUITING
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Biohaven Therapeutics Ltd.
NCT06549751 NOT YET RECRUITING
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Marker Therapeutics, Inc.
NCT06673329 RECRUITING
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT07156227 NOT YET RECRUITING
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT07583160 ENROLLING BY INVITATION
YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer
Changhai Hospital
NCT02496208 ACTIVE NOT RECRUITING
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
NCT06982222 NOT YET RECRUITING
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
National Cancer Institute (NCI)
NCT07584668 ACTIVE NOT RECRUITING
Safety, Tolerability and Pharmacokinetics of EM-I-2024
National Medical Research Radiological Centre of the Ministry of Health of Russia
NCT06904066 RECRUITING
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Cancer Institute (NCI)
NCT07582822 NOT YET RECRUITING
JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC
Biotech Pharmaceutical Co., Ltd.
NCT07583654 NOT YET RECRUITING
Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors
West China Hospital
NCT07584226 RECRUITING
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
NCT04963153 ACTIVE NOT RECRUITING
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
NCT05877599 RECRUITING
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
NCT07509034 NOT YET RECRUITING
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Cancer Institute (NCI)
NCT04704661 ACTIVE NOT RECRUITING
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
NCT07584499 RECRUITING
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
Sun Yat-sen University
NCT07419841 RECRUITING
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
NCT02298959 ACTIVE NOT RECRUITING
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT07584954 RECRUITING
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
Jun Zhou
NCT04855435 RECRUITING
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
NCT06465069 RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06150157 RECRUITING
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
NCT06659341 RECRUITING
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Bayer
NCT05614739 RECRUITING
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company
NCT05906537 ACTIVE NOT RECRUITING
SKB410 for Injection in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06589596 RECRUITING
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
NCT06132113 RECRUITING
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
NCT07458347 RECRUITING
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
NCT06747390 RECRUITING
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Ryan Carey
NCT06596473 RECRUITING
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
NCT07578571 NOT YET RECRUITING
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
NCT04337177 ACTIVE NOT RECRUITING
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
NCT07222267 RECRUITING
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
BeOne Medicines
NCT07560943 RECRUITING
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
West China Hospital
NCT04502602 ACTIVE NOT RECRUITING
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
Virginia Commonwealth University
NCT06625593 RECRUITING
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
NCT07128680 RECRUITING
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
NCT07562815 NOT YET RECRUITING
Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors
West China Hospital
NCT05581004 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT07247110 RECRUITING
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
NCT07414836 RECRUITING
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
NCT07563972 RECRUITING
Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors
West China Hospital
NCT07226349 RECRUITING
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
NCT07524348 RECRUITING
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Samsung Bioepis Co., Ltd.
NCT04389632 RECRUITING
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06257264 RECRUITING
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT05538130 RECRUITING
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT07181681 RECRUITING
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
NCT06826040 RECRUITING
SKB445 for Injection in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT07082920 RECRUITING
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
NCT04898634 ACTIVE NOT RECRUITING
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Janssen Research & Development, LLC
NCT06004245 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
NCT07087197 RECRUITING
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05954312 RECRUITING
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
NCT06651229 RECRUITING
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Janssen Research & Development, LLC
NCT06253520 ACTIVE NOT RECRUITING
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Cancer Institute (NCI)
NCT06663319 RECRUITING
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
NCT05567185 ACTIVE NOT RECRUITING
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Janssen Pharmaceutical K.K.
NCT02123758 ACTIVE NOT RECRUITING
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
NCT07371104 RECRUITING
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Daewoong Pharmaceutical Co. LTD.
NCT02592317 ACTIVE NOT RECRUITING
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
NCT06251310 RECRUITING
SW-682 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
NCT05963867 RECRUITING
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Boehringer Ingelheim
NCT06641908 RECRUITING
Anti-GD2 ADC M3554 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT06428331 RECRUITING
A Study of SKB518 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT07107230 RECRUITING
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Janssen Research & Development, LLC
NCT04644770 ACTIVE NOT RECRUITING
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
NCT03523442 ACTIVE NOT RECRUITING
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
NCT05818683 RECRUITING
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
NCT05367635 RECRUITING
A Study of SKB315 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06788509 ENROLLING BY INVITATION
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
NCT06178614 RECRUITING
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
NCT07223125 RECRUITING
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Janssen Research & Development, LLC
NCT06311578 RECRUITING
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
NCT07161414 RECRUITING
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
AstraZeneca
NCT04606381 ACTIVE NOT RECRUITING
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
Janssen Research & Development, LLC
NCT06014502 RECRUITING
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis
NCT06618001 ACTIVE NOT RECRUITING
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Janssen Research & Development, LLC
NCT06736327 RECRUITING
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT04577833 ACTIVE NOT RECRUITING
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development, LLC
NCT07319871 RECRUITING
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
NCT05981703 RECRUITING
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
NCT05599984 ACTIVE NOT RECRUITING
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
NCT04170153 ACTIVE NOT RECRUITING
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono Research & Development Institute, Inc.
NCT06555744 ACTIVE NOT RECRUITING
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC Inc.
NCT06726369 RECRUITING
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT07572006 NOT YET RECRUITING
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Janssen Research & Development, LLC
NCT07300150 RECRUITING
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PAQ Therapeutics, Inc.
NCT06835569 RECRUITING
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
NCT05220046 ACTIVE NOT RECRUITING
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
NCT03560882 ACTIVE NOT RECRUITING
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Joaquina Baranda
NCT07403721 RECRUITING
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
NCT07197671 RECRUITING
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
University of Wisconsin, Madison
NCT07566247 NOT YET RECRUITING
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
Akeso
NCT07387068 RECRUITING
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
NCT04620603 ACTIVE NOT RECRUITING
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Case Comprehensive Cancer Center
NCT05835687 RECRUITING
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT06057038 ACTIVE NOT RECRUITING
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
NCT06313593 RECRUITING
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT07195916 RECRUITING
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
NCT06095089 RECRUITING
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Janssen Research & Development, LLC
NCT07218003 ENROLLING BY INVITATION
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
NCT06031441 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT07563829 NOT YET RECRUITING
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
NextPoint Therapeutics, Inc.
NCT05067283 RECRUITING
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Merck Sharp & Dohme LLC
NCT06480552 RECRUITING
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D LLC
NCT06132503 RECRUITING
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Lantern Pharma Inc.
NCT05489237 RECRUITING
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
NCT05458219 RECRUITING
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT06619587 RECRUITING
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Genentech, Inc.
NCT06179160 RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
NCT04250545 ACTIVE NOT RECRUITING
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT07561554 RECRUITING
Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
Haisco Pharmaceutical Group Co., Ltd.
NCT05536141 RECRUITING
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Arcus Biosciences, Inc.
NCT07334119 RECRUITING
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
NCT06349837 RECRUITING
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
NCT05308732 ACTIVE NOT RECRUITING
Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy
Instituto Nacional de Cancer, Brazil
NCT07469891 RECRUITING
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
NCT06218914 RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
NCT03366116 RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT06120075 ACTIVE NOT RECRUITING
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT06441331 RECRUITING
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
ITM Solucin GmbH
NCT07558200 NOT YET RECRUITING
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT02626312 ACTIVE NOT RECRUITING
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
NCT04597411 ACTIVE NOT RECRUITING
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
NCT05359445 ACTIVE NOT RECRUITING
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Immatics Biotechnologies GmbH
NCT07021066 RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune Inc.
NCT04084067 RECRUITING
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
NCT06648434 RECRUITING
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
NCT02993146 ACTIVE NOT RECRUITING
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
NCT05378425 ACTIVE NOT RECRUITING
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics Ltd
NCT02589522 ACTIVE NOT RECRUITING
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT02495896 ACTIVE NOT RECRUITING
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
NCT04460937 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
NCT02142803 ACTIVE NOT RECRUITING
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02595879 ACTIVE NOT RECRUITING
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
National Cancer Institute (NCI)
NCT06074497 ACTIVE NOT RECRUITING
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
Kangabio AUSTRALIA LTD PTY
NCT07413328 RECRUITING
HWS116 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
NCT04958239 ACTIVE NOT RECRUITING
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
NCT05109975 ACTIVE NOT RECRUITING
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Debiopharm International SA
NCT07162038 RECRUITING
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT07553793 NOT YET RECRUITING
Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients
Peking Union Medical College Hospital
NCT04890613 RECRUITING
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Senhwa Biosciences, Inc.
NCT06147037 RECRUITING
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT05879978 ACTIVE NOT RECRUITING
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Boehringer Ingelheim
NCT04483778 ACTIVE NOT RECRUITING
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT06389123 RECRUITING
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
University of California, Davis
NCT07552376 NOT YET RECRUITING
This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.
Shanghai Qilu Pharmaceutical Research and Development Center LTD
NCT05187182 RECRUITING
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
NCT04913285 ACTIVE NOT RECRUITING
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Pierre Fabre Medicament
NCT07469982 RECRUITING
A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors
Shouyao Holdings (Beijing) Co. LTD
NCT07166601 RECRUITING
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT06132828 RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
Zhejiang Doer Biologics Co., Ltd.
NCT05276310 RECRUITING
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
NCT07177937 RECRUITING
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
NCT07075185 RECRUITING
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Kelonia Therapeutics, Inc.
NCT07260305 RECRUITING
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
NCT06816992 RECRUITING
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
NCT04388852 ACTIVE NOT RECRUITING
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
NCT04235777 RECRUITING
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Cancer Institute (NCI)
NCT06801002 RECRUITING
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Jabez Bioscience, Inc
NCT06926283 RECRUITING
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
NCT05782361 ACTIVE NOT RECRUITING
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Institute of Cancer Research, United Kingdom
NCT05349890 ACTIVE NOT RECRUITING
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
NCT04222413 RECRUITING
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT05557045 RECRUITING
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
NCT06720987 RECRUITING
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT06806046 ACTIVE NOT RECRUITING
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NCT03696030 ACTIVE NOT RECRUITING
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
City of Hope Medical Center
NCT07541573 RECRUITING
GTB-5550 in Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT06607185 ACTIVE NOT RECRUITING
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT04521686 ACTIVE NOT RECRUITING
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT07545356 NOT YET RECRUITING
A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
NCT06347068 RECRUITING
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
NCT02204098 ACTIVE NOT RECRUITING
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
Washington University School of Medicine
NCT07346846 RECRUITING
A Study of BGM-2121 in Patients With Advanced Solid Tumors
BioGate Precision Medicine Corp.
NCT06532565 RECRUITING
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Gilead Sciences
NCT05537740 ACTIVE NOT RECRUITING
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
NCT07524322 RECRUITING
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Regor Pharmaceuticals Inc.
NCT07360314 RECRUITING
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT01590069 ACTIVE NOT RECRUITING
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
M.D. Anderson Cancer Center
NCT06884618 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Hoffmann-La Roche
NCT07542704 NOT YET RECRUITING
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT06997029 RECRUITING
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
NCT06586957 RECRUITING
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
NCT06964009 RECRUITING
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Elizabeth Stover, MD, PhD
NCT07541534 NOT YET RECRUITING
A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT05571839 ACTIVE NOT RECRUITING
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07539285 RECRUITING
A Study of HDM2024 in Participants With Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT04855656 RECRUITING
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Debiopharm International SA
NCT07482592 RECRUITING
Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT05208762 RECRUITING
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06270706 RECRUITING
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
NCT06892379 RECRUITING
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06561685 RECRUITING
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT07538648 RECRUITING
A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors
Zhejiang Cancer Hospital
NCT06326411 RECRUITING
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Nested Therapeutics, Inc
NCT06131840 RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06447662 RECRUITING
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
NCT07538479 NOT YET RECRUITING
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
West China Hospital
NCT06034002 RECRUITING
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT07114601 RECRUITING
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly and Company
NCT07218913 RECRUITING
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
NCT07046923 RECRUITING
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
NCT06545942 ACTIVE NOT RECRUITING
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06544655 ACTIVE NOT RECRUITING
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04503278 RECRUITING
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
BioNTech Cell & Gene Therapies GmbH
NCT07213791 RECRUITING
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
NCT06597721 RECRUITING
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
NCT06307795 RECRUITING
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
NCT07258836 RECRUITING
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Eli Lilly and Company
NCT06576037 RECRUITING
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
NCT03922555 RECRUITING
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Massachusetts General Hospital
NCT03133650 ACTIVE NOT RECRUITING
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
Memorial Sloan Kettering Cancer Center
NCT07533708 NOT YET RECRUITING
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
Shanghai Henlius Biotech
NCT06082960 ACTIVE NOT RECRUITING
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
NCT01187199 ACTIVE NOT RECRUITING
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
NCT06959706 RECRUITING
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
NCT03435952 ACTIVE NOT RECRUITING
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
M.D. Anderson Cancer Center
NCT06049212 ACTIVE NOT RECRUITING
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Merck Sharp & Dohme LLC
NCT07380334 RECRUITING
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06066424 RECRUITING
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
NCT05497778 ACTIVE NOT RECRUITING
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
NCT07229313 RECRUITING
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
NCT03634267 ACTIVE NOT RECRUITING
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
M.D. Anderson Cancer Center
NCT07441694 RECRUITING
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT03114462 RECRUITING
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
M.D. Anderson Cancer Center
NCT05483868 RECRUITING
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
NCT07532018 RECRUITING
DXP-106 in Solid Tumor Patients.
Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
NCT06049576 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
NCT05039801 RECRUITING
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT06974110 RECRUITING
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT03162627 ACTIVE NOT RECRUITING
Selumetinib and Olaparib in Solid Tumors
M.D. Anderson Cancer Center
NCT07094204 RECRUITING
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
NCT01481532 NOT YET RECRUITING
Open Label Clinical Trial of Intravenous Crotoxin Part 3
Celtic Biotech Ltd
NCT06233942 RECRUITING
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
NCT04897321 RECRUITING
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
NCT06803680 RECRUITING
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeiGene
NCT06120283 RECRUITING
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
NCT07518043 NOT YET RECRUITING
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
NCT07362888 RECRUITING
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Adcendo ApS
NCT05718895 RECRUITING
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Antengene Biologics Limited
NCT07395258 RECRUITING
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT05238922 RECRUITING
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
NCT05430373 RECRUITING
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Grit Biotechnology
NCT06026410 RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology, Inc.
NCT06220864 RECRUITING
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
NCT06001788 RECRUITING
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
NCT06718621 RECRUITING
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT04847063 RECRUITING
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Cancer Institute (NCI)
NCT07284186 RECRUITING
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
NCT04533750 ACTIVE NOT RECRUITING
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
NCT04520711 ACTIVE NOT RECRUITING
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
NCT02381561 ACTIVE NOT RECRUITING
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
NCT01480154 ACTIVE NOT RECRUITING
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
NCT07524140 NOT YET RECRUITING
Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.
Eilean Therapeutics
NCT07408258 NOT YET RECRUITING
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
OncoC4, Inc.
NCT01366144 ACTIVE NOT RECRUITING
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
NCT04470024 RECRUITING
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
Providence Health & Services
NCT05509790 ACTIVE NOT RECRUITING
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
Eli Lilly and Company
NCT07040943 RECRUITING
Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
West China Hospital
NCT06352359 RECRUITING
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4, Inc.
NCT03911388 RECRUITING
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
NCT06487624 RECRUITING
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
FBD Biologics Limited
NCT06403436 ACTIVE NOT RECRUITING
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
TOLREMO therapeutics AG
NCT06625775 RECRUITING
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT07217171 RECRUITING
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
NCT02503722 ACTIVE NOT RECRUITING
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04491942 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
NCT06515613 RECRUITING
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
NCT06582017 RECRUITING
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
NCT02627443 ACTIVE NOT RECRUITING
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT02015117 ACTIVE NOT RECRUITING
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
NCT07525141 RECRUITING
A Study of JNJ-1761981 in Participants With Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
NCT06238479 ACTIVE NOT RECRUITING
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06960395 RECRUITING
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology, Inc.
NCT07165132 RECRUITING
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
NCT07519564 NOT YET RECRUITING
A Phase I Clinical Study to Evaluate the PK, PD, Efficacy, and Safety of GB18 Injection in Patients With Tumor Cachexia
Kexing Biopharm Co., Ltd.
NCT06832982 RECRUITING
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
Shanghai Pushi Medical Science Co. Ltd
NCT07190833 RECRUITING
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
NCT05858736 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
OncoC4, Inc.
NCT06672523 RECRUITING
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
Bristol-Myers Squibb
NCT03594422 RECRUITING
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Ascentage Pharma Group Inc.
NCT07141706 RECRUITING
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT04794699 ACTIVE NOT RECRUITING
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
IDEAYA Biosciences
NCT05635591 ENROLLING BY INVITATION
KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
Tongji Hospital
NCT07517198 RECRUITING
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT05462717 ACTIVE NOT RECRUITING
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
NCT05003895 RECRUITING
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Cancer Institute (NCI)
NCT04516447 RECRUITING
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT07054307 RECRUITING
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
Jiyan Liu
NCT07090499 RECRUITING
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT05861895 RECRUITING
HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
HighField Biopharmaceuticals Corporation
NCT04044859 ACTIVE NOT RECRUITING
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM CT, LLC
NCT07170592 NOT YET RECRUITING
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
NCT07424547 RECRUITING
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
NCT07426757 NOT YET RECRUITING
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Pfizer
NCT02637934 RECRUITING
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Abramson Cancer Center at Penn Medicine
NCT07438782 RECRUITING
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT06773091 RECRUITING
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
Shanghai NK Cell Technology Co., LTD
NCT06657144 RECRUITING
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT07455617 RECRUITING
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
NCT06422520 ACTIVE NOT RECRUITING
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
NCT07008118 RECRUITING
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT06878248 ACTIVE NOT RECRUITING
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Calibr, a division of Scripps Research
NCT02937272 ACTIVE NOT RECRUITING
A Study of LY3200882 in Participants With Solid Tumors
Eli Lilly and Company
NCT07277413 RECRUITING
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
NCT05752552 RECRUITING
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
DeuterOncology
NCT07144085 RECRUITING
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
Yi Tian
NCT06342986 ACTIVE NOT RECRUITING
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT06451497 RECRUITING
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
NCT05521984 RECRUITING
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
NCT07402915 RECRUITING
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
AstraZeneca
NCT04893434 ACTIVE NOT RECRUITING
Novel Imaging Technique to Assess Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
NCT05614102 ACTIVE NOT RECRUITING
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Bayer
NCT05891171 ACTIVE NOT RECRUITING
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences, Inc.
NCT07503808 RECRUITING
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
NCT07176975 NOT YET RECRUITING
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
NCT06770569 RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
NCT04722523 RECRUITING
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT03860272 ACTIVE NOT RECRUITING
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
NCT04197934 ACTIVE NOT RECRUITING
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
NCT04328844 ACTIVE NOT RECRUITING
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
NCT05753501 ACTIVE NOT RECRUITING
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
NCT05763004 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
ImmunOs Therapeutics AG
NCT06687941 RECRUITING
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Aptamer Sciences, Inc.
NCT05017012 ACTIVE NOT RECRUITING
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
Merck Sharp & Dohme LLC
NCT05768932 RECRUITING
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
NCT07383506 NOT YET RECRUITING
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Cogent Biosciences, Inc.
NCT04221204 ACTIVE NOT RECRUITING
A Monotherapy in Subjects With Advanced Solid Tumors
3D Medicines (Beijing) Co., Ltd.
NCT04670679 ACTIVE NOT RECRUITING
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Erasca, Inc.
NCT06858813 RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie
NCT07262164 RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
Shanghai Virogin Biotech Co., Ltd.
NCT06328439 ACTIVE NOT RECRUITING
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
NCT06421935 ACTIVE NOT RECRUITING
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
EMD Serono Research & Development Institute, Inc.
NCT05936359 RECRUITING
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT04189614 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
AbbVie
NCT07490236 RECRUITING
Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors
Hebei Medical University Fourth Hospital
NCT05838768 ACTIVE NOT RECRUITING
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Novartis Pharmaceuticals
NCT06818812 ACTIVE NOT RECRUITING
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
NCT06667141 RECRUITING
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Acrivon Therapeutics
NCT06917079 RECRUITING
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT04514484 ACTIVE NOT RECRUITING
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
NCT05277051 ACTIVE NOT RECRUITING
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT07482319 NOT YET RECRUITING
A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors
Beijing Geekgene Technology Co., LTD
NCT03044613 ACTIVE NOT RECRUITING
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06293898 RECRUITING
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
NCT07015697 RECRUITING
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Daiichi Sankyo
NCT04419532 ACTIVE NOT RECRUITING
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT05143970 RECRUITING
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Institut Paoli-Calmettes
NCT05948865 RECRUITING
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
NCT06158139 RECRUITING
Autologous CAR-T Cells Targeting B7-H3 in PDAC
UNC Lineberger Comprehensive Cancer Center
NCT05635643 RECRUITING
Study of CHS-114 in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT02789228 ACTIVE NOT RECRUITING
Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors
Children's National Research Institute
NCT04823897 RECRUITING
A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours
PharmaMatrix Holdings Ltd
NCT04192344 RECRUITING
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Abbisko Therapeutics Co, Ltd
NCT05719558 RECRUITING
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03478462 ACTIVE NOT RECRUITING
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Cellectar Biosciences, Inc.
NCT06248411 RECRUITING
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
NCT04443088 RECRUITING
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Shenzhen Ionova Life Sciences Co., Ltd.
NCT06585488 RECRUITING
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeiGene
NCT07480681 NOT YET RECRUITING
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
Shanghai Henlius Biotech
NCT07481357 RECRUITING
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
Dong-A ST Co., Ltd.
NCT06804824 RECRUITING
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
NCT05694715 RECRUITING
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
NCT06927297 RECRUITING
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
West China Hospital
NCT07038369 ACTIVE NOT RECRUITING
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
NCT07477743 RECRUITING
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
HC Biopharma Inc.
NCT07475559 NOT YET RECRUITING
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT07473726 NOT YET RECRUITING
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT06716138 RECRUITING
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
NCT07454031 NOT YET RECRUITING
Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
Peking University
NCT05853367 RECRUITING
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Merck Sharp & Dohme LLC
NCT05285358 RECRUITING
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
NCT06704724 ACTIVE NOT RECRUITING
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
NCT05957536 RECRUITING
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
D3 Bio (Wuxi) Co., Ltd
NCT07207707 RECRUITING
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT05382364 ACTIVE NOT RECRUITING
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
Pfizer
NCT07372625 RECRUITING
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
PMV Pharmaceuticals, Inc
NCT07457541 ACTIVE NOT RECRUITING
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
Tomsk National Research Medical Center of the Russian Academy of Sciences
NCT05238792 RECRUITING
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
Children's National Research Institute
NCT05176483 RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT07467629 RECRUITING
QLS5212 for Participants With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06598800 RECRUITING
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeiGene
NCT07029399 RECRUITING
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
NCT06563375 RECRUITING
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
M.D. Anderson Cancer Center
NCT06234397 RECRUITING
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT03006172 ACTIVE NOT RECRUITING
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
NCT04572295 ACTIVE NOT RECRUITING
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Eisai Co., Ltd.
NCT03968406 RECRUITING
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
NCT07462442 NOT YET RECRUITING
Study of QLS5308 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT07460765 NOT YET RECRUITING
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
NCT06269978 RECRUITING
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Arjun Mittra
NCT05781048 ACTIVE NOT RECRUITING
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06533059 RECRUITING
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
NCT03264664 ACTIVE NOT RECRUITING
Study of E7386 in Participants With Selected Advanced Neoplasms
Eisai Inc.
NCT06171750 RECRUITING
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ankyra Therapeutics, Inc
NCT07454668 NOT YET RECRUITING
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
NCT05103631 ACTIVE NOT RECRUITING
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
NCT05661201 RECRUITING
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Georgetown University
NCT07189949 RECRUITING
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.
NCT06508138 ENROLLING BY INVITATION
Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05122546 ACTIVE NOT RECRUITING
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
NCT01970722 ACTIVE NOT RECRUITING
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
NCT07374848 RECRUITING
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
Zai Lab (Shanghai) Co., Ltd.
NCT04928508 RECRUITING
Advanced or Recurrent Solid Tumors Treated With SHetA2
University of Oklahoma
NCT04661384 ACTIVE NOT RECRUITING
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
City of Hope Medical Center
NCT04900818 RECRUITING
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT06868433 RECRUITING
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
NCT06251544 NOT YET RECRUITING
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Baylor College of Medicine
NCT03313778 ACTIVE NOT RECRUITING
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
ModernaTX, Inc.
NCT06321484 RECRUITING
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
NCT07297160 NOT YET RECRUITING
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
Baylor College of Medicine
NCT07447856 RECRUITING
A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain
Memorial Sloan Kettering Cancer Center
NCT07046559 RECRUITING
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Eli Lilly and Company
NCT05873686 RECRUITING
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
NCT03207672 ACTIVE NOT RECRUITING
Study of E7389 Liposomal Formulation in Participants With Solid Tumor
Eisai Co., Ltd.
NCT07321106 RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
NCT06537310 ACTIVE NOT RECRUITING
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT07446816 RECRUITING
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
NCT06994806 RECRUITING
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT07304128 RECRUITING
A Study of PLB-002 in Advanced Solid Tumors
Primelink BioTherapeitics(ShenZhen) Limited
NCT07064122 RECRUITING
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
AstraZeneca
NCT02721459 ACTIVE NOT RECRUITING
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06715124 ACTIVE NOT RECRUITING
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
NCT07269080 RECRUITING
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
University of Illinois at Chicago
NCT04473781 RECRUITING
Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT06612645 RECRUITING
Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
Chulalongkorn University
NCT04336241 ACTIVE NOT RECRUITING
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
NCT06759649 RECRUITING
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Compugen Ltd
NCT07382817 RECRUITING
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
M.D. Anderson Cancer Center
NCT06402201 RECRUITING
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
CDR-Life AG
NCT04735978 ACTIVE NOT RECRUITING
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune, Inc.
NCT03833700 ACTIVE NOT RECRUITING
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Eisai Co., Ltd.
NCT07361562 RECRUITING
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Cogent Biosciences, Inc.
NCT05914376 ACTIVE NOT RECRUITING
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
Hangzhou Converd Co., Ltd.
NCT04288089 ACTIVE NOT RECRUITING
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Eisai Inc.
NCT03448042 ACTIVE NOT RECRUITING
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
NCT05907304 ACTIVE NOT RECRUITING
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Erasca, Inc.
NCT03830320 RECRUITING
Positron Emission Tomography (PET) Imaging of Thrombosis
Massachusetts General Hospital
NCT07279428 RECRUITING
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT03203525 ACTIVE NOT RECRUITING
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
NCT07434609 NOT YET RECRUITING
Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Nanolattix Biotechnology Co., Ltd.
NCT06104488 RECRUITING
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
NCT06521554 RECRUITING
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent Inc.
NCT07382544 RECRUITING
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
M.D. Anderson Cancer Center
NCT04250155 ACTIVE NOT RECRUITING
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT06799065 RECRUITING
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Accent Therapeutics
NCT07190469 RECRUITING
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
ProteinQure Inc.
NCT05753722 RECRUITING
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Incendia Therapeutics
NCT00750841 ACTIVE NOT RECRUITING
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
NCT07423117 NOT YET RECRUITING
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
IntoCell, Inc
NCT05527184 ACTIVE NOT RECRUITING
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
NCT04649385 ACTIVE NOT RECRUITING
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT05396833 ACTIVE NOT RECRUITING
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono Research & Development Institute, Inc.
NCT03252938 ACTIVE NOT RECRUITING
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT07337525 RECRUITING
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Pilatus Biosciences Inc
NCT07197554 RECRUITING
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
NCT06524570 RECRUITING
Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy
UMC Utrecht
NCT04485013 RECRUITING
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
NCT07066657 RECRUITING
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ArriVent BioPharma, Inc.
NCT06885697 RECRUITING
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06566079 RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
NCT04928677 RECRUITING
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
Memorial Sloan Kettering Cancer Center
NCT07123103 RECRUITING
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT07148050 RECRUITING
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Seattle Children's Hospital
NCT07238075 RECRUITING
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
Adcytherix SAS
NCT04973163 ACTIVE NOT RECRUITING
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Boehringer Ingelheim
NCT06778863 RECRUITING
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics, Inc.
NCT05103683 RECRUITING
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
NCT06973863 RECRUITING
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
PharmaEngine
NCT07094113 RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
NCT06943677 RECRUITING
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT07329894 RECRUITING
Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
Beijing GoBroad Hospital
NCT07407985 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT07407504 NOT YET RECRUITING
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT04449874 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
NCT07404332 NOT YET RECRUITING
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
Mohammed Milhem
NCT04617522 RECRUITING
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Gilead Sciences
NCT06440005 RECRUITING
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex, Inc.
NCT07252479 RECRUITING
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Adlai Nortye Biopharma Co., Ltd.
NCT06623396 RECRUITING
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT07036133 RECRUITING
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
Acrotech Biopharma Inc.
NCT06750185 RECRUITING
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
BioNTech SE
NCT05947474 ACTIVE NOT RECRUITING
ORB-011 In Patients With Advanced Solid Tumors
Orionis Biosciences Inc
NCT05082259 RECRUITING
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Institute of Cancer Research, United Kingdom
NCT05787587 RECRUITING
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT07080242 RECRUITING
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
SystImmune Inc.
NCT05239143 ACTIVE NOT RECRUITING
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
NCT05479812 ACTIVE NOT RECRUITING
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Werewolf Therapeutics, Inc.
NCT05620017 RECRUITING
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
NCT03740256 RECRUITING
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT07391644 NOT YET RECRUITING
A Study of JSKN027 in Patients With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT06507306 RECRUITING
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT06650163 RECRUITING
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Jonsson Comprehensive Cancer Center
NCT06655246 RECRUITING
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
NCT04459273 ACTIVE NOT RECRUITING
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Jonsson Comprehensive Cancer Center
NCT06880549 ACTIVE NOT RECRUITING
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.
NCT07390838 RECRUITING
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT03120624 ACTIVE NOT RECRUITING
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
Mayo Clinic
NCT07349537 RECRUITING
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines, Inc.
NCT07292818 RECRUITING
Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
UNC Lineberger Comprehensive Cancer Center
NCT05892718 RECRUITING
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
FBD Biologics Limited
NCT06244485 RECRUITING
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Daiichi Sankyo
NCT05352750 ACTIVE NOT RECRUITING
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
Sonnet BioTherapeutics
NCT06469281 RECRUITING
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
NCT07381829 RECRUITING
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
HC Biopharma Inc.
NCT07215637 RECRUITING
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
NCT06911489 RECRUITING
Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients
Chengdu New Radiomedicine Technology Co. LTD.
NCT06364696 ACTIVE NOT RECRUITING
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Astellas Pharma Inc
NCT05791448 RECRUITING
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
University of Southern California
NCT06717750 RECRUITING
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
NCT04389281 RECRUITING
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Immunolight, LLC
NCT06809114 RECRUITING
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Axcynsis Therapeutics Pte Ltd
NCT07377591 RECRUITING
A Study of HDM2006 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT04391049 ACTIVE NOT RECRUITING
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
NCT04150042 RECRUITING
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology, Inc.
NCT06644300 RECRUITING
Study of BM230 in Patients With Advanced Solid Tumors
Suzhou Biomissile Pharmaceuticals Co., Ltd.
NCT05983432 RECRUITING
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
NCT06792552 RECRUITING
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
NCT06993116 ACTIVE NOT RECRUITING
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
Guangdong Hengrui Pharmaceutical Co., Ltd
NCT06484985 RECRUITING
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Axter Therapeutics (Beijing) Co., Ltd
NCT07269145 RECRUITING
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06266299 RECRUITING
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co., Ltd.
NCT06287918 NOT YET RECRUITING
A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
3H (Suzhou) Pharmaceuticals Co., Ltd.
NCT07368127 NOT YET RECRUITING
A Study of TPD3310 in Patients With Advanced Malignant Tumors
TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
NCT02057133 ACTIVE NOT RECRUITING
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
NCT05174637 ACTIVE NOT RECRUITING
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT05827614 ACTIVE NOT RECRUITING
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Boundless Bio, Inc.
NCT06821048 RECRUITING
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
Weijia Fang, MD
NCT07363967 RECRUITING
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors
Beijing StoneWise Technology Co., Ltd
NCT07363369 NOT YET RECRUITING
Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
West China Hospital
NCT06150183 ACTIVE NOT RECRUITING
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
BioNTech SE
NCT07358806 RECRUITING
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
NCT07042100 RECRUITING
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
NCT07358884 NOT YET RECRUITING
First in Human Study of QLS5316 in Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT05653869 ACTIVE NOT RECRUITING
A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions
Applied Pharmaceutical Science, Inc.
NCT07361107 RECRUITING
Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)
Northwell Health
NCT05914545 RECRUITING
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT07348653 NOT YET RECRUITING
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
NCT07356856 NOT YET RECRUITING
Efficacy and Safety of Microtransplantation for Advanced and Relapsed Solid Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
NCT06609187 RECRUITING
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07356453 RECRUITING
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
FoRx Therapeutics AG
NCT06612840 RECRUITING
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06503783 RECRUITING
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07317505 RECRUITING
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
NCT05519449 RECRUITING
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Janux Therapeutics
NCT07351903 RECRUITING
A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT06736379 RECRUITING
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
NCT06932952 ACTIVE NOT RECRUITING
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V.
NCT07186452 RECRUITING
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT01087554 ACTIVE NOT RECRUITING
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
NCT07231458 RECRUITING
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Abalos Therapeutics GmbH
NCT06927570 RECRUITING
A Study of HS-20122 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT07345637 NOT YET RECRUITING
Phase I Study of FXS887 in the Treatment of Solid Tumors
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT07294872 NOT YET RECRUITING
A Study of TIL in Advanced Solid Tumors (CZ)
Shanghai Juncell Therapeutics
NCT06302426 RECRUITING
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
NCT06751329 RECRUITING
A Study of DM002 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT07275242 RECRUITING
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06302621 RECRUITING
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
NCT06234423 RECRUITING
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
OnCusp Therapeutics, Inc.
NCT06859762 RECRUITING
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06400472 RECRUITING
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
NCT05092373 RECRUITING
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
NCT02715284 ACTIVE NOT RECRUITING
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Tesaro, Inc.
NCT05156866 ACTIVE NOT RECRUITING
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
NCT07197645 RECRUITING
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
Telix Pharmaceuticals (Innovations) Pty Limited
NCT06466187 ACTIVE NOT RECRUITING
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07181473 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
NCT03875287 ACTIVE NOT RECRUITING
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07333820 NOT YET RECRUITING
Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201
Yonsei University
NCT06816108 RECRUITING
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Ono Pharmaceutical Co., Ltd.
NCT04111458 ACTIVE NOT RECRUITING
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
Boehringer Ingelheim
NCT02988960 ACTIVE NOT RECRUITING
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
AbbVie
NCT04673448 ACTIVE NOT RECRUITING
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
NCT06856499 RECRUITING
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
NCT05902520 ACTIVE NOT RECRUITING
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
AgonOx, Inc.
NCT07131189 ACTIVE NOT RECRUITING
A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd
NCT03843359 ACTIVE NOT RECRUITING
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT06990464 RECRUITING
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
NCT05614258 ACTIVE NOT RECRUITING
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
Adagene Inc
NCT06235437 RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Ascendo Biotechnology Co., Ltd.
NCT06985368 RECRUITING
A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
NCT06781983 RECRUITING
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
NCT06999187 RECRUITING
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06298058 RECRUITING
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Shanghai Institute Of Biological Products
NCT07277270 RECRUITING
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT07232407 RECRUITING
A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06512116 RECRUITING
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
Shanghai Institute Of Biological Products
NCT07319364 RECRUITING
A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT03602157 ACTIVE NOT RECRUITING
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
NCT07274852 RECRUITING
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT03955978 ACTIVE NOT RECRUITING
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
NCT05544929 ACTIVE NOT RECRUITING
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT03912064 ACTIVE NOT RECRUITING
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
NCT07077434 RECRUITING
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT07252414 RECRUITING
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT06384352 RECRUITING
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07310134 RECRUITING
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
NCT06724926 ACTIVE NOT RECRUITING
Concurrent Azeliragon With Craniospinal Irradiation
NYU Langone Health
NCT07232524 RECRUITING
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06350006 RECRUITING
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT02208375 ACTIVE NOT RECRUITING
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
NCT06368921 RECRUITING
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
NCT06908434 RECRUITING
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT05957081 RECRUITING
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
PharmAbcine
NCT05007782 RECRUITING
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Gilead Sciences
NCT06882135 RECRUITING
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
NCT07100210 RECRUITING
A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity
Xingchen Peng
NCT05075993 ACTIVE NOT RECRUITING
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
NCT06952010 RECRUITING
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
NCT06022029 RECRUITING
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine, Inc.
NCT07251166 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT07230977 RECRUITING
GenSci139 in Patients With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT06328673 ACTIVE NOT RECRUITING
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
D2M Biotherapeutics Inc.
NCT07256756 NOT YET RECRUITING
A Study of GC203 TIL in Advanced Solid Tumors (NF)
Shanghai Juncell Therapeutics
NCT04777994 RECRUITING
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Calico Life Sciences LLC
NCT05306132 RECRUITING
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
NCT07292402 RECRUITING
JSKN022 in Subjects With Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT03423628 RECRUITING
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
NCT06131398 ACTIVE NOT RECRUITING
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Amgen
NCT07128914 RECRUITING
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
GeneSail Biotech (Shanghai) Co., Ltd.
NCT05270213 RECRUITING
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Riboscience, LLC.
NCT05802056 RECRUITING
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Mayo Clinic
NCT06065371 RECRUITING
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
NCT05276973 ACTIVE NOT RECRUITING
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
NCT06727812 RECRUITING
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
NCT05836324 RECRUITING
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT06551142 RECRUITING
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
GlaxoSmithKline
NCT07291050 NOT YET RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04541082 RECRUITING
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT07275073 RECRUITING
JMT106 Injection in the Treatment of Advanced Solid Tumors
Shanghai JMT-Bio Inc.
NCT06797336 RECRUITING
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
PAQ Therapeutics, Inc.
NCT07288957 RECRUITING
A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors
Abbisko Therapeutics Co, Ltd
NCT06724016 RECRUITING
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT05471856 RECRUITING
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
NCT05856981 RECRUITING
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
NCT07285395 RECRUITING
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
NCT06108050 RECRUITING
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Jazz Pharmaceuticals
NCT05159700 ACTIVE NOT RECRUITING
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Zhuhai Yufan Biotechnologies Co., Ltd
NCT05539430 ACTIVE NOT RECRUITING
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Legend Biotech USA Inc
NCT04898543 ACTIVE NOT RECRUITING
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
NCT06414460 RECRUITING
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
NCT06375187 RECRUITING
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Shanghai Juncell Therapeutics
NCT06724042 NOT YET RECRUITING
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
NCT07275853 NOT YET RECRUITING
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
TCRx Therapeutics Co.Ltd
NCT07257640 RECRUITING
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
Zhejiang University
NCT07274085 RECRUITING
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT04329494 RECRUITING
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
NCT06241456 RECRUITING
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT05338658 RECRUITING
Study of PAT in Patients With Solid Tumor Cancers
Masonic Cancer Center, University of Minnesota
NCT07231120 RECRUITING
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia
Jiangsu Nutai Biologics Co., Ltd
NCT07269899 RECRUITING
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Sun Yat-sen University
NCT06107868 ACTIVE NOT RECRUITING
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
University Health Network, Toronto
NCT06115642 RECRUITING
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT03257761 ACTIVE NOT RECRUITING
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
NCT05245500 RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
NCT07134998 RECRUITING
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Jiangsu HengRui Medicine Co., Ltd.
NCT07265921 RECRUITING
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT05859074 RECRUITING
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT07260513 ACTIVE NOT RECRUITING
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
Suzhou Genhouse Bio Co., Ltd.
NCT07021898 RECRUITING
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Erasca, Inc.
NCT02869217 ACTIVE NOT RECRUITING
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
NCT05013216 RECRUITING
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07260591 RECRUITING
VSV-02 Compassionate Use in Advanced Solid Tumors
The First Affiliated Hospital of Xinxiang Medical College
NCT06912087 RECRUITING
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
NCT07259889 RECRUITING
Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors
Guangzhou Xiling Biotechnology Co., Ltd.
NCT07257497 NOT YET RECRUITING
Safety and Efficacy of Combining a Vitamin B6-Limited Diet With Immunotherapy in Solid Tumor Patients: A Clinical Study Protocol
West China Hospital
NCT07208136 RECRUITING
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Jemincare
NCT03983954 ACTIVE NOT RECRUITING
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NCT07252661 NOT YET RECRUITING
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
NCT06215846 ENROLLING BY INVITATION
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
NCT05547321 RECRUITING
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
NCT05901285 RECRUITING
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Vaxiion Therapeutics
NCT06662760 RECRUITING
Clinical Trial of TQB3002 in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT07081984 RECRUITING
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Therorna
NCT07106827 RECRUITING
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
NCT05631899 ACTIVE NOT RECRUITING
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT05117476 ACTIVE NOT RECRUITING
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Cullinan Therapeutics Inc.
NCT07232420 RECRUITING
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06238401 RECRUITING
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
NCT05743621 RECRUITING
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Weill Medical College of Cornell University
NCT06915753 RECRUITING
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Tyra Biosciences, Inc
NCT03618381 ACTIVE NOT RECRUITING
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT07123415 RECRUITING
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Aptabio Therapeutics, Inc.
NCT07237464 RECRUITING
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants
Shenzhen Kexing Pharmaceutical Co., Ltd.
NCT06328738 ACTIVE NOT RECRUITING
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
NCT05608148 RECRUITING
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Kyushu University
NCT06897735 NOT YET RECRUITING
Exploratory Study of Inhaled Afatinib Dimaleate PK Profile
Petrov, Andrey
NCT04999384 RECRUITING
First in Human, Dose Escalation Study of AN4005
Adlai Nortye Biopharma Co., Ltd.
NCT07229898 RECRUITING
A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
Henan Genuine Biotech Co., Ltd.
NCT06618651 RECRUITING
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06258408 RECRUITING
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
Broadenbio Ltd., Co.
NCT07142980 RECRUITING
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.
NCT05629689 RECRUITING
A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
GE Healthcare
NCT06143007 ACTIVE NOT RECRUITING
A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
Broadenbio Ltd., Co.
NCT07231081 RECRUITING
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
Tcelltech Inc.
NCT05661461 RECRUITING
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Aadi Bioscience, Inc.
NCT03582475 ACTIVE NOT RECRUITING
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
NCT03093909 RECRUITING
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
NCT02321501 ACTIVE NOT RECRUITING
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT07139990 RECRUITING
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
University of Texas Southwestern Medical Center
NCT06675136 RECRUITING
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
City of Hope Medical Center
NCT06006273 RECRUITING
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
NCT06504368 RECRUITING
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT07098299 RECRUITING
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Barbara Ann Karmanos Cancer Institute
NCT06291987 RECRUITING
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
University of Chicago
NCT07224568 NOT YET RECRUITING
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
Seattle Children's Hospital
NCT06714617 ACTIVE NOT RECRUITING
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune Inc.
NCT05274048 RECRUITING
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
NCT03484299 RECRUITING
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
University of Louisville
NCT05029882 ACTIVE NOT RECRUITING
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
NCT05327946 ACTIVE NOT RECRUITING
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Boehringer Ingelheim
NCT02817633 ACTIVE NOT RECRUITING
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
NCT04446351 ACTIVE NOT RECRUITING
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT04169763 RECRUITING
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT04185883 ACTIVE NOT RECRUITING
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
NCT03889795 ACTIVE NOT RECRUITING
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
Danae Hamouda, MD
NCT05627063 ACTIVE NOT RECRUITING
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
Abbisko Therapeutics Co, Ltd
NCT01514552 ACTIVE NOT RECRUITING
The Use of Functional Confections in Promoting Oral Health
Ohio State University
NCT06084416 ACTIVE NOT RECRUITING
A Study of Sovilnesib in Subjects With Ovarian Cancer
Volastra Therapeutics, Inc.
NCT07216833 NOT YET RECRUITING
Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Kyunghee Burkitt, DO, PhD
NCT05948826 ACTIVE NOT RECRUITING
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
NCT06752681 RECRUITING
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT04058756 ACTIVE NOT RECRUITING
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis Pharmaceuticals
NCT07207681 NOT YET RECRUITING
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
The First Hospital of Jilin University
NCT06990698 RECRUITING
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
Zhuhai Fapon Biopharma Co., Ltd.
NCT07179692 RECRUITING
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT04887935 RECRUITING
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Washington University School of Medicine
NCT03993873 ACTIVE NOT RECRUITING
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
Turning Point Therapeutics, Inc.
NCT06933524 NOT YET RECRUITING
Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors
Autotelicbio
NCT07200479 NOT YET RECRUITING
A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
NCT06126666 RECRUITING
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
NCT06136884 RECRUITING
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A2A Pharmaceuticals Inc.
NCT04295863 RECRUITING
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
University of Chicago
NCT05423977 ENROLLING BY INVITATION
Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
NCT06088472 RECRUITING
TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Grit Biotechnology
NCT07196579 NOT YET RECRUITING
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
TCRx Therapeutics Co.Ltd
NCT04794972 RECRUITING
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05470348 RECRUITING
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05393427 ACTIVE NOT RECRUITING
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05631964 RECRUITING
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05385692 ACTIVE NOT RECRUITING
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06241898 RECRUITING
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
NCT04606472 ACTIVE NOT RECRUITING
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05194982 RECRUITING
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05461768 RECRUITING
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06953453 RECRUITING
A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors
Lee's Pharmaceutical Limited
NCT03191682 ACTIVE NOT RECRUITING
A First-in-Human Study of PRL3-ZUMAB
National University Hospital, Singapore
NCT05485974 ACTIVE NOT RECRUITING
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
HUYABIO International, LLC.
NCT05163028 ACTIVE NOT RECRUITING
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
HUYABIO International, LLC.
NCT06674538 ENROLLING BY INVITATION
Clinical Trial to Treat Stage IV Cancer Patients
Moonshot Antibodies
NCT06210815 RECRUITING
A Study of HLX42 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT05216432 RECRUITING
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Relay Therapeutics, Inc.
NCT06636435 RECRUITING
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Chiome Bioscience Inc.
NCT06500052 RECRUITING
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06533332 RECRUITING
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
NCT06493864 RECRUITING
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06475131 RECRUITING
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06469008 RECRUITING
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06549478 RECRUITING
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
City of Hope Medical Center
NCT04064359 RECRUITING
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Oxford BioTherapeutics Ltd
NCT06577987 RECRUITING
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT05055609 RECRUITING
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
Trethera
NCT06979674 RECRUITING
Study of ESG406 in Adults With Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
NCT05259709 RECRUITING
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
Regeneron Pharmaceuticals
NCT06983743 RECRUITING
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Erasca, Inc.
NCT05357651 RECRUITING
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
L & L Bio Co., Ltd., Ningbo, China
NCT05653882 ACTIVE NOT RECRUITING
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics, Inc.
NCT07110090 RECRUITING
Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05107674 RECRUITING
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
NCT06783569 RECRUITING
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
JiaRay Group
NCT07163325 RECRUITING
EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
Epics Therapeutics
NCT07100847 RECRUITING
Periprostatic Neurolysis in Prostate Cancer
University of Texas Southwestern Medical Center
NCT06239467 RECRUITING
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
OnKure, Inc.
NCT05533463 ACTIVE NOT RECRUITING
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Jiangsu HengRui Medicine Co., Ltd.
NCT06739291 RECRUITING
A Study of SIGX1094R in Patients With Advanced Solid Tumors
Signet Therapeutics
NCT07156253 RECRUITING
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
NCT05932862 RECRUITING
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
NCT05241834 ACTIVE NOT RECRUITING
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Eli Lilly and Company
NCT07086768 NOT YET RECRUITING
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
Lei Zheng
NCT04047251 ACTIVE NOT RECRUITING
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT06398418 RECRUITING
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Rise Therapeutics LLC
NCT06873659 RECRUITING
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen Inc.
NCT06694480 RECRUITING
Study of FID-022 in Participants With Advanced Solid Tumors
Fulgent Pharma LLC.
NCT07132541 RECRUITING
Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)
Minia University
NCT05701488 RECRUITING
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Jiping Wang, MD, PhD
NCT05076760 RECRUITING
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
NCT06806982 RECRUITING
A Study of VRN101099 in Patients With HER2-Positive Solid Tumors
Voronoi, Inc
NCT06040541 RECRUITING
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
NCT03611595 RECRUITING
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Peter Zage
NCT05836896 RECRUITING
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Technische Universität Dresden
NCT07139067 RECRUITING
Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors
Peking University
NCT05835609 RECRUITING
PM534 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar
NCT07056556 RECRUITING
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07136558 NOT YET RECRUITING
Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
NCT07135128 RECRUITING
A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors
Xiaorong Sun
NCT06036121 ACTIVE NOT RECRUITING
A Study of ADRX-0706 in Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT06487455 RECRUITING
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
Shanghai Pharmaceuticals Holding Co., Ltd
NCT04429542 RECRUITING
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT02099058 ACTIVE NOT RECRUITING
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie
NCT05906862 RECRUITING
AMT-253 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics (Australia) Pty Ltd
NCT07119996 NOT YET RECRUITING
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05718219 ACTIVE NOT RECRUITING
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT05717348 ACTIVE NOT RECRUITING
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
Elpiscience (Suzhou) Biopharma, Ltd.
NCT06547957 ACTIVE NOT RECRUITING
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
iTeos Therapeutics
NCT07117214 NOT YET RECRUITING
A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
Novartis Pharmaceuticals
NCT07118709 NOT YET RECRUITING
A Study of KC1086 in Patients With Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
NCT03893955 ACTIVE NOT RECRUITING
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT07118176 RECRUITING
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
NCT05836948 RECRUITING
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05279300 RECRUITING
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
NCT07110883 RECRUITING
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06375564 RECRUITING
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
The First Affiliated Hospital of Xiamen University
NCT05226507 ACTIVE NOT RECRUITING
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Nuvectis Pharma, Inc.
NCT07100249 RECRUITING
A Study of HDM2012 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT07110363 NOT YET RECRUITING
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
Biotroy Therapeutics
NCT07107178 NOT YET RECRUITING
A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
Biotroy Therapeutics
NCT04778839 RECRUITING
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
NCT05740202 ACTIVE NOT RECRUITING
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT04046133 ACTIVE NOT RECRUITING
Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus
Cardiff University
NCT07100925 NOT YET RECRUITING
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
Ankyra Therapeutics, Inc
NCT07101549 NOT YET RECRUITING
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
changjianhua
NCT07072325 NOT YET RECRUITING
Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers
West China Hospital
NCT03872947 ACTIVE NOT RECRUITING
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
NCT04572451 RECRUITING
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Yana Najjar
NCT05735496 ACTIVE NOT RECRUITING
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT07098052 RECRUITING
A Study of HDM2020 in Patients With Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT06463340 RECRUITING
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Schrödinger, Inc.
NCT06756035 RECRUITING
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
NCT02498912 ACTIVE NOT RECRUITING
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT05617755 ACTIVE NOT RECRUITING
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc.
NCT06220838 RECRUITING
Study SC-101 in Subjects With Advanced Malignancies
Tianjin ConjuStar Biologics Co., Ltd.
NCT07088588 NOT YET RECRUITING
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
NCT06761937 RECRUITING
Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients
Erasmus Medical Center
NCT06644755 RECRUITING
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT05217693 RECRUITING
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
NCT06992713 RECRUITING
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
NCT07071090 RECRUITING
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Heronova Pharmaceuticals
NCT03772561 RECRUITING
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
National University Hospital, Singapore
NCT05701709 RECRUITING
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06666270 RECRUITING
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
NCT01843413 ACTIVE NOT RECRUITING
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
Case Comprehensive Cancer Center
NCT06826313 RECRUITING
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
NCT06963814 RECRUITING
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
HC Biopharma Inc.
NCT06929663 RECRUITING
A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors
Akeso
NCT05881525 RECRUITING
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
TCRCure Biopharma Ltd.
NCT04457232 ACTIVE NOT RECRUITING
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
Jonsson Comprehensive Cancer Center
NCT06128148 RECRUITING
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Guangzhou JOYO Pharma Co., Ltd
NCT04511845 ACTIVE NOT RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Chugai Pharmaceutical
NCT06993870 RECRUITING
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.
NCT07060014 NOT YET RECRUITING
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
The Methodist Hospital Research Institute
NCT04046575 ACTIVE NOT RECRUITING
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Washington University School of Medicine
NCT05857969 RECRUITING
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
NCT02474368 ACTIVE NOT RECRUITING
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
Dana-Farber Cancer Institute
NCT06719362 RECRUITING
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
NCT02974738 ACTIVE NOT RECRUITING
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03336606 ACTIVE NOT RECRUITING
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
NCT07057349 NOT YET RECRUITING
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
Cytosite Biopharma Inc.
NCT07053904 ENROLLING BY INVITATION
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
PharmaEssentia
NCT07053735 NOT YET RECRUITING
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
Peking University First Hospital
NCT06980454 ACTIVE NOT RECRUITING
Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
Shanghai Henlius Biotech
NCT02112565 ACTIVE NOT RECRUITING
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
City of Hope Medical Center
NCT07045428 NOT YET RECRUITING
68Ga-GP-01 Injection in Solid Tumors Participants
GrandPharma (China) Co., Ltd.
NCT07050459 RECRUITING
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT06548217 ACTIVE NOT RECRUITING
A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co., Ltd.
NCT04721015 ACTIVE NOT RECRUITING
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
AbbVie
NCT05277766 RECRUITING
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
University Hospital, Ghent
NCT04740424 RECRUITING
FS222 First in Human Study in Patients With Advanced Malignancies
invoX Pharma Limited
NCT06415487 RECRUITING
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Acepodia Biotech, Inc.
NCT06410131 RECRUITING
Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16
Sound Biopharmaceuticals Ltd.
NCT07045454 RECRUITING
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT04827810 RECRUITING
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
Fox Chase Cancer Center
NCT06163391 RECRUITING
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
SOTIO Biotech AG
NCT04648202 ACTIVE NOT RECRUITING
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
invoX Pharma Limited
NCT06076291 ACTIVE NOT RECRUITING
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
NCT04603001 ACTIVE NOT RECRUITING
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT06240728 RECRUITING
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
NextPoint Therapeutics, Inc.
NCT05354323 ACTIVE NOT RECRUITING
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
NEC OncoImmunity AS
NCT07038044 NOT YET RECRUITING
Safety and Efficacy of an Arginine-Restricted Diet in Patients With Solid Tumors
West China Hospital
NCT05785754 RECRUITING
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
NCT04997993 RECRUITING
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
Deborah Doroshow
NCT06431594 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT06601218 RECRUITING
Impact of Daily Oral Cannabis Doses in Patients With Cancer
Shanna Babalonis, PhD
NCT07028047 NOT YET RECRUITING
Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study
Sun Yat-sen University
NCT05329103 RECRUITING
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Peel Therapeutics Inc
NCT06349811 RECRUITING
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07021534 RECRUITING
Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial
Zhejiang University
NCT07016997 RECRUITING
A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.
Chiome Bioscience Inc.
NCT04412616 RECRUITING
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
Changchun Intellicrown Pharmaceutical Co. LTD
NCT06883149 RECRUITING
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
Chinese PLA General Hospital
NCT06028373 RECRUITING
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited
NCT05205109 RECRUITING
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
Antengene Therapeutics Limited
NCT02608385 ACTIVE NOT RECRUITING
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
NCT07004296 RECRUITING
A Study of HDM2005 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT06063681 RECRUITING
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Stingray Therapeutics
NCT06963281 RECRUITING
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
NCT05740956 RECRUITING
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT03155061 ACTIVE NOT RECRUITING
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co., Ltd.
NCT06253195 ACTIVE NOT RECRUITING
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
BeiGene
NCT06878612 RECRUITING
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
Xingchen Peng
NCT06978062 NOT YET RECRUITING
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
European Organisation for Research and Treatment of Cancer - EORTC
NCT06898255 RECRUITING
A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia
Genfleet Therapeutics (Shanghai) Inc.
NCT07001592 RECRUITING
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT06954077 RECRUITING
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06998173 NOT YET RECRUITING
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
Danatlas Pharmaceuticals Co., Ltd
NCT05518253 RECRUITING
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Weijia Fang, MD
NCT04866641 RECRUITING
Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors
Taivex Therapeutics Corporation
NCT05704985 ACTIVE NOT RECRUITING
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT06644573 NOT YET RECRUITING
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
Nyree Penn
NCT06902350 RECRUITING
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
NCT03821935 ACTIVE NOT RECRUITING
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT06337084 RECRUITING
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Monopar Therapeutics
NCT04616534 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
National Cancer Institute (NCI)
NCT06912152 RECRUITING
MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors
Zhejiang University
NCT06246968 RECRUITING
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05048368 NOT YET RECRUITING
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
Sunshine Lake Pharma Co., Ltd.
NCT03440450 ACTIVE NOT RECRUITING
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT05678010 ACTIVE NOT RECRUITING
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT02663297 ACTIVE NOT RECRUITING
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT04137536 ACTIVE NOT RECRUITING
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT06970795 RECRUITING
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06958679 RECRUITING
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06307925 RECRUITING
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
HC Biopharma Inc.
NCT06968572 RECRUITING
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
Haisco Pharmaceutical Group Co., Ltd.
NCT06966583 NOT YET RECRUITING
NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC
Sichuan University
NCT05765851 ACTIVE NOT RECRUITING
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT06963398 NOT YET RECRUITING
A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT06963502 NOT YET RECRUITING
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT06962254 RECRUITING
Imatinib and Trametinib for KRAS-mutated Solid Tumor
China Medical University Hospital
NCT06954558 RECRUITING
A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
NCT06934616 NOT YET RECRUITING
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
Genor Biopharma Co., Ltd.
NCT05598151 RECRUITING
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT05167071 ACTIVE NOT RECRUITING
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Harbour BioMed (Guangzhou) Co. Ltd.
NCT06907628 RECRUITING
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06188624 RECRUITING
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT06944457 RECRUITING
Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
Pharosgen Co.,Ltd
NCT05967533 RECRUITING
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT06932094 NOT YET RECRUITING
Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06936735 NOT YET RECRUITING
Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT05749432 RECRUITING
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
Ganzhou Hemay Pharmaceutical Co., Ltd
NCT05919537 ACTIVE NOT RECRUITING
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Hummingbird Bioscience
NCT06235983 ACTIVE NOT RECRUITING
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT06475937 RECRUITING
A Study of DM001 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT06925659 NOT YET RECRUITING
A Study of QLM2011 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical (Hainan) Co., Ltd.
NCT06462365 RECRUITING
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
NCT05473624 RECRUITING
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06462716 ACTIVE NOT RECRUITING
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
NCT06094556 RECRUITING
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT05969314 ACTIVE NOT RECRUITING
To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer
Tata Memorial Hospital
NCT06258304 RECRUITING
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
GigaGen, Inc.
NCT06621563 RECRUITING
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06710379 RECRUITING
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT06096974 RECRUITING
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Shanghai YingLi Pharmaceutical Co. Ltd.
NCT04685473 ACTIVE NOT RECRUITING
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
NCT05495295 RECRUITING
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Phost'In Therapeutics
NCT05544240 RECRUITING
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Williams Cancer Foundation
NCT06913218 NOT YET RECRUITING
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
Akeso
NCT04751786 ACTIVE NOT RECRUITING
Dose Escalation Study of Immunomodulatory Nanoparticles
Radboud University Medical Center
NCT05868226 RECRUITING
PRE-I-SPY Phase I/Ib Oncology Platform Program
QuantumLeap Healthcare Collaborative
NCT06885645 NOT YET RECRUITING
First-In-Human Study in Participants With Advanced Solid Tumors
Chengdu Kanghong Biotech Co., Ltd.
NCT06446713 RECRUITING
PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer
University Medical Center Groningen
NCT05477849 RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
Shanghai Virogin Biotech Co., Ltd.
NCT06796699 RECRUITING
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT06897228 RECRUITING
PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors
Shenzhen Celconta Life Science Co., Ltd.
NCT06716619 RECRUITING
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
NCT04877717 ACTIVE NOT RECRUITING
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06587295 RECRUITING
Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy
National Cancer Centre, Singapore
NCT05828459 RECRUITING
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Onward Therapeutics
NCT06883539 RECRUITING
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
LaunXP Biomedical Co., Ltd.
NCT06541639 RECRUITING
EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors
Peking University
NCT04998422 RECRUITING
A Study of HG381 Administered to Patients With Advanced Solid Tumors
HitGen Inc.
NCT06046742 RECRUITING
A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
NCT06872580 NOT YET RECRUITING
A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06167317 RECRUITING
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Gilead Sciences
NCT06707610 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
NCT06595329 RECRUITING
Comparison Between Epidural Analgesia and Intrathecal Opioid Analgesia for Pain Management in Open Nephrectomy
University Hospital of Split
NCT04196257 RECRUITING
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings, Inc.
NCT05907980 RECRUITING
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Chugai Pharmaceutical
NCT06443489 RECRUITING
A Trial of SHR-4849 in Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06069570 RECRUITING
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Kiromic BioPharma Inc.
NCT06005740 RECRUITING
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
TORL Biotherapeutics, LLC
NCT06035744 RECRUITING
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Cullinan Therapeutics Inc.
NCT05607498 RECRUITING
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
NCT06687070 RECRUITING
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Ascentage Pharma Group Inc.
NCT05701306 RECRUITING
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Ascentage Pharma Group Inc.
NCT06484816 RECRUITING
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Shenzhen TargetRx Co., Ltd.
NCT06394414 RECRUITING
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06571422 RECRUITING
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT06831539 RECRUITING
Impact of PEG Bowel Preparation on Gut Microbiome Composition Recovery
Centre hospitalier de l'Université de Montréal (CHUM)
NCT04643574 ACTIVE NOT RECRUITING
NeoTIL in Advanced Solid Tumors
Centre Hospitalier Universitaire Vaudois
NCT05580991 ACTIVE NOT RECRUITING
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
Canwell Biotech Limited
NCT06051760 RECRUITING
NV-001 in the Treatment of Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06801470 RECRUITING
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
CD (Suzhou) Biopharma Co., Ltd.
NCT04762641 RECRUITING
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
NCT04701645 RECRUITING
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT04872166 RECRUITING
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Edgewood Oncology Inc.
NCT06800196 NOT YET RECRUITING
A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations
KinoTeck Therapeutics Co., Ltd
NCT06224855 RECRUITING
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Hangzhou DAC Biotechnology Co., Ltd.
NCT05341557 RECRUITING
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Betta Pharmaceuticals Co., Ltd.
NCT06349408 RECRUITING
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT05789602 RECRUITING
A Study of BPI-460372 in Advanced Solid Tumor Patients
Betta Pharmaceuticals Co., Ltd.
NCT03791112 ACTIVE NOT RECRUITING
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
NCT06772415 RECRUITING
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT06418061 RECRUITING
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT06299124 ACTIVE NOT RECRUITING
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
Regor Pharmaceuticals Inc.
NCT06782425 RECRUITING
Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T)
Shenzhen Celconta Life Science Co., Ltd.
NCT06779045 NOT YET RECRUITING
A Study of AK-1286 in Patients With Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
NCT06770764 RECRUITING
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
Trutino Biosciences Inc.
NCT06764836 RECRUITING
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT06763159 RECRUITING
A Study of HS-20124 in Patients with Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06686745 RECRUITING
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT06760117 RECRUITING
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
Sun Yat-sen University
NCT06755242 NOT YET RECRUITING
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06752447 NOT YET RECRUITING
A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors
Shandong New Time Pharmaceutical Co., LTD
NCT06404905 RECRUITING
Clinical Trial of BT02 in Patients With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05954091 NOT YET RECRUITING
OH2 Administered by Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
NCT06748872 NOT YET RECRUITING
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
Medigene AG
NCT04576091 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
NCT06730659 RECRUITING
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT06728189 RECRUITING
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors
Peking University Cancer Hospital & Institute
NCT06726564 RECRUITING
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
NCT06723964 ACTIVE NOT RECRUITING
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
AP Biosciences Inc.
NCT06426680 RECRUITING
A Study of the ILB-3101 in Patients with Advanced Solid Tumors
Innolake Biopharm
NCT04104607 RECRUITING
The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma
University Hospital Tuebingen
NCT06302062 RECRUITING
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
NCT06710821 NOT YET RECRUITING
Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors
Yizhuo Zhang
NCT05302037 RECRUITING
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
CytoMed Therapeutics Pte Ltd
NCT03842085 RECRUITING
Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
Beijing Mabworks Biotech Co., Ltd.
NCT06084286 RECRUITING
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Sichuan University
NCT06158477 RECRUITING
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Chengdu JOYO pharma Co., Ltd.
NCT06026254 ACTIVE NOT RECRUITING
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
ImmuneSensor Therapeutics Inc.
NCT06169579 ENROLLING BY INVITATION
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Shenzhen NewDEL Biotech, Co., Ltd
NCT05382325 ACTIVE NOT RECRUITING
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Merck Sharp & Dohme LLC
NCT05463952 ACTIVE NOT RECRUITING
A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
Pfizer
NCT05156203 RECRUITING
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
Taivex Therapeutics Corporation
NCT05278546 ACTIVE NOT RECRUITING
A Study of ILB2109 in Patients With Advanced Solid Malignancies
Innolake Biopharm
NCT03907527 ACTIVE NOT RECRUITING
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Precigen, Inc
NCT05983523 RECRUITING
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
PharmaEngine
NCT06652529 NOT YET RECRUITING
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
Aromics Therapeutics
NCT06190886 RECRUITING
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Proviva Therapeutics, Inc.
NCT04511871 ACTIVE NOT RECRUITING
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Shanghai PerHum Therapeutics Co., Ltd.
NCT05772455 RECRUITING
A Study of XZB-0004 in Patients With Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05548634 ACTIVE NOT RECRUITING
A Study of TAVO412 in Patients with Cancer
Tavotek Biotherapeutics
NCT05159440 ACTIVE NOT RECRUITING
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
NCT04093466 RECRUITING
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
NCT04387916 RECRUITING
A Study of KC1036 in Patients with Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
NCT05215574 ACTIVE NOT RECRUITING
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NCT06632574 RECRUITING
A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT02521844 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
NCT06160752 RECRUITING
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Tyra Biosciences, Inc
NCT03603951 ACTIVE NOT RECRUITING
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Jiangsu HengRui Medicine Co., Ltd.
NCT06621615 NOT YET RECRUITING
Clinical Study of CVL006 Injection in Advanced Solid Tumors
Convalife (Shanghai) Co., Ltd.
NCT03546426 ACTIVE NOT RECRUITING
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT06614751 NOT YET RECRUITING
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
Danatlas Pharmaceuticals Co., Ltd
NCT06615193 RECRUITING
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT06614686 RECRUITING
U87 CAR-T in Patients With Advanced Head and Neck Tumors
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NCT06259552 RECRUITING
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co., Ltd.
NCT06592417 RECRUITING
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT05773937 RECRUITING
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT04811703 RECRUITING
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer
Hospices Civils de Lyon
NCT06389526 NOT YET RECRUITING
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Coherus Oncology, Inc.
NCT03891706 RECRUITING
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
NCT06598735 NOT YET RECRUITING
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06594874 NOT YET RECRUITING
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT01883297 ACTIVE NOT RECRUITING
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University Health Network, Toronto
NCT04928612 RECRUITING
A Study of CBP-1018 in Patients With Advanced Solid Tumors
Coherent Biopharma (Suzhou) Co., Ltd.
NCT04740398 RECRUITING
A Study of CBP-1008 in Patients With Advanced Solid Tumor
Coherent Biopharma (Suzhou) Co., Ltd.
NCT06404281 RECRUITING
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
Changzhou No.2 People's Hospital
NCT05351502 RECRUITING
A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors
Beyond Air Inc.
NCT06558175 NOT YET RECRUITING
Reirradiation Dose Escalation in Thoracic Cancers
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT06553846 NOT YET RECRUITING
A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors
Fudan University
NCT05244551 RECRUITING
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Abbisko Therapeutics Co, Ltd
NCT06548672 RECRUITING
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
Biocity Biopharmaceutics Co., Ltd.
NCT06544720 RECRUITING
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
The Affiliated Hospital of Qingdao University
NCT06452160 RECRUITING
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences Inc.
NCT05266612 RECRUITING
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Virogin Biotech Canada Ltd
NCT06536400 RECRUITING
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
Haisco Pharmaceutical Group Co., Ltd.
NCT06271252 RECRUITING
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd.
NCT05076552 ACTIVE NOT RECRUITING
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Tachyon Therapeutics, Inc.
NCT05474859 NOT YET RECRUITING
Subjects With Advanced or Metastatic Solid Tumor Malignancies
Xenthera, Inc.
NCT06530082 NOT YET RECRUITING
A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06257680 RECRUITING
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
Aeonvital Biomedicine
NCT06528249 NOT YET RECRUITING
Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies
Zhejiang Provincial People's Hospital
NCT06386705 RECRUITING
TSN084 Treating Patients With Advanced Malignant Tumors
Tyligand Bioscience (Shanghai) Limited
NCT05878691 ACTIVE NOT RECRUITING
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Glenmark Specialty S.A.
NCT05731752 ACTIVE NOT RECRUITING
Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
NCT06332170 RECRUITING
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06336707 RECRUITING
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT05979155 RECRUITING
A Study of NWY001 in Subjects With Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
NCT06501183 RECRUITING
Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors
Shanghai Pudong Hospital
NCT05620862 ACTIVE NOT RECRUITING
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
Sun Yat-sen University
NCT06329206 RECRUITING
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT05010694 ACTIVE NOT RECRUITING
GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results
Suzhou Genhouse Bio Co., Ltd.
NCT06477614 RECRUITING
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT05830045 RECRUITING
A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06195293 RECRUITING
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT04952272 RECRUITING
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT06195384 RECRUITING
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT06196294 RECRUITING
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
NCT05300438 ACTIVE NOT RECRUITING
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
Tyligand Bioscience (Shanghai) Limited
NCT04842812 RECRUITING
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT05779917 RECRUITING
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
NCT05410717 RECRUITING
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT06473948 NOT YET RECRUITING
To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
Jemincare
NCT03778814 RECRUITING
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT03198052 RECRUITING
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
NCT03530397 ACTIVE NOT RECRUITING
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT05819684 RECRUITING
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06445517 RECRUITING
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
InSilico Medicine Hong Kong Limited
NCT06399419 RECRUITING
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Osel, Inc.
NCT06433726 RECRUITING
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
NCT06421610 RECRUITING
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
Odense University Hospital
NCT05564858 RECRUITING
A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT06418113 RECRUITING
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
Hospital San Carlos, Madrid
NCT06415500 NOT YET RECRUITING
A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites
Anhui Provincial Hospital
NCT06415903 NOT YET RECRUITING
A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT05650580 RECRUITING
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Tarapeutics Science Inc.
NCT06410092 RECRUITING
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
Sound Biopharmaceuticals Ltd.
NCT06403735 RECRUITING
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06086522 RECRUITING
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Qualigen Theraputics, Inc.
NCT05868174 RECRUITING
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Limited
NCT06394622 RECRUITING
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Fudan University
NCT05909241 RECRUITING
A Study of BA1202 in Patients With Advanced Solid Tumors
Shandong Boan Biotechnology Co., Ltd
NCT06383507 NOT YET RECRUITING
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Zhejiang University
NCT06374173 RECRUITING
A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
NCT06358053 NOT YET RECRUITING
CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
Corregene Biotechnology Co., Ltd
NCT05263479 RECRUITING
A Study of HS-20089 in Patients With Advanced Solid Tumors
Shanghai Hansoh Biomedical Co., Ltd
NCT06342336 RECRUITING
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Qingdao Sino-Cell Biomedicine Co., Ltd.
NCT06223256 RECRUITING
A Study of NBL-028 in Patients With Advanced Solid Tumors
NovaRock Biotherapeutics, Ltd
NCT06240546 RECRUITING
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
Luye Pharma Group Ltd.
NCT04965077 RECRUITING
Treatment of Advanced and Metastatic Solid Tumors With MIL97
Beijing Mabworks Biotech Co., Ltd.
NCT06307249 RECRUITING
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Lebanese University
NCT06101082 RECRUITING
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
China Medical University, China
NCT05877664 RECRUITING
Study of ZG0895.HCl in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06205082 ENROLLING BY INVITATION
A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor
LittDD Medicines Ltd
NCT06277804 NOT YET RECRUITING
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor
Letolab
NCT04282044 RECRUITING
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT06037317 RECRUITING
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors
Shouyao Holdings (Beijing) Co. LTD
NCT06225856 RECRUITING
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
Shanghai Yuyao Biotech Co., Ltd.
NCT06215950 RECRUITING
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Chongqing Precision Biotech Co., Ltd
NCT06211647 RECRUITING
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Ruimin Wang
NCT06209385 RECRUITING
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT05582590 NOT YET RECRUITING
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
NexImmune Inc.
NCT06197139 RECRUITING
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Xinlu Wang
NCT06193993 ACTIVE NOT RECRUITING
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
National University Hospital, Singapore
NCT06170294 RECRUITING
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
Peking University
NCT06166472 NOT YET RECRUITING
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
Akeso
NCT05940896 RECRUITING
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
RemeGen Co., Ltd.
NCT06134960 NOT YET RECRUITING
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
Peking University
NCT06134531 NOT YET RECRUITING
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
Nanfang Hospital, Southern Medical University
NCT06131216 NOT YET RECRUITING
Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06126406 RECRUITING
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT06121557 RECRUITING
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06121570 RECRUITING
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06010875 RECRUITING
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT06010862 RECRUITING
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT05866692 RECRUITING
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
TYK Medicines, Inc
NCT05895825 RECRUITING
A Study of EOC237 in Patients With Advanced Solid Tumor
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
NCT06093698 NOT YET RECRUITING
An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
ITabMed Co., Ltd.
NCT05621486 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors
Shanghai East Hospital
NCT06072989 RECRUITING
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
Shanghai East Hospital
NCT06043466 RECRUITING
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT06019702 RECRUITING
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
Sir Run Run Shaw Hospital
NCT06026774 RECRUITING
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Sir Run Run Shaw Hospital
NCT06026800 RECRUITING
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms
Sir Run Run Shaw Hospital
NCT06027346 RECRUITING
A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours
Shijiazhuang Yiling Pharmaceutical Co. Ltd
NCT05631886 RECRUITING
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
NCT05982080 RECRUITING
A Study to Investigate FP002 in Subjects With Advanced Malignancies
Guangdong Fapon Biopharma Inc.
NCT05788107 NOT YET RECRUITING
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
NCT05886374 RECRUITING
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
Hutchmed
NCT05940116 NOT YET RECRUITING
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT05933668 NOT YET RECRUITING
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor
Peking University
NCT05924906 NOT YET RECRUITING
A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors
Suzhou Neologics Bioscience Co., Ltd.
NCT05911464 RECRUITING
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT05823285 RECRUITING
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
NCT05361954 NOT YET RECRUITING
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
NCT05804864 NOT YET RECRUITING
A Study of KM501 in Patients With Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05783089 NOT YET RECRUITING
MSLN-targeted CAR-T Cells in Solid Tumors.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05766527 NOT YET RECRUITING
A Study of KM602 in Patients With Advanced Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05528055 RECRUITING
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT02477878 ACTIVE NOT RECRUITING
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT05392699 RECRUITING
ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05320874 NOT YET RECRUITING
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05172310 RECRUITING
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
Karolinska University Hospital
NCT07596693 RECRUITING
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
TCRx Therapeutics Co.Ltd
NCT07596381 NOT YET RECRUITING
FAK Inhibitor in Patients With Advanced Solid Tumors
InxMed (Shanghai) Co., Ltd.
NCT07593144 NOT YET RECRUITING
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
Foresight Therapeutics (Hefei) Co., Ltd.
NCT07589205 RECRUITING
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
NCT07591285 NOT YET RECRUITING
A Study of SYS6051 in Subjects With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT07591155 NOT YET RECRUITING
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT02797795 COMPLETED
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
Neovia Oncology Ltd.
NCT05673460 COMPLETED
A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
Merck Sharp & Dohme LLC
NCT04354246 COMPLETED
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
NCT05155332 SUSPENDED
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT05162755 COMPLETED
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
Institut de Recherches Internationales Servier
NCT05582850 TERMINATED
DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours
Domain Therapeutics SA
NCT02437227 COMPLETED
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
Royal Marsden NHS Foundation Trust
NCT06568614 TERMINATED
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
BeOne Medicines
NCT06487858 TERMINATED
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
BeOne Medicines
NCT05076396 COMPLETED
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar
NCT05549804 COMPLETED
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05387928 COMPLETED
A Study of KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06573294 TERMINATED
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Genmab
NCT06091930 COMPLETED
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
NCT01875601 COMPLETED
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT05111353 COMPLETED
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine
NCT07159828 TERMINATED
A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors
Axion Bio, Inc
NCT03144466 TERMINATED
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer
Royal Marsden NHS Foundation Trust
NCT05983133 TERMINATED
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05824663 COMPLETED
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
NCT04457778 COMPLETED
First in Human Study of M6223
EMD Serono Research & Development Institute, Inc.
NCT01445509 COMPLETED
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Cancer Institute (NCI)
NCT05300048 TERMINATED
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Faeth Therapeutics
NCT02211755 COMPLETED
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
National Cancer Institute (NCI)
NCT07554196 COMPLETED
A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
Huahui Health
NCT05085548 COMPLETED
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ProDa BioTech, LLC
NCT06104449 COMPLETED
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
Merck Sharp & Dohme LLC
NCT05430360 TERMINATED
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors
Grit Biotechnology
NCT02423057 COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01552434 TERMINATED
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
NCT04868773 COMPLETED
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
NCT06308263 COMPLETED
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NCT05341349 TERMINATED
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
NCT05036291 TERMINATED
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Ningbo Newbay Technology Development Co., Ltd
NCT06779851 TERMINATED
A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors
Bright Peak Therapeutics Inc
NCT05204147 SUSPENDED
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
City of Hope Medical Center
NCT05198349 TERMINATED
First in Human Study of M1069 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT02379416 COMPLETED
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
National Cancer Institute (NCI)
NCT06741072 SUSPENDED
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Ohio State University Comprehensive Cancer Center
NCT05022849 COMPLETED
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Janssen Research & Development, LLC
NCT03881488 COMPLETED
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
NCT05607199 TERMINATED
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Aurigene Discovery Technologies Limited
NCT05861947 TERMINATED
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Aurigene Discovery Technologies Limited
NCT05605119 TERMINATED
First in Human, Dose Escalation, Dose Expansion Study of AUR105
Aurigene Discovery Technologies Limited
NCT03317743 COMPLETED
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Idience Co., Ltd.
NCT07529535 SUSPENDED
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
NCT04241835 TERMINATED
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Epizyme, Inc.
NCT03114319 TERMINATED
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01352962 COMPLETED
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Cancer Institute (NCI)
NCT01642017 TERMINATED
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
Institut Claudius Regaud
NCT05639153 TERMINATED
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
Zhejiang Doer Biologics Co., Ltd.
NCT03403049 COMPLETED
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Montefiore Medical Center
NCT05879627 TERMINATED
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Bio-Thera Solutions
NCT06130254 TERMINATED
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
NCT04892017 TERMINATED
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
NCT04931823 TERMINATED
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
NCT06476548 COMPLETED
Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors
H. Lee Moffitt Cancer Center and Research Institute
NCT04050709 COMPLETED
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio, Inc.
NCT04303858 COMPLETED
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT03798626 COMPLETED
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis Pharmaceuticals
NCT05148325 COMPLETED
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors
Bio-Thera Solutions
NCT03449381 COMPLETED
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT06110195 TERMINATED
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
NCT06188208 TERMINATED
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
NCT05848466 COMPLETED
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Bio-Thera Solutions
NCT05933070 TERMINATED
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
Inmune Bio, Inc.
NCT02133625 COMPLETED
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
NCT04234113 TERMINATED
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
SOTIO Biotech AG
NCT03568058 COMPLETED
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Aaron Miller
NCT05727839 COMPLETED
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
NCT03420963 TERMINATED
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
NCT02215720 COMPLETED
Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors
Gustave Roussy, Cancer Campus, Grand Paris
NCT05411133 COMPLETED
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Arbele Pty Ltd
NCT06136598 COMPLETED
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
Merck Sharp & Dohme LLC
NCT04423029 COMPLETED
A Study of DF6002 Alone and in Combination With Nivolumab
Dragonfly Therapeutics
NCT04158336 COMPLETED
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT02642809 COMPLETED
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Washington University School of Medicine
NCT06298357 COMPLETED
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
University of Alabama at Birmingham
NCT06799533 TERMINATED
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Pfizer
NCT03258593 COMPLETED
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Cancer Institute (NCI)
NCT06056024 COMPLETED
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
Boehringer Ingelheim
NCT06894771 COMPLETED
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Merck Sharp & Dohme LLC
NCT01374620 COMPLETED
Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel
Centre Oscar Lambret
NCT06540066 TERMINATED
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeiGene
NCT05935098 TERMINATED
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeiGene
NCT01046487 COMPLETED
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
Centre Oscar Lambret
NCT03239145 COMPLETED
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
NCT04261413 COMPLETED
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
NCT05735366 COMPLETED
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
Chugai Pharmaceutical
NCT02858869 COMPLETED
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
NCT04695327 COMPLETED
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy
TILT Biotherapeutics Ltd.
NCT05346484 TERMINATED
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
Imugene Limited
NCT06063317 TERMINATED
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
Imugene Limited
NCT06287463 TERMINATED
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Deciphera Pharmaceuticals, LLC
NCT05999968 COMPLETED
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
NCT06625515 TERMINATED
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
NCT06546553 TERMINATED
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
NCT03388619 COMPLETED
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Cancer Institute (NCI)
NCT05381909 TERMINATED
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeiGene
NCT05233436 TERMINATED
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Pfizer
NCT05578092 TERMINATED
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
NCT03964233 COMPLETED
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
NCT02021422 COMPLETED
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
Baylor Research Institute
NCT05638334 TERMINATED
Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
Institut de Recherches Internationales Servier
NCT04397276 COMPLETED
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
NCT02073994 COMPLETED
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Institut de Recherches Internationales Servier
NCT05800964 COMPLETED
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen
NCT03065062 SUSPENDED
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
NCT02909777 COMPLETED
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Dana-Farber Cancer Institute
NCT06331559 TERMINATED
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT02122913 COMPLETED
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
Bayer
NCT05478486 COMPLETED
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
Godavari Biorefineries Limited
NCT05372367 COMPLETED
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Boehringer Ingelheim
NCT06560645 TERMINATED
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
NCT02952248 COMPLETED
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
NCT04640480 COMPLETED
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
NCT04991480 COMPLETED
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
NCT03156114 COMPLETED
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Boehringer Ingelheim
NCT00923806 TERMINATED
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
National Cancer Institute (NCI)
NCT04544995 TERMINATED
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
NCT02856425 COMPLETED
Trial Of Pembrolizumab And Nintedanib
Gustave Roussy, Cancer Campus, Grand Paris
NCT06299761 TERMINATED
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
Boundless Bio, Inc.
NCT06560632 TERMINATED
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
Repare Therapeutics
NCT03780725 TERMINATED
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
Boehringer Ingelheim
NCT04587479 COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT05209295 TERMINATED
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Bristol-Myers Squibb
NCT05194072 TERMINATED
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT02948426 TERMINATED
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT04501276 COMPLETED
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Adagene Inc
NCT03510104 COMPLETED
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Meryx, Inc.
NCT06130722 COMPLETED
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
Suzhou Forlong Biotechnology Co., Ltd
NCT03905148 COMPLETED
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
BeiGene
NCT04617314 COMPLETED
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
NCT05378737 COMPLETED
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Bio-Thera Solutions
NCT05678998 COMPLETED
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
NCT05864573 COMPLETED
Study of ZGGS15 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06337630 TERMINATED
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
Institut Curie
NCT04648254 COMPLETED
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Qurient Co., Ltd.
NCT04045496 COMPLETED
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT01695005 COMPLETED
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
NCT05025358 COMPLETED
A Study of LP-118 in Patients With Advanced Tumors
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT06626256 WITHDRAWN
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
NCT05012618 TERMINATED
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Chugai Pharmaceutical
NCT05483933 COMPLETED
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
NCT01273168 COMPLETED
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
National Cancer Institute (NCI)
NCT06846099 COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Risen (Suzhou) Pharma Tech Co., Ltd.
NCT00576134 COMPLETED
The Objective is to Respond to Patients' Needs in the Field of Larynx Replacement
University Hospital, Strasbourg, France
NCT03955640 TERMINATED
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
Thomas Jefferson University
NCT04428788 COMPLETED
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
NCT04936178 COMPLETED
A Study of NB003 in Patients With Advanced Malignancies
Ningbo Newbay Technology Development Co., Ltd
NCT01282697 COMPLETED
Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
University Hospital, Strasbourg, France
NCT05047536 TERMINATED
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
NCT05240898 COMPLETED
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
NCT03388632 COMPLETED
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Cancer Institute (NCI)
NCT03573310 COMPLETED
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Janssen Research & Development, LLC
NCT05287399 COMPLETED
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Ascletis Pharmaceuticals Co., Ltd.
NCT06509906 TERMINATED
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono Research & Development Institute, Inc.
NCT03245892 COMPLETED
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT05165433 COMPLETED
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
Akamis Bio
NCT04580446 COMPLETED
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
University of Texas Southwestern Medical Center
NCT06438783 TERMINATED
TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT03595059 COMPLETED
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
NCT05417750 COMPLETED
A Phase I Study of GC101 TIL in Advanced Solid Tumors
Shanghai Juncell Therapeutics
NCT03260504 TERMINATED
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
NCT05105971 COMPLETED
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Bio-Thera Solutions
NCT05155722 COMPLETED
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors
Bio-Thera Solutions
NCT03177291 COMPLETED
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
NCT05147350 TERMINATED
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
Debiopharm International SA
NCT03968653 TERMINATED
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
Debiopharm International SA
NCT05147272 TERMINATED
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Debiopharm International SA
NCT05252416 TERMINATED
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
NCT03279237 COMPLETED
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Massachusetts General Hospital
NCT03307785 COMPLETED
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
NCT03109080 COMPLETED
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
Institut Curie
NCT05586321 COMPLETED
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
Genmab
NCT06001580 COMPLETED
A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.
NCT06289894 TERMINATED
A Study of BRY805 in Participants With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.
NCT05668585 COMPLETED
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
C4 Therapeutics, Inc.
NCT05014139 TERMINATED
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Astellas Pharma Global Development, Inc.
NCT05938296 SUSPENDED
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
NCT02936102 TERMINATED
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT05980416 TERMINATED
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT04374877 COMPLETED
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT03468426 COMPLETED
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
Boehringer Ingelheim
NCT05252390 TERMINATED
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
NCT04017819 SUSPENDED
Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4
Stanford University
NCT03396445 COMPLETED
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
Merck Sharp & Dohme LLC
NCT05322408 COMPLETED
HCW9218 in Select Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT06171178 TERMINATED
A Study of ASP1012 in Adults With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03564821 COMPLETED
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT03770494 TERMINATED
A Study of LY3405105 in Participants With Advanced Cancer
Eli Lilly and Company
NCT03010176 COMPLETED
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Merck Sharp & Dohme LLC
NCT04824443 COMPLETED
Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19
Memorial Sloan Kettering Cancer Center
NCT06158958 TERMINATED
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
AbbVie
NCT01582191 COMPLETED
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
M.D. Anderson Cancer Center
NCT01852890 COMPLETED
Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I
Joseph J. Cullen
NCT02597036 TERMINATED
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT04568902 COMPLETED
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Eisai Co., Ltd.
NCT04543188 TERMINATED
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
NCT03144661 TERMINATED
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
NCT05646797 TERMINATED
A Study of ASP2074 in Adults With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT05858164 COMPLETED
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Bayer
NCT02680795 COMPLETED
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Acrotech Biopharma Inc.
NCT05859464 TERMINATED
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Zai Lab (Hong Kong), Ltd.
NCT05639751 COMPLETED
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Prelude Therapeutics
NCT05082610 COMPLETED
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Hummingbird Bioscience
NCT04272034 TERMINATED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT06336148 TERMINATED
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
NCT05025085 COMPLETED
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Agenus Inc.
NCT02512926 COMPLETED
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Stanford University
NCT04982926 TERMINATED
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
NCT05293496 COMPLETED
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
NCT02964013 COMPLETED
Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)
Merck Sharp & Dohme LLC
NCT04117958 TERMINATED
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Amgen
NCT05514444 COMPLETED
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
Merck Sharp & Dohme LLC
NCT03522142 TERMINATED
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Incyte Corporation
NCT05317078 TERMINATED
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Amgen
NCT03564691 COMPLETED
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Merck Sharp & Dohme LLC
NCT05976334 TERMINATED
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
NCT03972150 COMPLETED
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
NCT04631029 COMPLETED
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
NCT04215978 COMPLETED
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT06296056 COMPLETED
Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)
Seoul Hospital
NCT02674152 COMPLETED
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
NCT06098651 COMPLETED
A Study of DCR-STAT3 in Adults With Solid Tumors
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT04417465 COMPLETED
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
AbbVie
NCT05501821 COMPLETED
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Kling Biotherapeutics B.V.
NCT06264921 TERMINATED
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
NCT04674748 TERMINATED
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
Incyte Biosciences Japan GK
NCT01218854 COMPLETED
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
National Institutes of Health Clinical Center (CC)
NCT05200364 TERMINATED
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Sutro Biopharma, Inc.
NCT05385705 TERMINATED
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Vall d'Hebron Institute of Oncology
NCT06182579 TERMINATED
Phase I Study of RiMO-401 With Radiation in Advanced Tumors
Coordination Pharmaceuticals, Inc.
NCT06285097 TERMINATED
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
NCT04242147 TERMINATED
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Kadmon, a Sanofi Company
NCT05109832 COMPLETED
A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects
Impact Therapeutics, Inc.
NCT05390944 COMPLETED
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
NCT05904496 TERMINATED
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeiGene
NCT05391048 COMPLETED
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
Impact Therapeutics, Inc.
NCT05072106 COMPLETED
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
NCT03944499 COMPLETED
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT04446260 COMPLETED
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT04344795 COMPLETED
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Tempest Therapeutics
NCT05707676 TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
L & L Bio Co., Ltd., Ningbo, China
NCT04249843 TERMINATED
Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
MapKure, LLC
NCT03036228 COMPLETED
MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
Thomas Helleday Foundation
NCT06471712 COMPLETED
Clinical Study of 18F-LNC1007 Injection PET/CT
Yantai LNC Biotechnology Singapore PTE. LTD.
NCT05723640 COMPLETED
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
Yantai LNC Biotechnology Singapore PTE. LTD.
NCT04879849 COMPLETED
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Takeda
NCT06463782 COMPLETED
Clinical Study of 68Ga-LNC1007 Injection PET/CT
Yantai LNC Biotechnology Singapore PTE. LTD.
NCT04418167 SUSPENDED
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
NCT05114668 COMPLETED
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Kazia Therapeutics Limited
NCT03900442 COMPLETED
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
Prescient Therapeutics, Ltd.
NCT05063318 COMPLETED
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
NCT05490043 TERMINATED
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene (Hangzhou) Biologics Co., Ltd.
NCT04772989 COMPLETED
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT04169321 COMPLETED
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Cytosite Biopharma Inc.
NCT04970992 COMPLETED
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Da Zen Theranostics Inc
NCT04047862 COMPLETED
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
NCT05494918 COMPLETED
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
Alphamab (Australia) Co Pty Ltd.
NCT07138378 COMPLETED
A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.
Xspray Pharma AB
NCT06074705 TERMINATED
A Study of DS-1471a In Subjects With Advanced Solid Tumors
Daiichi Sankyo Co., Ltd.
NCT02784795 TERMINATED
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT03748186 COMPLETED
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Sutro Biopharma, Inc.
NCT03708328 COMPLETED
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT05388877 TERMINATED
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Mayo Clinic
NCT04147234 COMPLETED
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Boehringer Ingelheim
NCT06263582 COMPLETED
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
UNC Lineberger Comprehensive Cancer Center
NCT06165614 COMPLETED
Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya
UNC Lineberger Comprehensive Cancer Center
NCT03739931 COMPLETED
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
ModernaTX, Inc.
NCT05708924 TERMINATED
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT07121829 TERMINATED
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT06877533 TERMINATED
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
iTeos Belgium SA
NCT06372236 COMPLETED
UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors
Peking University
NCT03762447 COMPLETED
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT04487236 COMPLETED
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
Suzhou Zanrong Pharma Limited
NCT05997342 COMPLETED
A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT02776917 COMPLETED
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
Barbara Parker, MD
NCT05717140 WITHDRAWN
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Mayo Clinic
NCT06231550 COMPLETED
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
FindCure Biosciences (ZhongShan) Co., Ltd.
NCT02836600 COMPLETED
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT02903914 COMPLETED
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
NCT00716417 COMPLETED
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Boehringer Ingelheim
NCT06039384 TERMINATED
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Incyte Corporation
NCT02013154 COMPLETED
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Leap Therapeutics, Inc.
NCT06048367 COMPLETED
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
NCT02628574 COMPLETED
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
Leap Therapeutics, Inc.
NCT03059823 COMPLETED
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
Incyte Corporation
NCT03013218 COMPLETED
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
NCT04610736 COMPLETED
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Orphelia Pharma
NCT03307629 COMPLETED
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Noxopharm Limited
NCT04306900 COMPLETED
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
NCT05162469 COMPLETED
A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05391022 COMPLETED
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Constellation Pharmaceuticals
NCT04051827 COMPLETED
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Millennium Pharmaceuticals, Inc.
NCT03249792 TERMINATED
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Merck Sharp & Dohme LLC
NCT03654547 COMPLETED
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
TransThera Sciences (Nanjing), Inc.
NCT03034304 TERMINATED
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
NCT04257110 COMPLETED
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
NCT05983146 WITHDRAWN
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
NCT06886659 COMPLETED
A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)
Incepta Pharmaceuticals Ltd
NCT06255665 COMPLETED
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
Janssen Research & Development, LLC
NCT05444530 COMPLETED
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Janssen Research & Development, LLC
NCT04501770 COMPLETED
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
Wuhan YZY Biopharma Co., Ltd.
NCT03199586 COMPLETED
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
NCT05028556 COMPLETED
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
Wuhan YZY Biopharma Co., Ltd.
NCT04239092 TERMINATED
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
NCT04501744 COMPLETED
A Study of M701 (EpCAM and CD3) in Malignant Ascites
Wuhan YZY Biopharma Co., Ltd.
NCT01051635 COMPLETED
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT06235541 WITHDRAWN
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors
Genome & Company
NCT06161558 WITHDRAWN
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT06443710 COMPLETED
Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
NCT02123823 COMPLETED
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
NCT02204072 COMPLETED
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
NCT05387265 TERMINATED
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
CytomX Therapeutics
NCT04242199 COMPLETED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT04116320 TERMINATED
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
Craig L Slingluff, Jr
NCT01317420 COMPLETED
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Boehringer Ingelheim
NCT05323045 COMPLETED
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
Byondis B.V.
NCT03153280 TERMINATED
Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer
Cancer Trials Ireland
NCT05839600 TERMINATED
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Boehringer Ingelheim
NCT03289962 COMPLETED
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
NCT05487235 COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT05153330 TERMINATED
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
NCT03884556 COMPLETED
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
NCT05383703 COMPLETED
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
Moon (Guangzhou) Biotechnology Co., Ltd.
NCT05274451 TERMINATED
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
NCT06416436 WITHDRAWN
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
NCT05958199 SUSPENDED
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
NCT03990233 COMPLETED
A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
OSE Immunotherapeutics
NCT04991129 TERMINATED
The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer
Suzhou Junjing BioSciences Co., Ltd.
NCT06630247 TERMINATED
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03918278 COMPLETED
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
Merck Sharp & Dohme LLC
NCT02279433 COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
NCT03099174 COMPLETED
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
NCT04613492 TERMINATED
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
AstraZeneca
NCT04730843 COMPLETED
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
NCT04991506 COMPLETED
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
NCT06007482 COMPLETED
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma Australia Pty. Ltd.
NCT04975958 COMPLETED
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
NCT07030439 COMPLETED
A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
Impact Therapeutics, Inc.
NCT05594043 COMPLETED
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
Merck Sharp & Dohme LLC
NCT04278859 COMPLETED
Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
NCT02145741 COMPLETED
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
NCT06719973 WITHDRAWN
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
EMD Serono Research & Development Institute, Inc.
NCT05788484 COMPLETED
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT05625412 COMPLETED
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT01351103 COMPLETED
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis Pharmaceuticals
NCT06381050 COMPLETED
The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07019194 COMPLETED
An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
NCT04986865 TERMINATED
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited
NCT02836795 COMPLETED
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT02517918 COMPLETED
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Institut Bergonié
NCT02419495 TERMINATED
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT06535009 TERMINATED
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
Ono Pharmaceutical Co., Ltd.
NCT03277482 TERMINATED
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
NCT02720068 COMPLETED
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
Merck Sharp & Dohme LLC
NCT05192174 TERMINATED
Study of NIB101 in Participants With Advanced Solid Tumors
Noile-Immune Biotech, Inc
NCT05389462 TERMINATED
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
ADC Therapeutics S.A.
NCT03508570 COMPLETED
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
M.D. Anderson Cancer Center
NCT06344351 COMPLETED
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04972981 COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
NCT04642365 TERMINATED
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Hoffmann-La Roche
NCT04121286 COMPLETED
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Allist Pharmaceuticals, Inc.
NCT04927663 TERMINATED
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
Rahul Aggarwal
NCT05759949 COMPLETED
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Relay Therapeutics, Inc.
NCT02318771 COMPLETED
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05075564 COMPLETED
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma, Ltd.
NCT02507583 COMPLETED
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
david andrews
NCT05242822 TERMINATED
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Kinnate Biopharma
NCT05571969 SUSPENDED
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Allarity Therapeutics
NCT04261439 TERMINATED
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis Pharmaceuticals
NCT05494762 TERMINATED
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
BeiGene
NCT05757492 TERMINATED
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT04291079 COMPLETED
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Scholar Rock, Inc.
NCT05840510 TERMINATED
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Mirati Therapeutics Inc.
NCT00794131 COMPLETED
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
Genelux GmbH
NCT03260322 COMPLETED
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Astellas Pharma Global Development, Inc.
NCT04301011 TERMINATED
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Turnstone Biologics, Corp.
NCT02598726 COMPLETED
Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer
Mayo Clinic
NCT03954067 COMPLETED
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03544905 COMPLETED
Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
Haihe Biopharma Co., Ltd.
NCT06194877 TERMINATED
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLC
NCT02875223 TERMINATED
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
NCT04836195 COMPLETED
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
Pacylex Pharmaceuticals
NCT04209465 TERMINATED
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Black Diamond Therapeutics, Inc.
NCT04886622 COMPLETED
A Study of DT2216 in Relapsed/Refractory Malignancies
Dialectic Therapeutics, Inc
NCT04774952 COMPLETED
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
NCT06345001 COMPLETED
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Bayer
NCT03724890 COMPLETED
Study of Avelumab-M3814 Combinations
EMD Serono Research & Development Institute, Inc.
NCT04485416 SUSPENDED
Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors
University of California, Davis
NCT05940844 WITHDRAWN
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
NCT05620472 COMPLETED
Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1
Tomsk National Research Medical Center of the Russian Academy of Sciences
NCT03975387 TERMINATED
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Taiho Oncology, Inc.
NCT04943900 COMPLETED
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb
NCT05904236 TERMINATED
Safety and Tolerability of Intravenous Administration of ICVB-1042
IconOVir Bio
NCT05737706 TERMINATED
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Mirati Therapeutics Inc.
NCT04330664 COMPLETED
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Mirati Therapeutics Inc.
NCT02454010 COMPLETED
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT03597581 COMPLETED
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Inspirna, Inc.
NCT03894618 COMPLETED
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
NCT05828303 WITHDRAWN
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
NCT04108481 TERMINATED
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
University of Iowa
NCT04553692 TERMINATED
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
NCT01877382 COMPLETED
A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
NCT05584111 COMPLETED
Oral Administration of STC-15 in Subjects With Advanced Malignancies
STORM Therapeutics LTD
NCT03585764 TERMINATED
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Pennsylvania
NCT04137289 COMPLETED
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Boehringer Ingelheim
NCT04053283 COMPLETED
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
Akamis Bio
NCT05043714 COMPLETED
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
Akamis Bio
NCT01543763 COMPLETED
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Pamela Munster
NCT03195699 COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT05463432 COMPLETED
A Study of HR19024 in Subjects With Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05225584 COMPLETED
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Kymera Therapeutics, Inc.
NCT06597786 WITHDRAWN
A Study of Exercise Therapy in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT04586270 TERMINATED
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
NCT06873542 COMPLETED
A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
Heronova Pharmaceuticals
NCT05023928 COMPLETED
Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
Sichuan University
NCT02783300 COMPLETED
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
GlaxoSmithKline
NCT04882917 COMPLETED
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
EMD Serono Research & Development Institute, Inc.
NCT04105335 COMPLETED
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
Mina Alpha Limited
NCT01585623 COMPLETED
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Bristol-Myers Squibb
NCT05441501 COMPLETED
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
Janssen Research & Development, LLC
NCT05940571 COMPLETED
First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors
Medibiofarma S.L.
NCT04608045 COMPLETED
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
NCT03261011 COMPLETED
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
Akesobio Australia Pty Ltd
NCT04047290 COMPLETED
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Akesobio Australia Pty Ltd
NCT03352531 COMPLETED
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
Akesobio Australia Pty Ltd
NCT04572152 COMPLETED
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
Akeso
NCT03073395 COMPLETED
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Five Eleven Pharma, Inc.
NCT01220154 COMPLETED
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
David O'Malley
NCT04537715 COMPLETED
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Epizyme, Inc.
NCT01251562 COMPLETED
Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors
BPGbio
NCT05087992 COMPLETED
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
Boehringer Ingelheim
NCT01957735 COMPLETED
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
BPGbio
NCT02966548 COMPLETED
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
NCT06365918 WITHDRAWN
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
M.D. Anderson Cancer Center
NCT04249947 TERMINATED
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
NCT05943041 COMPLETED
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
GILongevity
NCT03654716 COMPLETED
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Dana-Farber Cancer Institute
NCT01314105 COMPLETED
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Boehringer Ingelheim
NCT02070549 COMPLETED
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
National Cancer Institute (NCI)
NCT00708448 COMPLETED
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
University of Utah
NCT04805307 COMPLETED
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
Keymed Biosciences Co.Ltd
NCT05178888 COMPLETED
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Mirati Therapeutics Inc.
NCT01649271 COMPLETED
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
NCT03436745 COMPLETED
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
National Cancer Institute (NCI)
NCT04999202 TERMINATED
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Bayer
NCT05241873 TERMINATED
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
NCT00950742 COMPLETED
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.
Boehringer Ingelheim
NCT04862780 TERMINATED
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
NCT02667873 COMPLETED
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
Stemline Therapeutics, Inc.
NCT01214616 COMPLETED
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
NCT01638533 COMPLETED
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
NCT05631574 TERMINATED
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Biomea Fusion Inc.
NCT04023669 COMPLETED
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
St. Jude Children's Research Hospital
NCT03247309 COMPLETED
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
Immatics US, Inc.
NCT03628677 COMPLETED
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT03404791 COMPLETED
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Janssen Research & Development, LLC
NCT02625857 COMPLETED
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC
NCT05295927 TERMINATED
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development, LLC
NCT05098405 TERMINATED
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Molecular Partners AG
NCT04406623 COMPLETED
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
Shattuck Labs, Inc.
NCT03447470 COMPLETED
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Redx Pharma Ltd
NCT03948763 TERMINATED
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Merck Sharp & Dohme LLC
NCT06258330 COMPLETED
Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors
Aummune Ltd.
NCT05601219 TERMINATED
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
Adanate, Inc
NCT05775406 COMPLETED
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
Kymera Therapeutics, Inc.
NCT01121588 TERMINATED
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Pfizer
NCT01946789 COMPLETED
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Altor BioScience
NCT05613036 COMPLETED
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body
Boehringer Ingelheim
NCT06302140 TERMINATED
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
Viracta Therapeutics, Inc.
NCT03667716 COMPLETED
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Compugen Ltd
NCT06681870 WITHDRAWN
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03936959 TERMINATED
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Eli Lilly and Company
NCT02751528 TERMINATED
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NantBioScience, Inc.
NCT04121676 COMPLETED
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
Agenus Inc.
NCT03854227 TERMINATED
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
NCT05382936 TERMINATED
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Stemline Therapeutics, Inc.
NCT06012708 COMPLETED
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713
New Cancer Cure-Bio Co.,Ltd.
NCT03329937 COMPLETED
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
Tesaro, Inc.
NCT06560138 WITHDRAWN
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
Atridia Pty Ltd.
NCT05176509 COMPLETED
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT04052971 COMPLETED
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
Abion Inc
NCT04727554 COMPLETED
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Amgen
NCT05169697 COMPLETED
A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT02630823 COMPLETED
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
NCT06228846 COMPLETED
An Phase I Study of YY001 in Patients with Advanced Solid Tumors
Shanghai Yuyao Biotech Co., Ltd.
NCT02076906 COMPLETED
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
AeRang Kim
NCT05904730 COMPLETED
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Lynkcell Europe
NCT05116709 COMPLETED
Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors
Bio-Thera Solutions
NCT05279690 COMPLETED
Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors
Icahn School of Medicine at Mount Sinai
NCT02610361 COMPLETED
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
BeiGene
NCT05394818 COMPLETED
The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT02723955 COMPLETED
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
NCT05414136 COMPLETED
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006
Bio-Thera Solutions
NCT05781360 TERMINATED
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT04404569 TERMINATED
Continued Treatment for Participants Enrolled in Studies of BXQ-350
Bexion Pharmaceuticals, Inc.
NCT03150810 COMPLETED
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
NCT04975256 TERMINATED
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Mirati Therapeutics Inc.
NCT03518554 COMPLETED
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT04908176 COMPLETED
A Drug-drug Interaction Study of Avapritinib and Midazolam
Blueprint Medicines Corporation
NCT05480865 TERMINATED
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
Navire Pharma Inc., a BridgeBio company
NCT04310592 TERMINATED
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Celularity Incorporated
NCT05375084 TERMINATED
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Navire Pharma Inc., a BridgeBio company
NCT03922204 COMPLETED
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
Merus B.V.
NCT06619951 COMPLETED
A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
Jiangsu vcare pharmaceutical technology co., LTD
NCT03030417 COMPLETED
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT05751837 COMPLETED
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal
Patrick Wagner, MD, FACS
NCT04672434 COMPLETED
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
NCT05831995 TERMINATED
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
ABM Therapeutics Corporation
NCT04319757 COMPLETED
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
NCT05018273 COMPLETED
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
Nykode Therapeutics ASA
NCT03387917 TERMINATED
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Swiss Cancer Institute
NCT05501912 TERMINATED
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
ABM Therapeutics Shanghai Company Limited
NCT05736224 COMPLETED
Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Yale University
NCT04526509 TERMINATED
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Adaptimmune
NCT02702492 TERMINATED
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
Karyopharm Therapeutics Inc
NCT05246111 COMPLETED
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NCT02143401 COMPLETED
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT00909025 COMPLETED
Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
Ganymed Pharmaceuticals GmbH
NCT05357911 COMPLETED
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
Nuvation Bio Inc.
NCT02972034 TERMINATED
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
Merck Sharp & Dohme LLC
NCT05357820 COMPLETED
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
Nuvation Bio Inc.
NCT00739453 COMPLETED
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Astellas Pharma Inc
NCT05990920 COMPLETED
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
NKGen Biotech, Inc.
NCT03027128 COMPLETED
QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
ImmunityBio, Inc.
NCT03834662 COMPLETED
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
Bristol-Myers Squibb
NCT03166631 TERMINATED
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
Boehringer Ingelheim
NCT05228015 TERMINATED
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Ikena Oncology
NCT02619253 COMPLETED
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Nabil Adra
NCT04145297 COMPLETED
Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
University of Utah
NCT02699515 COMPLETED
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
Merck KGaA, Darmstadt, Germany
NCT05784597 COMPLETED
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
Philogen S.p.A.
NCT02009449 COMPLETED
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT05712889 COMPLETED
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
NCT02635672 COMPLETED
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
NCT05943990 TERMINATED
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Adaptimmune
NCT03945253 COMPLETED
Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors
Astellas Pharma Inc
NCT06048705 TERMINATED
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Adaptimmune
NCT04855929 COMPLETED
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
Anaveon AG
NCT03833427 TERMINATED
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
Merck Sharp & Dohme LLC
NCT01529684 COMPLETED
A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body
Astellas Pharma Global Development, Inc.
NCT06448364 TERMINATED
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
Pfizer
NCT02113878 COMPLETED
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
NCT04504669 COMPLETED
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
AstraZeneca
NCT02456883 COMPLETED
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
Astellas Pharma Global Development, Inc.
NCT04795713 TERMINATED
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Molecular Templates, Inc.
NCT03666143 COMPLETED
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT01359982 COMPLETED
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
EpicentRx, Inc.
NCT04094506 COMPLETED
Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors
Astellas Pharma Inc
NCT03565445 COMPLETED
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Astellas Pharma Global Development, Inc.
NCT02199236 COMPLETED
Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management
Memorial Sloan Kettering Cancer Center
NCT03799003 TERMINATED
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03457532 COMPLETED
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Haihe Biopharma Co., Ltd.
NCT04635995 COMPLETED
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
NCT04130542 COMPLETED
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
NCT02383368 COMPLETED
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
Astellas Pharma Global Development, Inc.
NCT05231733 WITHDRAWN
Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors
SparX Biotech(Jiangsu) Co., Ltd.
NCT04525014 TERMINATED
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
EpicentRx, Inc.
NCT04096638 COMPLETED
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
invoX Pharma Limited
NCT02038673 COMPLETED
An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
Astellas Pharma Inc
NCT05076591 SUSPENDED
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT03215511 COMPLETED
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
Bayer
NCT04870840 COMPLETED
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
M.D. Anderson Cancer Center
NCT02265536 COMPLETED
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Eli Lilly and Company
NCT03960060 TERMINATED
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
Shanghai PerHum Therapeutics Co., Ltd.
NCT03994211 COMPLETED
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
BeiGene
NCT03809624 TERMINATED
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Inhibrx Biosciences, Inc
NCT03641586 COMPLETED
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
BeiGene
NCT04270864 TERMINATED
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
Gustave Roussy, Cancer Campus, Grand Paris
NCT05814536 TERMINATED
IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor
AnHeart Therapeutics Inc.
NCT05043298 COMPLETED
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT06554639 COMPLETED
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
Merck Sharp & Dohme LLC
NCT04908046 COMPLETED
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
Hutchmed
NCT02516813 COMPLETED
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
EMD Serono Research & Development Institute, Inc.
NCT06161493 WITHDRAWN
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Haider Mahdi
NCT03087591 COMPLETED
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
Wake Forest University Health Sciences
NCT04861987 COMPLETED
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
Processa Pharmaceuticals
NCT04021277 TERMINATED
PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin
EXACT Therapeutics AS
NCT01127178 TERMINATED
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Eisai Inc.
NCT03466268 COMPLETED
Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Haihe Biopharma Co., Ltd.
NCT06631625 COMPLETED
Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries.
Alexandria University
NCT03220347 TERMINATED
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Celgene
NCT03507491 COMPLETED
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
NCT02480374 COMPLETED
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Imunon
NCT03936465 COMPLETED
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Dana-Farber Cancer Institute
NCT03946800 COMPLETED
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT04659629 COMPLETED
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Neurogene Inc.
NCT03864042 COMPLETED
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
NCT02791334 COMPLETED
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Eli Lilly and Company
NCT02338622 COMPLETED
Trial of Olaparib in Combination With AZD5363 (ComPAKT)
Royal Marsden NHS Foundation Trust
NCT02193633 COMPLETED
A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Royal Marsden NHS Foundation Trust
NCT05298592 COMPLETED
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
Bristol-Myers Squibb
NCT03251378 COMPLETED
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchison Medipharma Limited
NCT04672460 COMPLETED
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04130763 COMPLETED
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1
Peking University
NCT04713891 COMPLETED
A Study of KF-0210 in Advanced Solid Tumors Patients
Keythera Pharmaceuticals (Australia) Pty Ltd
NCT02944864 TERMINATED
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT03447314 COMPLETED
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
GlaxoSmithKline
NCT02994953 TERMINATED
A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
EMD Serono Research & Development Institute, Inc.
NCT01346358 COMPLETED
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
Eli Lilly and Company
NCT01394016 COMPLETED
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Eli Lilly and Company
NCT03604783 TERMINATED
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT03873883 COMPLETED
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
iTeos Therapeutics
NCT03744403 COMPLETED
A Study of CS1001 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
NCT04182516 TERMINATED
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
NCT04335253 COMPLETED
First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
iTeos Therapeutics
NCT04087018 COMPLETED
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
Arcus Biosciences, Inc.
NCT03028766 COMPLETED
WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer
University of Birmingham
NCT05002868 COMPLETED
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
Rhizen Pharmaceuticals SA
NCT04965818 TERMINATED
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Taiho Oncology, Inc.
NCT02903771 COMPLETED
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Kazia Therapeutics Limited
NCT05117177 COMPLETED
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
iTeos Therapeutics
NCT03783403 TERMINATED
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Celgene
NCT03523819 COMPLETED
A Study of CS1002 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
NCT04742556 COMPLETED
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
Boehringer Ingelheim
NCT03516123 COMPLETED
A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors
CStone Pharmaceuticals
NCT02301104 COMPLETED
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Taiho Oncology, Inc.
NCT03410927 TERMINATED
A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
Taiho Oncology, Inc.
NCT01867879 COMPLETED
Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
NCT02134067 TERMINATED
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
NCT01867866 COMPLETED
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Taiho Oncology, Inc.
NCT02025803 COMPLETED
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
NCT01874522 COMPLETED
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Taiho Oncology, Inc.
NCT02031055 COMPLETED
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
NCT02301117 COMPLETED
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
NCT03814005 COMPLETED
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
NCT04770246 TERMINATED
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
Taiho Oncology, Inc.
NCT04366648 COMPLETED
Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor
JenKem Technology Co., Ltd.
NCT04747470 TERMINATED
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
NCT06372574 WITHDRAWN
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
Genentech, Inc.
NCT05065710 COMPLETED
A Study of ZL-1211 in Patients With Advanced Solid Tumor
Zai Biopharmaceutical (Suzhou) Co., Ltd.
NCT03284723 TERMINATED
PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
Pfizer
NCT05088070 COMPLETED
Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
NCT06529445 COMPLETED
Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects
Jiangsu vcare pharmaceutical technology co., LTD
NCT02964507 TERMINATED
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
GlaxoSmithKline
NCT06004921 COMPLETED
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
Arcus Biosciences, Inc.
NCT05996445 TERMINATED
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
NCT03343054 COMPLETED
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Pfizer
NCT03187288 COMPLETED
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
University Health Network, Toronto
NCT01606241 COMPLETED
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
NCT04349969 COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
Akesobio Australia Pty Ltd
NCT02520778 COMPLETED
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05569512 TERMINATED
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Malika Kapadia
NCT03355066 TERMINATED
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
NCT02595866 COMPLETED
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
NCT03192345 COMPLETED
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
NCT06297642 TERMINATED
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06044142 COMPLETED
Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment
Riyadh Elm University
NCT00878423 COMPLETED
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
Astex Pharmaceuticals, Inc.
NCT05764915 TERMINATED
A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
Regor Pharmaceuticals Inc.
NCT01847326 COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
University of Chicago
NCT05101109 COMPLETED
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
ABL Bio, Inc.
NCT06172309 COMPLETED
A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
Nanjing Chia-tai Tianqing Pharmaceutical
NCT03154294 COMPLETED
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
NCT03329001 COMPLETED
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
Tesaro, Inc.
NCT04675528 COMPLETED
Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study
Daehwa Pharmaceutical Co., Ltd.
NCT03435250 TERMINATED
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Institut de Recherches Internationales Servier
NCT05702424 COMPLETED
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
IGM Biosciences, Inc.
NCT03667482 COMPLETED
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
NCT04305249 TERMINATED
Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
Antengene Therapeutics Limited
NCT03641547 COMPLETED
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
University of Oxford
NCT05039931 WITHDRAWN
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05338346 TERMINATED
A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
Antengene Discovery Limited
NCT03956056 TERMINATED
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
NCT02857998 COMPLETED
A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Hutchison Medipharma Limited
NCT02110563 TERMINATED
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT04410224 COMPLETED
Study of ASN004 in Patients With Advanced Solid Tumors
Kirilys Therapeutics Inc.
NCT05769959 TERMINATED
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Hoffmann-La Roche
NCT03752398 COMPLETED
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Xencor, Inc.
NCT03829111 COMPLETED
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
City of Hope Medical Center
NCT04505839 COMPLETED
First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
ST Pharm Co., Ltd.
NCT05578820 COMPLETED
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
NCT03934814 COMPLETED
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
I-Mab Biopharma US Limited
NCT04641871 COMPLETED
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
NCT05621525 TERMINATED
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
LianBio LLC
NCT05594875 COMPLETED
A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors
Atridia Pty Ltd.
NCT03451825 TERMINATED
Phase I/II Study of Avelumab in Pediatric Cancer Participants
EMD Serono Research & Development Institute, Inc.
NCT03301896 TERMINATED
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis Pharmaceuticals
NCT05731934 COMPLETED
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
NCT03621982 TERMINATED
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
NCT04638491 COMPLETED
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Luye Pharma Group Ltd.
NCT00543387 COMPLETED
Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)
Merck Sharp & Dohme LLC
NCT00963547 TERMINATED
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
Merck Sharp & Dohme LLC
NCT05309187 COMPLETED
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
Immune-Onc Therapeutics
NCT02318329 COMPLETED
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Five Prime Therapeutics, Inc.
NCT05054348 COMPLETED
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
Immune-Onc Therapeutics
NCT03066154 TERMINATED
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
The Netherlands Cancer Institute
NCT02552953 COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Cyclacel Pharmaceuticals, Inc.
NCT03434262 COMPLETED
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
NCT04357587 COMPLETED
Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer
Case Comprehensive Cancer Center
NCT02834611 COMPLETED
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Keystone Nano, Inc
NCT05631327 TERMINATED
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
Jazz Pharmaceuticals
NCT03199040 TERMINATED
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Washington University School of Medicine
NCT03666273 COMPLETED
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
Bayer
NCT05508100 COMPLETED
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
Immune-Onc Therapeutics
NCT03629756 COMPLETED
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT03720678 COMPLETED
A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
Arcus Biosciences, Inc.
NCT04400383 COMPLETED
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
CARsgen Therapeutics Co., Ltd.
NCT04190628 TERMINATED
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
NCT03238027 COMPLETED
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Syndax Pharmaceuticals
NCT02663518 TERMINATED
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
NCT04887194 COMPLETED
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
NCT02261285 COMPLETED
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co., Ltd.
NCT02261298 COMPLETED
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co., Ltd.
NCT01832116 COMPLETED
89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
University Medical Center Groningen
NCT02517398 COMPLETED
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT05309512 TERMINATED
Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT04281420 TERMINATED
A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Antengene Therapeutics Limited
NCT03874897 COMPLETED
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
NCT04873895 TERMINATED
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Abramson Cancer Center at Penn Medicine
NCT01279291 TERMINATED
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
NCT02867007 COMPLETED
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin, Inc.
NCT00921336 COMPLETED
Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor
Kyowa Kirin Co., Ltd.
NCT02301130 COMPLETED
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Kyowa Kirin, Inc.
NCT05152212 COMPLETED
Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
Lyvgen Biopharma Holdings Limited
NCT03650348 COMPLETED
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
NCT04694781 COMPLETED
Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
NCT04349280 TERMINATED
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
GlaxoSmithKline
NCT05518201 COMPLETED
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Shanghai Bovax Biotechnology Co., Ltd.
NCT05678283 WITHDRAWN
A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT05001516 COMPLETED
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
Turning Point Therapeutics, Inc.
NCT06372223 COMPLETED
A Food Effect Study of SPH5030 Tablets.
Shanghai Pharmaceuticals Holding Co., Ltd
NCT04059588 COMPLETED
A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin
Rockefeller University
NCT02516553 COMPLETED
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
Boehringer Ingelheim
NCT04306224 COMPLETED
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
ImmuneOncia Therapeutics Inc.
NCT05061537 TERMINATED
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
NCT03250832 COMPLETED
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
Tesaro, Inc.
NCT04040699 COMPLETED
KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor
Peking University
NCT04557306 COMPLETED
Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
CHABiotech CO., Ltd
NCT03490669 COMPLETED
Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
AstraZeneca
NCT04148937 COMPLETED
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
NCT03206021 COMPLETED
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
The Hospital for Sick Children
NCT06219499 WITHDRAWN
Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841
OncoC4, Inc.
NCT04095273 COMPLETED
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Bayer
NCT06137651 WITHDRAWN
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Northwestern University
NCT03329950 COMPLETED
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
NCT04901806 TERMINATED
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
Pyramid Biosciences
NCT05128539 TERMINATED
A Study Explore JS001+JS002 in Patients With Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
NCT03590054 COMPLETED
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Rahul Aggarwal
NCT04682431 TERMINATED
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
NCT03010982 COMPLETED
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Epizyme, Inc.
NCT04586335 TERMINATED
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
NCT02022982 COMPLETED
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
Dana-Farber Cancer Institute
NCT04200963 COMPLETED
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT05472506 WITHDRAWN
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Ikena Oncology
NCT04761601 TERMINATED
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
NCT05231746 COMPLETED
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
STCube, Inc.
NCT04914351 COMPLETED
HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
Shanghai HyaMab Biotech Co.,Ltd.
NCT05547906 COMPLETED
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
MetaFines
NCT01409135 COMPLETED
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
Astellas Pharma Inc
NCT05121948 TERMINATED
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
HiberCell, Inc.
NCT04834778 COMPLETED
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
HiberCell, Inc.
NCT04144140 TERMINATED
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Eisai Inc.
NCT04069026 COMPLETED
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
Bayer
NCT05496595 TERMINATED
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
NCT03604445 TERMINATED
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
Boehringer Ingelheim
NCT03705351 TERMINATED
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
NCT04158583 TERMINATED
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT05051241 COMPLETED
A Study of GFH018 in Patients With Advanced Solid Tumors
Zhejiang Genfleet Therapeutics Co., Ltd.
NCT04920383 TERMINATED
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Alpine Immune Sciences, Inc.
NCT06198556 COMPLETED
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03343301 COMPLETED
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
Five Prime Therapeutics, Inc.
NCT05277402 COMPLETED
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
NCT03523390 COMPLETED
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
NCT04892043 TERMINATED
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
NCT05078593 COMPLETED
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
NCT05248074 COMPLETED
To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers
Abion Inc
NCT05498480 COMPLETED
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
Bristol-Myers Squibb
NCT03345784 TERMINATED
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
National Cancer Institute (NCI)
NCT03728179 COMPLETED
RACIN in Patients With Advanced TIL-negative Solid Tumors
Centre Hospitalier Universitaire Vaudois
NCT04341311 TERMINATED
Phase I Study of Marizomib + Panobinostat for Children With DIPG
Dana-Farber Cancer Institute
NCT03516214 COMPLETED
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
University of Cologne
NCT05408871 TERMINATED
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
Yale University
NCT03964259 COMPLETED
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Virginia Commonwealth University
NCT00930332 TERMINATED
Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain
NCIC Clinical Trials Group
NCT05641324 TERMINATED
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Anaveon AG
NCT04842630 TERMINATED
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT04921878 COMPLETED
A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT04675996 TERMINATED
First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors
InteRNA
NCT05400265 COMPLETED
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
Shanghai Henlius Biotech
NCT03209401 TERMINATED
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Georgetown University
NCT04857138 COMPLETED
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT04074343 COMPLETED
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
NCT03255070 COMPLETED
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx, Inc.
NCT04862767 COMPLETED
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Autotelicbio
NCT03012230 COMPLETED
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
Mayo Clinic
NCT05099536 WITHDRAWN
3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
3D Medicines (Beijing) Co., Ltd.
NCT04564417 TERMINATED
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
Pierre Fabre Medicament
NCT04609579 TERMINATED
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
NCT02828098 COMPLETED
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Highlight Therapeutics
NCT04025216 TERMINATED
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Kite, A Gilead Company
NCT05848843 WITHDRAWN
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
NCT02564900 COMPLETED
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo Co., Ltd.
NCT02457845 COMPLETED
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
Gregory K. Friedman, MD
NCT01954316 COMPLETED
A Study of CFI-400945 Fumarate in Patients With Advanced Cancer
University Health Network, Toronto
NCT05002140 COMPLETED
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
XRad Therapeutics Inc
NCT04235101 COMPLETED
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
Byondis B.V.
NCT06165809 WITHDRAWN
A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT01825603 COMPLETED
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
University of Nebraska
NCT04483505 COMPLETED
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
Fundacion CRIS de Investigación para Vencer el Cáncer
NCT03912831 TERMINATED
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Gilead Sciences
NCT05930457 COMPLETED
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
The First Affiliated Hospital of Guangzhou Medical University
NCT01206465 COMPLETED
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
University of Nebraska
NCT03219268 COMPLETED
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
NCT03565367 COMPLETED
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
Daniel M. Spielman
NCT04096716 TERMINATED
Mapping Draining Lymph Nodes in CNS Malignancies
Washington University School of Medicine
NCT04267939 TERMINATED
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Bayer
NCT03454451 COMPLETED
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
NCT02482168 COMPLETED
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
NCT05814835 COMPLETED
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
Chinese PLA General Hospital
NCT04944888 COMPLETED
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Chinese PLA General Hospital
NCT03463473 COMPLETED
A Phase I Study of MSB2311 in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT04272944 COMPLETED
A Study of MSB2311 in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT03928314 TERMINATED
Study of ORIC-101 in Combination With Anticancer Therapy
ORIC Pharmaceuticals
NCT05490381 WITHDRAWN
Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
University of Washington
NCT03525392 TERMINATED
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
NCT05800249 COMPLETED
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
Shanghai HyaMab Biotech Co.,Ltd.
NCT05861778 COMPLETED
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
NCT05159518 COMPLETED
A Study of PRT2527 in Participants With Advanced Solid Tumors
Prelude Therapeutics
NCT04513067 TERMINATED
A Safety Study of YQ23 in Advanced Solid Tumors Patients
New Beta Innovation Limited
NCT03229278 COMPLETED
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
NCT03131765 COMPLETED
Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors
Yisheng Biopharma (Singapore) Pte. Ltd.
NCT03861403 TERMINATED
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
NCT04892875 WITHDRAWN
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
Jennifer Choe
NCT05644626 WITHDRAWN
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
BeiGene
NCT04147247 COMPLETED
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
Boehringer Ingelheim
NCT05791474 WITHDRAWN
ATI-2231 in Advanced Solid Tumor Malignancies
Washington University School of Medicine
NCT04473716 COMPLETED
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Shanghai Jiao Tong University School of Medicine
NCT03225105 TERMINATED
M3541 in Combination With Radiotherapy in Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT04393506 COMPLETED
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Shanghai Jiao Tong University School of Medicine
NCT02693080 COMPLETED
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
Stanford University
NCT03954704 TERMINATED
Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors
Gilead Sciences
NCT04830501 COMPLETED
Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT04602117 WITHDRAWN
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
NCT05017623 COMPLETED
A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT03810742 COMPLETED
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
NCT02467361 COMPLETED
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Sumitomo Pharma America, Inc.
NCT01781455 COMPLETED
A Study of BBI503 in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT01775423 COMPLETED
A Study of BBI608 in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT03429218 COMPLETED
First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT02729298 COMPLETED
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT03715504 COMPLETED
Study of TP-3654 in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT02483247 COMPLETED
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
NCT03416816 TERMINATED
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
NCT03941262 COMPLETED
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
NKGen Biotech, Inc.
NCT02834780 COMPLETED
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
H3 Biomedicine Inc.
NCT05369221 COMPLETED
Feasibility of ReSpace™ Hydrogel to Establish a Stable Cervical-rectal Space
Peking Union Medical College Hospital
NCT04630522 COMPLETED
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
Shanghai JMT-Bio Inc.
NCT05905341 WITHDRAWN
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
NCT02432326 COMPLETED
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT05221385 TERMINATED
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT03304210 COMPLETED
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
University Hospital, Ghent
NCT04337853 COMPLETED
Radiotherapy of Tongue Cancer Using an Intraoral Stent
Oslo University Hospital
NCT02616185 TERMINATED
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Pfizer
NCT03240861 TERMINATED
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
Jonsson Comprehensive Cancer Center
NCT01099644 TERMINATED
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum
Y-mAbs Therapeutics
NCT02054806 COMPLETED
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Merck Sharp & Dohme LLC
NCT04475523 COMPLETED
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
Curis, Inc.
NCT04247126 COMPLETED
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
NCT02644460 COMPLETED
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
Emory University
NCT04162327 COMPLETED
A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
NCT04958434 TERMINATED
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT05600582 WITHDRAWN
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Codagenix, Inc
NCT01332682 COMPLETED
Resistance Training and Physical Functioning in Head and Neck Cancer Patients
University of Alabama at Birmingham
NCT03099109 COMPLETED
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
Eli Lilly and Company
NCT04404140 TERMINATED
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hoffmann-La Roche
NCT02718911 COMPLETED
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT03690154 TERMINATED
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT05073484 TERMINATED
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients
Bio-Thera Solutions
NCT03188965 COMPLETED
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Bayer
NCT05120375 TERMINATED
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China
Bio-Thera Solutions
NCT03122106 TERMINATED
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
NCT04635631 COMPLETED
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
Pfizer
NCT02897375 COMPLETED
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
NCT00993044 COMPLETED
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
Children's Hospital Los Angeles
NCT03730337 COMPLETED
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co., Ltd.
NCT00803569 COMPLETED
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Ludwig Institute for Cancer Research
NCT01632436 WITHDRAWN
Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment
CTI BioPharma
NCT05828277 WITHDRAWN
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
NCT03859752 SUSPENDED
TR1801-ADC in Patients With Tumors That Express c-Met
Open Innovation Partners, Inc.
NCT05395052 TERMINATED
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT00648648 COMPLETED
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
Merck Sharp & Dohme LLC
NCT04551885 TERMINATED
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT05069935 TERMINATED
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT05698888 TERMINATED
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
Virtuoso BINco, Inc.
NCT04865159 TERMINATED
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Kura Oncology, Inc.
NCT05921916 COMPLETED
Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers
Medibiofarma S.L.
NCT01047007 TERMINATED
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
NCT04729205 TERMINATED
Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies
Lipomedix Pharmaceuticals Inc.
NCT03714958 COMPLETED
Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type
Centre Leon Berard
NCT04628988 COMPLETED
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
Celgene
NCT03452332 COMPLETED
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
M.D. Anderson Cancer Center
NCT04357756 COMPLETED
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT03109041 COMPLETED
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
CivaTech Oncology
NCT05040932 COMPLETED
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
Eucure (Beijing) Biopharma Co., Ltd
NCT04912466 COMPLETED
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
NCT05470933 TERMINATED
A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors
Suzhou Junjing BioSciences Co., Ltd.
NCT01772563 COMPLETED
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
Boehringer Ingelheim
NCT02536183 TERMINATED
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
AeRang Kim
NCT03139370 TERMINATED
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Kite, A Gilead Company
NCT04293094 COMPLETED
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
Volastra Therapeutics, Inc.
NCT04116710 COMPLETED
A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors
Heat Biologics
NCT04257617 COMPLETED
A Trial of ZL-1201 in Subjects With Advanced Cancer
Zai Lab (Shanghai) Co., Ltd.
NCT02959619 COMPLETED
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
Betta Pharmaceuticals Co., Ltd.
NCT03990454 COMPLETED
Safety Study of SLC-391 in Subjects With Solid Tumors
SignalChem Lifesciences Corporation
NCT05119998 COMPLETED
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
NCT04467853 TERMINATED
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors
Shanghai East Hospital
NCT04131426 COMPLETED
Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia
University of Rochester
NCT03808870 COMPLETED
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer
NatureWise Biotech & Medicals Corporation
NCT02277717 COMPLETED
First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients
Byondis B.V.
NCT04601402 COMPLETED
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
NCT02459301 COMPLETED
A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
Canadian Cancer Trials Group
NCT05129280 TERMINATED
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
Hoffmann-La Roche
NCT04214093 TERMINATED
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
AstraZeneca
NCT04034238 COMPLETED
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
National Cancer Institute (NCI)
NCT03745989 COMPLETED
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
Merck Sharp & Dohme LLC
NCT04585841 COMPLETED
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
University of Copenhagen
NCT04456140 COMPLETED
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Mayo Clinic
NCT04541225 TERMINATED
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
NCT02503774 COMPLETED
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
MedImmune LLC
NCT03927573 TERMINATED
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
AvenCell Europe GmbH
NCT04695847 COMPLETED
M1231 in Participants With Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT04601285 TERMINATED
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT03790488 COMPLETED
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
Jounce Therapeutics, Inc.
NCT03829436 COMPLETED
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT00880074 COMPLETED
FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03028103 COMPLETED
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Epizyme, Inc.
NCT04914117 COMPLETED
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
RemeGen Co., Ltd.
NCT01029366 COMPLETED
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
University of Pennsylvania
NCT05913115 COMPLETED
A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
Amgen
NCT01525394 COMPLETED
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
Eisai Inc.
NCT01773421 COMPLETED
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
Eisai Inc.
NCT05153408 TERMINATED
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
NCT04440943 COMPLETED
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT03333031 TERMINATED
A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies
Herbert Lyerly
NCT03499444 COMPLETED
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
pharmaand GmbH
NCT02986100 COMPLETED
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
pharmaand GmbH
NCT03733951 COMPLETED
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT03521037 COMPLETED
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
pharmaand GmbH
NCT01009190 COMPLETED
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
pharmaand GmbH
NCT04348916 TERMINATED
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Oncorus, Inc.
NCT04989829 COMPLETED
Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT05046808 COMPLETED
Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03954366 COMPLETED
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
pharmaand GmbH
NCT01430572 COMPLETED
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
M.D. Anderson Cancer Center
NCT02583269 COMPLETED
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Wake Forest University Health Sciences
NCT04186637 TERMINATED
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
Alpine Immune Sciences, Inc.
NCT03871855 TERMINATED
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT02333188 COMPLETED
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
University of Chicago
NCT03311412 COMPLETED
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT05877651 COMPLETED
MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
HRYZ Biotech Co.
NCT04849273 TERMINATED
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Turning Point Therapeutics, Inc.
NCT05199519 COMPLETED
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345
Innovent Biologics (Suzhou) Co. Ltd.
NCT03892018 TERMINATED
The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
Athenex, Inc.
NCT03588039 TERMINATED
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Athenex, Inc.
NCT05336279 COMPLETED
Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition
Jiangsu HengRui Medicine Co., Ltd.
NCT02351765 COMPLETED
ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers
The Christie NHS Foundation Trust
NCT04341259 COMPLETED
A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.
Hoffmann-La Roche
NCT02761694 TERMINATED
Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT03310541 COMPLETED
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
NCT01912625 TERMINATED
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01420874 COMPLETED
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
NCT04184869 COMPLETED
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Acrotech Biopharma Inc.
NCT05236049 COMPLETED
Use of an Allograft Set-up (SclerFIX) as Replacement of Sclera Graft for Support of Enucleation Implant
TBF Genie Tissulaire
NCT03884517 TERMINATED
Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
Bio-Thera Solutions
NCT03841110 COMPLETED
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT04088604 COMPLETED
Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
Luye Pharma Group Ltd.
NCT04686383 COMPLETED
Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors
Calgent Biotechnology Co., Ltd
NCT03802955 COMPLETED
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Adagene (Suzhou) Limited
NCT04144842 COMPLETED
Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017
Alligator Bioscience AB
NCT04650451 SUSPENDED
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Bellicum Pharmaceuticals
NCT04893551 TERMINATED
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
BerGenBio ASA
NCT01191775 COMPLETED
A Study of PNT2258 in Patients With Advanced Solid Tumors
Sierra Oncology LLC - a GSK company
NCT03507699 COMPLETED
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
Sheba Medical Center
NCT03730142 COMPLETED
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Shanghai Jiatan Pharmatech Co., Ltd
NCT04135261 COMPLETED
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
NCT04084951 COMPLETED
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
NCT03758781 COMPLETED
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03713905 COMPLETED
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
Guangzhou Gloria Biosciences Co., Ltd.
NCT03396211 COMPLETED
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
NCT02737787 COMPLETED
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT04112498 COMPLETED
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Bristol-Myers Squibb
NCT02890368 TERMINATED
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
NCT04089449 COMPLETED
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Prelude Therapeutics
NCT04381325 TERMINATED
A Study of MSB0254 Injection in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT01332279 WITHDRAWN
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Fox Chase Cancer Center
NCT04630769 COMPLETED
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Masonic Cancer Center, University of Minnesota
NCT03849469 COMPLETED
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Xencor, Inc.
NCT04746612 TERMINATED
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
Haihe Biopharma Co., Ltd.
NCT03426254 WITHDRAWN
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
Center Trials & Treatment
NCT01570296 COMPLETED
A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR
National Cancer Centre, Singapore
NCT01393509 COMPLETED
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Memorial Sloan Kettering Cancer Center
NCT03886831 COMPLETED
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
NCT03775850 COMPLETED
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Evelo Biosciences, Inc.
NCT04991740 COMPLETED
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
NCT05388279 TERMINATED
A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT05264038 COMPLETED
A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514
Oncocross Australia Pty Ltd.
NCT05187858 COMPLETED
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Lupin Ltd.
NCT02278250 COMPLETED
First in Human Study of M4344 in Participants With Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT04060511 COMPLETED
A Study of HS-10342 in Patients With Advanced Solid Tumor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT02219711 COMPLETED
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Mirati Therapeutics Inc.
NCT02452268 TERMINATED
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Novartis Pharmaceuticals
NCT04911894 COMPLETED
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT05531708 WITHDRAWN
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
Shanghai Pudong Hospital
NCT04911881 COMPLETED
A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT02721589 COMPLETED
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03689192 COMPLETED
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Herlev Hospital
NCT03545971 COMPLETED
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
NCT02742935 COMPLETED
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT04557384 TERMINATED
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
Eli Lilly and Company
NCT04196283 COMPLETED
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
AbbVie
NCT03758001 COMPLETED
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT03589651 COMPLETED
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Incyte Corporation
NCT03889275 COMPLETED
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
MedImmune LLC
NCT03901950 COMPLETED
Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
Evopoint Biosciences Inc.
NCT03431948 COMPLETED
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
University of Chicago
NCT04542291 COMPLETED
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Washington University School of Medicine
NCT04683354 COMPLETED
Study of HL-085 in Patients With Advanced Solid Tumor Tumors
Kechow Pharma, Inc.
NCT05347979 COMPLETED
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
Corcept Therapeutics
NCT03370302 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies
Calithera Biosciences, Inc
NCT02000934 COMPLETED
A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies
Calithera Biosciences, Inc
NCT03359733 WITHDRAWN
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
Calithera Biosciences, Inc
NCT02834247 TERMINATED
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
NCT03338881 WITHDRAWN
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
Calithera Biosciences, Inc
NCT00658671 COMPLETED
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
CASI Pharmaceuticals, Inc.
NCT05230290 COMPLETED
Clinical Study of KD6001 in Advanced Solid Tumours
Shanghai Kanda Biotechnology Co., Ltd.
NCT02959905 COMPLETED
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
BGI, China
NCT01379287 COMPLETED
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT04835714 TERMINATED
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
Boehringer Ingelheim
NCT04252339 COMPLETED
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT05381935 WITHDRAWN
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma, Ltd.
NCT04202705 COMPLETED
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
Byondis B.V.
NCT03420742 COMPLETED
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
NCT05060276 WITHDRAWN
Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
NCT01607905 COMPLETED
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
NCT02197572 COMPLETED
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
NCT02032810 COMPLETED
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04430842 COMPLETED
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
NCT04797468 WITHDRAWN
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
Shanghai Henlius Biotech
NCT04839367 COMPLETED
Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)
Clarity Pharmaceuticals Ltd
NCT01528046 COMPLETED
Metformin in Children With Relapsed or Refractory Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT02825940 COMPLETED
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT02998736 COMPLETED
Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy
Ottawa Hospital Research Institute
NCT05472220 WITHDRAWN
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
Pamela Munster
NCT04316169 WITHDRAWN
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
NCT04049903 COMPLETED
Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors
Molecular Partners AG
NCT02607813 TERMINATED
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Novartis Pharmaceuticals
NCT04659096 COMPLETED
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
Ionis Pharmaceuticals, Inc.
NCT03906643 WITHDRAWN
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies
Herbert Lyerly
NCT04699929 COMPLETED
A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT04097769 COMPLETED
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
Waterstone Hanxbio Pty Ltd
NCT04678921 COMPLETED
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
I-Mab Biopharma US Limited
NCT04080024 COMPLETED
A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer
Spago Nanomedical AB
NCT03082209 COMPLETED
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
AbbVie
NCT03051477 COMPLETED
Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03815682 TERMINATED
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Repertoire Immune Medicines
NCT05132803 WITHDRAWN
TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03517488 COMPLETED
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor, Inc.
NCT05528120 COMPLETED
Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
Jiangsu vcare pharmaceutical technology co., LTD
NCT03809767 COMPLETED
A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
CStone Pharmaceuticals
NCT04336124 COMPLETED
Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
TaiRx, Inc.
NCT03386942 COMPLETED
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
Eisai Inc.
NCT01015222 COMPLETED
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT02627274 COMPLETED
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Hoffmann-La Roche
NCT02857270 COMPLETED
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
NCT03934359 COMPLETED
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
Shanghai De Novo Pharmatech Co., Ltd.
NCT03349073 COMPLETED
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
NCT03195764 TERMINATED
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
NCT00807859 COMPLETED
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
NCT04322552 COMPLETED
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03926013 COMPLETED
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
NCT00890617 COMPLETED
Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis
Barbara Ann Karmanos Cancer Institute
NCT00784108 COMPLETED
Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.
University of California, Irvine
NCT01220999 COMPLETED
A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
Ludwig Institute for Cancer Research
NCT03856541 COMPLETED
A Study of SHR-A1403 in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT04457180 COMPLETED
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT02437370 COMPLETED
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
University of California, Davis
NCT01977638 COMPLETED
Phase 1 Trial of CXD101 in Patients With Advanced Cancer
Oxford University Hospitals NHS Trust
NCT00794781 COMPLETED
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Eisai Inc.
NCT02937116 COMPLETED
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT02252211 COMPLETED
Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
Ludwig Institute for Cancer Research
NCT00616941 COMPLETED
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ludwig Institute for Cancer Research
NCT00972309 COMPLETED
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
National Cancer Institute (NCI)
NCT02829099 COMPLETED
A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors
Janssen Research & Development, LLC
NCT04049617 TERMINATED
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Gilead Sciences
NCT03883919 COMPLETED
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Washington University School of Medicine
NCT04861948 TERMINATED
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT05469490 WITHDRAWN
Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
Luke, Jason, MD
NCT01407562 TERMINATED
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
NCT03335540 COMPLETED
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
Bristol-Myers Squibb
NCT02049593 COMPLETED
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
NCT02943733 TERMINATED
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
University of Wisconsin, Madison
NCT03129776 TERMINATED
Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer
Sunnybrook Health Sciences Centre
NCT03616574 COMPLETED
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Holy Stone Healthcare Co., Ltd
NCT05262842 WITHDRAWN
JS001+IMP4297 in Patients With Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
NCT03894540 TERMINATED
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Ipsen
NCT00981162 COMPLETED
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Roswell Park Cancer Institute
NCT01730118 COMPLETED
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
National Cancer Institute (NCI)
NCT05440006 COMPLETED
A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT04272203 TERMINATED
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
AbbVie
NCT03056833 COMPLETED
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Ronald Buckanovich
NCT05008913 TERMINATED
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
AstraZeneca
NCT04554667 COMPLETED
Heavy Lifting Strength Training in Head and Neck Cancer Survivors
University of Alberta
NCT04878484 WITHDRAWN
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
Athenex, Inc.
NCT01113476 COMPLETED
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
M.D. Anderson Cancer Center
NCT03182673 TERMINATED
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT02706392 TERMINATED
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
NCT00819221 TERMINATED
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
AstraZeneca
NCT05520372 COMPLETED
Autologous Immune Enhancement Therapy (AIET) for Cancer Patients
Vinmec Research Institute of Stem Cell and Gene Technology
NCT01642342 TERMINATED
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
University of Southern California
NCT01014936 COMPLETED
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
EMD Serono
NCT02862457 COMPLETED
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
Merck Sharp & Dohme LLC
NCT03782467 COMPLETED
Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015
Alligator Bioscience AB
NCT03970382 SUSPENDED
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
NCT03088527 COMPLETED
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
Stemline Therapeutics, Inc.
NCT02278965 COMPLETED
Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
Katherine D. Crew
NCT01573780 TERMINATED
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
NCT04261075 COMPLETED
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
MedImmune LLC
NCT01862718 TERMINATED
Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms
National Institutes of Health Clinical Center (CC)
NCT04324372 COMPLETED
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
Sunshine Lake Pharma Co., Ltd.
NCT01525069 TERMINATED
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Washington University School of Medicine
NCT01061411 COMPLETED
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
NCT01924260 COMPLETED
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Edward Kim
NCT01673217 COMPLETED
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
NCT04108676 COMPLETED
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT02926768 COMPLETED
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Checkpoint Therapeutics, Inc.
NCT04428086 COMPLETED
A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.
Jiangsu HengRui Medicine Co., Ltd.
NCT02719691 COMPLETED
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
University of Colorado, Denver
NCT02977195 COMPLETED
First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors
Centre Leon Berard
NCT01527136 COMPLETED
Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Roswell Park Cancer Institute
NCT01540253 COMPLETED
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
Roswell Park Cancer Institute
NCT01497392 COMPLETED
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Roswell Park Cancer Institute
NCT02071862 COMPLETED
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
NCT03517956 COMPLETED
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
Bayer
NCT03133247 COMPLETED
A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients
Atridia Pty Ltd.
NCT03080311 COMPLETED
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
Ascentage Pharma Group Inc.
NCT02935907 COMPLETED
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
Ascentage Pharma Group Inc.
NCT03642834 COMPLETED
Study of ICP-105 in Solid Tumors Patients
Beijing InnoCare Pharma Tech Co., Ltd.
NCT01468922 COMPLETED
Pazopanib and ARQ 197 for Advanced Solid Tumors
National Cancer Institute (NCI)
NCT03502681 TERMINATED
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Monika Joshi, MD
NCT03102320 COMPLETED
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Bayer
NCT01984502 COMPLETED
CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer
University of Texas Southwestern Medical Center
NCT02535325 COMPLETED
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02602119 COMPLETED
Intraoperative Imaging of Pulmonary Nodules by OTL38
University of Pennsylvania
NCT03852511 COMPLETED
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
Akamis Bio
NCT02644291 COMPLETED
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02508532 COMPLETED
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
NCT02630199 COMPLETED
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Samsung Medical Center
NCT03023319 COMPLETED
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Nagla Abdel Karim
NCT04335604 COMPLETED
A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors
Onconic Therapeutics Inc.
NCT03588650 COMPLETED
A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors
Shanghai Henlius Biotech
NCT03270176 COMPLETED
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
Debiopharm International SA
NCT02833753 COMPLETED
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
University of Massachusetts, Worcester
NCT05010096 WITHDRAWN
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT03312842 COMPLETED
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
NCT03444753 TERMINATED
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Bristol-Myers Squibb
NCT03666988 TERMINATED
First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
GlaxoSmithKline
NCT03525795 COMPLETED
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
Constellation Pharmaceuticals
NCT02801097 TERMINATED
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
EpicentRx, Inc.
NCT04653142 COMPLETED
A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT03053466 COMPLETED
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Apollomics (Australia) Pty. Ltd.
NCT03916094 COMPLETED
Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
Shanghai Henlius Biotech
NCT03851146 COMPLETED
A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours
Peter MacCallum Cancer Centre, Australia
NCT03172936 TERMINATED
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Novartis Pharmaceuticals
NCT04009460 TERMINATED
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
NCT03071757 COMPLETED
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT02897778 COMPLETED
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02734433 COMPLETED
Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
Daiichi Sankyo Co., Ltd.
NCT02315066 COMPLETED
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
NCT03000257 COMPLETED
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
NCT04035473 COMPLETED
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Athenex, Inc.
NCT03726294 COMPLETED
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
NatureWise Biotech & Medicals Corporation
NCT02354898 COMPLETED
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
Sumitomo Pharma Co., Ltd.
NCT03366428 COMPLETED
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
Daiichi Sankyo Co., Ltd.
NCT01791595 COMPLETED
A Phase I Trial of AZD3965 in Patients With Advanced Cancer
Cancer Research UK
NCT01655225 COMPLETED
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
NCT02035358 COMPLETED
Immunotherapy Study for Metastatic Renal Cell Cancer
NewLink Genetics Corporation
NCT03147768 COMPLETED
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
Laser Tissue Welding, Inc.
NCT03682744 WITHDRAWN
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
NCT02076620 COMPLETED
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Philogen S.p.A.
NCT03924245 TERMINATED
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Vanderbilt-Ingram Cancer Center
NCT02364492 COMPLETED
A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse
Institut Pasteur
NCT02324439 COMPLETED
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
Southern Illinois University
NCT02410512 COMPLETED
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT02646748 COMPLETED
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
NCT01553071 TERMINATED
Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
South Plains Oncology Consortium
NCT03600090 COMPLETED
Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
NCT03579628 COMPLETED
AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors
Valerio Therapeutics
NCT01904123 COMPLETED
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
NCT03951116 COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors
Fochon Pharmaceuticals, Ltd.
NCT01790035 TERMINATED
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Washington University School of Medicine
NCT00702494 COMPLETED
Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
BioInvent International AB
NCT03138538 TERMINATED
M8891 First in Human in Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT02427581 WITHDRAWN
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Washington University School of Medicine
NCT03203876 COMPLETED
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT02526017 COMPLETED
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics, Inc.
NCT01226732 COMPLETED
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
SCRI Development Innovations, LLC
NCT02442414 COMPLETED
A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors
Sihuan Pharmaceutical Holdings Group Ltd.
NCT03101488 COMPLETED
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT03739138 TERMINATED
Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)
Merck Sharp & Dohme LLC
NCT03910530 COMPLETED
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
Incyte Biosciences Japan GK
NCT03551782 COMPLETED
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
NCT03953742 COMPLETED
Study of CPI-200 in Patients With Advanced Tumors
Coordination Pharmaceuticals, Inc.
NCT02250157 COMPLETED
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Athenex, Inc.
NCT03475251 COMPLETED
A Study of CS1003 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
NCT02493751 COMPLETED
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
Pfizer
NCT03987685 COMPLETED
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Athenex, Inc.
NCT02596503 COMPLETED
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
NCT02559024 TERMINATED
Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
Providence Health & Services
NCT02235688 COMPLETED
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
ImmunityBio, Inc.
NCT01706835 COMPLETED
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
ImmunityBio, Inc.
NCT01673438 COMPLETED
Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
ImmunityBio, Inc.
NCT04522557 COMPLETED
Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT02705963 COMPLETED
A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors
Novartis Pharmaceuticals
NCT03248843 COMPLETED
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT02723864 COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT04811898 COMPLETED
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
NCT02947165 COMPLETED
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT03665129 TERMINATED
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
Innate Pharma
NCT02909452 COMPLETED
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT03015324 COMPLETED
Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
Peng Wang, MD PhD
NCT01362374 COMPLETED
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
NCT03168438 TERMINATED
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
NCT03084926 COMPLETED
First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors
Molecular Partners AG
NCT03823989 COMPLETED
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
Lipomedix Pharmaceuticals Inc.
NCT01143779 COMPLETED
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib
M.D. Anderson Cancer Center
NCT04810208 TERMINATED
Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
Lidds AB
NCT02675439 TERMINATED
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Chinook Therapeutics, Inc. (formerly Aduro)
NCT01441115 TERMINATED
ECI301 and Radiation for Advanced or Metastatic Cancer
National Cancer Institute (NCI)
NCT04191928 COMPLETED
Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
Thomas Jefferson University
NCT00999401 COMPLETED
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
Cyclacel Pharmaceuticals, Inc.
NCT01772004 COMPLETED
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
EMD Serono Research & Development Institute, Inc.
NCT02573259 COMPLETED
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Pfizer
NCT03400306 WITHDRAWN
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
AbbVie
NCT02660034 COMPLETED
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
BeiGene
NCT00730639 COMPLETED
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
Bristol-Myers Squibb
NCT03348514 COMPLETED
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
NCT02189174 TERMINATED
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
Novartis Pharmaceuticals
NCT02716948 COMPLETED
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04973020 COMPLETED
A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers
Jiangsu HengRui Medicine Co., Ltd.
NCT02767921 TERMINATED
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
University of Southern California
NCT01324141 TERMINATED
Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer
National Cancer Institute (NCI)
NCT03319459 COMPLETED
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT02407990 COMPLETED
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
BeiGene
NCT03364049 COMPLETED
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
Merck Sharp & Dohme LLC
NCT01922752 COMPLETED
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
NCT03497429 COMPLETED
A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
Takeda
NCT03661632 COMPLETED
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04508179 COMPLETED
A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects
7 Hills Pharma, LLC
NCT02282371 COMPLETED
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT03752177 TERMINATED
A Study of LY3415244 in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT05086848 COMPLETED
A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT05086822 COMPLETED
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT00989651 COMPLETED
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT02914470 COMPLETED
Carboplatin-cyclophosphamide Combined With Atezolizumab
The Netherlands Cancer Institute
NCT05084456 WITHDRAWN
Oral Docetaxel in Patients With Normal or Impaired Liver Function
Modra Pharmaceuticals
NCT03147378 COMPLETED
Food Effect Study of ModraDoc006 in Combination With Ritonavir
Modra Pharmaceuticals
NCT04585724 WITHDRAWN
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Emory University
NCT04418141 COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
Curon Biopharmaceutical (Australia) Co Pty Ltd
NCT03895684 COMPLETED
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
Salarius Pharmaceuticals, LLC
NCT03489343 COMPLETED
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT01910597 COMPLETED
Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors
Prince of Songkla University
NCT01586624 COMPLETED
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
NCT04252248 TERMINATED
Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage
University Hospital Heidelberg
NCT03006029 COMPLETED
Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
Theramab LLC
NCT03745807 COMPLETED
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT03607955 WITHDRAWN
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
Washington University School of Medicine
NCT03403725 TERMINATED
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
Menarini Group
NCT03009292 COMPLETED
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
Eisai Co., Ltd.
NCT04158349 TERMINATED
Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer
University of Utah
NCT03991494 COMPLETED
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
BeiGene
NCT04071262 COMPLETED
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
Eli Lilly and Company
NCT03051035 TERMINATED
First-in-Human Study of KO-947 in Non-Hematological Malignancies
Kura Oncology, Inc.
NCT02111824 TERMINATED
A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy
The Methodist Hospital Research Institute
NCT02478866 COMPLETED
Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
Betta Pharmaceuticals Co., Ltd.
NCT04014257 COMPLETED
A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies
Handok Inc.
NCT02730481 COMPLETED
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
Athenex, Inc.
NCT04111445 TERMINATED
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
NCT02588612 COMPLETED
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
NCT02777710 COMPLETED
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Centre Leon Berard
NCT01723020 COMPLETED
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
Kartos Therapeutics, Inc.
NCT03057145 COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Geoffrey Shapiro, MD, PhD
NCT02655822 COMPLETED
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Corvus Pharmaceuticals, Inc.
NCT03471286 TERMINATED
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04771390 COMPLETED
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
Bayer
NCT04351165 COMPLETED
BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects
Impact Therapeutics, Inc.
NCT04584515 COMPLETED
IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
Impact Therapeutics, Inc.
NCT04187456 COMPLETED
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body
AstraZeneca
NCT02564198 COMPLETED
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Eli Lilly and Company
NCT02058550 COMPLETED
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
Stanford University
NCT02367196 COMPLETED
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
Celgene
NCT02177682 TERMINATED
Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
Novartis Pharmaceuticals
NCT02227082 COMPLETED
Olaparib and Radiotherapy in Inoperable Breast Cancer
The Netherlands Cancer Institute
NCT01826877 COMPLETED
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT01063816 COMPLETED
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)
NCT03636750 COMPLETED
A Study of Injection HB002.1T in Subjects With Solid Tumor
Huabo Biopharm Co., Ltd.
NCT04312282 TERMINATED
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
Odonate Therapeutics, Inc.
NCT04178902 TERMINATED
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
AbbVie
NCT04258527 COMPLETED
Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
Innovent Biologics (Suzhou) Co. Ltd.
NCT03967093 TERMINATED
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
Bexion Pharmaceuticals, Inc.
NCT02859857 COMPLETED
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
Bexion Pharmaceuticals, Inc.
NCT04427774 TERMINATED
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
NCT02546531 COMPLETED
Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Washington University School of Medicine
NCT02908451 TERMINATED
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
AbGenomics B.V Taiwan Branch
NCT03360734 COMPLETED
Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors
Glycotope GmbH
NCT02715531 COMPLETED
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
NCT03292783 COMPLETED
This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001
ABL Bio, Inc.
NCT01343043 COMPLETED
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
GlaxoSmithKline
NCT03077607 COMPLETED
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
NCT02232243 COMPLETED
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Peng Wang, MD PhD
NCT01848834 COMPLETED
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Merck Sharp & Dohme LLC
NCT01840579 COMPLETED
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
Merck Sharp & Dohme LLC
NCT02168725 TERMINATED
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
Traws Pharma, Inc.
NCT03332576 COMPLETED
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03804515 TERMINATED
A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
Spectrum Pharmaceuticals, Inc
NCT01760525 COMPLETED
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
Novartis Pharmaceuticals
NCT02533674 COMPLETED
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
PharmaMar
NCT02292173 COMPLETED
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT02097810 COMPLETED
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
Hoffmann-La Roche
NCT02162888 COMPLETED
A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
Eagle Pharmaceuticals, Inc.
NCT02609230 COMPLETED
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Fox Chase Cancer Center
NCT02827968 COMPLETED
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT03359850 COMPLETED
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Tesaro, Inc.
NCT03006887 COMPLETED
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Co., Ltd.
NCT03481816 COMPLETED
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
National Cancer Institute (NCI)
NCT04498520 WITHDRAWN
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Pamela Munster
NCT02528357 COMPLETED
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
GlaxoSmithKline
NCT02499224 COMPLETED
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
CellabMED
NCT04419623 COMPLETED
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Telios Pharma, Inc.
NCT03009214 COMPLETED
A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
amcure GmbH
NCT01976741 COMPLETED
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
NCT03205176 COMPLETED
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AstraZeneca
NCT03234712 COMPLETED
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
AbbVie
NCT01765790 COMPLETED
Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
Baxalta now part of Shire
NCT03706274 WITHDRAWN
PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
CytomX Therapeutics
NCT04868344 COMPLETED
A Study of MRG003 in Patients With Advanced Solid Tumors
Shanghai Miracogen Inc.
NCT02817113 TERMINATED
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
Orient Europharma Co., Ltd.
NCT03604679 COMPLETED
SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors
SymBio Pharmaceuticals
NCT03406364 COMPLETED
Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
Metagone Biotech Inc.
NCT02608229 TERMINATED
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Washington University School of Medicine
NCT01065662 COMPLETED
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Susana M. Campos, MD
NCT02237638 COMPLETED
Phase I Study on VEGF Vaccination in Metastatic Solid Tumors
Amsterdam UMC, location VUmc
NCT03495323 COMPLETED
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
NCT04162301 TERMINATED
A Study of CS3002 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
NCT04839120 COMPLETED
PK, PD, Tolerability and Safety of MDPK67b in Healthy Volunteers
Med Discovery SA
NCT03507543 COMPLETED
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
NCT02110355 COMPLETED
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Kartos Therapeutics, Inc.
NCT03722186 SUSPENDED
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
NCT03449030 TERMINATED
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
Millennium Pharmaceuticals, Inc.
NCT03992326 TERMINATED
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
Centre Hospitalier Universitaire Vaudois
NCT01938612 COMPLETED
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
AstraZeneca
NCT04025307 TERMINATED
Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours
IQVIA Pty Ltd
NCT03213964 COMPLETED
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
Masonic Cancer Center, University of Minnesota
NCT03134638 TERMINATED
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Syros Pharmaceuticals
NCT03515824 TERMINATED
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)
Merck Sharp & Dohme LLC
NCT03318445 COMPLETED
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
Pamela Munster
NCT01624766 COMPLETED
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
M.D. Anderson Cancer Center
NCT02997176 COMPLETED
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Pfizer
NCT02897765 COMPLETED
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
BioNTech US Inc.
NCT01322802 COMPLETED
Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
University of Washington
NCT04338724 COMPLETED
A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
NCT02740270 COMPLETED
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
Novartis Pharmaceuticals
NCT01169532 COMPLETED
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Fox Chase Cancer Center
NCT02699749 COMPLETED
A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors
Millennium Pharmaceuticals, Inc.
NCT03489369 COMPLETED
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT04274907 TERMINATED
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
AbbVie
NCT00786669 COMPLETED
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
Children's Hospital Medical Center, Cincinnati
NCT02392793 COMPLETED
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
St. Jude Children's Research Hospital
NCT04488016 COMPLETED
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
AstraZeneca
NCT03125200 TERMINATED
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
ADC Therapeutics S.A.
NCT02132754 COMPLETED
Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
Merck Sharp & Dohme LLC
NCT01878890 COMPLETED
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
Institut Bergonié
NCT04675021 COMPLETED
Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects
AstraZeneca
NCT01183559 COMPLETED
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Fox Chase Cancer Center
NCT01531361 COMPLETED
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
M.D. Anderson Cancer Center
NCT01197170 COMPLETED
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
NCT01302808 COMPLETED
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
NCT02866916 WITHDRAWN
Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)
Institut Claudius Regaud
NCT03760614 WITHDRAWN
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
Abramson Cancer Center at Penn Medicine
NCT02900157 COMPLETED
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT03736850 COMPLETED
Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
CStone Pharmaceuticals
NCT02721043 COMPLETED
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Nina Bhardwaj
NCT04275960 COMPLETED
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
Bayer
NCT02392611 COMPLETED
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Gilead Sciences
NCT03708211 COMPLETED
A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT02608125 TERMINATED
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
Principia Biopharma, a Sanofi Company
NCT03162562 TERMINATED
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
CanariaBio Inc.
NCT03096340 TERMINATED
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Intezyne Technologies, Inc.
NCT01482156 COMPLETED
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01421004 COMPLETED
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01529307 TERMINATED
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT00715182 COMPLETED
A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer
Novartis Pharmaceuticals
NCT02703571 TERMINATED
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01030055 COMPLETED
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01596647 COMPLETED
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01700270 COMPLETED
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT01443481 COMPLETED
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Novartis Pharmaceuticals
NCT01155713 COMPLETED
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT00880308 COMPLETED
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01324479 COMPLETED
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01769768 COMPLETED
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
Novartis Pharmaceuticals
NCT00997399 COMPLETED
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
Novartis Pharmaceuticals
NCT01240655 COMPLETED
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01546428 COMPLETED
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01968915 COMPLETED
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT02925104 COMPLETED
A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT01576666 COMPLETED
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01007968 COMPLETED
Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
Novartis Pharmaceuticals
NCT00739414 COMPLETED
Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01106508 COMPLETED
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01237236 COMPLETED
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
Novartis Pharmaceuticals
NCT01911936 COMPLETED
A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT04109092 WITHDRAWN
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
Eisai Inc.
NCT02626234 COMPLETED
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01905228 COMPLETED
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Incuron
NCT02520752 COMPLETED
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01155453 COMPLETED
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
Novartis Pharmaceuticals
NCT01278849 TERMINATED
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
Novartis Pharmaceuticals
NCT01240642 TERMINATED
An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404
Novartis Pharmaceuticals
NCT01132625 COMPLETED
Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
Novartis Pharmaceuticals
NCT01285466 COMPLETED
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis Pharmaceuticals
NCT01195376 COMPLETED
A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01278758 TERMINATED
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
Novartis Pharmaceuticals
NCT01285453 COMPLETED
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
Novartis Pharmaceuticals
NCT01068483 COMPLETED
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis Pharmaceuticals
NCT02077933 COMPLETED
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis Pharmaceuticals
NCT02051751 COMPLETED
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Novartis Pharmaceuticals
NCT01387321 COMPLETED
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies
Novartis Pharmaceuticals
NCT01283503 COMPLETED
A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT02798978 COMPLETED
A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects
GlaxoSmithKline
NCT04195373 WITHDRAWN
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
Themis Bioscience GmbH
NCT03790423 COMPLETED
18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
Rigshospitalet, Denmark
NCT03976050 TERMINATED
Phase I Study of HL-085 in Patients With Advanced Solid Tumors
Shanghai Kechow Pharma, Inc.
NCT02706535 COMPLETED
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
GlaxoSmithKline
NCT00765973 COMPLETED
Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors
Spectrum Pharmaceuticals, Inc
NCT04006301 COMPLETED
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
Janssen Research & Development, LLC
NCT04142554 WITHDRAWN
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
UNC Lineberger Comprehensive Cancer Center
NCT04274933 TERMINATED
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
AbbVie
NCT02595918 TERMINATED
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
National Cancer Institute (NCI)
NCT03443622 WITHDRAWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
SupremeCure Pharma Inc.
NCT02781805 TERMINATED
Pilot Study of Bisphosphonates for Breast Cancer
University of Wisconsin, Madison
NCT02215096 COMPLETED
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
GlaxoSmithKline
NCT03101280 COMPLETED
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Hoffmann-La Roche
NCT03226574 COMPLETED
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
NCT03272256 COMPLETED
Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
ImmunoMet Therapeutics, Inc.
NCT01935973 COMPLETED
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
NCT01432951 COMPLETED
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Eli Lilly and Company
NCT01337765 COMPLETED
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
NCT01633970 COMPLETED
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT00637702 COMPLETED
A Study of ARRY-334543 in Patients With Advanced Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT00836888 COMPLETED
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Ono Pharmaceutical Co., Ltd.
NCT04577703 COMPLETED
First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors
Sunshine Lake Pharma Co., Ltd.
NCT02045602 COMPLETED
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Theriva Biologics SL
NCT00710736 COMPLETED
A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT00833326 COMPLETED
A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT01363232 COMPLETED
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT01469130 COMPLETED
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT03189030 TERMINATED
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
Aduro Biotech, Inc.
NCT03553108 COMPLETED
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
AstraZeneca
NCT01943461 COMPLETED
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Merck KGaA, Darmstadt, Germany
NCT02476955 TERMINATED
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT01352273 COMPLETED
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT00881569 COMPLETED
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
Daiichi Sankyo
NCT02919696 COMPLETED
A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers
Eli Lilly and Company
NCT01999972 COMPLETED
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
NCT02355535 COMPLETED
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Vanquish Oncology, Inc.
NCT02429466 COMPLETED
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Nasser Hanna
NCT01219699 COMPLETED
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
Novartis Pharmaceuticals
NCT01316822 COMPLETED
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT01514123 COMPLETED
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
Circadian Technologies Ltd.
NCT00959127 COMPLETED
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT01649336 COMPLETED
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT02078349 COMPLETED
Phase I Study of KPT330 in Asian Patients
National University Hospital, Singapore
NCT00744562 COMPLETED
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT02622074 COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
Merck Sharp & Dohme LLC
NCT01277146 COMPLETED
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT03384316 COMPLETED
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Cancer Institute (NCI)
NCT01957007 COMPLETED
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
OncoMed Pharmaceuticals, Inc.
NCT01345201 COMPLETED
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT03375086 COMPLETED
A Study of APX3330 in Patients With Advanced Solid Tumors
Apexian Pharmaceuticals, Inc.
NCT03961100 COMPLETED
A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
Genentech, Inc.
NCT03539484 TERMINATED
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Hoffmann-La Roche
NCT03030287 COMPLETED
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
OncoMed Pharmaceuticals, Inc.
NCT02916095 COMPLETED
Kanitinib in Treating Patients With Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
NCT01953783 COMPLETED
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
Millennium Pharmaceuticals, Inc.
NCT02121990 COMPLETED
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Memorial Sloan Kettering Cancer Center
NCT02658214 COMPLETED
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
NCT03008018 COMPLETED
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours
Karus Therapeutics Limited
NCT03119428 TERMINATED
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT02482441 COMPLETED
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
OncoMed Pharmaceuticals, Inc.
NCT02722954 COMPLETED
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT03295942 TERMINATED
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
OncoMed Pharmaceuticals, Inc.
NCT01608867 COMPLETED
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT02298387 COMPLETED
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT01778439 COMPLETED
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT02069145 COMPLETED
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
OncoMed Pharmaceuticals, Inc.
NCT01425008 COMPLETED
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Millennium Pharmaceuticals, Inc.
NCT02405065 COMPLETED
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573
Hanmi Pharmaceutical Company Limited
NCT03118817 COMPLETED
Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers
Hanmi Pharmaceutical Company Limited
NCT01832506 COMPLETED
A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors
Merck KGaA, Darmstadt, Germany
NCT00717704 COMPLETED
Solid Tumors Using Ixabepilone and Dasatinib
Medstar Health Research Institute
NCT01976910 COMPLETED
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer"
DEKK-TEC, Inc.
NCT01048008 COMPLETED
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
DEKK-TEC, Inc.
NCT04260360 WITHDRAWN
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
NanOlogy, LLC
NCT04013048 COMPLETED
Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT02881138 COMPLETED
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
NCT03511222 TERMINATED
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
NCT01249443 TERMINATED
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
NCT03089645 COMPLETED
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
MedImmune LLC
NCT01099631 COMPLETED
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Masonic Cancer Center, University of Minnesota
NCT02924766 COMPLETED
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
Janssen Research & Development, LLC
NCT02955251 COMPLETED
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
AbbVie
NCT02212730 TERMINATED
A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
Merck Sharp & Dohme LLC
NCT01525602 COMPLETED
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Daiichi Sankyo
NCT03407976 TERMINATED
Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
University of Utah
NCT01749397 COMPLETED
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT02348320 COMPLETED
Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Washington University School of Medicine
NCT01388335 COMPLETED
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
Eli Lilly and Company
NCT01092689 WITHDRAWN
The Role of Meat-borne Carcinogens in Pancreatic Cancer
University of Minnesota
NCT02812875 COMPLETED
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Curis, Inc.
NCT01862328 COMPLETED
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT02317302 TERMINATED
FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer
Washington University School of Medicine
NCT03343613 TERMINATED
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Eli Lilly and Company
NCT02512237 TERMINATED
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
Zhejiang Medicine Co., Ltd.
NCT03164603 COMPLETED
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
NewLink Genetics Corporation
NCT02881190 COMPLETED
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
NCT01596140 COMPLETED
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
M.D. Anderson Cancer Center
NCT02837991 TERMINATED
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Celldex Therapeutics
NCT02992977 TERMINATED
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
Agenus Inc.
NCT01803282 COMPLETED
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
NCT03256331 TERMINATED
Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients
Belx Bio-Pharmaceutical (Taiwan) Corporation
NCT04332549 WITHDRAWN
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
Sun Pharma Advanced Research Company Limited
NCT03235570 COMPLETED
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
Incyte Corporation
NCT00739609 TERMINATED
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
NewLink Genetics Corporation
NCT03644056 COMPLETED
Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors
ImmuneOncia Therapeutics Inc.
NCT02648711 TERMINATED
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
NewLink Genetics Corporation
NCT04126668 COMPLETED
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
AnewPharma
NCT02507544 COMPLETED
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TaiRx, Inc.
NCT03027284 COMPLETED
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
NCT03733587 COMPLETED
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
Genexine, Inc.
NCT02223052 COMPLETED
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
NCT03478995 COMPLETED
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Genexine, Inc.
NCT01643499 COMPLETED
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
NCT01470365 COMPLETED
3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors
Fox Chase Cancer Center
NCT03547388 COMPLETED
Moderate Whole Body Hyperthermia for Patients Undergoing Re-irradiation for Head and Neck Cancer -Influence on the Tumor Microenvironment
Charite University, Berlin, Germany
NCT03677531 COMPLETED
Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy
OHSU Knight Cancer Institute
NCT03700294 TERMINATED
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
ADC Therapeutics S.A.
NCT02316197 COMPLETED
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia
Merck KGaA, Darmstadt, Germany
NCT02162836 COMPLETED
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical K.K.
NCT01312376 TERMINATED
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
Abramson Cancer Center at Penn Medicine
NCT02452775 TERMINATED
Autologous OC-L Vaccine and Ovarian Cancer
Abramson Cancer Center at Penn Medicine
NCT03920839 WITHDRAWN
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
NCT02324257 COMPLETED
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Hoffmann-La Roche
NCT01548924 TERMINATED
Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
Centro Nacional de Investigaciones Oncologicas CARLOS III
NCT02529553 COMPLETED
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
NCT01831089 COMPLETED
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
PharmaMar
NCT02665416 COMPLETED
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Hoffmann-La Roche
NCT02363829 COMPLETED
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
Abramson Cancer Center at Penn Medicine
NCT04118842 COMPLETED
A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin
AstraZeneca
NCT00921739 COMPLETED
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
Duke University
NCT01383668 WITHDRAWN
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
Mayo Clinic
NCT02124148 COMPLETED
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
NCT03680560 TERMINATED
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Cogent Biosciences, Inc.
NCT01536054 COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Roswell Park Cancer Institute
NCT02540551 TERMINATED
Sentinel Node Detection in Ovarian Cancer
Maastricht University Medical Center
NCT01393990 COMPLETED
A Study of LY2228820 in Participants With Advanced Cancer
Eli Lilly and Company
NCT01502800 COMPLETED
Clinical Trial of ARQ 761 in Advanced Solid Tumors
University of Texas Southwestern Medical Center
NCT01254617 COMPLETED
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
National Cancer Institute (NCI)
NCT00692900 COMPLETED
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
University of Pittsburgh
NCT02681796 COMPLETED
Epidural Analgesia Use in Pancreatic Resections
Washington University School of Medicine
NCT02082626 TERMINATED
Study of Eribulin in Children With Cancer to Determine Safety
University of Oklahoma
NCT02946671 COMPLETED
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
NCT02261220 COMPLETED
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT03277209 TERMINATED
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
Weill Medical College of Cornell University
NCT01621217 COMPLETED
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0
Lund University Hospital
NCT03242993 COMPLETED
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
University of Lausanne Hospitals
NCT02551185 COMPLETED
ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Celgene
NCT02082977 TERMINATED
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
GlaxoSmithKline
NCT01564251 COMPLETED
A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma
Genentech, Inc.
NCT02466802 COMPLETED
Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Virginia Commonwealth University
NCT03258515 COMPLETED
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
AstraZeneca
NCT03425773 COMPLETED
Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care
Cellid Co., Ltd.
NCT02590952 COMPLETED
A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
Hutchison Medipharma Limited
NCT02601248 COMPLETED
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
Hutchison Medipharma Limited
NCT02630251 TERMINATED
Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors
GlaxoSmithKline
NCT02092792 COMPLETED
A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors
Genentech, Inc.
NCT02650713 COMPLETED
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Hoffmann-La Roche
NCT03052205 COMPLETED
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Idera Pharmaceuticals, Inc.
NCT01114958 COMPLETED
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
University of California, San Diego
NCT02576665 TERMINATED
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
NCT03306420 TERMINATED
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
EMD Serono Research & Development Institute, Inc.
NCT02219724 COMPLETED
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT02800889 WITHDRAWN
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
CTI BioPharma
NCT01653470 COMPLETED
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Bristol-Myers Squibb
NCT02383212 COMPLETED
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
NCT01292655 COMPLETED
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT02743637 COMPLETED
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
SynDevRx, Inc.
NCT03159585 COMPLETED
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Zhujiang Hospital
NCT03676101 COMPLETED
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
NCT02647983 WITHDRAWN
Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection
Sunnybrook Health Sciences Centre
NCT02350673 COMPLETED
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT02476552 COMPLETED
Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer
Tesaro, Inc.
NCT02620839 TERMINATED
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
Pamela Munster
NCT02358200 TERMINATED
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Pamela Munster
NCT03326986 COMPLETED
Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)
Merck Sharp & Dohme LLC
NCT01488513 COMPLETED
ABC294640 in Treating Patients With Advanced Solid Tumors
RedHill Biopharma Limited
NCT01583777 COMPLETED
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Acrotech Biopharma Inc.
NCT01165658 TERMINATED
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
M.D. Anderson Cancer Center
NCT02014116 TERMINATED
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
Eli Lilly and Company
NCT01445522 COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
National Cancer Institute (NCI)
NCT03042910 COMPLETED
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
Pfizer
NCT01988896 COMPLETED
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT01287130 COMPLETED
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
National Cancer Institute (NCI)
NCT01336985 TERMINATED
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
National Institutes of Health Clinical Center (CC)
NCT01445405 COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
National Cancer Institute (NCI)
NCT01237067 COMPLETED
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
National Cancer Institute (NCI)
NCT02304393 COMPLETED
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT01295827 COMPLETED
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Merck Sharp & Dohme LLC
NCT04193319 COMPLETED
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT02075112 COMPLETED
Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck
Emory University
NCT02391480 COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
AbbVie
NCT02614456 COMPLETED
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
Fox Chase Cancer Center
NCT00985868 COMPLETED
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
Cancer Research UK
NCT01770353 COMPLETED
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Ipsen
NCT02071537 COMPLETED
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
University of Cincinnati
NCT02751918 COMPLETED
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Bayer
NCT01585415 TERMINATED
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
National Cancer Institute (NCI)
NCT02679131 TERMINATED
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Acrotech Biopharma Inc.
NCT00674024 COMPLETED
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
National Cancer Institute (NCI)
NCT00859118 COMPLETED
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
University of Wisconsin, Madison
NCT00652626 COMPLETED
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
Celgene
NCT02518958 COMPLETED
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
EpicentRx, Inc.
NCT02586987 COMPLETED
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
NCT00747474 COMPLETED
Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
Taiwan Liposome Company
NCT02146222 COMPLETED
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
University of Wisconsin, Madison
NCT03057366 COMPLETED
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT01251926 COMPLETED
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
National Cancer Institute (NCI)
NCT01163071 TERMINATED
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
Celgene
NCT00848718 COMPLETED
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
Merck Sharp & Dohme LLC
NCT01478685 COMPLETED
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
NCT02288507 WITHDRAWN
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
NCT02661815 TERMINATED
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
Dana-Farber Cancer Institute
NCT03126864 TERMINATED
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02553499 TERMINATED
Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)
Merck Sharp & Dohme LLC
NCT02267707 TERMINATED
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
Celgene
NCT00915083 COMPLETED
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
Celgene
NCT02857166 COMPLETED
Study of JS001 in Participants With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT03619616 COMPLETED
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
NCT02471846 COMPLETED
A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT03120130 SUSPENDED
Study of Amblyomin-X in Advanced Solid Tumor
União Química Farmacêutica Nacional S/A
NCT01004224 COMPLETED
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Novartis Pharmaceuticals
NCT01184326 COMPLETED
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
NCT01723475 COMPLETED
First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer
Bayer
NCT02274623 COMPLETED
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
OPKO Health, Inc.
NCT00688415 COMPLETED
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
Celgene
NCT02559492 TERMINATED
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
NCT02259010 COMPLETED
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Millennium Pharmaceuticals, Inc.
NCT01135563 COMPLETED
Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours
The Hospital for Sick Children
NCT02711345 TERMINATED
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
Novartis Pharmaceuticals
NCT02759666 COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
Atridia Pty Ltd.
NCT03182257 TERMINATED
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
Ono Pharmaceutical Co., Ltd.
NCT03081819 COMPLETED
A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer
Kyunghee University Medical Center
NCT03427073 TERMINATED
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Almac Discovery
NCT02250170 COMPLETED
Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
Korea Otsuka Pharmaceutical Co., Ltd.
NCT02644278 COMPLETED
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
EMD Serono Research & Development Institute, Inc.
NCT00858429 COMPLETED
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Northwestern University
NCT01924689 COMPLETED
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
BioMed Valley Discoveries, Inc
NCT02307240 COMPLETED
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
Curis, Inc.
NCT02953197 COMPLETED
18F-FDG-PET Guided Dose-Painting With Intensity Modulated Radiotherapy in Oropharyngeal Tumours
Guy's and St Thomas' NHS Foundation Trust
NCT01375699 COMPLETED
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
Virginia Commonwealth University
NCT02705482 COMPLETED
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
MedImmune LLC
NCT02387138 COMPLETED
A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan
Institut du Cancer de Montpellier - Val d'Aurelle
NCT01868022 COMPLETED
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
GlaxoSmithKline
NCT00656123 COMPLETED
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02737072 TERMINATED
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
Eli Lilly and Company
NCT02629549 TERMINATED
Intraoperative Imaging of Pituitary Adenomas by OTL
University of Pennsylvania
NCT03286296 COMPLETED
LZM009 to Treat Patients With Advanced Solid Tumors
Livzon Pharmaceutical Group Inc.
NCT02778126 COMPLETED
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
Eli Lilly and Company
NCT02300610 COMPLETED
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT00900614 COMPLETED
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
Aprea Therapeutics
NCT03494231 TERMINATED
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
Henlix, Inc
NCT02707328 TERMINATED
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
The Cooper Health System
NCT00969553 COMPLETED
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
Boehringer Ingelheim
NCT03677960 TERMINATED
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
NCT02389751 COMPLETED
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
M.D. Anderson Cancer Center
NCT01945710 COMPLETED
An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
Eisai Limited
NCT01639911 COMPLETED
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
University of Illinois at Chicago
NCT02004717 COMPLETED
Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors
Daiichi Sankyo Co., Ltd.
NCT02952989 TERMINATED
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Seagen Inc.
NCT04026321 COMPLETED
Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US
Livzon Pharmaceutical Group Inc.
NCT02058901 COMPLETED
Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
Amsterdam UMC, location VUmc
NCT01621542 COMPLETED
Clinical Study of WT2725 in Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT01938443 COMPLETED
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors
GlaxoSmithKline
NCT01281514 COMPLETED
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
Fox Chase Cancer Center
NCT01863485 COMPLETED
Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
AnewPharma
NCT03188328 TERMINATED
Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas
Alfasigma S.p.A.
NCT03349255 TERMINATED
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Aeon Therapeutics (Shanghai) Co., Ltd.
NCT01966445 COMPLETED
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
GlaxoSmithKline
NCT02367352 TERMINATED
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT03313557 COMPLETED
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
AstraZeneca
NCT01898078 COMPLETED
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Millennium Pharmaceuticals, Inc.
NCT03362723 COMPLETED
A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Hoffmann-La Roche
NCT01648764 COMPLETED
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
Eli Lilly and Company
NCT01288989 COMPLETED
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Eli Lilly and Company
NCT02642016 COMPLETED
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
Celldex Therapeutics
NCT01212107 COMPLETED
A Phase 1 Study of LY2874455 in Participants With Advanced Cancer
Eli Lilly and Company
NCT02476123 COMPLETED
Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Kyowa Kirin Co., Ltd.
NCT01830816 COMPLETED
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
Millennium Pharmaceuticals, Inc.
NCT02106845 COMPLETED
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Bayer
NCT02309177 COMPLETED
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Celgene
NCT02825563 COMPLETED
A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT02324621 COMPLETED
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
NCT02250781 COMPLETED
Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
NCT02069158 COMPLETED
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
Cristiana Sessa
NCT01164709 COMPLETED
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
NCT01962532 COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
NCT03138408 TERMINATED
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
AbbVie
NCT03175497 COMPLETED
Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors
Taizhou EOC Pharma Co., Ltd.
NCT02160106 COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
MedPacto, Inc.
NCT00874731 COMPLETED
A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)
Merck Sharp & Dohme LLC
NCT00858377 COMPLETED
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Amgen
NCT01305512 COMPLETED
Pharmacokinetic, Safety and Tolerability Study of SPARC1028
Sun Pharma Advanced Research Company Limited
NCT01304303 COMPLETED
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
Sun Pharma Advanced Research Company Limited
NCT02622932 COMPLETED
Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT00993512 COMPLETED
Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
PCI Biotech AS
NCT01844947 COMPLETED
Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Dr Anders Ullén
NCT01877811 COMPLETED
Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors
Hoffmann-La Roche
NCT02548390 TERMINATED
Study of Intravenous RXDX-107 in Patients With Solid Tumors
Hoffmann-La Roche
NCT01791088 COMPLETED
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
University of Chicago
NCT02145559 COMPLETED
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
University of Chicago
NCT02540876 COMPLETED
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
University of Chicago
NCT01380184 COMPLETED
Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)
Merck Sharp & Dohme LLC
NCT00909831 COMPLETED
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Abramson Cancer Center at Penn Medicine
NCT02672865 COMPLETED
Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer
Loma Linda University
NCT02105233 COMPLETED
Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid
St. Olavs Hospital
NCT00923390 TERMINATED
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
National Cancer Institute (NCI)
NCT01537107 COMPLETED
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Mayo Clinic
NCT02717572 COMPLETED
18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
Washington University School of Medicine
NCT02565758 COMPLETED
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
AbbVie
NCT00670488 COMPLETED
Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
Merck Sharp & Dohme LLC
NCT03192943 COMPLETED
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
Bristol-Myers Squibb
NCT01524224 COMPLETED
A Dose-Escalation Study in Participants With Advanced Cancer
Eli Lilly and Company
NCT02129205 TERMINATED
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
Pfizer
NCT02703298 COMPLETED
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients
TaiRx, Inc.
NCT01273155 COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
National Cancer Institute (NCI)
NCT01844583 COMPLETED
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Millennium Pharmaceuticals, Inc.
NCT01231594 COMPLETED
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Novartis Pharmaceuticals
NCT02483858 COMPLETED
Study of Oral PQR309 in Patients With Advanced Solid Tumors
PIQUR Therapeutics AG
NCT01209832 TERMINATED
A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
Eli Lilly and Company
NCT00979134 TERMINATED
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
AstraZeneca
NCT01512758 COMPLETED
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
Millennium Pharmaceuticals, Inc.
NCT01490749 COMPLETED
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
Emory University
NCT02045095 TERMINATED
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT03311477 COMPLETED
A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors
AbbVie
NCT02221960 COMPLETED
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
MedImmune LLC
NCT00962091 COMPLETED
Study of MLN8237 in Participants With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT02813902 WITHDRAWN
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
Massachusetts General Hospital
NCT02458339 COMPLETED
Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
The University of Texas Health Science Center, Houston
NCT02745769 COMPLETED
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Eli Lilly and Company
NCT00816361 COMPLETED
A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT01341457 COMPLETED
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
Eli Lilly and Company
NCT01431534 TERMINATED
A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)
Merck Sharp & Dohme LLC
NCT01713972 COMPLETED
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
Manisha Shah
NCT02070406 TERMINATED
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
Jonsson Comprehensive Cancer Center
NCT02016729 COMPLETED
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Kartos Therapeutics, Inc.
NCT02444793 TERMINATED
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Pfizer
NCT02601274 TERMINATED
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
Hutchison Medipharma Limited
NCT02973399 TERMINATED
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Esanex Inc.
NCT02298946 COMPLETED
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
NCT02688101 COMPLETED
Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
Collaborative Medicinal Development Pty Limited
NCT02345174 COMPLETED
Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors
GlaxoSmithKline
NCT01094288 COMPLETED
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Millennium Pharmaceuticals, Inc.
NCT02555644 COMPLETED
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Eli Lilly and Company
NCT01049893 COMPLETED
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Daiichi Sankyo
NCT01588678 COMPLETED
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
NCT02076451 COMPLETED
Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
NCT01149720 COMPLETED
Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
Daiichi Sankyo
NCT01517399 COMPLETED
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
Daiichi Sankyo
NCT00697632 COMPLETED
Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
Mirati Therapeutics Inc.
NCT02150733 COMPLETED
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
Daiichi Sankyo
NCT02179918 COMPLETED
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Pfizer
NCT03202992 COMPLETED
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
NCT03011320 COMPLETED
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
Endocyte
NCT01999738 COMPLETED
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Endocyte
NCT02731742 TERMINATED
Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)
Merck Sharp & Dohme LLC
NCT01206816 COMPLETED
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
NCT00969761 COMPLETED
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
Boehringer Ingelheim
NCT01858155 COMPLETED
Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors
C17 Council
NCT01145885 COMPLETED
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Boehringer Ingelheim
NCT01646203 COMPLETED
A Study of IMC-TR1 in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT01394003 TERMINATED
A Study of LY2584702 in Participants With Advanced Cancer
Eli Lilly and Company
NCT02582931 COMPLETED
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
Washington University School of Medicine
NCT02418624 COMPLETED
Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer
The Netherlands Cancer Institute
NCT02171260 COMPLETED
This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas
Eisai Inc.
NCT02963389 COMPLETED
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients
Dong-A ST Co., Ltd.
NCT01286987 COMPLETED
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
NCT01173913 COMPLETED
Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir
The Netherlands Cancer Institute
NCT01284335 TERMINATED
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT01457131 TERMINATED
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
National Cancer Institute (NCI)
NCT02122770 COMPLETED
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT01296568 COMPLETED
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
Eli Lilly and Company
NCT03450109 COMPLETED
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
Luye Pharma Group Ltd.
NCT01214668 COMPLETED
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
Eli Lilly and Company
NCT01938846 COMPLETED
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
Boehringer Ingelheim
NCT01923337 COMPLETED
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
University of California, Davis
NCT01078649 COMPLETED
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Debiopharm International SA
NCT02556463 TERMINATED
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
MedImmune LLC
NCT01128842 COMPLETED
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
Puma Biotechnology, Inc.
NCT02860780 COMPLETED
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
NCT01386346 COMPLETED
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
Weill Medical College of Cornell University
NCT01332721 COMPLETED
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Tracon Pharmaceuticals Inc.
NCT01116336 COMPLETED
Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck
Emory University
NCT03145909 TERMINATED
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
AbbVie
NCT03153163 COMPLETED
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
Hoffmann-La Roche
NCT02245204 COMPLETED
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
NCT02966171 TERMINATED
A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
Hutchison Medipharma Limited
NCT00768469 COMPLETED
Study Evaluating Safety And Tolerability, Solid Tumor
Puma Biotechnology, Inc.
NCT02214147 COMPLETED
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Millennium Pharmaceuticals, Inc.
NCT02268825 TERMINATED
Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers
University of Utah
NCT01086332 TERMINATED
Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer
University of Iowa
NCT03237416 COMPLETED
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Bayer
NCT00940498 COMPLETED
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
Pfizer
NCT01714947 COMPLETED
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Millennium Pharmaceuticals, Inc.
NCT01347866 TERMINATED
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
Pfizer
NCT02648425 COMPLETED
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
ASLAN Pharmaceuticals
NCT01358968 COMPLETED
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
Eli Lilly and Company
NCT02636426 COMPLETED
Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study
Amsterdam UMC, location VUmc
NCT00926640 COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Cancer Institute (NCI)
NCT01185548 TERMINATED
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
Eli Lilly and Company
NCT02508441 TERMINATED
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
Andes Biotechnologies
NCT01240577 COMPLETED
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT01833546 COMPLETED
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
NCT01820325 TERMINATED
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
Novartis Pharmaceuticals
NCT03496519 WITHDRAWN
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
University of Colorado, Denver
NCT01688206 COMPLETED
A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT01986426 COMPLETED
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
NCT02845414 WITHDRAWN
Study of CD133KDEL Toxin in the Treatment for Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT03320525 TERMINATED
Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)
Herlev Hospital
NCT02277392 WITHDRAWN
A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine
NCT00997360 WITHDRAWN
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00742105 TERMINATED
Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan
Novartis Pharmaceuticals
NCT02442531 COMPLETED
A Study of CriPec® Docetaxel Given to Patients With Solid Tumours
Cristal Therapeutics
NCT01971515 COMPLETED
First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
EMD Serono
NCT00838539 COMPLETED
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Puma Biotechnology, Inc.
NCT02939846 WITHDRAWN
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
GlaxoSmithKline
NCT01497925 COMPLETED
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
Polaris Group
NCT02046421 COMPLETED
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT02191761 COMPLETED
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Biosplice Therapeutics, Inc.
NCT02650635 TERMINATED
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Mayo Clinic
NCT01695733 TERMINATED
Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy
Washington University School of Medicine
NCT01438554 COMPLETED
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00878111 COMPLETED
Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour
AGC Biologics S.p.A.
NCT01303705 COMPLETED
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Providence Health & Services
NCT02134600 COMPLETED
OmegaChild - Omega-3 Supplementation to Children Previously Treated for Cancer
Per Kogner
NCT01463696 TERMINATED
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
Merck Sharp & Dohme LLC
NCT00779584 COMPLETED
A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)
Merck Sharp & Dohme LLC
NCT00960063 TERMINATED
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
NCT03330990 COMPLETED
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Hoffmann-La Roche
NCT03285607 WITHDRAWN
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Washington University School of Medicine
NCT01243762 TERMINATED
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
NCT01021748 COMPLETED
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Merck Sharp & Dohme LLC
NCT01463631 COMPLETED
A Study of LY3007113 in Participants With Advanced Cancer
Eli Lilly and Company
NCT01214642 COMPLETED
A Dose-Escalation Study for Patients With Advanced Cancer
Eli Lilly and Company
NCT01348347 COMPLETED
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
NCT01647789 TERMINATED
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
Novartis Pharmaceuticals
NCT01437007 COMPLETED
TKM 080301 for Primary or Secondary Liver Cancer
National Cancer Institute (NCI)
NCT01804530 TERMINATED
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
Plexxikon
NCT02673736 TERMINATED
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
Plexxikon
NCT01151670 COMPLETED
Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
Wake Forest University Health Sciences
NCT01022853 COMPLETED
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Boehringer Ingelheim
NCT01971476 COMPLETED
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
Boehringer Ingelheim
NCT02063958 COMPLETED
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Esanex Inc.
NCT02780011 WITHDRAWN
Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Eric Bernicker, MD
NCT02386111 TERMINATED
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
NCT01458067 COMPLETED
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
GlaxoSmithKline
NCT03111069 WITHDRAWN
Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children
M.D. Anderson Cancer Center
NCT01484015 COMPLETED
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
NCT02987504 TERMINATED
Study of Samalizumab in Patients With Advanced Cancer
Alexion Pharmaceuticals, Inc.
NCT01800071 COMPLETED
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
Cancer Research UK
NCT01705002 COMPLETED
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
Lipomedix Pharmaceuticals Inc.
NCT00678132 COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
National Cancer Institute (NCI)
NCT01246102 COMPLETED
AT13387 in Adults With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT02839694 WITHDRAWN
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
National Cancer Institute (NCI)
NCT01120288 COMPLETED
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases
National Cancer Institute (NCI)
NCT01259479 COMPLETED
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
National Cancer Institute (NCI)
NCT02166255 COMPLETED
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT00958724 COMPLETED
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
Puma Biotechnology, Inc.
NCT03082053 COMPLETED
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
ASLAN Pharmaceuticals
NCT00816400 COMPLETED
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
MedImmune LLC
NCT01690741 COMPLETED
Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies
Immune System Key Ltd
NCT02146313 COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Genentech, Inc.
NCT02439489 COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors
Fondazione Michelangelo
NCT03077477 WITHDRAWN
Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
Aminex Therapeutics, Inc.
NCT00878449 COMPLETED
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
AbbVie (prior sponsor, Abbott)
NCT02485119 COMPLETED
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
Bayer
NCT02065063 COMPLETED
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
GlaxoSmithKline
NCT01705106 TERMINATED
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
University of Chicago
NCT02035527 COMPLETED
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
NCT02057289 TERMINATED
A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
Children's Hospital Medical Center, Cincinnati
NCT02760797 COMPLETED
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT00736372 COMPLETED
A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer
Cascadian Therapeutics Inc.
NCT01978964 COMPLETED
Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors
Cascadian Therapeutics Inc.
NCT02323893 COMPLETED
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
CellSight Technologies, Inc.
NCT00837928 COMPLETED
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
John Grecula
NCT01556789 COMPLETED
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Cascadian Therapeutics Inc.
NCT02098967 COMPLETED
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
Hoffmann-La Roche
NCT02690350 TERMINATED
An Open Study Assessing the Safety and Tolerability of U3-1784
Daiichi Sankyo
NCT02036281 COMPLETED
A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain
University of Texas Southwestern Medical Center
NCT02222363 TERMINATED
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Vivolux AB
NCT02210663 COMPLETED
A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
AbbVie
NCT02833506 WITHDRAWN
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
NCT02275039 COMPLETED
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
City of Hope Medical Center
NCT02543645 TERMINATED
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
NCT03502395 COMPLETED
Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion
Assiut University
NCT02592785 COMPLETED
Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Bayer
NCT01762280 COMPLETED
A Phase I Study of Famitinib Malate in Patients With Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT00784914 COMPLETED
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
City of Hope Medical Center
NCT00820768 WITHDRAWN
A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Celgene
NCT01875705 COMPLETED
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT01440998 COMPLETED
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
NCT02558140 COMPLETED
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT02192541 TERMINATED
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Cancer Institute (NCI)
NCT01526473 COMPLETED
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901
H. Kim Lyerly
NCT02671955 TERMINATED
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
Janssen Research & Development, LLC
NCT01275612 WITHDRAWN
Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers
Mario Negri Institute for Pharmacological Research
NCT01520389 COMPLETED
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Merrimack Pharmaceuticals
NCT00931931 COMPLETED
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Timothy Cripe
NCT01400555 COMPLETED
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cougar Biotechnology, Inc.
NCT01470209 COMPLETED
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Emory University
NCT01494688 COMPLETED
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT01224730 COMPLETED
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
AEterna Zentaris
NCT01809210 COMPLETED
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
AstraZeneca
NCT02349139 TERMINATED
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
Asana BioSciences
NCT02004106 COMPLETED
A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT01744054 TERMINATED
Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
Washington University School of Medicine
NCT00790816 COMPLETED
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Novartis Pharmaceuticals
NCT01691807 COMPLETED
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Novartis Pharmaceuticals
NCT02243917 TERMINATED
A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors
Cleave Biosciences, Inc.
NCT03168035 COMPLETED
Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
NanoCarrier Co., Ltd.
NCT01505153 COMPLETED
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
Gradalis, Inc.
NCT01767623 COMPLETED
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
Hoffmann-La Roche
NCT01822756 TERMINATED
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
Incyte Corporation
NCT01702285 TERMINATED
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
Curis, Inc.
NCT01219777 COMPLETED
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ritu Salani
NCT03422874 WITHDRAWN
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Dartmouth-Hitchcock Medical Center
NCT01335893 COMPLETED
Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green
University of Pennsylvania
NCT01704963 COMPLETED
A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Janssen Pharmaceutical K.K.
NCT02228811 TERMINATED
A Study of DCC-2701 in Participants With Advanced Solid Tumors
Deciphera Pharmaceuticals, LLC
NCT01903083 COMPLETED
Chemoimmunotherapy and Radiation in Pancreatic Cancer
Providence Health & Services
NCT02164838 COMPLETED
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
Children's Oncology Group
NCT01519817 COMPLETED
Cancer Vaccine Targeting Brachyury Protein in Tumors
National Cancer Institute (NCI)
NCT02318394 COMPLETED
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
MedImmune LLC
NCT02168777 TERMINATED
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Bayer
NCT02363855 COMPLETED
Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects
Bayer
NCT02359058 COMPLETED
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Eli Lilly and Company
NCT00825201 COMPLETED
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
City of Hope Medical Center
NCT03205891 WITHDRAWN
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
M.D. Anderson Cancer Center
NCT01929941 TERMINATED
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Incyte Corporation
NCT02296879 COMPLETED
A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types
Young Suk Park
NCT02014337 COMPLETED
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Corcept Therapeutics
NCT01813474 COMPLETED
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
NCT00908167 COMPLETED
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
NCT01677559 COMPLETED
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Washington University School of Medicine
NCT00807755 TERMINATED
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
University of California, Davis
NCT01336842 COMPLETED
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
University of California, Davis
NCT02194049 COMPLETED
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
University of California, Davis
NCT01987362 COMPLETED
A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies
Hoffmann-La Roche
NCT01339650 COMPLETED
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AbbVie (prior sponsor, Abbott)
NCT01012362 TERMINATED
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00921869 COMPLETED
A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
Eisai Co., Ltd.
NCT02828930 COMPLETED
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
Hoffmann-La Roche
NCT00610493 COMPLETED
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
NCT01200316 COMPLETED
Rocking Motion: Physiologic Effect on the Surgical Stress Response
M.D. Anderson Cancer Center
NCT01072266 COMPLETED
A Dose-escalation Study in Subjects With Advanced Malignancies
Incyte Corporation
NCT00649207 COMPLETED
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
AbbVie (prior sponsor, Abbott)
NCT01413893 COMPLETED
An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
AbbVie
NCT01121133 COMPLETED
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
AbbVie
NCT00982566 COMPLETED
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
AbbVie
NCT01472016 COMPLETED
Study of ABT-700 in Subjects With Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)
NCT00733187 COMPLETED
Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
AbbVie (prior sponsor, Abbott)
NCT00891605 COMPLETED
Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
AbbVie
NCT01199224 COMPLETED
To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors
AbbVie
NCT00887757 COMPLETED
Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
AbbVie
NCT01255657 COMPLETED
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
AbbVie (prior sponsor, Abbott)
NCT01009073 COMPLETED
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
AbbVie (prior sponsor, Abbott)
NCT02009631 COMPLETED
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
AbbVie
NCT01617928 COMPLETED
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
AbbVie (prior sponsor, Abbott)
NCT02593708 TERMINATED
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Michelle Melisko
NCT00650910 COMPLETED
Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer
GlaxoSmithKline
NCT00849329 COMPLETED
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
GlaxoSmithKline
NCT01231568 COMPLETED
An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor
GlaxoSmithKline
NCT01954043 COMPLETED
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
GlaxoSmithKline
NCT01437254 COMPLETED
To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer
AHS Cancer Control Alberta
NCT01192165 COMPLETED
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
GlaxoSmithKline
NCT01725100 COMPLETED
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
GlaxoSmithKline
NCT01387204 COMPLETED
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
GlaxoSmithKline
NCT00996762 COMPLETED
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
GlaxoSmithKline
NCT02040480 COMPLETED
Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib
GlaxoSmithKline
NCT00880321 COMPLETED
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
GlaxoSmithKline
NCT00821054 COMPLETED
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
GlaxoSmithKline
NCT00920257 COMPLETED
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
GlaxoSmithKline
NCT01340846 COMPLETED
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
GlaxoSmithKline
NCT01290354 COMPLETED
Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer
GlaxoSmithKline
NCT00722293 COMPLETED
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
NCT01827644 COMPLETED
Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers
GlaxoSmithKline
NCT01738451 COMPLETED
A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors
GlaxoSmithKline
NCT01658553 COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
GlaxoSmithKline
NCT01340833 COMPLETED
Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
GlaxoSmithKline
NCT01262963 COMPLETED
An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
GlaxoSmithKline
NCT01476137 COMPLETED
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
GlaxoSmithKline
NCT01582997 COMPLETED
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors
GlaxoSmithKline
NCT01647659 COMPLETED
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
GlaxoSmithKline
NCT00955773 COMPLETED
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
GlaxoSmithKline
NCT01331941 COMPLETED
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
Amgen
NCT01898715 COMPLETED
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Millendo Therapeutics, Inc.
NCT03247283 COMPLETED
Pharmacokinetics and Metabolism Study in Healthy Male Participants
Bristol-Myers Squibb
NCT01380756 COMPLETED
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Amgen
NCT01721525 COMPLETED
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Memorial Sloan Kettering Cancer Center
NCT01186484 COMPLETED
Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer
Janssen Pharmaceutical K.K.
NCT01473095 COMPLETED
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT01938638 COMPLETED
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
Bayer
NCT01159522 COMPLETED
A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy
SynCore Biotechnology Co., Ltd.
NCT02303366 COMPLETED
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
Peter MacCallum Cancer Centre, Australia
NCT01281488 COMPLETED
Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors
City of Hope Medical Center
NCT01411410 COMPLETED
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Bayer
NCT03007771 WITHDRAWN
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
Washington University School of Medicine
NCT02151357 TERMINATED
Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor
Standard Chem. & Pharm. Co., Ltd.
NCT01460537 COMPLETED
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
Bayer
NCT01581541 TERMINATED
PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment
National Cancer Institute (NCI)
NCT01449058 COMPLETED
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Array BioPharma
NCT01671592 COMPLETED
Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)
Pawel Kalinski
NCT02658708 COMPLETED
Bright Light on Fatigue in Women Being Treated for Breast Cancer
Washington University School of Medicine
NCT00572078 COMPLETED
Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
Safi Shahda
NCT03283046 WITHDRAWN
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
NCT02286219 COMPLETED
Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
Bristol-Myers Squibb
NCT01727076 COMPLETED
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
National Cancer Institute (NCI)
NCT01881217 COMPLETED
First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
Bayer
NCT02745756 WITHDRAWN
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
H. Lee Moffitt Cancer Center and Research Institute
NCT00575952 COMPLETED
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
Gynecologic Oncology Group
NCT01955473 COMPLETED
Japanese Phase 1 Trial of Sym004 in Solid Tumors
Merck KGaA, Darmstadt, Germany
NCT01668017 TERMINATED
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Merck KGaA, Darmstadt, Germany
NCT01508104 TERMINATED
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
NCT00624936 COMPLETED
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
NCT01302405 TERMINATED
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
Prism Pharma Co., Ltd.
NCT01713036 COMPLETED
Oral Bioavailability and Mass Balance Trial With Pimasertib
Merck KGaA, Darmstadt, Germany
NCT03246009 COMPLETED
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
Tianjin SinoBiotech Ltd.
NCT01975116 COMPLETED
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Pediatric Brain Tumor Consortium
NCT01610479 COMPLETED
A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
Taiho Pharmaceutical Co., Ltd.
NCT00706576 COMPLETED
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
University of Missouri-Columbia
NCT00728468 COMPLETED
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
Pfizer
NCT00776867 COMPLETED
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT01143753 COMPLETED
A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
Hoffmann-La Roche
NCT02674555 WITHDRAWN
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT01849744 TERMINATED
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
Verastem, Inc.
NCT01892046 COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Esanex Inc.
NCT02082665 COMPLETED
Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam
GlaxoSmithKline
NCT02014909 COMPLETED
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Celldex Therapeutics
NCT00659178 COMPLETED
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
GlaxoSmithKline
NCT00853528 COMPLETED
Stereotactic Radiosurgery in Treating Patients With Spinal Metastases
Boston Medical Center
NCT01677780 COMPLETED
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
Hoffmann-La Roche
NCT01682473 COMPLETED
A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
Zenyaku Kogyo Co., Ltd.
NCT00987766 COMPLETED
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Vanderbilt-Ingram Cancer Center
NCT02428036 COMPLETED
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
Takara Bio Inc.
NCT01236586 WITHDRAWN
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
NCT00644072 COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
National Cancer Institute (NCI)
NCT01419548 WITHDRAWN
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems
National Cancer Institute (NCI)
NCT01182883 WITHDRAWN
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT02412462 COMPLETED
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
Alethia Biotherapeutics
NCT02915172 WITHDRAWN
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT01168011 COMPLETED
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Traws Pharma, Inc.
NCT01165905 COMPLETED
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Traws Pharma, Inc.
NCT00861783 COMPLETED
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Traws Pharma, Inc.
NCT02107235 COMPLETED
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Traws Pharma, Inc.
NCT01125891 COMPLETED
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Traws Pharma, Inc.
NCT00861328 COMPLETED
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Traws Pharma, Inc.
NCT02020577 COMPLETED
Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours
Boehringer Ingelheim
NCT01670175 COMPLETED
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
University of California, San Francisco
NCT02052492 COMPLETED
Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors
Efranat Ltd.
NCT02578316 COMPLETED
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
Eisai Inc.
NCT01339871 COMPLETED
Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT00920803 COMPLETED
A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases
Sirtris, a GSK Company
NCT00996671 COMPLETED
Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers
GlaxoSmithKline
NCT01910545 COMPLETED
Phase 1 Study of OTS167 in Patients With Solid Tumors
OncoTherapy Science, Inc.
NCT02429804 TERMINATED
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Stanford University
NCT00513474 COMPLETED
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
NCT00654160 COMPLETED
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Mayo Clinic
NCT01415297 COMPLETED
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
Niiki Pharma Inc.
NCT00670553 COMPLETED
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
Novartis Pharmaceuticals
NCT01138033 COMPLETED
Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors
GlaxoSmithKline
NCT01442870 COMPLETED
Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy
Tufts Medical Center
NCT01248858 TERMINATED
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.
GlaxoSmithKline
NCT00610948 COMPLETED
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
UNC Lineberger Comprehensive Cancer Center
NCT01577745 COMPLETED
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
MedImmune LLC
NCT01129349 COMPLETED
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Amgen
NCT01949545 COMPLETED
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
Amgen
NCT02274610 COMPLETED
Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer
Samyang Biopharmaceuticals Corporation
NCT01494012 TERMINATED
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Stanford University
NCT01635712 COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Esanex Inc.
NCT01571024 COMPLETED
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT00937417 WITHDRAWN
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
NCT01416038 COMPLETED
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT00769093 TERMINATED
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
OHSU Knight Cancer Institute
NCT01049880 COMPLETED
A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer
Joseph J. Cullen
NCT01471210 COMPLETED
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
NCT01420146 COMPLETED
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Jules Bordet Institute
NCT03117101 COMPLETED
Study of the AL3810 in the Treatment of Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
NCT01520220 COMPLETED
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
Eli Lilly and Company
NCT01359696 COMPLETED
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Genentech, Inc.
NCT01940133 COMPLETED
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
PIQUR Therapeutics AG
NCT02240212 COMPLETED
Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
Novartis Pharmaceuticals
NCT01957995 COMPLETED
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors
University of Southern California
NCT02040558 TERMINATED
Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors
Mallinckrodt
NCT00731276 COMPLETED
Irinotecan in Treating Asian Patients With Solid Tumors
National Cancer Centre, Singapore
NCT01297452 COMPLETED
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT01248949 COMPLETED
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT02812056 WITHDRAWN
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
M.D. Anderson Cancer Center
NCT00878904 COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
University of California, San Francisco
NCT01537744 COMPLETED
A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00662636 COMPLETED
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
NCT01155791 TERMINATED
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
Sandy Srinivas
NCT01943188 TERMINATED
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
Stanford University
NCT02031731 COMPLETED
The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT01248273 COMPLETED
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Memorial Sloan Kettering Cancer Center
NCT01049841 COMPLETED
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT01449370 COMPLETED
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
Millennium Pharmaceuticals, Inc.
NCT01884584 COMPLETED
Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer
Emory University
NCT01390818 COMPLETED
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
EMD Serono
NCT01005797 COMPLETED
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
NCT02216669 WITHDRAWN
Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer
Maastricht Radiation Oncology
NCT02836821 COMPLETED
Effect of Rifampicin on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
NCT02836171 COMPLETED
Effect of Itraconazole on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
NCT03062982 COMPLETED
Food-Effect and Metabolism Study in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT01853046 COMPLETED
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Bayer
NCT02331381 TERMINATED
Imaging and Plan Workflow in a Novel Low-Field Magnetic Resonance Imaging (MRI) Radiotherapy Device
Washington University School of Medicine
NCT01287546 COMPLETED
A Study of LY2875358 in Participants With Advanced Cancer
Eli Lilly and Company
NCT01299701 TERMINATED
A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors
Novartis Pharmaceuticals
NCT02262455 COMPLETED
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
NCT02718378 COMPLETED
Evaluation of Safety and Efficacy of Estetrol in Healthy Men
Pantarhei Oncology B.V.
NCT02257476 COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
Emory University
NCT02048709 COMPLETED
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
Genentech, Inc.
NCT02536469 COMPLETED
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
NCT01088464 COMPLETED
Study of IMC-11F8 in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT02640365 COMPLETED
A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT01604759 COMPLETED
Polarized Reflectance Spectroscopy for Oral Lesions
British Columbia Cancer Agency
NCT02078089 TERMINATED
Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
Costantine Albany
NCT01991938 TERMINATED
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Verastem, Inc.
NCT01482377 COMPLETED
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
Hoffmann-La Roche
NCT01406119 COMPLETED
An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)
NCT01980667 COMPLETED
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
PharmaMar
NCT00787033 COMPLETED
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
Verastem, Inc.
NCT01837667 COMPLETED
Phase I Study of LB-100 With Docetaxel in Solid Tumors
Lixte Biotechnology Holdings, Inc.
NCT01308944 COMPLETED
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Washington University School of Medicine
NCT00949949 COMPLETED
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Mayo Clinic
NCT01188252 COMPLETED
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Bayer
NCT00555724 COMPLETED
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Biogen
NCT00996892 TERMINATED
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT00741403 COMPLETED
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
Cornerstone Pharmaceuticals
NCT00618735 COMPLETED
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
Biogen
NCT01915576 COMPLETED
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Bayer
NCT01204450 TERMINATED
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
UNC Lineberger Comprehensive Cancer Center
NCT01976143 COMPLETED
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
Nektar Therapeutics
NCT01832298 COMPLETED
Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
NCT01967043 COMPLETED
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Kinex Pharmaceuticals Inc.
NCT00892567 COMPLETED
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
Craig L Slingluff, Jr
NCT02264886 COMPLETED
Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies
Washington University School of Medicine
NCT02112162 TERMINATED
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery
Washington University School of Medicine
NCT00637390 TERMINATED
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
University of Michigan Rogel Cancer Center
NCT02442063 COMPLETED
Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions
Bayer
NCT02353026 COMPLETED
Phase I Study of Intravenous Artesunate for Solid Tumors
Georgetown University
NCT02081495 COMPLETED
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
NCT01773434 COMPLETED
A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)
Eisai Co., Ltd.
NCT01462175 COMPLETED
A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia
Hoffmann-La Roche
NCT01358903 COMPLETED
A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
Hoffmann-La Roche
NCT01356173 COMPLETED
Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
Genentech, Inc.
NCT00985374 TERMINATED
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors
Hoffmann-La Roche
NCT00773526 COMPLETED
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
Hoffmann-La Roche
NCT01363024 COMPLETED
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
Genentech, Inc.
NCT01974258 WITHDRAWN
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
NCT00623870 COMPLETED
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
Hoffmann-La Roche
NCT00721266 COMPLETED
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.
Hoffmann-La Roche
NCT02536391 COMPLETED
Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
Genentech, Inc.
NCT00811993 TERMINATED
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
NCT01283178 TERMINATED
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
Virginia Commonwealth University
NCT01605916 COMPLETED
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
AstraZeneca
NCT02134340 COMPLETED
A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours
Centre for Probe Development and Commercialization
NCT01565746 COMPLETED
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Bayer
NCT01497470 COMPLETED
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
Achieve Life Sciences
NCT02380313 WITHDRAWN
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
NCT01522820 COMPLETED
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
NCT00884546 COMPLETED
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
Bristol-Myers Squibb
NCT01457417 COMPLETED
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
Leap Therapeutics, Inc.
NCT02033551 COMPLETED
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
AbbVie
NCT02260544 COMPLETED
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
Dr. Reddy's Laboratories Limited
NCT01413022 COMPLETED
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
NCT01986218 TERMINATED
Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
Bristol-Myers Squibb
NCT01447225 COMPLETED
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Merrimack Pharmaceuticals
NCT02150135 COMPLETED
Effect of Oncothermia on Improvement of Quality of Life in Unresectable Pancreatic Cancer Patients
Seoul National University Hospital
NCT01352884 COMPLETED
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer
MedImmune LLC
NCT00734305 COMPLETED
Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Merrimack Pharmaceuticals
NCT02126527 WITHDRAWN
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer
Mayo Clinic
NCT02876627 COMPLETED
Effect Aerobic Training on Women With Breast Cancer After Chemotherapy
University of Isfahan
NCT01851096 COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Esanex Inc.
NCT02867397 COMPLETED
Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
Disphar International B.V.
NCT00736619 COMPLETED
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT02276768 COMPLETED
Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method
gicare Pharma Inc.
NCT01528137 TERMINATED
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Stanford University
NCT02845999 COMPLETED
Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab
Centre Hospitalier Universitaire de Besancon
NCT02317419 TERMINATED
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
Hoffmann-La Roche
NCT02063230 COMPLETED
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
AstraZeneca
NCT01007695 TERMINATED
Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot
University of Utah
NCT01986166 COMPLETED
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
Genentech, Inc.
NCT01325558 COMPLETED
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
NCT02018874 COMPLETED
A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine
Gustave Roussy, Cancer Campus, Grand Paris
NCT01532011 COMPLETED
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
M.D. Anderson Cancer Center
NCT01213160 COMPLETED
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
AstraZeneca
NCT01284192 COMPLETED
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Astellas Pharma Inc
NCT01578564 COMPLETED
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
Soricimed Biopharma Inc
NCT01431547 COMPLETED
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Merck Sharp & Dohme LLC
NCT02122809 COMPLETED
Phase I Study of Chiauranib in Patients With Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
NCT01155258 COMPLETED
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
NCT01912222 COMPLETED
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
Millennium Pharmaceuticals, Inc.
NCT02054754 COMPLETED
Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects
e-Therapeutics PLC
NCT01546519 COMPLETED
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
Genentech, Inc.
NCT01202032 COMPLETED
Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
Centre Leon Berard
NCT01418677 COMPLETED
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
Eisai Inc.
NCT01778920 COMPLETED
Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)
University of Pennsylvania
NCT01242605 COMPLETED
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
University College, London
NCT01327313 COMPLETED
A Study of EMD525797 in Solid Tumor Patients in Japan
Merck KGaA, Darmstadt, Germany
NCT01212380 COMPLETED
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Ohio State University Comprehensive Cancer Center
NCT00876044 COMPLETED
A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
Sanofi
NCT01110603 TERMINATED
A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
Tesaro, Inc.
NCT02235740 TERMINATED
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
Novartis
NCT01353781 COMPLETED
Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies
AstraZeneca
NCT01391533 COMPLETED
Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors
Sanofi
NCT02531919 COMPLETED
Extended Use of Sodium Bicarbonate in Patients With Cancer
University of Arizona
NCT01711034 COMPLETED
A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT02221505 TERMINATED
Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia
Novartis Pharmaceuticals
NCT01357330 COMPLETED
Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
Sanofi
NCT01182168 COMPLETED
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
Memorial Sloan Kettering Cancer Center
NCT01562275 COMPLETED
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT02220049 COMPLETED
Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors
Gustave Roussy, Cancer Campus, Grand Paris
NCT01634893 COMPLETED
Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
The University of Texas Health Science Center at San Antonio
NCT01930292 TERMINATED
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
Debiopharm International SA
NCT01446458 COMPLETED
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
Emory University
NCT01683149 COMPLETED
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT00798200 COMPLETED
Community Based Exercise Program for Well Cancer Survivors
Hamilton Health Sciences Corporation
NCT00993239 COMPLETED
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
TetraLogic Pharmaceuticals
NCT02432612 WITHDRAWN
A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer
GW Pharmaceuticals Ltd
NCT00985777 COMPLETED
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
H. Lee Moffitt Cancer Center and Research Institute
NCT01791374 COMPLETED
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
Amgen
NCT01665183 COMPLETED
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Polaris Group
NCT01664000 COMPLETED
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
Cellceutix Corporation
NCT01450384 COMPLETED
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
Virginia Commonwealth University
NCT01693445 COMPLETED
S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer
Hallym University Medical Center
NCT00714181 COMPLETED
Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
Abramson Cancer Center at Penn Medicine
NCT01497626 TERMINATED
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Georgetown University
NCT02470559 WITHDRAWN
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Barbara Ann Karmanos Cancer Institute
NCT02537561 WITHDRAWN
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Washington University School of Medicine
NCT02154646 COMPLETED
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
Eli Lilly and Company
NCT02444884 COMPLETED
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors
Children's Oncology Group
NCT01300533 COMPLETED
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
BIND Therapeutics
NCT01883635 COMPLETED
Exercise Intervention for Cancer Survivors and Caregivers
University of Rochester
NCT00920868 COMPLETED
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
Herbert Hurwitz, MD
NCT02131506 TERMINATED
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT00869895 COMPLETED
A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
Eisai Inc.
NCT02292732 WITHDRAWN
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
GlaxoSmithKline
NCT02096341 TERMINATED
A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001
EpicentRx, Inc.
NCT01118819 TERMINATED
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
BioMed Valley Discoveries, Inc
NCT01405391 COMPLETED
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
PharmaMar
NCT01940172 COMPLETED
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
TetraLogic Pharmaceuticals
NCT01748721 COMPLETED
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Morphotek
NCT02563951 COMPLETED
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Maxinase Life Sciences Ltd.
NCT01012427 COMPLETED
Percutaneous Renal Tumor Cryoablation Followed by Biopsy
Memorial Sloan Kettering Cancer Center
NCT02004548 COMPLETED
Phase I Clinical Study of Metatinib Tromethamine Tablet
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT00671411 COMPLETED
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
Memorial Sloan Kettering Cancer Center
NCT01095848 COMPLETED
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT01056029 COMPLETED
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
GenSpera, Inc.
NCT01335269 COMPLETED
A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer
Boehringer Ingelheim
NCT01815294 COMPLETED
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
NCT00669136 TERMINATED
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma
Lisa H. Butterfield, Ph.D.
NCT01004822 TERMINATED
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
Pfizer
NCT01122615 COMPLETED
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
M.D. Anderson Cancer Center
NCT00980239 COMPLETED
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
M.D. Anderson Cancer Center
NCT00877474 COMPLETED
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
PharmaMar
NCT00678769 COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
National Cancer Institute (NCI)
NCT01245543 WITHDRAWN
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Daiichi Sankyo
NCT01293630 COMPLETED
A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors
Sanofi
NCT01833923 COMPLETED
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT00932126 TERMINATED
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
Pfizer
NCT01685489 WITHDRAWN
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Bastyr University
NCT01265927 COMPLETED
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Indiana University
NCT01585870 COMPLETED
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
Bayer
NCT01128998 COMPLETED
Sorafenib Plus S-1 in Advanced Solid Tumors
National Health Research Institutes, Taiwan
NCT00756340 COMPLETED
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
St. Jude Children's Research Hospital
NCT01253681 COMPLETED
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
Amgen
NCT00884676 COMPLETED
Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
Jaime Merchan
NCT01054313 COMPLETED
Docetaxel and Sirolimus in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT01548482 COMPLETED
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01963715 TERMINATED
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
ImmunoGen, Inc.
NCT00770536 COMPLETED
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
NCT01317927 COMPLETED
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
Spectrum Pharmaceuticals, Inc
NCT02525536 COMPLETED
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors
Takeda
NCT01560325 COMPLETED
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
Chong Kun Dang Pharmaceutical
NCT01071018 COMPLETED
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Merck Sharp & Dohme LLC
NCT00817518 COMPLETED
A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors
Hoffmann-La Roche
NCT00792558 WITHDRAWN
Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers
Bristol-Myers Squibb
NCT01295632 COMPLETED
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Merck Sharp & Dohme LLC
NCT01584284 COMPLETED
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
Genelux Corporation
NCT00796484 TERMINATED
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
Exelixis
NCT01553656 COMPLETED
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Exelixis
NCT00704392 WITHDRAWN
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
Exelixis
NCT00998296 COMPLETED
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
Boehringer Ingelheim
NCT01901172 COMPLETED
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Hoffmann-La Roche
NCT00997022 COMPLETED
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
Columbia University
NCT01652794 COMPLETED
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
Case Comprehensive Cancer Center
NCT01334073 COMPLETED
Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors
University Hospital, Bordeaux
NCT01750580 COMPLETED
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
Bristol-Myers Squibb
NCT02496949 COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors
Chinese Academy of Medical Sciences
NCT00798252 COMPLETED
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Bristol-Myers Squibb
NCT02201823 COMPLETED
Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients
Ability Pharmaceuticals SL
NCT01466569 COMPLETED
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
AbGenomics B.V Taiwan Branch
NCT01544322 COMPLETED
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
MEI Pharma, Inc.
NCT01542047 TERMINATED
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
New Mexico Cancer Research Alliance
NCT00947739 COMPLETED
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
New Mexico Cancer Research Alliance
NCT01490047 WITHDRAWN
Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Ludwig Institute for Cancer Research
NCT00800150 TERMINATED
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center
NCT01602289 COMPLETED
A Study of LY2875358 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
NCT00709020 COMPLETED
White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors
City of Hope Medical Center
NCT01846429 TERMINATED
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
H. Lee Moffitt Cancer Center and Research Institute
NCT00770263 COMPLETED
Erlotinib and Temsirolimus for Solid Tumors
Washington University School of Medicine
NCT01919710 COMPLETED
Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Tianjin SinoBiotech Ltd.
NCT00951158 TERMINATED
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
NCT01434459 TERMINATED
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Emory University
NCT01463982 COMPLETED
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
Hanmi Pharmaceutical Company Limited
NCT02097875 COMPLETED
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Blaze Bioscience Australia Pty Ltd
NCT01584544 COMPLETED
Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer
Chinese Academy of Medical Sciences
NCT00682279 WITHDRAWN
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
GlaxoSmithKline
NCT01392521 COMPLETED
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
Bayer
NCT00666081 WITHDRAWN
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
GlaxoSmithKline
NCT01065025 COMPLETED
Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies
4SC AG
NCT01071304 COMPLETED
Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)
Merck Sharp & Dohme LLC
NCT00691548 COMPLETED
Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients
Maastricht Radiation Oncology
NCT01555242 COMPLETED
A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas
Omnitura Therapeutics, Inc.
NCT01603979 COMPLETED
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
AVEO Pharmaceuticals, Inc.
NCT01727869 COMPLETED
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Regeneron Pharmaceuticals
NCT01268943 COMPLETED
Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
Chinese Academy of Medical Sciences
NCT01970553 COMPLETED
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
PharmaMar
NCT01081808 TERMINATED
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
Roger Williams Medical Center
NCT01688960 COMPLETED
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Regeneron Pharmaceuticals
NCT00888043 COMPLETED
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors
Herbert Hurwitz, MD
NCT01234012 COMPLETED
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
ImmunoFrontier, Inc.
NCT01629758 COMPLETED
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Bristol-Myers Squibb
NCT01334177 COMPLETED
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
University of Washington
NCT01324115 TERMINATED
NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors
Cancer Research UK
NCT01137552 TERMINATED
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
Amgen
NCT01495663 COMPLETED
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
Cellectar Biosciences, Inc.
NCT00880568 COMPLETED
Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)
Merck Sharp & Dohme LLC
NCT02312804 WITHDRAWN
Ph Ib/BGJ398/Cervix and Other Solid Tumors
The University of Texas Health Science Center at San Antonio
NCT00704054 COMPLETED
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
Merck Sharp & Dohme LLC
NCT00781846 COMPLETED
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
Merck Sharp & Dohme LLC
NCT01688791 TERMINATED
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Endocyte
NCT02049281 TERMINATED
A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
Endocyte
NCT00730379 COMPLETED
A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
Merck Sharp & Dohme LLC
NCT01417403 TERMINATED
Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases
Virginia Commonwealth University
NCT01844869 COMPLETED
An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
Teva Branded Pharmaceutical Products R&D, Inc.
NCT00959582 COMPLETED
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
Merck Sharp & Dohme LLC
NCT01028755 COMPLETED
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
Bayer
NCT01280487 COMPLETED
A Safety Study of Oral ZSTK474 in Patients With Cancer
Zenyaku Kogyo Co., Ltd.
NCT00635596 COMPLETED
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Amgen Research (Munich) GmbH
NCT00911898 COMPLETED
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
Merrimack Pharmaceuticals
NCT02048943 WITHDRAWN
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Roswell Park Cancer Institute
NCT01097460 COMPLETED
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
Merrimack Pharmaceuticals
NCT01131234 COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01340040 COMPLETED
Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects
AstraZeneca
NCT02308631 COMPLETED
Endoscopically Assisted Colostomy With Colopexy for Critically Ill Patients Without General Anesthesia or Laparotomy
University of Sao Paulo
NCT01193595 COMPLETED
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Sanofi
NCT00984425 COMPLETED
The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Istituto Clinico Humanitas
NCT01329549 TERMINATED
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
Boehringer Ingelheim
NCT00667147 COMPLETED
Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib
University of Southern California
NCT01165385 COMPLETED
Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors
UNICANCER
NCT01186601 COMPLETED
Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
Life Molecular Imaging SA
NCT01238939 COMPLETED
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
Nippon Kayaku Co., Ltd.
NCT01238952 COMPLETED
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd.
NCT01103310 COMPLETED
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
Life Molecular Imaging SA
NCT01158274 COMPLETED
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT02033148 WITHDRAWN
Icotinib Hydrochloride in Treating Patients With Advanced Cancers
Roswell Park Cancer Institute
NCT01088763 TERMINATED
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
NCT00742911 COMPLETED
Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver
University of Utah
NCT00914914 COMPLETED
Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
Dr. Tapas K. Das Gupta
NCT01164163 COMPLETED
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
NCT01245205 COMPLETED
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
National Cancer Institute (NCI)
NCT02136342 TERMINATED
Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer
Chinese Academy of Medical Sciences
NCT01447355 COMPLETED
Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation
National Cancer Institute (NCI)
NCT01065623 TERMINATED
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors
Bayer
NCT01339104 COMPLETED
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
Bayer
NCT01292668 COMPLETED
Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer
Roswell Park Cancer Institute
NCT01762410 SUSPENDED
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
NCT01779336 SUSPENDED
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
NCT01835184 TERMINATED
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT01183364 COMPLETED
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
NCT00968916 COMPLETED
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors
Sanofi
NCT01279603 COMPLETED
Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas
Genus Oncology, LLC
NCT01057355 WITHDRAWN
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Mayo Clinic
NCT01046864 COMPLETED
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
Bristol-Myers Squibb
NCT01905111 COMPLETED
A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer
Boehringer Ingelheim
NCT00724100 TERMINATED
A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors
Albany Molecular Research, Inc.
NCT01392976 COMPLETED
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors
Clovis Oncology, Inc.
NCT01313065 COMPLETED
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
Vaccinex Inc.
NCT00927823 COMPLETED
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients
Pfizer
NCT01215864 COMPLETED
Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors
Traslational Cancer Drugs Pharma, SL
NCT01191216 COMPLETED
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00621725 COMPLETED
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
AstraZeneca
NCT01693991 COMPLETED
Randomized Controlled Trial of the Meaning-Making Intervention (MMi)
Jewish General Hospital
NCT01003158 COMPLETED
Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.
AstraZeneca
NCT00759928 COMPLETED
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
SCRI Development Innovations, LLC
NCT01222546 COMPLETED
Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors
Chugai Pharma Europe Ltd.
NCT01664273 TERMINATED
Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer
Copenhagen University Hospital at Herlev
NCT00609141 COMPLETED
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
National Cancer Institute (NCI)
NCT01005355 COMPLETED
Study of IMC-1121B in Patients With Advanced Solid Tumors
Eli Lilly and Company
NCT01436565 COMPLETED
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
Sanofi
NCT01401504 COMPLETED
Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors
Astellas Pharma Inc
NCT00906698 COMPLETED
Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2
Boehringer Ingelheim
NCT01169675 COMPLETED
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
Boehringer Ingelheim
NCT00729833 TERMINATED
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Pfizer
NCT00934882 COMPLETED
Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
Bayer
NCT01198184 COMPLETED
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01217450 COMPLETED
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT01957280 COMPLETED
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Daiichi Sankyo
NCT01240538 COMPLETED
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT01018836 TERMINATED
Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Rutgers, The State University of New Jersey
NCT00933985 TERMINATED
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
NCT01231919 COMPLETED
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
NCT00880282 COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
National Cancer Institute (NCI)
NCT01235897 COMPLETED
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
NCT01141244 COMPLETED
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT01725555 COMPLETED
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
Axelar AB
NCT01491594 TERMINATED
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
Duke University
NCT01096355 COMPLETED
Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies
National Cancer Institute (NCI)
NCT01243359 COMPLETED
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
National Cancer Institute (NCI)
NCT01233505 TERMINATED
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00884845 COMPLETED
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
PharmaMar
NCT00942799 COMPLETED
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
Genzyme, a Sanofi Company
NCT00890747 COMPLETED
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
NCT01641575 TERMINATED
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
Clovis Oncology, Inc.
NCT00601614 WITHDRAWN
Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
NCT00666991 COMPLETED
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
CritiTech, Inc.
NCT01455571 COMPLETED
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT01364844 COMPLETED
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo
NCT00622414 COMPLETED
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT00701298 TERMINATED
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT01145456 COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01012102 COMPLETED
EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors
Merck KGaA, Darmstadt, Germany
NCT01050985 COMPLETED
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Georgetown University
NCT01168752 COMPLETED
Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma
Debiopharm International SA
NCT01273090 COMPLETED
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Children's Oncology Group
NCT00978523 COMPLETED
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Arno Therapeutics
NCT01170897 COMPLETED
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Halozyme Therapeutics
NCT01306630 COMPLETED
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
AVEO Pharmaceuticals, Inc.
NCT01354041 COMPLETED
Fear of Recurrence Pilot Intervention for Women With Breast Cancer
University of California, San Francisco
NCT00725634 COMPLETED
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
AVEO Pharmaceuticals, Inc.
NCT00827177 COMPLETED
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT02043756 COMPLETED
Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT01423903 COMPLETED
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT00769288 COMPLETED
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT01728480 WITHDRAWN
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy
Roswell Park Cancer Institute
NCT00842244 COMPLETED
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
NCT01496534 TERMINATED
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
Matthew Galsky
NCT00949026 WITHDRAWN
Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis
Emory University
NCT00756223 COMPLETED
Phase I Study of BI 831266 in Patients With Advanced Solid Tumours
Boehringer Ingelheim
NCT01567384 WITHDRAWN
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
Emory University
NCT01409018 COMPLETED
Pharmacokinetics of Itraconazole in Pediatric Cancer Patients
Seoul National University Hospital
NCT01096030 COMPLETED
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
Bayer
NCT00927966 COMPLETED
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
Suzanne George, MD
NCT01714765 COMPLETED
Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
Queen Mary University of London
NCT00708006 COMPLETED
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Human Genome Sciences Inc.
NCT01110486 COMPLETED
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)
NCT00689065 TERMINATED
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
NCT01110083 TERMINATED
First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors
EMD Serono
NCT01095302 COMPLETED
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
Sanofi
NCT00929903 COMPLETED
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
National Cancer Institute (NCI)
NCT01161836 COMPLETED
An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)
Sanofi
NCT01000376 COMPLETED
Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors
Eisai Limited
NCT01159301 TERMINATED
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01291407 COMPLETED
A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer
Chinese Academy of Medical Sciences
NCT00721669 COMPLETED
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
ImmunoGen, Inc.
NCT01332929 COMPLETED
Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis
Centre Francois Baclesse
NCT01618253 WITHDRAWN
Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
Medical College of Wisconsin
NCT01166490 COMPLETED
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
Seagen Inc.
NCT01212341 COMPLETED
Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor
Seoul National University Hospital
NCT00569036 COMPLETED
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT00935961 COMPLETED
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT01297530 TERMINATED
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies
Bayer
NCT00749502 COMPLETED
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
Tesaro, Inc.
NCT00869388 COMPLETED
A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors
Washington University School of Medicine
NCT01079286 COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT01451008 COMPLETED
Compression Anastomosis Using the Compression Anastomotic Ring-locking Procedure (CARP)
Region Skane
NCT01320020 TERMINATED
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Neovii Biotech
NCT00906360 TERMINATED
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
NCT01282333 TERMINATED
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00994500 COMPLETED
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
NCT01476085 TERMINATED
Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)
GlaxoSmithKline
NCT01401868 COMPLETED
Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
MEI Pharma, Inc.
NCT00909402 COMPLETED
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Bristol-Myers Squibb
NCT00732082 TERMINATED
Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
Washington University School of Medicine
NCT01313598 COMPLETED
GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors
Galapagos NV
NCT01228760 COMPLETED
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
Astellas Pharma Inc
NCT01413906 COMPLETED
Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors
Bristol-Myers Squibb
NCT00659568 COMPLETED
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
London Health Sciences Centre
NCT01213381 COMPLETED
Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors
Sanofi
NCT00925743 COMPLETED
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer
Sanofi
NCT01335256 COMPLETED
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
Bayer
NCT01225536 COMPLETED
Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT01118611 COMPLETED
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors
Cancer Research UK
NCT00996515 COMPLETED
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
New Mexico Cancer Research Alliance
NCT00698243 COMPLETED
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
Astellas Pharma Inc
NCT01017939 COMPLETED
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
NCT00910754 COMPLETED
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
NCT00756847 COMPLETED
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
Sanofi
NCT00938574 COMPLETED
Study With Atu027 in Patients With Advanced Solid Cancer
Silence Therapeutics GmbH
NCT00842452 COMPLETED
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
Steven Waggoner, MD
NCT01611623 COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Esanex Inc.
NCT00834704 COMPLETED
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Halozyme Therapeutics
NCT00996957 COMPLETED
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
NCT00719524 COMPLETED
AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
Sanofi
NCT00651365 TERMINATED
A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT00937482 TERMINATED
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00816686 TERMINATED
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
Astellas Pharma Inc
NCT00816764 COMPLETED
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
Astellas Pharma Inc
NCT01016054 TERMINATED
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Astellas Pharma Inc
NCT01058616 COMPLETED
Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour
Lytix Biopharma AS
NCT01602627 TERMINATED
Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies
Dale Shepard, MD, PhD
NCT00555620 COMPLETED
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
NCT01472003 COMPLETED
An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types
AbbVie (prior sponsor, Abbott)
NCT00891072 COMPLETED
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01055795 COMPLETED
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
Herbert Hurwitz
NCT00849550 COMPLETED
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
Herbert Hurwitz
NCT01416623 TERMINATED
A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
NCT01336582 COMPLETED
Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer
Samyang Biopharmaceuticals Corporation
NCT00772876 COMPLETED
A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies
Piramal Enterprises Limited
NCT01568632 WITHDRAWN
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
National Cancer Institute (NCI)
NCT00840190 COMPLETED
A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies
Piramal Enterprises Limited
NCT00921661 COMPLETED
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
Sanofi
NCT01604863 SUSPENDED
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Human Genome Sciences Inc., a GSK Company
NCT00752011 COMPLETED
Phase I Study of TAS-106 in Combo With Carboplatin
M.D. Anderson Cancer Center
NCT01158079 COMPLETED
Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment
Alnylam Pharmaceuticals
NCT01161186 COMPLETED
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
NCT00738335 WITHDRAWN
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
University of California, San Francisco
NCT01286974 TERMINATED
A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
Abbott
NCT00609921 COMPLETED
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
Kyowa Kirin Co., Ltd.
NCT01092052 TERMINATED
Study of NMS-1116354 in Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
NCT01014429 COMPLETED
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
NCT01041235 COMPLETED
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Azaya Therapeutics, Inc.
NCT01521299 WITHDRAWN
A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors
Dartmouth-Hitchcock Medical Center
NCT01506934 TERMINATED
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Abbott
NCT00660153 COMPLETED
Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
AVEO Pharmaceuticals, Inc.
NCT00920595 COMPLETED
Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
Cephalon
NCT01294735 COMPLETED
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
Merck Sharp & Dohme LLC
NCT01098838 COMPLETED
Safety and Efficacy of LCL161 in Patients With Solid Tumors
Novartis Pharmaceuticals
NCT01042782 COMPLETED
Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction
Krankenhaus Nordwest
NCT01170975 COMPLETED
Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules
Genta Incorporated
NCT00612703 COMPLETED
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT00874042 COMPLETED
Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT01139346 COMPLETED
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
Alaunos Therapeutics
NCT00793897 COMPLETED
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT01637194 COMPLETED
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Fox Chase Cancer Center
NCT00999882 COMPLETED
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
AstraZeneca
NCT01226901 TERMINATED
A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)
Merck Sharp & Dohme LLC
NCT00761696 COMPLETED
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
Infinity Pharmaceuticals, Inc.
NCT01201018 COMPLETED
Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment
Oshadi Drug Administration
NCT01204996 COMPLETED
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
Centocor, Inc.
NCT00888108 COMPLETED
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
Abbott
NCT00595686 COMPLETED
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Esanex Inc.
NCT00647764 COMPLETED
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Esanex Inc.
NCT01599143 COMPLETED
Identifying Therapeutic Factors in an 8-Week (30 Hour) Mindfulness-Based Stress Reduction (MBSR) Program
North York General Hospital
NCT01323933 COMPLETED
First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors
Gilead Sciences
NCT01147029 TERMINATED
GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy
Cancer Research UK
NCT01106248 COMPLETED
QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
Eisai Limited
NCT00626158 COMPLETED
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
University of California, San Francisco
NCT00949559 COMPLETED
Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors
Esperance Pharmaceuticals Inc
NCT01072890 COMPLETED
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
University of California, Davis
NCT00804310 TERMINATED
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
University of California, Davis
NCT00706095 COMPLETED
Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System
Eisai Inc.
NCT01381341 COMPLETED
To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.
Abbott
NCT00692640 COMPLETED
Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
Sanofi
NCT00860860 COMPLETED
Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer
Radboud University Medical Center
NCT00734890 COMPLETED
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
NCT00892801 TERMINATED
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
NCT00908908 COMPLETED
A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
Eisai Inc.
NCT01548170 COMPLETED
To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
NCT00777699 COMPLETED
Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors
Sanofi
NCT00661414 COMPLETED
Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors
Lpath, Inc.
NCT01028859 COMPLETED
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
Chong Kun Dang Pharmaceutical
NCT01063946 COMPLETED
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
Sanofi
NCT00555672 COMPLETED
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
Pfizer
NCT00935844 COMPLETED
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
Millennium Pharmaceuticals, Inc.
NCT00831896 COMPLETED
Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies
Millennium Pharmaceuticals, Inc.
NCT00898716 COMPLETED
Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
Bristol-Myers Squibb
NCT00697879 COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
Chroma Therapeutics
NCT00796055 TERMINATED
Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors
MedImmune LLC
NCT01401933 COMPLETED
Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Abbott
NCT01141257 COMPLETED
Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug
Pieris Pharmaceuticals GmbH
NCT00920205 COMPLETED
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Myrexis Inc.
NCT00906750 COMPLETED
A Study of a Live Intranasal Influenza Vaccine in Children With Cancer
St. Jude Children's Research Hospital
NCT01210846 COMPLETED
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
AVEO Pharmaceuticals, Inc.
NCT00862901 COMPLETED
Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma
Tufts Medical Center
NCT01062620 COMPLETED
A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
Axelar AB
NCT01299415 TERMINATED
Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor
Novartis Pharmaceuticals
NCT01290380 TERMINATED
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
Novartis Pharmaceuticals
NCT00882180 COMPLETED
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
Alnylam Pharmaceuticals
NCT01114191 COMPLETED
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
Abbott
NCT00886457 TERMINATED
5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
Nevada Cancer Institute
NCT01386866 COMPLETED
Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors
Amgen
NCT01151384 COMPLETED
Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors
INSYS Therapeutics Inc
NCT00748891 COMPLETED
DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)
AstraZeneca
NCT00783328 COMPLETED
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
Pfizer
NCT00973076 COMPLETED
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
AstraZeneca
NCT01021150 COMPLETED
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors
Sanofi
NCT00788099 COMPLETED
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
PharmaMar
NCT00631410 COMPLETED
Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
Pfizer
NCT00750425 COMPLETED
Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
NCT00937664 TERMINATED
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
AstraZeneca
NCT00754104 WITHDRAWN
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
Abbott
NCT01018745 COMPLETED
Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
Bristol-Myers Squibb
NCT01021358 COMPLETED
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
NCT00733031 TERMINATED
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
AstraZeneca
NCT01247532 COMPLETED
Pilot Study of Mindfulness-Based Stress Reduction for Patients With Persistent Cancer-Related Fatigue
Indiana University
NCT00989443 COMPLETED
Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions
Mithra Pharmaceuticals
NCT00778128 COMPLETED
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
Clavis Pharma
NCT00730470 COMPLETED
Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors
U3 Pharma GmbH
NCT00925275 COMPLETED
Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors
Cellectar, Inc
NCT00773929 COMPLETED
Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer
Millennium Pharmaceuticals, Inc.
NCT01023386 COMPLETED
A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer
Astellas Pharma Inc
NCT00909558 SUSPENDED
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Envita Medical Center, Inc.
NCT01000896 WITHDRAWN
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
AstraZeneca
NCT00886353 COMPLETED
Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)
Apeiron Biologics
NCT00656461 COMPLETED
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
CASI Pharmaceuticals, Inc.
NCT00608803 COMPLETED
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
Alaunos Therapeutics
NCT00613652 COMPLETED
A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients
AstraZeneca
NCT00690053 COMPLETED
Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET)
Maastricht Radiation Oncology
NCT00664170 COMPLETED
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Mast Therapeutics, Inc.
NCT00827203 SUSPENDED
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
NCT00621556 TERMINATED
Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
Massachusetts General Hospital
NCT00753480 SUSPENDED
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Genentech, Inc.
NCT00578916 COMPLETED
Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects
Bristol-Myers Squibb
NCT00606879 TERMINATED
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX Pharmaceuticals, Inc.
NCT00607399 TERMINATED
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX Pharmaceuticals, Inc.
NCT04108208 ACTIVE NOT RECRUITING
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
NCT07405086 RECRUITING
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
NCT05203172 RECRUITING
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
NCT06457503 RECRUITING
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Coherus Oncology, Inc.
NCT07312370 NOT YET RECRUITING
Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing
LanZhou University
NCT07486713 RECRUITING
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
NCT03016741 ACTIVE NOT RECRUITING
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
NCT05376878 RECRUITING
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
City of Hope Medical Center
NCT07426484 NOT YET RECRUITING
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
NCT06764095 RECRUITING
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
NCT07042581 RECRUITING
A Study of Revaree Plus in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06786429 NOT YET RECRUITING
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Eunice Dube
NCT07303816 NOT YET RECRUITING
Statins to Prevent Cancer Associated Blood Clots
Brigham and Women's Hospital
NCT07262957 RECRUITING
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT07272512 RECRUITING
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
Shanghai Zhongshan Hospital
NCT05255003 RECRUITING
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Tzu-Fei Wang
NCT06016855 RECRUITING
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
NCT05525767 RECRUITING
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
Hebei Medical University Fourth Hospital
NCT06251076 RECRUITING
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
NCT07158164 RECRUITING
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
NCT03229200 ACTIVE NOT RECRUITING
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
NCT07217600 RECRUITING
Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy
Chongqing University Cancer Hospital
NCT07214714 NOT YET RECRUITING
Hemodynamic and Cardiac Effects of Dexmedetomidine Versus Fentanyl by Intravenous Infusion as Adjuncts to General Anesthesia in Patients Undergoing Major Abdominal Cancer Surgeries.
Assiut University
NCT06934057 RECRUITING
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris
NCT07124351 RECRUITING
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Cedars-Sinai Medical Center
NCT07162259 NOT YET RECRUITING
Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
Yan Xue
NCT04532606 RECRUITING
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Peking University First Hospital
NCT06897527 NOT YET RECRUITING
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
GlaxoSmithKline
NCT06903312 RECRUITING
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT07010393 NOT YET RECRUITING
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Fujian Medical University
NCT07001709 RECRUITING
Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)
Deventer Ziekenhuis
NCT06603870 RECRUITING
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Ottawa Hospital Research Institute
NCT06963593 NOT YET RECRUITING
Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy
Peking University
NCT03844360 RECRUITING
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Wei Zhao
NCT06897917 NOT YET RECRUITING
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Henan Cancer Hospital
NCT06887933 NOT YET RECRUITING
A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
GlaxoSmithKline
NCT06871787 NOT YET RECRUITING
Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
Istanbul University
NCT05465031 RECRUITING
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Silesian Centre for Heart Diseases
NCT05245877 RECRUITING
Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
Helsinki University Central Hospital
NCT06824792 NOT YET RECRUITING
Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System
NING LI
NCT06820255 RECRUITING
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT06627036 RECRUITING
Dermoscopy vs Standard Marking for the Completeness of Excision of Keratinocyte Skin Cancers: The ClearMark Trial
Hull University Teaching Hospitals NHS Trust
NCT06408688 RECRUITING
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
University Hospital, Basel, Switzerland
NCT06706921 RECRUITING
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06118710 RECRUITING
Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment
Erasmus Medical Center
NCT06145321 ACTIVE NOT RECRUITING
Continuous Versus Bolus Administration of G-CSF in Children With Cancer
Chang Gung Memorial Hospital
NCT05148494 RECRUITING
TES RCT Fleet Enema vs Oral Mechanical Bowel Prep
Nova Scotia Health Authority
NCT06498037 RECRUITING
Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.
Erasmus Medical Center
NCT05078671 RECRUITING
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
Radboud University Medical Center
NCT05957822 RECRUITING
Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery
Konkuk University Medical Center
NCT06381557 NOT YET RECRUITING
Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules
Qiang Fu
NCT05440240 RECRUITING
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
Regionshospitalet Silkeborg
NCT05452213 RECRUITING
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
Institut fuer Frauengesundheit
NCT05185505 RECRUITING
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
The Methodist Hospital Research Institute
NCT04281667 ACTIVE NOT RECRUITING
Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery
Helsinki University Central Hospital
NCT02775227 ACTIVE NOT RECRUITING
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
Helsinki University Central Hospital
NCT07598214 RECRUITING
Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients
Beni-Suef University
NCT07590648 NOT YET RECRUITING
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
Hospital Universitari Vall d'Hebron Research Institute
NCT05651282 COMPLETED
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
University of British Columbia
NCT02555748 COMPLETED
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
Institut Claudius Regaud
NCT03151213 COMPLETED
Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver
Sherief Abd-Elsalam
NCT03573960 COMPLETED
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Eisai Pharmaceuticals India Pvt. Ltd
NCT07022938 COMPLETED
Nutritional Supplement for Treating Chemotherapy Induced Neuropathy
Aristotle University Of Thessaloniki
NCT04952766 COMPLETED
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
Centre Hospitalier Régional d'Orléans
NCT04319198 COMPLETED
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
NCT05834569 TERMINATED
Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients
Korea University Guro Hospital
NCT04513522 COMPLETED
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Bristol-Myers Squibb
NCT01932125 COMPLETED
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Hoffmann-La Roche
NCT01720550 COMPLETED
PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care
PhytoHealth Corporation
NCT04347122 TERMINATED
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction
University of Kansas Medical Center
NCT06924229 COMPLETED
Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment
Sohag University
NCT04724460 COMPLETED
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
Takeshi Morimoto
NCT01943409 COMPLETED
Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils
Johane Allard
NCT06023368 WITHDRAWN
Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray
Marianne Hutti
NCT05688384 COMPLETED
Patient-Controlled Sedation in Port Implantation (PACSPI-2)
Region Jönköping County
NCT06576336 COMPLETED
A Randomized Clinical Trial About Use of 3D Laparoscopy Versus 2D Laparoscopy in Adrenal Surgery
University of Palermo
NCT03927391 COMPLETED
Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects
Radboud University Medical Center
NCT05054998 COMPLETED
Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT00942968 COMPLETED
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
Pfizer
NCT04574947 COMPLETED
Lidocaine And Neuromonitoring in Thyroid Surgery
Saint Petersburg State University, Russia
NCT06316908 COMPLETED
Permanent Celiac Plexus Block: Comparison of Pain Score in Unilateral and Bilateral Posterior Percutaneous Approach
Sindh Institute of Urology and Transplantation
NCT04931615 COMPLETED
ARTISS a Single-centre Randomised Control Study
Mid and South Essex NHS Foundation Trust
NCT05075538 TERMINATED
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
Jules Bordet Institute
NCT03858166 TERMINATED
Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
Shandong University
NCT04707196 COMPLETED
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
Eli Lilly and Company
NCT03895502 COMPLETED
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
Takeshi Morimoto
NCT03469271 COMPLETED
Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
Mayo Clinic
NCT01023984 WITHDRAWN
Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas
European Association for Endoscopic Surgery
NCT05061654 WITHDRAWN
CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
Hamad Medical Corporation
NCT02359175 COMPLETED
Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study
Odense University Hospital
NCT04072068 COMPLETED
Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
Gruppo Oncologico Italiano di Ricerca Clinica
NCT02174575 WITHDRAWN
Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
Tokyo Medical and Dental University
NCT00819832 TERMINATED
Anderson Circulating Tumor Cell Burden (CTCB) Study
M.D. Anderson Cancer Center
NCT03145012 COMPLETED
Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity
Nova Scotia Health Authority
NCT01975064 COMPLETED
Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia
Uppsala University
NCT02549677 COMPLETED
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
Ruijin Hospital
NCT03333655 COMPLETED
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
Hoffmann-La Roche
NCT01887041 TERMINATED
Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer
Universitätsklinikum Hamburg-Eppendorf
NCT02688881 COMPLETED
Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
Samsung Medical Center
NCT02691793 COMPLETED
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
Samsung Medical Center
NCT04074460 COMPLETED
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study
Peter MacCallum Cancer Centre, Australia
NCT04479579 COMPLETED
Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
McMaster University
NCT02334722 COMPLETED
1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
University of Florida
NCT01176916 COMPLETED
Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Pfizer
NCT02479347 COMPLETED
Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT04779567 COMPLETED
Usefulness of Acetaminophen Associated With Strong Opioids for Acute Pain in Cancer Patients
Pontificia Universidad Catolica de Chile
NCT01413607 TERMINATED
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
Ricardo Rendon
NCT02444572 COMPLETED
Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®
Les Laboratoires des Médicaments Stériles
NCT03980704 COMPLETED
Preoperative High Protein vs Immunodiet in Surgical Cancer Patients
Stanley Dudrick's Memorial Hospital
NCT03040024 TERMINATED
Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients
Emory University
NCT00847912 COMPLETED
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
VA Office of Research and Development
NCT01789281 COMPLETED
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis Pharmaceuticals
NCT03469310 COMPLETED
Minimizing Narcotic Analgesics After Endocrine Surgery
Minerva A Romero Arenas
NCT03063255 COMPLETED
Comparison of Obturator Nerve Blockade and Neuromuscular Blockade
University of Florida
NCT02015923 TERMINATED
Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases
Hospital Universitari de Bellvitge
NCT03639415 WITHDRAWN
Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain
Fujian Cancer Hospital
NCT04607525 COMPLETED
Dexmedetomidine Infusion Effect on Hemodynamic Variables During Craniotomy
Ain Shams University
NCT03723447 COMPLETED
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
Cedars-Sinai Medical Center
NCT01739764 COMPLETED
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Hoffmann-La Roche
NCT04699760 COMPLETED
The Effects of n-3 LCPUFAs in Patients With Colorectal Cancer
University of Copenhagen
NCT03210376 COMPLETED
Neuromuscular Blockade on Shoulder Pain of Elderly
M.D. Anderson Cancer Center
NCT03176849 COMPLETED
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Phoenix Children's Hospital
NCT01588184 COMPLETED
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Hoffmann-La Roche
NCT03138967 COMPLETED
Investigation of Sugammadex in Outpatient Urological Procedures
M.D. Anderson Cancer Center
NCT03397914 COMPLETED
Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections
National Cancer Institute, Egypt
NCT03199911 COMPLETED
Topical Antibiotic Prophylaxis for Eyelids
University of California, San Francisco
NCT02744664 COMPLETED
Cryotherapy Combine Icotinib for Advanced NSCLC Treatment
Fuda Cancer Hospital, Guangzhou
NCT02015650 TERMINATED
Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Medical University Innsbruck
NCT02627560 COMPLETED
The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy
St. Olavs Hospital
NCT02815319 COMPLETED
Schedules of Dexamethasone in Patients Incorrectly Taking Dexamethasone Premedication (REaCT-dexamethasone)
Ottawa Hospital Research Institute
NCT03176199 COMPLETED
A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
NCT03176121 COMPLETED
Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
NCT01972490 COMPLETED
Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases
Xu jianmin
NCT04187755 COMPLETED
Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever
Indonesia University
NCT03583944 COMPLETED
A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
Eisai Inc.
NCT02721563 COMPLETED
A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC
Shandong Cancer Hospital and Institute
NCT02721576 TERMINATED
A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC
Shandong Cancer Hospital and Institute
NCT02721550 TERMINATED
A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC
Shandong Cancer Hospital and Institute
NCT01865721 COMPLETED
Optimizing the Use of Entonox® During Screening Colonoscopy
Sheffield Teaching Hospitals NHS Foundation Trust
NCT02819921 TERMINATED
Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
Seoul National University Hospital
NCT01189409 TERMINATED
Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients
British Columbia Cancer Agency
NCT02475057 COMPLETED
Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
Rabin Medical Center
NCT03514550 COMPLETED
Effects of Anesthesia on Immunity in Cancer
Meshalkin Research Institute of Pathology of Circulation
NCT02869321 COMPLETED
Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy
Central Hospital, Nancy, France
NCT02895529 TERMINATED
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
Xian-Janssen Pharmaceutical Ltd.
NCT03355079 TERMINATED
Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy
Fresenius Kabi
NCT02350543 TERMINATED
Peri-operative Aspirin Continuation Versus Discontinuation
Rabin Medical Center
NCT02839889 TERMINATED
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
Hospice of Henderson County, Inc.
NCT03172988 TERMINATED
Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery
Peking University First Hospital
NCT01588990 COMPLETED
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
Hoffmann-La Roche
NCT01607255 COMPLETED
Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)
VA Office of Research and Development
NCT02095951 COMPLETED
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Children's Hospital of Michigan
NCT01948960 COMPLETED
Influence of Exceptional Patient Characteristics on Everolimus Exposure
Radboud University Medical Center
NCT02660229 COMPLETED
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
Mundipharma Korea Ltd
NCT02800330 COMPLETED
The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
Erasmus Medical Center
NCT03586154 COMPLETED
Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain
Mansoura University
NCT02581176 COMPLETED
Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
University Hospital, Akershus
NCT02532634 COMPLETED
Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
Kangdong Sacred Heart Hospital
NCT02009306 COMPLETED
Nasal Fentanyl and Buccal Midazolam for Dying Patients
Gloucestershire Hospitals NHS Foundation Trust
NCT01653171 COMPLETED
Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy
Pontificia Universidad Catolica de Chile
NCT03384511 COMPLETED
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
NCT02909049 COMPLETED
Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy
Complexo Hospitalario Universitario de A Coruña
NCT01313780 COMPLETED
A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
Mundipharma Korea Ltd
NCT02476526 COMPLETED
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
VA Greater Los Angeles Healthcare System
NCT02248571 COMPLETED
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
iOMEDICO AG
NCT00688038 COMPLETED
Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy
M.D. Anderson Cancer Center
NCT01882218 WITHDRAWN
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
University of Louisville
NCT02728921 COMPLETED
The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery
Region Skane
NCT01849588 TERMINATED
HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
Massachusetts General Hospital
NCT01989845 COMPLETED
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
Seoul National University Hospital
NCT01675531 COMPLETED
A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Mundipharma Korea Ltd
NCT01041612 COMPLETED
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Taewoong Medical Co., Ltd.
NCT02597582 COMPLETED
LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients
Taichung Veterans General Hospital
NCT01961544 COMPLETED
Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
Eisai Korea Inc.
NCT02810899 COMPLETED
Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
Peking University First Hospital
NCT02880072 COMPLETED
Absorption of Orally Ingested Phosphate in Refeeding Syndrome
Jens Rikardt Andersen
NCT01719757 COMPLETED
PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain
Mundipharma Korea Ltd
NCT02566096 COMPLETED
Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively
Assiut University
NCT02805166 COMPLETED
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
NCT01328054 COMPLETED
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
GlaxoSmithKline
NCT02173964 COMPLETED
Pinverin Application Trial to Reduce Bowel Uptake of FDG (Fluorodeoxyglucose)
Seoul National University Hospital
NCT01658280 COMPLETED
Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies
Azienda Ospedaliero, Universitaria Ospedali Riuniti
NCT01402089 COMPLETED
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Markus Joerger
NCT01809106 COMPLETED
RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
Mario Negri Institute for Pharmacological Research
NCT02622880 COMPLETED
Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients
Instituto de Investigación Hospital Universitario La Paz
NCT00793871 COMPLETED
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
Pfizer
NCT02593942 COMPLETED
Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy
Yeditepe University Hospital
NCT02044224 COMPLETED
Effects of Dexmedetomidine During IRE Procedures for Solid Tumours
Uppsala University Hospital
NCT02243059 WITHDRAWN
Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
Maastricht University Medical Center
NCT01317589 COMPLETED
Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
Maastricht University Medical Center
NCT00747916 TERMINATED
Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space("ICE PLS")
CSA Medical, Inc.
NCT02213653 TERMINATED
Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency
Centre Francois Baclesse
NCT01315522 COMPLETED
Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents
Seoul National University Hospital
NCT02343081 COMPLETED
Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
Monte Verde SA
NCT01348048 COMPLETED
A Trial Investigating the Effect of Specialised Palliative Care on Symptoms, Survival, Economical Factors and Satisfaction
Bispebjerg Hospital
NCT02101164 WITHDRAWN
Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
Amgen
NCT02016391 COMPLETED
Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours
Uppsala University Hospital
NCT00771199 COMPLETED
An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
Janssen-Cilag Ltd.
NCT01471756 COMPLETED
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
Mayo Clinic
NCT02000739 WITHDRAWN
Genetically-informed Therapies for Patients With Metastatic Cancer
Dartmouth-Hitchcock Medical Center
NCT01887158 COMPLETED
Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection
Ospedale Santa Maria delle Croci
NCT01365143 TERMINATED
Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
Mayo Clinic
NCT01949974 WITHDRAWN
Integral Attention Program With or Without Palliative Chemotherapy in Advanced Cancer Patients
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
NCT00980889 COMPLETED
RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction
Stockholm South General Hospital
NCT00951262 COMPLETED
Intervention Study on Life Review Among Advanced Cancer Patients in Fuzhou, China
The Hong Kong Polytechnic University
NCT01056913 COMPLETED
NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
St John of God Hospital, Vienna
NCT01758341 COMPLETED
Radiofrequency Ablation for Malignant Biliary Obstruction
Medical University of Vienna
NCT01733342 COMPLETED
Single-center Randomized Trial for Comparison of Performance Between Domestic and Imported Chemoport
Seoul National University Hospital
NCT01862198 COMPLETED
The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent
Inje University
NCT00766831 COMPLETED
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
Janssen Korea, Ltd., Korea
NCT00664911 COMPLETED
Combination Chemotherapy in Treating Older Patients With Solid Tumour,
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT00925444 COMPLETED
Staple-line Reinforcement for Prevention of Pulmonary Air Leakage
Assistance Publique - Hôpitaux de Paris
NCT01621100 COMPLETED
Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients
Janssen Korea, Ltd., Korea
NCT01006356 COMPLETED
An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
Janssen Korea, Ltd., Korea
NCT01143974 COMPLETED
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
Chinese Academy of Medical Sciences
NCT01481831 COMPLETED
Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting
Shanghai Changzheng Hospital
NCT00808184 COMPLETED
Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype
National University Hospital, Singapore
NCT01107756 COMPLETED
A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen
Sanofi
NCT01318473 COMPLETED
The Use of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided With Lesions Smaller Than 15 mm
ActiViews Ltd.
NCT00842829 TERMINATED
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Cephalon
NCT01040884 COMPLETED
Safety And Accuracy Study Of The Actisight™ Needle Guidance System In Patients Undergoing CT-Guided Procedures
ActiViews Ltd.
NCT01205230 COMPLETED
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
GlaxoSmithKline
NCT01418118 COMPLETED
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
Oxford University Hospitals NHS Trust
NCT00616135 COMPLETED
Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy
Cytori Therapeutics
NCT01022905 COMPLETED
Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients
University Hospital, Geneva
NCT00606515 COMPLETED
Pharmacokinetics Study of Liposomal Paclitaxel in Humans
Shandong Luye Pharmaceutical Co., Ltd.
Full Solid Tumor (Advanced) Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only